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Abstract 
Depression is among the leading causes of disability worldwide, affecting more than 
350 million people globally. Currently available antidepressant drugs have 
unsatisfactory efficacy, with up to 60% of depressed patients failing to respond 
adequately to treatment. Emerging evidence has highlighted a potential role for the 
multidrug efflux transporter P-glycoprotein (P-gp; encoded by the ABCB1 gene), 
expressed at the blood-brain barrier (BBB), in the aetiology of treatment-resistant 
depression. In the research outlined in this thesis, the potential of P-gp inhibition as 
a strategy to enhance the brain distribution and pharmacodynamic effects of 
antidepressant drugs was investigated in preclinical studies. 
Microdialysis-based pharmacokinetic studies revealed that administration of the P-
gp inhibitors verapamil or cyclosporin A (CsA) enhanced the BBB transport of the 
antidepressants imipramine and escitalopram in the conscious, freely moving rat. 
Furthermore, P-gp inhibition by verapamil increased brain concentrations of 
escitalopram following chronic administration in mice. 
In addition to these in vivo studies, both imipramine and escitalopram were found 
to be transported substrates of human P-gp using an in vitro bidirectional transport 
model in Madine-Darby canine kidney cells transfected with ABCB1 (MDCK-MDR1). 
These data indicate that in vivo findings demonstrating that P-gp limits the brain 
levels of these two antidepressants in rodents may translate to humans. Moreover, 
using the same in vitro model, we found that human P-gp exerted no effect on the 
transport of four other antidepressants: amitriptyline, duloxetine, fluoxetine and 
mirtazapine. 
To build on the above-mentioned pharmacokinetic studies, the effect of P-gp 
inhibition on pharmacodynamic responses to antidepressant treatment was 
investigated in vivo. Pre-treatment with verapamil augmented the behavioural 
effects of escitalopram in the tail suspension test (TST), a widely used and well-
validated model to assess antidepressant-like activity in mice. However, similar 
augmentation effects in the TST were not observed in studies involving CsA. 
Abstract 
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Moreover, pre-treatment with CsA exacerbated the behavioural manifestation of 
an escitalopram-induced mouse model of serotonin syndrome, a serious adverse 
reaction associated with serotonergic drugs. This finding highlights the potential for 
unwanted side-effects which may occur as a result of increasing brain levels of 
antidepressants by P-gp inhibition, although further studies are needed to fully 
elucidate the mechanism(s) at play. 
Taken together, the research outlined in this thesis demonstrates that P-gp may 
restrict brain concentrations of escitalopram and imipramine in patients. 
Furthermore, we have shown that chronic treatment with a P-gp inhibitor and a P-
gp substrate antidepressant results in elevated brain levels of the antidepressant. 
Moreover, increasing the brain distribution of an antidepressant by P-gp inhibition 
can result in an augmentation of antidepressant-like activity in vivo. These findings 
raise the possibility that P-gp inhibition may represent a potentially beneficial 
strategy to augment antidepressant treatment in clinical practice. Further studies 
are now warranted to evaluate the safety and efficacy of this approach. 
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1.1. Central nervous system barriers 
The central nervous system (CNS), consisting of the brain and spinal cord, acts as 
the main processing centre for the entire nervous system. The neurons in the CNS 
communicate with each other via chemical and electrical signals which involve the 
movement of small ionic molecules across neuronal membranes. Thus, it is crucial 
that the ionic composition of the extracellular fluid in the CNS, which bathes the 
central neurons, is strictly controlled and regulated to facilitate precise intercellular 
signalling (Abbott, 2013). In contrast, the ionic composition of the blood varies 
considerably; for example, following food intake or exercise. It is therefore 
important that ion transport into and out of the CNS is tightly controlled to 
maintain ion homeostasis for optimal neuronal signalling. This is achieved by a 
number of CNS barriers, including the blood-brain barrier (BBB) and the blood-
cerebrospinal fluid barrier (BCSFB), which separate the CNS from the periphery 
(Figure 1.1). In addition to their contribution to ion homeostasis, the CNS barriers 
serve several additional functions, as outlined in Table 1.1. 
Table 1.1: Functions of CNS barriers (adapted from Abbott, 2013) 
Functions of central nervous system barriers 
Maintenance of ion homeostasis, which is essential for optimal neural signalling 
Regulation of molecular traffic, thereby ensuring sufficient uptake of essential nutrients 
and clearance of metabolic waste products 
Protection of the CNS from toxins 
Maintenance of a low protein environment in the CNS, thereby limiting proliferation and 
preserving neural connectivity 
Separation  of central and peripheral neurotransmitter pools, thereby limiting cross-talk 
and facilitating non-synaptic signalling in the CNS 
Facilitation of immune surveillance while guarding against inflammation and resultant cell 
damage 
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The BBB, discussed in more detail in Section 1.2, exists at the level of the 
endothelial cells which line the blood microvessels in the brain, and is the most 
important interface for molecular flux between the blood and the brain (Abbott et 
al., 2010). The BCSFB consists of the epithelium of the choroid plexus, which is the 
modified ependymal lining of the ventricles in the brain which secretes CSF (Laterra 
et al., 1999b). Some solutes and drugs enter the brain primarily across the BCSFB, 
while others enter via both the BBB and BCSFB (Abbott, 2013). However, the 
majority of solutes and drugs gain entry to the brain via the BBB. The arachnoid 
barrier is another CNS barrier existing at the arachnoid epithelium in the middle 
layer of the meninges, which form the outer covering of the CNS. The arachnoid 
barrier plays a very limited role in the entry of solutes into the brain (Abbott, 2013).  
 
 
Figure 1.1: Location of the CNS barriers (Abbott, 2013) 
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1.2. The blood-brain barrier: a major obstacle in the delivery of 
drugs to the brain 
The BBB plays a key role in maintaining homeostasis within the CNS; preserving the 
composition of the internal milieu despite variations in the periphery and 
protecting the brain against toxins, bacteria and viruses (Figure 1.2A). In addition, 
the BBB regulates the uptake of endogenous molecules and xenobiotics into the 
brain (Pardridge, 2007a; Neuwelt et al., 2008; Pariante, 2008; Zlokovic, 2008; 
Abbott et al., 2010; Neuwelt et al., 2011). 
Drug delivery is one of the major hurdles in the development of novel therapeutics 
for brain disorders (Pardridge, 2005). While alternative approaches exist to achieve 
direct drug delivery to the brain, there are severe disadvantages associated with 
such approaches (discussed in more detail in Section 1.2.4.1). As a result, most 
centrally acting drugs are administered peripherally (usually either orally or 
parenterally). Therefore, transport across the blood-brain barrier (BBB) needs to be 
achieved for these drugs to reach therapeutic concentrations at their site of action 
in the brain. The extensive network of blood capillaries in the brain, with an average 
of 40 µm between microvessels, means that, once drugs cross the BBB, the 
distances over which diffusion needs to take place to reach target cells are short 
(Pardridge, 2010). Therefore, in order to achieve widespread drug delivery 
throughout the brain, drug delivery across the BBB is the preferred route of drug 
transport.  
Crucially, over 98% of small molecule drugs with potential for treatment of CNS 
disorders are unable to cross the BBB to reach target sites within the brain, while 
practically no large molecule therapeutics are able to penetrate the BBB (Figure 
1.2B) (Pardridge, 2005; Neuwelt et al., 2008). This means that many CNS disorders 
remain undertreated, even those with well-understood pathophysiology resulting 
in clearly defined therapeutic targets, such as Huntington’s disease (Figure 1.2C). 
Moreover, emerging evidence indicates that certain small molecule drugs used 
clinically in the management of so-called “treatable” CNS disorders, such as 
depression and epilepsy, may not reach adequate concentrations in the brains of 
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some patients, thereby potentially contributing to the high prevalence of treatment 
failure in these diseases (Loscher and Potschka, 2005b; Uhr et al., 2008). 
 
Figure 1.2: The BBB - a bottleneck in drug development (adapted from Pardridge, 
2005). A. Whole body autoradiogram of a mouse demonstrating that radiolabelled 
histamine penetrates all parts of the body apart from the CNS due to the CNS 
barriers. B. Statistics revealing the scale of the challenge presented by the BBB in the 
delivery of drugs to the brain. C. Only 5% of small molecule drugs are for the 
treatment of CNS disorders, and these are aimed at only four therapeutic 
indications. 
1.2.1. Structure and function of the BBB 
The BBB consists of three main ‘barriers’ which regulate molecular flux between the 
blood and the brain. The ‘physical barrier’ consists of the tight junctions formed 
between the brain capillary endothelial cells (BCECs) lining the blood capillaries in 
the brain, which form the fundamental building block of the BBB (Figure 1.3).   
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Figure 1.3: The blood-brain barrier (O'Brien et al., 2012b). A. The BBB consists of 
endothelial cells in the cerebral capillaries which, together with closely associated 
perivascular elements, such as pericytes, astrocyte endfoot processes and neurons, 
form the neurovascular unit. B. Illustration of tight junctions at the BBB C. Several 
drug efflux pumps, such as P-glycoprotein (P-gp), breast cancer resistance protein 
(BCRP) and multidrug resistance-associated proteins (MRP), are expressed at the 
BBB.   
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Interactions between BCECs and other components of the neurovascular unit 
(Hawkins and Davis, 2005), which consists of BCECs and perivascular cells such as 
astrocytes, pericytes and neurons, induce the BBB-specific properties of the BCECs 
(Janzer and Raff, 1987; Hayashi et al., 1997; Abbott et al., 2006; Armulik et al., 
2010). In addition, the dynamic permeability of the BBB varies in response to intra- 
and intercellular signalling among these cells (Neuwelt et al., 2011).  
One of the key characteristics of the BBB is the formation of tight junctions 
between endothelial cells (Reese and Karnovsky, 1967; Brightman and Reese, 
1969). These tight intercellular junctions consist of a highly complex network of 
transmembrane and intracellular linking proteins, as well as signalling and 
regulatory proteins (Figure 1.3B) (Wolburg and Lippoldt, 2002; Ballabh et al., 2004; 
Wolburg et al., 2009; Abbott et al., 2010). Transmembrane proteins, such as 
occludin, claudin-3,-5 and -12 and three members of the immunoglobulin 
superfamily, junctional adhesion molecules (JAMs), endothelial selective adhesion 
molecules (ESAM) and the coxsackie- and adenovirus receptor (CAR), tightly link the 
endothelial cells together. Transmembrane proteins are linked to the actin 
cytoskeleton within the cell via first- and second-order cytoplasmic accessory 
scaffold molecules. Important first-order adaptor components, which bind directly 
to the transmembrane proteins, include the zona occludens proteins (ZO 1-3), while 
cingulin and junction associated coiled-coil protein (JACOP) are examples of second 
order adaptor proteins. Signalling and regulatory molecules include multi-PDZ-
protein 1 (MUPP1), afadin (AF6) and 7H6. The adherens junction lends structural 
support to the endothelial tissue. It is made up of vascular endothelial cadherin (VE-
cadherin), with the scaffolding proteins α-, β- and γ-catenin and desmoplakin, and 
the platelet-endothelial cell adhesion molecule (PECAM), which mediates 
homophilic adhesion. 
The tight junctions between BCECs result in a continuous cellular wall, thereby 
effectively sealing the paracellular route of transport, which is important for 
hydrophilic or polar molecules which cannot penetrate the lipid environment of the 
cell membrane (Zlokovic, 2008; Abbott et al., 2010). Thus, molecules must 
predominantly traverse the BBB via the transcellular route to gain access to the 
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brain (discussed in more detail in Section 1.2.2). However, a lack of fenestrations 
and low levels of transcytosis result in relatively low levels of transcellular transport 
at the BBB (Hawkins and Davis, 2005). Therefore, in general, physicochemical 
properties such as lipophilicity, molecular weight and charge determine the ability 
of a compound to cross the BBB, with only low molecular weight, lipophilic 
molecules able to penetrate the physical barrier presented by the BCECs.  
In addition to the ‘physical barrier’ presented by the tight junctions between BCECs, 
there is also an ‘enzymatic barrier’ present at the BBB. Many drug metabolizing 
enzymes, including members of the cytochrome P450 (CYP) family and others such 
as glutathione-S-transferase and UDP-glucuronosyltransferase, are localized at the 
BBB (Ghersi-Egea et al., 1994; Bauer et al., 2008; Dauchy et al., 2008; Dutheil et al., 
2009; Eyal et al., 2009). However, it is worth noting that the profile of CYP450 
enzymes present at the BBB differs considerably to that of the liver. CYP1B1 has 
been reported to be the most prominent CYP450 enzyme at the BBB, whereas CYPs 
3A4, 2C9 or 2D6, involved in the hepatic metabolism of roughly 50% of drugs, were 
not detected at the BBB (Dauchy et al., 2008). Nonetheless, compounds which are 
substrates of the BBB enzymes may be broken down as they traverse BCECs, 
thereby resulting in reduced bioavailability in the brain.  
Furthermore, several uptake and efflux transporter proteins, expressed at the 
luminal and/or abluminal membranes of the BCECs, play a vital role in the 
regulation of molecule transfer across the BBB (Figure 1.3C) (Pardridge, 2007a). 
From a drug delivery perspective, the expression of drug efflux transporters at the 
BBB can limit brain exposure to substrate drugs, thereby constituting an ‘efflux 
barrier’ (Urquhart and Kim, 2009). Therefore, the brain permeability of certain 
compounds, which are subject to metabolism and/or drug efflux at the BBB, is 
much lower than would be predicted based on physicochemical properties alone 
(Cordoncardo et al., 1989; Begley, 2004; Hermann and Bassetti, 2007).  
Chapter 1: General Introduction 
9 
1.2.2. Routes of transport across the BBB 
The potential routes of drug transport across the BBB can be classified into three 
broad categories: (1) passive transport; (2) carrier-mediated transport; and (3) 
receptor-mediated transport (Figure 1.4).  
 
Figure 1.4: Routes of drug transport across the BBB. 1. Passive transport: (a) The 
paracellular route of transport, important for polar solutes, is effectively sealed at 
the BBB due to the presence of tight junctions between cells. (b) Low molecular 
weight, non-polar, unionized, lipophilic solutes can traverse the BBB via the 
transcellular route of passive transport. 2. Carrier-mediated transport: (a) Efflux 
transporters expressed at the BBB can limit the permeability of solutes availing of 
the transcellular route of transport by actively extruding them back against a 
concentration gradient. (b) Influx transporters facilitate the uptake of essential 
solutes, such as glucose, which otherwise would not reach the brain. 3. Receptor-
mediated transport: Transport receptors, such as the transferrin receptor, expressed 
at the BBB bind to specific substrates, such as transferrin. The receptor-substrate 
complex is internalised within the cell and trafficked to the opposite membrane, 
where the substrate is released. The receptor is subsequently recycled to its original 
membrane. 
 
Passive transport involves drug diffusion down a concentration gradient, from a 
region of high concentration (i.e. blood) to lower concentration (i.e. brain tissue), 
and therefore does not require an energy source. It can be sub-divided into 
paracellular (i.e. between cells) and transcellular (i.e. through cells) transport.  
In general, the paracellular route of transport is important for low molecular 
weight, hydrophilic, polar molecules which cannot traverse the lipid environment of 
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the cell membrane. However, owing to the aforementioned tight junctions at the 
BBB, under normal, healthy physiological conditions, the paracellular route of 
transport is effectively sealed at the BBB. Therefore, polar drug molecules are, in 
general, unable to cross the BBB and are not suitable candidates for the treatment 
of CNS disorders as a result (Pardridge, 2005; Abbott, 2013).  
In contrast, small molecular weight, non-polar, lipophilic drug molecules can exploit 
the transcellular route of transport across the BBB, but only when they are in their 
unbound free state (i.e. not bound by plasma proteins). Such drug molecules must 
exhibit sufficient lipophilicity to be able to pass through the lipid bilayer and must 
typically be less than 400-500 Da in size to avoid steric hindrance (Pardridge, 2005). 
Thus, in general, low molecular weight, lipophilic drugs represent the category of 
drug best able to reach the brain (Figure 1.5). 
 
Figure 1.5: Relationship between lipid solubility, corrected for differences in 
molecular weight, and brain uptake rate of selected compounds (Laterra et al., 
1999a). Higher values for oil/water partition coefficient correspond to greater 
lipophilicity. In general, brain uptake increases with increasing lipophilicity 
(compounds represented by black circles). Exceptions include substrates of active 
uptake processes (represented by orange squares), which exhibit greater uptake 
than would be predicted based on lipophilicity alone and substrates of efflux 
transporters or compounds which are highly plasma protein bound (represented by 
white triangles), which display lower uptake than would be predicted based on 
lipophilicity alone. 
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However, low molecular weight lipophilic drug candidates are also susceptible to 
active extrusion by efflux pumps (discussed in more detail in Section 1.2.3) and 
enzymatic breakdown at the BBB, which could therefore restrict their brain 
bioavailability.  
In addition to active efflux processes, several active carrier-mediated uptake or 
influx transporters are also expressed at the BBB (Table 1.2). Essential nutrients 
such as glucose, amino acids, amines, nucleosides, monocarboxylates and small 
peptides avail of this route of transport (Laterra et al., 1999a). As a result, an 
adequate supply of these molecules, which otherwise would not cross the BBB, is 
maintained in the brain. Some therapeutic compounds, such as L-DOPA (the 
precursor of dopamine used in the treatment of Parkinson’s disease) via the large 
neutral amino acid-transport system, gain access to the brain by exploiting naturally 
occurring carrier-mediated transport systems at the BBB (Laterra et al., 1999a). 
Most proteins are unable to cross the BBB due to their large size and hydrophilicity. 
As a result, concentrations of plasma proteins in the brain are very low. However, 
specific receptor-mediated transport processes exist at the BBB to facilitate the 
transcytosis of particular proteins, such as insulin and transferrin. Efforts have been 
made to exploit receptor-mediated transcytosis to enhance the delivery of peptide-
based therapeutics to the brain, known as the ‘molecular Trojan horse approach’ 
(Pardridge, 2007a). 
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Table 1.2: Transport systems that operate from blood to brain (adapted from 
Laterra et al., 1999a) 
Transport System Typical substrate 
Metabolic substrates 
Hexose Glucose 
Monocarboxylic acid Lactate 
Large neutral amino acid Phenylalanine 
Basic amino acid Lysine 
Acidic amino acid Glutamate 
β-amino acid Taurine 
Amine Choline 
Purine Adenine 
Nucleoside Adenosine 
Saturated fatty acid Octanoate 
Vitamins and co-factors 
Thiamine Thiamine 
Pantothenic acid Pantothenic acid 
Biotin Biotin 
Vitamin B6 Pyridoxal 
Riboflavin Riboflavin 
Niacinamine Niacinamine 
Carnitine Carnitine 
Inositol myo-Inositol 
Electrolytes 
Sodium Sodium 
Potassium  Potassium  
Chloride Chloride 
Hormones 
Thyroid hormones T3 
Vasopressin Arginine vasopressin 
Insulin Insulin 
Other peptides 
Transferrin Transferrin 
Enkephalins Leu-enkephalin 
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1.2.3. Drug efflux transporters at the BBB 
As mentioned in Section 1.2.2, several drug transporters are expressed at the BBB. 
Efflux transporters from the adenosine triphosphate binding-cassette (ABC) 
superfamily, in particular, exert significant functional transport at the BBB. ABC 
transporters are primary active transporters, which use adenosine triphosphate 
(ATP) hydrolysis to power the active efflux of their substrates against concentration 
gradients. Forty-nine members of the ABC superfamily have been described in 
humans, and these are divided in to 7 major sub-families: ABCA to ABCG (Sharom, 
2008).  
ABC transporters are expressed at various sites within the body, including the 
kidney, liver, intestine and adrenal gland. Importantly, several members of the ABC 
superfamily are localized at the BBB (Figure 1.6); including P-glycoprotein (P-gp; 
encoded by the multidrug resistance 1 (MDR1/ABCB1) gene), breast cancer 
resistance protein (BCRP; encoded by ABCG2) and multidrug resistance-associated 
proteins 4 and 5 (MRP4 and 5; encoded by ABCC4 and 5 respectively) (Begley, 2004; 
Loscher and Potschka, 2005a; Nies, 2007; Dauchy et al., 2008). The functional 
impact of these ABC transporters on the brain accumulation of several drugs has 
been elucidated in preclinical studies involving knockout mice and specific inhibitors 
(de Vries et al., 2007). There is significant overlap in substrate specificity between 
P-gp, BCRP and the MRPs, and many commonly used drugs are included among 
their substrates (de Vries et al., 2007; Sharom, 2008; Zhou, 2008). Interestingly, P-
gp and BCRP appear to work in concert to synergistically limit the brain penetration 
of certain drugs, including the anti-cancer agents topotecan and lapatinib (de Vries 
et al., 2007; Polli et al., 2009). 
Furthermore, ABC transporters have been implicated in resistance to 
pharmacotherapy, most notably in oncology, where the expression of these efflux 
pumps by cancer cells may confer resistance to chemotherapy with cytotoxic drugs 
in cancer patients (Gottesman et al., 2002; Szakacs et al., 2006). In addition, there is 
increasing evidence that ABC transporter-mediated drug efflux at the BBB may limit 
brain drug delivery of several CNS drugs (Loscher and Potschka, 2005b), thereby 
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leading to treatment failure in various brain disorders, including brain cancer 
(Pauwels et al., 2007), epilepsy (Siddiqui et al., 2003) and stroke (Spudich et al., 
2006). In the field of psychiatry, much recent attention had been given to the role 
of efflux pumps in the pharmacokinetic profile of antidepressant drugs. Increasing 
evidence suggests that P-gp, in particular, may limit the ability of several 
antidepressants to cross the BBB, thus resulting in inadequate brain concentrations 
and therefore contributing to the poor success rate of current antidepressant 
therapies (Uhr et al., 2008). The role of P-gp in the contribution to treatment failure 
in CNS disorders is discussed in more detail in Section 1.3.5. 
 
Figure 1.6: Drug transporters at the BBB. Several drug efflux and uptake 
transporters are expressed at the BBB. P-gp, BCRP and the MRPs expressed at the 
apical (i.e. blood) membranes of BCECs restrict the transport of their substrates 
across the BBB. There is also limited evidence of P-gp expression at the basolateral 
(i.e. brain) membrane (Bendayan et al., 2006), although the functional relevance of 
this is unclear. 
 
1.2.4. Approaches to overcome the BBB to achieve drug delivery 
to the brain 
Existing methods to enhance the brain delivery of drugs which cannot cross the BBB 
are largely inadequate for various reasons. They can be divided into two broad 
categories: invasive and non-invasive approaches. 
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1.2.4.1. Invasive approaches 
Invasive transcranial drug delivery approaches involve bypassing the brain barriers 
to directly administer drugs to the brain, such as direct intracerebroventricular (ICV) 
injection or the intracerebral implantation of a controlled release drug delivery 
device (Pardridge, 2007b).  
Severe limitations associated with these techniques, not least the requirement for 
surgical intervention, preclude their widespread use in clinical practice. In 
particular, transcranial drug delivery techniques fail to achieve adequate drug 
distribution throughout the brain due to the inefficiency of drug diffusion in brain 
tissue (Pardridge, 2005). While high local concentration are achieved at the site of 
injection or implantation, which can lead to toxicity, sufficient drug levels are not 
reached at more distant brain regions as drug concentrations decline exponentially 
with distance from the injection/implantation site (Pardridge, 2010). Attempts have 
been made to overcome this limitation by utilising convection-enhanced-diffusion, 
which involves the continuous infusion of fluid into the brain following 
implantation, but to limited effect (Salvatore et al., 2006). Therefore, primarily due 
to the invasive nature of the approach and the problems associated with drug 
diffusion in brain tissue, direct transcranial drug administration only represents a 
viable strategy in particular circumstances, such as brain cancer, where the clinical 
benefit outweighs the risk involved.  
1.2.4.2. Non-invasive approaches 
Considering that the brain is served by an extensive network of blood capillaries, 
with typically only 40 µm between capillaries in the brain, it is ideal to deliver drugs 
intended for global brain distribution via the vascular route (Pardridge, 2010). This 
represents a challenge for therapeutics which are unable to cross the BBB. 
However, certain strategies exist to enhance the delivery of such drugs to the brain. 
One potential approach to achieve this goal is by transient disruption of the BBB to 
facilitate drug delivery to the brain. This can be done by the intracarotid infusion of 
hyper-osmotic solutions, as described by Neuwelt and colleagues over 30 years ago 
(Neuwelt et al., 1979; Neuwelt et al., 1980). However, this strategy has been 
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rejected as impractical for general widespread use due to the obvious 
disadvantages associated with non-selective disruption of the important protective 
and homeostatic functions played by the BBB, including the inducement of epileptic 
type seizures (Marchi et al., 2007). Future research, perhaps involving the use of 
RNA interference (Campbell et al., 2011), localised ultrasound irradiation (Mesiwala 
et al., 2002; Hynynen, 2008) or selective pharmacological modulation of BBB 
permeability (Carman et al., 2011), may facilitate highly selective alteration of BBB 
function to enable the targeted delivery of drugs to the brain.  
Alternatively, rather than disrupting the BBB per se, attempts have been made to 
enhance drug transport across the intact, fully functional BBB. These efforts have 
included altering drug molecules using medicinal chemistry approaches (Greig et 
al., 1990), linking drug molecules to CNS-targeting moieties (the BBB molecular 
‘Trojan Horse’ approach) (Pardridge, 2006) or the incorporation of drug molecules 
into colloidal carriers (Kreuter et al., 2003). The incorporation of CNS drug 
molecules into colloidal drug carriers, thereby potentially masking unwanted 
physicochemical properties, protecting from enzymatic degradation or drug efflux 
and enhancing CNS bioavailability via increased transmembrane diffusion, 
represents a particularly promising novel approach to achieve drug delivery to the 
brain via the bloodstream without necessitating disruption of the BBB (Wohlfart et 
al., 2011a).  
1.2.5. Methods to predict or measure drug transport across the 
BBB 
Various approaches, ranging from in silico to in vitro and in vivo, exist to assess drug 
transport across the BBB. Each of these approaches has associated strengths and 
weaknesses, as will be outlined in the forthcoming sections, and can be best 
employed at different stages in the drug discovery process.  
1.2.5.1. In silico 
In silico approaches to evaluate drug transport across the BBB make use of 
computer-based simulations to predict whether a compound will penetrate the BBB 
based on its molecular characteristics. In general, in silico approaches facilitate 
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relatively cheap and rapid high-throughput screening of the BBB permeability of 
potential lead compounds in early drug discovery, but typically only achieve ~70-
80% prediction accuracy (Goodwin and Clark, 2005; Dureja and Madan, 2007; 
Broccatelli et al., 2012).  
These in silico models are based on relationships between BBB permeability, as 
measured experimentally in vitro or, preferably, in vivo, and molecular 
characteristics of the test compounds used. For example, early work in this field 
focused on the relationship between lipophilicity and BBB permeability (Oldendorf, 
1974; Levin, 1980).  
The utility of in silico models is primarily dependent on the quality and quantity of 
the training and test datasets on which the model is based and the molecular 
descriptors included in the model (Mensch et al., 2009). 
With regards to such datasets, the ‘garbage in, garbage out’ dictum applies 
(Mensch et al., 2009). It is crucial that the in vivo data on which the model is based 
is appropriate and accurate, ideally generated under the same experimental 
conditions in the same laboratory. In addition, it is necessary to be aware of the 
limitations of the model in terms of its ‘chemical space’, as attempting to apply a 
model to make predictions to molecules from outside the chemical space of the 
dataset could result in misleading and inaccurate results (Goodwin and Clark, 2005). 
Several molecular descriptors which influence BBB permeability have been 
identified. Since early studies reported links between lipophilicity and BBB 
permeability (Oldendorf, 1974; Levin, 1980), further key characteristics, such as 
molecular weight, the polar surface area and the number of hydrogen-bond 
acceptors, have come to light (Mensch et al., 2009). However, predicting BBB 
permeability based on such physicochemical parameters alone focuses on passive 
transcellular transport only, and neglects carrier-mediated and enzymatic processes 
which may influence brain bioavailability. This is a major disadvantage of the 
majority of models. Increasing recent effort has focused on developing quantitative 
structure activity relationship (QSAR) models to predict if a compound will be 
subject to active transport processes (as discussed in section 1.3.7.1). Integration of 
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such QSAR information in more complex in silico models may facilitate more 
accurate prediction of BBB permeability in the future, but to date no in silico model 
which fully reflects the intricacies of the BBB exists (Mensch et al., 2009). 
1.2.5.2. In vitro 
A valid, predictive and representative in vitro screening tool would be of enormous 
benefit in the development and design of novel approaches to overcome the BBB, 
and to predict the BBB permeability of novel drug compounds. Ideally, such a model 
would consist of a readily available, convenient, predictable and reproducible 
immortalized endothelial cell line, with brain endothelial cell characteristics, low 
paracellular permeability (due to the formation of tight junctions) and functional 
expression the various transporters and enzymes present at the BBB in vivo to 
physiologically relevant levels. However, no such ideal in vitro model has been 
developed as yet (Cecchelli et al., 1999; Reichel et al., 2003; Garberg et al., 2005; 
Avdeef, 2011).  
In vitro systems used to investigate drug permeability across the BBB can be divided 
into two broad categories: cells derived from a cerebral origin and cells not derived 
from a cerebral origin (Table 1.3). 
Brain capillary endothelial cells (BCECs), the fundamental building block of the BBB, 
have been isolated with little or no contamination by other cell types (e.g. glial cells, 
pericytes etc) from a range of species, including mouse, rat, cow, sheep, pig 
monkey and human, and generally produce confluent cell monolayers after 9 days 
in culture. However, the isolation of BCECs for primary systems requires time-
consuming, technically challenging and tedious work, and can be responsible for 
inter-lab variations (Reichel et al., 2003). In addition, cultured BCECs lose or down-
regulate many key characteristics of the BBB in vivo, such as tight junctional 
complexity, specific transporters and enzymes, especially when isolated from their 
natural milieu (Cecchelli et al., 1999). This limitation can be somewhat overcome by 
co-culturing BCECs with astrocytes, however, other limitations still apply (Cecchelli 
et al., 1999). Immortalised brain endothelial cell lines, which demonstrate high 
TEER values when cultured on transwell systems, have been recently developed 
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(Weksler et al., 2005; Poller et al., 2008). These systems may represent a useful 
investigational tool in the future, but further validation is needed before their 
predictive utility can be definitely evaluated. 
Alternatively, cells derived from a non-BBB origin which form confluent monolayers 
with tight junctions when grown on an appropriate transwell support, can be used 
to determine drug permeability across a biological membrane which may reflect 
BBB permeability (Hellinger et al., 2012). Furthermore, such non-cerebral cell lines 
may possess, or can be transfected with, certain properties which exist at the BBB, 
such as P-gp expression. Cell lines commonly used for this purpose include the 
naturally P-gp-expressing human colorectal adenocarcinoma (Caco-2) cells and 
ABCB1-transfected, P-gp expressing Madine-Darby canine kidney cells (MDCK-
MDR1). These model cell-lines are polarized, with distinct apical and basolateral 
membrane domains, when cultured on an appropriate transwell support.  
As P-gp is exclusively expressed on the apical membrane of the cultured cells, the 
comparison of apical-to-basolateral (A→B) permeability and basolateral-to-apical 
(B→A) permeability for a test compound indicates if it is a P-gp substrate (Lin, 
2007). Furthermore, these cell systems can be used to determine a drug’s apparent 
permeability (Papp) across a P-gp expressing membrane. However, the fact that 
these cells are from a non-cerebral origin is a considerable disadvantage, especially 
when one considers that membrane properties influence P-gp mediated transport 
(Romsicki and Sharom, 1999; Hellinger et al., 2012). In addition, non-cerebral cells 
transfected with a singular aspect of the BBB, such as P-gp for example, fail to fully 
reflect the variety of complex active processes present at the BBB in vivo. 
Nonetheless, they can represent useful models for the prediction of BBB transport 
(Hellinger et al., 2012). 
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Table 1.3: In vitro models to predict drug transport across the BBB (adapted from Reichel et al., 2003; Garberg et al., 2005; Mensch et al., 
2009)  
Method Advantages Limitations 
Cells derived from a cerebral origin 
Isolated brain 
capillaries / 
microvessels 
 Can be isolated from various sources 
(animal/human) 
 Metabolically active 
 Reflective of in vivo situation 
 Significant loss of ATP → significant loss of activity 
 Difficult to access luminal surface of microvessels, therefore can 
only conduct drug transport experiments from abluminal to 
luminal side 
 Thus unsuitable for BBB-permeability screening 
Primary BCECs 
(monoculture) 
 Close to in vivo situation 
 Maintain many BBB-specific in vivo features 
 Can be prepared from a variety of sources (bovine 
and porcine preferred due to higher yield than from 
rats; ethical and tissue access constraints with 
human sources) 
 Some significant BBB-features down-regulated or lost during 
preparation 
 Tend to overestimate Pe values for lipid-mediated transport and 
underestimate Pe for carrier-mediated transport 
 Lose expression of BBB-specific proteins (e.g. drug transport 
pumps) 
Primary BCECs 
(co-culture or 
astrocyte-
conditioned 
medium) 
 As per monoculture, plus: 
 Up-regulation of P-gp function and increased TEER 
relative to monocultures; therefore closer 
approximation of in vivo situation 
 Time and resources required to isolate, seed and incubate 
primary BCECs and astrocytes 
 Poor reproducibility 
Immortalized 
BCECs 
 Avoid disadvantages of primary systems with 
respect to time, effort and reproducibility 
 Form monolayers 
 Useful for mechanistic and biochemical studies 
 Do not generate complete tight junctions (to date), therefore 
unsuitable for studying BBB transport due to paracellular 
leakiness 
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Method Advantages Limitations 
Cells derived from non-cerebral origin 
MDCK  Reproducible, high TEER value 
 Low sucrose permeability 
 Easy to grow 
 Can be transfected with P-gp (to achieve polarized 
expression) 
 Most representative of in vivo permeability for 
passive and P-gp-effluxed compounds  
 Does not express other BBB-specific proteins which may play 
significant roles in drug transport 
Caco-2  Well-established model for permeability studies 
(intestinal) 
 Naturally expressed P-gp in a polarised fashion when 
cultured on a transwell support 
 Many differences from BCECs – morphology, protein expression, 
metabolism etc 
 Expression of a variety of other efflux and uptake transporters in 
addition to P-gp 
Pe: apparent permeability; TEER: transepithelial electrical resistance (a measure of the tightness of junctions between cultured cells) 
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1.2.5.3. In vivo and in situ approaches 
Due to the limitations of the available in silico and in vitro BBB models, and the 
complexity of the processes ongoing at the BBB, in vivo models remain the best way 
of assessing the ability of a compound to cross the BBB. Moreover, in vivo 
approaches provide crucial reference information for the testing and validation of 
other models (Mensch et al., 2009). Several different in vivo approaches to 
investigate drug transport across the BBB exist, including intravenous injection 
followed by decapitation and brain collection, the brain uptake index approach, 
brain perfusion, imaging studies and microdialysis. These approaches vary in terms 
of their sensitivity and usefulness (Bickel, 2005; Nicolazzo et al., 2006; Mensch et 
al., 2009).  
Intravenous injection followed by decapitation and determination of drug 
concentration in brain tissue represents a relatively simple, sensitive and 
representative method of measuring brain uptake and has been described as the 
‘gold standard’ for assessing BBB permeability (Nicolazzo et al., 2006). However, 
using this approach, it is only possible to obtain brain concentrations at a terminal 
time-point (i.e. one time-point per animal) and it is therefore necessary to use a 
large number of animals to elucidate the brain distribution kinetics of a drug using 
this method. Furthermore, as the brain vasculature accounts for approximately 5% 
of the total brain volume (Wohlfart et al., 2011b), it is necessary to consider the 
presence of drug within the brain capillaries which has not actually crossed the BBB 
but will appear in brain homogenate samples. Many studies fail to account for this 
issue, which in turn limits the conclusions that can be drawn from such studies in 
relation to the BBB penetration of the compound of interest.  
The problem of drug present in the cerebral vasculature can be overcome to some 
extent by using the capillary depletion technique (Triguero et al., 1990), which 
utilises density centrifugation to separate vascular components from other brain 
tissue. Thus it is possible to measure drug concentrations in the supernatant, which 
should theoretically only contain tissue from the brain parenchyma. However, 
capillary depletion is an imperfect technique. For example, drug bound to low 
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affinity or non-specific binding sites on the plasma membrane of brain capillary 
endothelial cells may dissociate during the centrifugation process, thus producing 
misleading results (Pardridge, 1995).  
The brain uptake index (BUI) and isolated brain perfusion in situ techniques offer 
some advantages compared to the intravenous administration approach outlined 
above (Bickel, 2005). Both of these techniques specifically investigate processes 
ongoing at the BBB, thereby avoiding factors such as metabolism in other organs 
which can complicate deconvolution of data from intravenous studies. In addition, 
the composition of the intravascular fluid in the cerebral microvasculature can be 
readily manipulated, thereby facilitating investigation of the impact of factors such 
as test solute concentration, protein binding and osmotic pressure on BBB 
permeability (Bickel, 2005). 
The BUI, first reported in the 1970s (Oldendorf, 1970) is a single pass technique, 
whereby the test compound (along with a reference compound which is 
impermeable to the brain as a control to correct for the fraction of the bolus 
remaining in the vascular lumen at the time of sampling) is rapidly injected into the 
common carotid artery of anaesthetised animals. Brain uptake is determined by 
sampling of brain tissue 5-15 sec after the injection. The short timeframe involved 
eliminates systemic recirculation and wash-out as potential confounding factors 
(Bickel, 2005). However, the single pass nature of the technique limits the utility of 
the BUI to substances with moderate-to-high BBB permeability, as the uptake of 
less rapidly permeable compounds may not be detected. Morphine, for example, 
has well-established CNS effects, but its BUI is scarcely above that of impermeant 
vascular markers (Bickel, 2005). In addition, the short timeframe involved precludes 
identification of slower uptake processes, such as receptor mediated endocytosis. 
Some of these deficiencies can be overcome by adopting brain perfusion methods. 
These approaches typically involve catheterization of the carotid artery and 
disruption of endogenous blood flow to the brain, for example by severing the 
heart ventricles. An oxygenated physiological buffer containing the test compound 
is then perfused for a period of time up to 10 minutes (Bickel, 2005). Thus, the 
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identification of compounds taken up into the brain via receptor mediated 
transport, which takes place over a period of minutes rather than seconds, can be 
achieved using this technique (Bickel, 2005). 
Both the BUI and brain perfusion in situ approaches involve the use of anaesthesia 
in the animals during the experiment, which may be a severe limitation given the 
potential effects of anaesthesia on BBB permeability (Saija et al., 1989; Tetrault et 
al., 2008; Thal et al., 2012). In addition, the problems previously outlined in relation 
to drug contained within the brain vasculature also apply. The intracerebral 
microdialysis technique offers several advantages compared to these methods. 
1.2.5.4. Intracerebral microdialysis 
Intracerebral microdialysis facilitates the determination of unbound concentrations 
of both endogenous and exogenous substances in brain extracellular fluid (ECF) as a 
function of time in conscious, freely moving animals (de Lange et al., 2000; Plock 
and Kloft, 2005; Anderzhanova and Wotjak, 2013). Derived from earlier attempts to 
sample amino acid and electrolytes in neuronal extracellular fluid across a semi-
permeable membrane, using the ‘push-pull’ method, the modern-day intracerebral 
microdialysis technique was pioneered by Ungerstedt and co-workers at the 
Karolinska institute in Stockholm, Sweden in the 1970s and 1980 (Ungerstedt and 
Pycock, 1974; Darvesh et al., 2011). While it has predominantly been used to 
monitor fluctuations in brain concentrations of neurotransmitters such as 
serotonin, dopamine and noradrenaline in response to various interventions 
(Ungerstedt and Hallstrom, 1987; Di Chiara et al., 1996), it has also been used to 
monitor brain extracellular fluid levels of many drugs, including morphine 
(Groenendaal et al., 2007), imipramine (Sato et al., 1994) and buspirone (Tsai and 
Chen, 1997).  
The key component of the microdialysis system is the microdialysis probe, which 
consists of a small semi-permeable hollow membrane connected to inlet and outlet 
tubing. The microdialysis probe can be surgically inserted into various body fluids or 
body tissues, including the brain. Moreover, the probe can be targeted to specific 
brain regions of interest with a high degree of accuracy using a stereotaxic frame. 
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While microdialysis probes can come in a variety of different designs (de Lange et 
al., 2000), the most commonly used design in intracerebral studies is the concentric 
design (Figure 1.7A). At the microdialysis probe membrane, unbound molecules 
capable of passing through the semi-permeable membrane will diffuse across the 
membrane down their concentration gradients, either into or out of the probe 
lumen (Figure 1.7B). According to Fick’s first and second laws (Fick, 1855), the rate 
of diffusion is directly proportional to the concentration gradient. Therefore, the 
amount of an analyte present in the dialysate will be proportional to the 
concentration in the periprobe fluid (Anderzhanova and Wotjak, 2013). 
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Figure 1.7: Intracerebral microdialysis. A The microdialysis probe consists of inlet and outlet tubing, connected to a semipermeable 
membrane. The membrane length and the active area can be tailored to target specific brain regions of interest. The perfusate is 
continuously pumped through the probe at a slow flow rate B. Compounds with sufficiently low molecular weight (green circles) will 
diffuse into the probe down their concentration gradient, and be pumped out through the outlet tubing. C-D The microdialysis probe 
can be specifically targeted to a brain region of interest with a high degree of accuracy using a stereotaxic frame during implantation. 
Moreover, the probe remains intact in conscious, freely moving animals, thereby facilitating sampling without a need for anaesthesia. 
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During a microdialysis experiment, the probe is continuously perfused with an 
aqueous solution, known as the perfusate, which mimics the ionic composition of 
the periprobe fluid, at a constant low flow rate (typically 0.5-5 µl.min-1). Outlet 
tubing connects the membrane of the probe to the collection vial, in which the 
sample, known as the dialysate, is collected for analysis by a suitable analytical 
technique capable of dealing with the typically small volumes and low 
concentrations associated with microdialysis studies. The concentration of the 
analyte in the dialysate will reflect the concentration in the periprobe fluid. 
However, as microdialysis experiments are not conducted under equilibrium 
conditions, the dialysate concentration will always be lower than the actual 
concentration in the fluid surrounding the probe. The relationship between 
dialysate and periprobe concentrations is termed ‘probe recovery’ (Anderzhanova 
and Wotjak, 2013)  
The probe recovery is dependent on many factors, including flow rate, membrane 
properties, perfusate composition, physicochemical properties of the analyte of 
interest and temperature (de Lange et al., 2000). Probe recovery can be easily 
determined in vitro by immersing the probe in a well filled with a solution of known 
concentration of the analyte of interest, and then comparing dialysate 
concentrations to well concentrations. Determination of in vivo probe recovery is 
more difficult, but can be achieved by retrodialysis (where the molecule of interest 
is included in the perfusate in a naive animal and percentage loss is calculated) 
(Bouw and Hammarlund-Udenaes, 1998). A limitation of this approach is the 
assumption that drug diffusion will be equal in both directions (i.e. the percentage 
loss in retrodialysis experiments will be equal to the percentage gain in traditional 
microdialysis experiments). More sophisticated approaches to establish in vivo 
probe recovery, which do not make this assumption, include the no-net-flux 
(Lonnroth et al., 1987) or the more complex dynamic-no-net-flux methods (Olson 
and Justice, 1993).  
The no-net-flux methodologies involve perfusing different concentrations (Cinlet) of 
the compound of interest through the probe in a subject in which steady-state 
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levels of the drug have been achieved. The resulting dialysate concentrations 
(Coutlet) are measured, and the difference between Cinlet and resultant Coutlet are 
plotted as a function of Cinlet (Figure 1.8). This plot will cross the x-axis at the point 
where Cinlet is equal to the concentration in the periprobe fluid (as there has been 
no loss or gain of the compound). If the plot is linear, and if true steady-state 
conditions exist, the slope of the function will equal the in vivo recovery of the 
probe for that compound (de Lange et al., 2000; Anderzhanova and Wotjak, 2013).  
 
 
While the use of these techniques to establish in vivo probe recovery facilitates the 
calculation of actual analyte concentrations in the brain ECF, there are several 
limitations and difficulties associated with them (de Lange et al., 2000). For 
Figure 1.8: The principle of the no-net-flux method to determine in vivo 
microdialysis recovery (Anderzhanova and Wotjak, 2013). Different concentrations 
of the compound of interest (Cinlet) are perfused through a microdialysis probe 
implanted in an animal in which steady state levels of the compound have been 
achieved and maintained. The concentration emerging from the probe (Coutlet) is 
determined, and the difference between the perfusate and dialysate concentrations 
(i.e. Cinlet - Coutlet) is plotted as a function of the perfusate concentration. The point at 
which the plot crosses the x-axis represents the point at which the perfusate 
concentration is equal to that of the periprobe fluid, and the slope of the line is equal 
to the in vivo receovery of the probe for that compound. 
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example, they involve extremely time-consuming and challenging methodologies, 
and attempts to validly employ these techniques are often fraught with difficulties. 
To overcome these difficulties, a modified ‘ultraslow’ quantitative microdialysis 
technique has been recently developed (Cremers et al., 2009). However, this 
approach is proprietary, and cost issues may preclude its use, particularly in 
academia. Therefore, in certain circumstances, it is on balance preferable to 
calibrate probes in vitro only, and to selectively use probes with similar rates of 
recovery to enable comparison of relative changes in dialysate concentrations 
between different animals without a need to extrapolate absolute brain ECF 
concentrations (Page and Lucki, 2002; Anderzhanova and Wotjak, 2013). While this 
approach does not yield quantitative results per se, it facilitates evaluation and 
comparison of relative levels of the analyte in different treatment groups. 
Intracerebral microdialysis offers several key advantages over other approaches to 
determine BBB transport (de Lange et al., 2000; Anderzhanova and Wotjak, 2013). 
Using microdialysis, it is possible to sample from the brain ECF repeatedly over time 
in the same animal, thus facilitating a high degree of temporal resolution 
unattainable with other methods. In addition, this serves to reduce the number of 
animals required to conduct a pharmacokinetic study, in accordance with the 
‘reduction’ principal of the 3Rs in animal research (http://www.nc3rs.org.uk/). 
Moreover, the animal is both conscious and freely moving throughout the sampling 
period (Figure 1.7C), therefore avoiding potential effects of anaesthesia on BBB 
function. In addition, microdialysis samples only contain drug which has penetrated 
the BBB and is present in the brain ECF, as opposed to other techniques which 
determine the concentration of drug in brain tissue which includes cerebral 
capillaries. Furthermore, only unbound drug molecules will cross the microdialysis 
probe semipermeable membrane, and it is these free drug molecules which are 
pharmacologically active. Therefore, microdialysis facilitates the measurement of 
pharmacologically relevant active site concentrations of drug molecules in the brain 
(Hammarlund-Udenaes, 2010). 
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1.3. P-glycoprotein 
P-glycoprotein (P-gp) was first identified in the 1970s, when it was discovered to 
confer resistance to cancer cells against chemotherapeutic agents in vitro (Juliano 
and Ling, 1976), and was subsequently found to be localized in blood capillaries in 
the brain (Cordoncardo et al., 1989; Thiebaut et al., 1989). P-gp is widely expressed 
at specific sites within the body, including the BBB (Figure 1.9). It is the most 
studied, and arguably most functionally important, member of the ABC family of 
drug efflux transporters. 
 
Figure 1.9: Distribution of P-gp within the body (Marzolini et al., 2004) 
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1.3.1. Structure and function of P-glycoprotein 
P-gp is encoded by the ABCB1 (also known as MDR1) gene, located on chromosome 
7 at q21 with 28 exons encoding a protein of 1,280 amino acids, in humans (Ieiri, 
2012). It is a 170-kDa membrane-bound broad-spectrum efflux pump, consisting of 
twelve highly hydrophobic transmembrane domains, arranged as two bundles of six 
helices linked by a highly charged extracellular ‘linker region’, and two intracellular 
ATP-binding sites, known as nucleotide binding domains (NBDs) (Zhou, 2008; Aller 
et al., 2009). 
The hydrophobic ‘vacuum cleaner’ and flippase models have been proposed to 
describe P-gp-mediated drug translocation (Shapiro and Ling, 1997; Aller et al., 
2009; Colabufo et al., 2010). In the hydrophobic ‘vacuum cleaner’ model, P-gp pulls 
its substrates from the lipid bilayer and pumps them out of the cell through its 
central cavity. According to the flippase model, P-gp ‘scans’ the inner leaflet of the 
lipid bilayer and binds specific lipids and hydrophobic drugs prior to their extrusion 
by ‘flipping’ the phospholipids from the inner to outer leaflets of the lipid bilayer. 
The flippase model and the hydrophobic ‘vacuum cleaner’ model are not mutually 
exclusive, and a combination of both models is illustrated in Figure 1.10 (Aller et al., 
2009; Eckford and Sharom, 2009). The active drug efflux process is powered by ATP 
hydrolysis at the cytoplasmic NBDs (Sharom, 2008). 
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Figure 1.10: Schematic illustrating the mechanism of action of P-gp (O'Brien et al., 
2012b). A. In its substrate-binding conformation, P-gp contains a large substrate-
binding pocket (SBP), comprising mostly of hydrophobic and aromatic residues. Lipid 
soluble P-gp substrate molecules travel into the SBP from the inner leaflet of the 
phospholipid (PL) bilayer membrane. Substrate-P-gp interactions lead to the binding 
of two ATP molecules to the nucleotide binding domain (NBD). B. ATP-binding 
causes dimerization of the NBDs, leading to a conformational change, resulting in 
an outward facing configuration. This outward facing arrangement facilitates the 
release of substrates into the extracellular environment or the outer leaflet of the PL 
bilayer, and sterically prevents the substrate from travelling into the intracellular 
space. Thus, P-gp acts as a unidirectional efflux pump (see (Aller et al., 2009)). 
 
1.3.2. P-gp substrates and inhibitors 
One of the hallmarks of P-gp is its substrate promiscuity, as it transports a wide 
range of structurally unrelated compounds (Table 1.4) (Aller et al., 2009). Although 
P-gp substrates are generally hydrophobic amphipathic compounds, no chemical 
characteristic that clearly distinguishes between P-gp substrates and non-substrates 
has been determined (Schinkel, 1999). Interestingly, there is a significant overlap in 
substrate specificity between P-gp and drug metabolizing enzymes, such as 
cytochrome P450 (CYP) enzymes (Wacher et al., 1995; Uhr et al., 2004). Thus, P-gp 
and drug metabolizing enzymes in BCECs may work in tandem to reduce the ability 
of certain drug molecules, which are substrates of both, to pass through the BBB in 
a so-called “drug transporter-metabolism alliance” (as originally proposed in 
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relation to drug absorption from the gut) (Benet, 2009). According to this 
hypothesis, P-gp efflux would prevent the intact substrate from passing through the 
BBB, resulting in a cycle where drug molecules passively diffuse into the BCEC, 
followed by active P-gp mediated extrusion. Each time drug molecules diffuse into 
the BCEC in this cycle, a certain proportion of the molecules would be broken down 
by the drug metabolizing enzymes, while unchanged molecules would be recycled 
back out of the cell by P-gp. 
Compounds that interact with P-gp can be classified as substrates, modulators or 
inhibitors (Colabufo et al., 2010). Substrates are subjected to active efflux by P-gp, 
and therefore have a reduced ability to penetrate P-gp expressing membranes. 
Modulators reduce substrate binding via a negative allosteric interaction, thereby 
reducing P-gp-mediated substrate efflux; whereas inhibitors reduce P-gp function 
by interfering with the substrate or nucleotide binding steps (Colabufo et al., 2010). 
Therefore, modulators and inhibitors achieve the same pharmacological effect, 
albeit via different mechanisms, and for the purposes of this thesis are considered 
synonymous. Some, but not all, P-gp substrates also reduce P-gp function, and as 
such can be classed as both substrates and inhibitors.  
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Table 1.4: List of selected P-gp substrates and inhibitors (O'Brien et al., 2012b) 
Drug class Selected examples 
P-gp substrates 
Anticancer agents Daunorubicin, doxorubicin, etoposide, imatinib, 
methotrexate, mitoxantrone, paclitaxel, vinblastine, 
vincristine 
Antidiarrhoeal 
agents 
Loperamide 
Antihistamines Cetrizine, desloratadine, fexofenadine 
Antipsychotics Risperidone 
Antiretroviral 
drugs 
Amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, 
saquinavir 
Cardioactive drugs Amiodarone, digoxin, diltiazem, quinidine, verapamil 
Antiemetics Domperidone, ondansetron 
β-blockers Talinolol 
H2 receptor 
antagonists 
Cimetidine, ranitidine 
P-gp inhibitors 
First generation Amiodarone, cyclosporin A, nifedipine, quinidine, verapamil 
Second generation Dexverapamil, GF120918 (elacridar), PSC-833 (valspodar), 
VX-710 (biricodar) 
Third generation LY-335979 (zosuquidar), LY475776, OC144-093, R-101933 
(laniquidar), XR-9576 (tariquidar) 
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1.3.3. Regulation of P-gp expression and activity 
In common with other ABC transporters, the expression and activity of P-gp at the 
BBB are altered in response to factors including xenobiotics, inflammation, infection 
and disease (Miller, 2010).  
In rodents, the increase in P-gp expression and activity in response to xenobiotics is 
mediated via ligand-activated intracellular receptors, primarily the pregnane-X 
receptor (PXR) (known as the steroid and xenobiotic receptor (SXR) in humans 
(Loscher and Potschka, 2005b)) and the constitutive androstane receptor (CAR) 
(Bauer et al., 2004; Bauer et al., 2006; Wang et al., 2010). Interestingly, as well as 
upregulating efflux transporters such as P-gp, activation of PXR and CAR also 
induces the expression of metabolic enzymes in a coordinated defensive response 
to xenobiotic exposure (Bauer et al., 2008; Pascussi et al., 2008; Kohle and Bock, 
2009). Both receptors are activated by numerous endogenous ligands, including bile 
acids, and by several drugs, many of which are subjected to efflux or metabolism by 
the transporters and enzymes regulated by the receptors themselves (Miller, 2010). 
Furthermore, PXR and CAR have common activating ligands, including the clinically 
used drugs rifampicin, taxol, dexamethasone and phenobarbital (Kliewer et al., 
2002; Willson and Kliewer, 2002). In addition, PXR and CAR share common target 
genes, and both associate with the retinoid-X receptor before binding to DNA 
(Miller, 2010). 
The importance of xenobiotic-mediated increases in efflux transporter expression 
were highlighted in a study in which transgenic mice expressing human PXR (hPXR) 
were treated with the hPXR ligand, and clinically used antibiotic, rifampicin (Bauer 
et al., 2006). The dosing regimen, designed to achieve free plasma rifampicin levels 
equivalent to those achieved in patients undergoing course of rifampicin treatment, 
resulted in a 2-3 fold increase in P-gp protein levels in intestine, liver and brain 
capillaries. Moreover, this resulted in a 70% reduction in the antinociceptive effects 
of methadone, an analgesic drug which is a transported P-gp substrate (Bauer et al., 
2006). This demonstrates the potential pharmacodynamic consequences of 
xenobiotic-mediated drug transporter induction at the BBB.  
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In addition to xenobiotics, inflammation and immune activation can modulate P-gp 
expression and activity. These effects are highly complex and can result in up- or 
down-regulation of P-gp (Roberts and Goralski, 2008). In essence, acute 
inflammation or infection appears to result in reduced P-gp function and increased 
accumulation of P-gp substrates in the brain, whereas P-gp function is recovered or 
enhanced following chronic inflammation (Roberts and Goralski, 2008). 
Furthermore, P-gp expression and activity may be altered in different disease 
states, particularly in neurodegenerative diseases, such as Alzheimer’s disease for 
example (Vogelgesang et al., 2002; Zlokovic, 2008). Indeed, β-amyloid (Aβ), a 
protein involved in the pathophysiology of Alzheimer’s disease, is a transported 
substrate of P-gp in vitro and in vivo (Kuhnke et al., 2007; Hartz et al., 2010), while 
the deposition of Aβ is inversely correlated with P-gp expression in the brains of 
elderly non-demented humans (Vogelgesang et al., 2002). Moreover, increasing P-
gp expression by PXR activation results in reduced brain accumulation of Aβ in a 
mouse model of Alzheimer’s disease (Hartz et al., 2010). Thus, reduced P-gp 
function has been hypothesized to be involved in the pathophysiology of 
Alzheimer’s disease, resulting in increased deposition of the pathological protein Aβ 
(Vogelgesang et al., 2004; Zlokovic, 2008). 
1.3.4. Single nucleotide polymorphisms in ABCB1 
Genetic heterogeneity in ABCB1 may influence P-gp functionality, and therefore 
lead to clinically relevant inter-individual differences in the pharmacokinetics of P-
gp substrates. Indeed, more than 50 SNPs in ABCB1 have been identified in humans 
(Table 1.5) (Stein et al., 1994; Hoffmeyer et al., 2000; Cascorbi et al., 2001; Ito et al., 
2001; Kim et al., 2001; Cascorbi, 2006; Salama et al., 2006; Kimchi-Sarfaty et al., 
2007; Sakurai et al., 2007) (see also: http://pharmacogenetics.ucsf.edu/cgi-
bin/Gene.py?hgncSymbol=ABCB1).  
Most studies in this regard have focused on three SNPs in particular: rs1128503 
(C1236T; exon 12), rs2032582 (T2677G; exon 21) and rs1045642 (C3435T; exon 26). 
However, despite an abundance of studies, the functional impact of these SNPs, or 
indeed of the others, remains largely unclear and somewhat controversial (Ieiri, 
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2012). Given the substantial influence of environmental factors, such as xenobiotics 
and infections (as discussed in Section 1.3.3), it is perhaps unsurprising that robust 
genetic effects have not been observed. Moreover, some of these SNPs exist in 
linkage disequilibrium with each other, and therefore focusing on individual SNPs, 
as opposed to their role in haplotypes, may have obscured potentially relevant 
genetic effects on P-gp functionality (Ambudkar et al., 2003; Marzolini et al., 2004). 
Several studies have reported that specific ABCB1 SNPs can have an impact on P-gp 
expression and function in humans, and therefore influence the pharmacokinetics 
of certain drugs which are transported substrates of P-gp (Hoffmeyer et al., 2000; 
Johne et al., 2002; Fukui et al., 2007; Ieiri, 2012). The first such study reported that 
the synonymous C3435T SNP was associated with reduced P-gp expression in 
individuals homozygous for the T allele compared to those homozygous for the C 
allele (Hoffmeyer et al., 2000). This resulted in higher steady-state plasma levels of 
the P-gp substrate digoxin following oral administration in those homozygous for 
the T allele, indicating that intestinal P-gp was not limiting its oral absorption to the 
same extent as in C/C carriers due to reduced P-gp expression (Hoffmeyer et al., 
2000). While this study has been replicated to an extent (Kurata et al., 2002), others 
have reported directly contradictory findings, with lower digoxin bioavailability in 
T/T carriers (Sakaeda et al., 2001). This example highlights inconsistencies in the 
available data in relation to the functional impact of ABCB1 SNPs in general (Ieiri, 
2012).  
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Table 1.5: List of selected ABCB1 SNPs, associated amino acid changes and their 
frequencies in different ethnic groups 
dbSNP ID SNP 
AA 
substitution 
Mutant allele frequency (%) 
African Asian Caucasian 
rs9282564 A61G Asn21Asp 2.5 1.7 8 
rs2229109 G1199A Ser400Asn 1 0 2.5 
rs1128503 C1236T Silent 20.9 68.5 45.9 
rs2032582 G2677T Ala893Ser 10 45 46.4 
rs2032582 G2677A Ala893Thr 0.5 6.7 3.6 
rs1045642 C3435T Silent 20.2 40 56.1 
rs2235015 G→T Intronic 30 6.7 15.8 
rs2032583 T→C Intronic n/a n/a n/a 
Mutant allele frequency data obtained from: http://pharmacogenetics.ucsf.edu 
 
1.3.5. The contribution of P-gp efflux to treatment failure 
Efflux of P-gp substrate drugs has been linked to treatment failure in many 
diseases, most notably in cancer (Gottesman et al., 2002; Szakacs et al., 2006). 
Indeed, P-gp was first identified as a result of it conferring treatment resistance to 
certain anticancer agents in vitro (Dano, 1973; Juliano and Ling, 1976). Thus, the 
name ‘multidrug resistance transporter’ was originally coined for P-gp, and it is still 
often referred to by this term. Certain cancerous cells and tumours are known to 
overexpress P-gp (Gottesman et al., 2002), and several cytotoxic drugs are avidly 
transported P-gp substrates (Table 1.4). As a result, such cytotoxic drugs can be 
ineffective in the treatment of P-gp overexpressing cancers, such as acute myeloid 
leukaemia (Leith et al., 1999). Moreover, P-gp at the BBB contributes to the lack of 
efficacy of these anticancer agents in the treatment of brain tumours (Kemper et 
al., 2004).  
Much recent interest has focused on the role of P-gp in treatment resistance 
beyond oncology, with evidence implicating a potential involvement of P-gp efflux 
in drug-resistant brain diseases such as CNS HIV infection, epilepsy, schizophrenia 
and depression (Loscher and Potschka, 2005b).  
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Several antiretroviral drugs used in the treatment of HIV are transported substrates 
of P-gp (Table 1.4). In the CNS, HIV infection mostly targets microglia and, to a 
lesser extent, astrocytes (Speth et al., 2005), and P-gp expression is upregulated in 
HIV-infected astroglial and microglial cells (Langford et al., 2004). Therefore, P-gp 
efflux presents an obstacle to successful treatment of CNS HIV at two stages: firstly 
in limiting the distribution of antiretroviral drugs across the BBB, and secondly in 
preventing their intracellular accumulation within infected cells. 
Approximately one third of patients with epilepsy are resistant to treatment (Kwan 
and Brodie, 2000). Multidrug resistance transporters, including P-gp, are 
overexpressed in BCECs and astrocytes in epileptogenic brain tissue from patients 
with refractory epilepsy (Tishler et al., 1995; Dombrowski et al., 2001; Aronica et 
al., 2003; Aronica et al., 2004; Feldmann et al., 2013). Increasing in vitro and in vivo 
evidence indicates that many, but not all, commonly prescribed anti-epileptic drugs 
are transported substrates of efflux transporters, such as P-gp, at the BBB (Zhang et 
al., 2012). Thus, overexpression of P-gp may prevent therapeutically effective 
concentrations of the antiepileptic drugs from reaching the epileptic neurons, 
thereby contributing to the high incidence of medically intractable epilepsy 
(Potschka, 2012; Zhang et al., 2012). Indeed, preclinical and small-scale clinical 
studies investigating the effect of P-gp inhibition as an adjunctive strategy in 
epilepsy have reported promising results (Summers et al., 2004; van Vliet et al., 
2006) 
In the field of psychiatry, much recent interest has focused on the role of P-gp in 
the treatment of schizophrenia and depression (Loscher and Potschka, 2005b). Over 
20% of patients with schizophrenia do not respond to treatment with 
antipsychotics (Van Sant and Buckley, 2011). The majority of clinically used 
antipsychotic drugs, such as amisulpride, aripiprazole risperidone and olanzapine, 
are transported substrates of P-gp at the BBB (El Ela et al., 2004; Wang et al., 
2004a; Wang et al., 2004c; Doran et al., 2005; Wang et al., 2009). Clozapine, on the 
other hand, is considered not to be a P-gp substrate (Schinkel et al., 1996; El Ela et 
al., 2004) and is generally accepted to be more effective than other antipsychotics 
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in the management of treatment-resistant schizophrenia (Kane et al., 1988; Van 
Sant and Buckley, 2011), leading to speculation that its lack of transport by P-gp 
may contribute to its relative efficacy (Loscher and Potschka, 2005b). However, the 
evidence supporting a substantial role for P-gp in treatment resistant schizophrenia 
is not fully convincing, and further research is required before drawing conclusions 
in this regard, not least considering a more recent study reported that clozapine is a 
P-gp substrate (Doran et al., 2005). 
A growing body of preclinical and clinical evidence points toward a role for P-gp in 
antidepressant treatment. This topic is discussed in detail in Section 1.5.  
1.3.6. P-gp inhibition as a strategy to augment the therapeutic 
effects of P-gp substrate drugs 
Given the contribution of P-gp efflux to treatment failure, it has been proposed that 
co-administration of P-gp inhibitors with P-gp substrate drugs may represent a 
potential strategy to overcome P-gp-mediated drug resistance. Indeed, preclinical 
studies, both in vitro and in vivo, have offered hope that this strategy could prove 
to be beneficial in cancer and epilepsy (Fellner et al., 2002; Clinckers et al., 2005). In 
addition, small scale studies in humans have yielded promising preliminary results 
(List et al., 2001; Summers et al., 2004). 
However, larger scale clinical trials to date, which have focused primarily on the use 
of P-gp inhibitors in combination with cytotoxic drugs in treatment resistant cancer, 
have not proven to be successful due to pharmacokinetic and pharmacodynamic 
limitations, largely associated with the toxicity of the chemotherapeutic drug or a 
lack of therapeutic benefit (Szakacs et al., 2006; Colabufo et al., 2010; Shaffer et al., 
2012).  
For example, a high profile failure in this field involved a Phase III clinical trial of the 
third generation P-gp inhibitor tariquidar as an adjunctive therapy in non-small cell 
lung cancer (NSCLC) (http://clinicaltrials.gov/show/NCT00042302). This trial, 
involving co-administration of the tariquidar and the cytotoxic drugs paclitaxel and 
carboplatin in patients with advanced stage NSCLC, was terminated prematurely 
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due to safety concerns. Tariquidar administration exacerbated side-effects 
associated with the cytotoxic drugs, without improving patient outcomes (Szakacs 
et al., 2006). The failure of this study was perceived as a major blow in the 
development of P-gp inhibitors as a clinical augmentation strategy, despite the fact 
that there were fundamental flaws in the study design (Szakacs et al., 2006). Firstly, 
NSCLC has not been associated with P-gp overexpression, meaning that there was 
no clear rationale underpinning adjunctive treatment with a P-gp inhibitor (Szakacs 
et al., 2006). Secondly, the dose of tariquidar used in the clinical trial has been 
subsequently revealed to be inadequate to achieve substantial inhibition of P-gp 
(Kreisl et al., 2010). 
Despite these setbacks, the availability of specific and potent modulators of P-gp 
function at the BBB may lead to a therapeutically useful role for P-gp inhibitors in 
the future. In particular, the potential of P-gp inhibition as an adjunctive strategy in 
treatment resistant diseases aside from cancer, thereby avoiding problems 
associated with potentiation of cytotoxic activity in healthy tissues, remains 
underinvestigated. It should be noted, however, that a recent paper, published on 
behalf of the International Transporter Consortium, questions whether clinical 
modulation of efflux transport at the human BBB is likely to become a therapeutic 
option in future (Kalvass et al., 2013). 
1.3.7. Methods to assess drug interactions with P-gp at the BBB 
Several different methodological approaches, ranging from in silico to in vivo and 
human imaging studies, can be employed to assess drug interactions with P-gp. 
Such studies can focus on drug-P-gp interactions in general, or with a specific 
emphasis on interactions at the BBB in particular. 
1.3.7.1. In silico approaches 
As outlined in Section 1.2.5.1, attempts to predict or identify transported substrates 
of efflux transporters based on structural properties have proven to be challenging 
(Sharom, 2008). Recent advancements have led to more complex algorithms and a 
better understanding of molecular characteristics that increase the likelihood of 
being subjected to transport by P-glycoprotein (Desai et al., 2013). For example, 
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most transported substrates of P-gp possess one or two hydrophobic centres, an 
aromatic ring, electron donor and/or hydrogen bond donor and acceptor groups 
(Raub, 2006). This knowledge can prove useful in the optimisation and selection of 
lead compounds for further investigation, based on a desire to select substrates or 
non-substrates of P-gp. However, in vitro or in vivo experimental approaches 
remain the only reliable method to confidently identify transported substrates of P-
gp. 
1.3.7.2. In vitro studies 
Several in vitro screening assays can be used to determine interactions between 
test compounds and P-gp, and thereby classify drugs as P-gp substrates or 
inhibitors (Polli et al., 2001). Functional assays used to identify P-gp substrates 
include the ATPase activity and bidirectional transcellular transport assays.  
The relationship between P-gp activity and the breakdown of ATP is exploited in the 
ATPase activity assay, whereby the release of inorganic phosphate as a result of ATP 
hydrolysis following drug incubation with a P-gp expressing membrane is monitored 
(Sarkadi et al., 1992). This facilitates high-throughput identification of compounds 
that interact with P-gp. However, many compounds identified as so-called P-gp 
‘substrates’ using this assay may not be subject to significant P-gp transport 
(Schwab et al., 2003), and this is a major limitation of the ATPase activity assay. As a 
result, this assay is of limited utility in the accurate identification of compounds that 
are meaningfully subjected to P-gp-mediated transport (Balimane et al., 2006). 
Bidirectional transcellular transport assays represent the gold standard for 
identifying P-gp substrates in vitro, and are the most accurate predictive model for 
the identification of P-gp substrates in vivo (Balimane et al., 2006; Feng et al., 2008) 
(Figure 1.11). However, these monolayer efflux assays are labour intensive and, 
consequently, time consuming with a relatively low-throughput.  
Many cell-lines suitable for use in bidirectional transcellular transport assays are 
available, including the naturally P-gp-expressing human colorectal 
adenocarcinoma (Caco-2) cells and ABCB1-transfected Madine-Darby canine kidney 
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cells (MDCK-MDR1). These model cell-lines are polarized, with distinct apical and 
basolateral membrane domains, when cultured on an appropriate transwell 
support. As P-gp is exclusively expressed on the apical membrane of the cultured 
cells, the comparison of apical-to-basolateral (A→B) permeability and basolateral-
to-apical (B→A) permeability for a test compound indicates if it is a P-gp substrate. 
A (B→A)/(A→B) transport ratio (TR) of > 2.0 is indicative of P-gp mediated efflux 
(Lin, 2007). 
The presence of other endogenous efflux transporters, in addition to P-gp, in these 
cell systems may influence transport. Therefore, it is advisable to use specific and 
potent P-gp inhibitors, in conjunction with the TR, to determine if P-gp mediated 
efflux is the transport mechanism at play, and thus if the test compound is a P-gp 
substrate. Furthermore, for ABCB1-transfected cell lines, such as MDCK-MDR1, a 
‘corrected’ transport ratio (cTR) can be calculated by dividing the TR obtained in the 
ABCB1-transfected cells by the TR obtained in the respective wild-type cell line 
(Zhang et al., 2006; Kuteykin-Teplyakov et al., 2010). However, the expression of 
endogenous drug transporters in these cell lines can be affected by transfection 
with the human ABCB1 gene (Kuteykin-Teplyakov et al., 2010). This must be taken 
into consideration when interpreting cTR values.  
Similarly, known P-gp substrates can be used in the bidirectional transcellular 
transport assay to determine if a test compound is a P-gp inhibitor. P-gp substrates 
commonly used for this purpose include digoxin, loperamide and talinolol (Pariante 
et al., 2003b; El Ela et al., 2004; Zhang et al., 2006). A decrease in the TR for the P-
gp substrate following co-incubation with the test compound is indicative of P-gp 
inhibition by the test compound. 
Other assays, which are less laborious and therefore offer higher throughput, can 
be used for the identification and classification of P-gp inhibitors. These P-gp 
inhibition assays utilise fluorescent P-gp substrates, such as calcein acetoxymethyl 
ester (calcein AM) or rhodamine 123, can be easily automated, and have the 
considerable advantage of a generic fluorescent output. Increased intracellular 
accumulation (as measured by increased fluorescence) of the fluorescent P-gp 
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substrate in P-gp expressing cells following co-incubation with the test compound 
thus gives an indirect measure of P-gp inhibition (Varga et al., 1996; Ibrahim et al., 
2000; Stormer et al., 2001; Weiss et al., 2003; Feng et al., 2008). Similarly, the 
susceptibility of P-gp-expressing-cells to P-gp-substrate cytotoxic drugs, such as 
doxorubicin or vinblastine, can be determined. Enhanced cytotoxicity in the 
presence of the test compound is indicative of P-gp-inhibition (Merry et al., 1991; 
Jaffrezou et al., 1995). 
 
Figure 1.11: Schematic of in vitro bidirectional transport assay. A cell line 
expressing P-gp in a polarised fashion, on the apical membrane only (e.g. MDCK-
MDR1), is cultured as a monolayer on a semipermeable membrane at the base of a 
transwell insert. Tight junctions form between the cells, thus limiting paracellular 
transport. Transport studies are carried out in both the apical-to-basolateral (A→B) 
direction, by adding the compound of interest to the apical chamber and sampling 
from the basolateral chamber, and the basolateral-to-apical (B→A) direction. Based 
on these experiments, the permeability of the compound in each direction can be 
calculated, and the permeability in the B→A direction can be compared to the A→B 
direction to yield a transport ratio. As P-gp, expressed on the apical membrane only, 
will limit the permeability of its transported substrates in the A→B direction, but not 
in the B→A direction, P-gp substrates will exhibit greater permeability in the B→A 
direction than the A→B direction, thus yielding a transport ratio greater than 1. 
Non-substrates of P-gp will yield transport ratios of approximately 1.  
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1.3.7.3. In vivo studies 
While P-gp is encoded by a single gene in humans (ABCB1), its functions are 
performed by two homologues in mice: the abcb1a and abcb1b genes (Devault and 
Gros, 1990). The overall tissue distribution of P-gp overlaps well between the two 
species (Ebinger and Uhr, 2006), and there seems to be a high level of correlation in 
substrate specificities between mouse and human P-gp based on in vitro studies 
(Feng et al., 2008), despite concern relating to potential species differences 
(Yamazaki et al., 2001; Katoh et al., 2006; Baltes et al., 2007; Syvanen et al., 2009). 
Thus, it appears that mouse-based models are useful, if imperfect, tools for 
predicting P-gp-drug interactions in humans. 
Abcb1a P-gp is highly expressed at the murine BBB, while it appears that abcb1b P-
gp is also expressed at the BBB, but to a much lesser extent (Pariante, 2008). Thus 
the generation of abcb1 knockout mice, firstly single knockout abcb1a(-/-) mice in 
1994 (Schinkel et al., 1994), followed by double knockout abcb1ab(-/-) in 1997 
(Schinkel et al., 1997), has facilitated the study of the influence of P-gp on brain 
pharmacokinetics of various drugs. P-gp deficient mice display normal viability, 
thereby indicating that organisms can survive with a complete absence of P-gp 
activity (Schinkel et al., 1997). This is an important consideration when evaluating 
P-gp inhibition as a potential treatment strategy in patients.  
By comparing brain/plasma drug concentration ratios between these P-gp-deficient 
knockout mice to those of wild-type controls, it has been possible to identify drugs 
as P-gp substrates in vivo. Alternatively, established P-gp inhibitors, such as 
verapamil and cyclosporin A, can be administered to wild-type animals to 
investigate the influence of P-gp inhibition on brain pharmacokinetics. 
1.3.7.4. Human studies 
Positron emission tomography (PET) imaging can be used to measure P-gp function 
in human volunteers or patient populations, using radiolabelled substrates, such as 
99m/94mTc-sestamibi, 11C-verapamil, 18F-paclitaxel or 11C-N-desmethyl-loperamide (de 
Klerk et al., 2009; Wagner et al., 2009; Kreisl et al., 2010). Assessing P-gp function in 
this way could be useful in predicting drug resistance in patients to be treated with 
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P-gp substrate therapeutics, identifying disease-states which are associated with 
alterations in P-gp activity or in assessing the ability of compounds to inhibit P-gp at 
different doses in humans (de Klerk et al., 2009; Wagner et al., 2009; Kreisl et al., 
2010). However, imaging techniques are not generally used to identify drugs which 
are subject to P-gp-mediated efflux at the BBB, as it would be necessary to generate 
radio-labelled versions of each drug of interest to carry out such assessments. 
1.4. Depression 
Clinical depression is a common and devastating mood disorder, affecting more 
than 350 million people globally (World Health Organisation, 2012). According to 
the World Health Organisation, depression is the leading cause of disability 
worldwide, and is a major contributor to the global burden of disease (World 
Health Organisation, 2012). 
Major depressive disorder is diagnosed based on symptomatic criteria, such as 
those outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; 
Table 1.6) (American Psychiatric Association, 2013) or the International 
Classification of Diseases (ICD). Suicide is an all-too-common tragic consequence of 
depression; alarmingly suicide was the tenth leading cause of death in the United 
States in 2010 (Centers for Disease Control and Prevention, 2013), and is a well-
recognised problem in Ireland and beyond. Given the severity of the symptoms 
associated with depression and its widespread prevalence, there is a major need to 
unravel the pathophysiology of the disorder, and to achieve optimal treatment 
strategies. 
  
Chapter 1: General Introduction 
 
47 
Table 1.6: Symptoms of major depressive disorder (DSM-5) 
 Symptom 
1 Depressed mood or irritable most of the day, nearly every day 
2 Decreased interest or pleasure in most activities, most of each day 
3 Significant weight change (5%) or change in appetite 
4 Change in sleep: either insomnia or hypersomnia 
5 Change in activity: psychomotor agitation or retardation 
6 Fatigue or loss or energy 
7 Feelings of worthlessness or excessive/inappropriate guilt 
8 Diminished ability to think or concentrate, or increased indecisiveness 
9 Thoughts of death or suicide, or having a suicide plan 
N.B. At least 5 of these 9 symptoms, including one of the first two, present nearly every 
day for more than two weeks for clinical diagnosis of major depressive disorder 
 
1.4.1. Neurobiology of depression 
While considerable advances have been made since Hippocrates proposed that an 
excess of black bile was the cause of melancholia, the neurobiological mechanisms 
underlying depression, and its exact aetiology, remain unclear despite extensive 
research (Cryan and Holmes, 2005; Krishnan and Nestler, 2008). Genetic and 
environmental factors, such as stress in particular, play an important role in 
conferring susceptibility to depression, with gene-environment interactions thought 
to be particularly important (Wong and Licinio, 2001). Numerous hypotheses, 
involving monoaminergic, neurotrophic, neuroendocrine and neuroimmune 
mechanisms, have been proposed to underpin the neurobiological changes that 
result in depression (Wong and Licinio, 2001; Duman and Monteggia, 2006; 
Krishnan and Nestler, 2008; Leonard and Myint, 2009). While each of these 
hypotheses has merit, none offers a comprehensive explanation of depression on 
its own, as several mechanisms are likely to contribute to what is a 
symptomatically, biologically and genetically heterogeneous disorder (Krishnan and 
Nestler, 2008).  
Over 50 years ago, serendipitous observations in relation to reserpine and 
iproniazid and imipramine, drugs developed as antihypertensive, antituberculosis 
and antihistamine agents, respectively, led to the ‘monoamine hypothesis’ of 
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depression, which postulates that depression occurs as a result of reduced 
monoaminergic transmission in the brain (Slattery et al., 2004; Krishnan and 
Nestler, 2008). Reserpine treatment resulted in a depletion of monoamine stores, 
inducing depressive symptomatology in a subset of patients, whereas treatment 
with iproniazid or imipramine, which were later shown to enhance central 
serotonin and noradrenaline neurotransmission, was found to elevate mood in 
depressed patients. However, the cause of depression is far from being a simple 
case of deficiencies in monoaminergic signalling, as highlighted by limitations of the 
monoamine hypothesis of depression (Krishnan and Nestler, 2008). While 
monoamine-based antidepressant drugs elicit rapid increases in monoamine 
transmission, it requires weeks of treatment for them to produce a clinically 
relevant enhancement of mood. Moreover, a high proportion of depressed patients 
do not respond to treatment with these antidepressants at all (Fava, 2003). Thus, it 
is now thought that acute increases in monoamine transmission by antidepressants 
result in secondary neuroplastic changes which require a longer timescale to exert 
their effect on mood (Krishnan and Nestler, 2008). Nonetheless, the vast majority 
of clinically used antidepressants today act to increase monoamine 
neurotransmission acutely, as efforts to identify and exploit other druggable targets 
in depression have mostly proven to be unsuccessful (Table 1.7).  
Another popular hypothesis pertaining to the pathogenesis of depression involves 
neurotrophins and neurogenesis (Duman and Monteggia, 2006). Stress, one of the 
main precipitating factors of depression in humans (Gold and Chrousos, 2002), and 
antidepressant treatment have opposing effects on neurotrophic factors (Duman 
and Monteggia, 2006). Preclinical studies have revealed that stress decreases the 
expression of neurotrophic factors, such as brain-derived neurotrophic factor 
(BDNF), in limbic structures associated with mood, and that these effects are 
reversed or blocked by antidepressant treatment (Duman and Monteggia, 2006). 
Similar BDNF deficits have been observed in post-mortem hippocampus samples 
from suicide victims with depression (Karege et al., 2005). Moreover, neuroimaging 
and post-mortem studies have revealed volumetric deficits in specific brain regions, 
including the prefrontal cortex and hippocampus, in subsets of depressed patients 
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(Cotter et al., 2001; Sheline, 2003), while preclinical studies have demonstrated 
that several antidepressants induce adult hippocampal neurogenesis (Sahay and 
Hen, 2007). Taken together, these observations support the concept that deficits in 
neurotrophins, such as BDNF, may be at play in depression. Indeed, much 
preclinical evidence points to a role for BDNF in depression and antidepressant 
response (Duman and Monteggia, 2006). Moreover, direct infusion of BDNF into 
the hippocampus induces an antidepressant-like effect in rodent models of 
depression, such as the forced swim test or the learned helplessness model 
(discussed in more detail in Section 1.4.5) (Siuciak et al., 1997; Shirayama et al., 
2002; Hoshaw et al., 2005). However, the ‘BDNF hypothesis of depression’ has 
drawn criticism, as further preclinical studies failed to replicate some of these 
findings, with some reporting directly opposing effects (Groves, 2007). Thus, it now 
appears that, while BDNF-mediated signalling is involved in neuroplastic responses 
to stress and chronic antidepressant treatment, these effects are both region- and 
antidepressant-specific (Krishnan and Nestler, 2008). 
Small increases in serum glucocorticoid levels are commonly reported in depressed 
patients (Holsboer, 2000; Parker et al., 2003; Julio-Pieper and Dinan, 2010), 
pointing to a potential role for dysregulation of the stress response via the 
hypothalamic-pituitary-adrenal axis in the pathophysiology of depression. This 
hypothesis is supported by the fact that some depression-like symptoms can by 
induced in rodents by chronic administration of glucocorticoids (Gourley et al., 
2008), while depression is common among patients with Cushing’s syndrome, a 
feature of which is extreme hypercortisolaemia (McEwen, 2007). Moreover, excess 
glucocorticoids can reduce proliferation rates in the hippocampus, thereby 
potentially contributing the volumetric deficits in hippocampal volume observed in 
depression (a trait also seen in Cushing’s syndrome), as discussed above (McEwen, 
2007). 
Further evidence points to a potential involvement of neuroimmune mechanisms in 
depression, resulting in the ‘cytokine or inflammatory hypothesis’ of depression 
(Raison et al., 2006; Leonard, 2010). Depression is a common side-effect of 
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cytokine-treatment with interferons or interleukins for diseases such as hepatitis C, 
multiple sclerosis and cancer, affecting over 30% of patients (Loftis and Hauser, 
2004; Dantzer et al., 2008; Leonard, 2010), and elevated levels of the cytokine IL-6 
have been observed in depressed patients (Maes et al., 1995). Furthermore, 
depressive disorders occur more frequently in diseases involving immune 
dysfunction; cytokines can activate the HPA axis (a common trait in depression, as 
discussed above); and cytokines can influence monoaminergic signalling in the brain 
(which has been associated with depression as per the ‘monoamine hypothesis’) 
(Dunn et al., 2005). Taken together, these associations indicate that immune 
activation may play a role in at least a subset of depression cases. 
Relatively recent findings have triggered an interest in the glutamate system in 
depression (Cryan and O'Leary, 2010). Sub-anaesthetic doses of ketamine, a 
psychomimetic non-competitive antagonist of the n-methyl-d-aspartate (NMDA) 
glutamate receptor, have been reproducibly shown to elicit a rapidly acting, but 
transient, antidepressant effect in patients who have not responded to other 
antidepressant treatments (Berman et al., 2000; Zarate et al., 2006). However, 
while the NMDA receptor, and downstream targets such as mTOR (Li et al., 2010), 
represent promising novel targets for drug treatment, at present there is limited 
evidence to suggest an important role for glutamatergic dysfunction in depression 
per se and further studies are required to more fully characterize the potential 
mechanisms at play (Krishnan and Nestler, 2008). 
1.4.2. Treatment of depression 
As stated earlier in Section 1.4.1, serendipity has played a bigger role than 
hypothesis-driven drug discovery in the development of treatments for depression 
to date (Slattery et al., 2004). 
Both pharmacological and non-pharmacological treatment strategies for the 
treatment of depression exist (Table 1.7). In general, more invasive non-
pharmacological strategies, such as electroconvulsive therapy (ECT) or deep brain 
stimulation, are reserved for severe cases in which other approaches have failed 
(Hollon et al., 2002). 
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Antidepressant drugs are categorised into different classes, based on structural 
characteristics and/or mechanisms of action, including selective serotonin reuptake 
inhibitors (SSRIs), tricyclic antidepressants (TCAs) and monoamine oxidase 
inhibitors (MAOIs) (Hollon et al., 2002; Joint Formulary Committee, 2013). 
However, with the possible exception of agomelatine, a recently approved 
melatonin receptor agonist and 5-HT2C receptor antagonist, all currently available 
antidepressant drugs, regardless of class, primarily act by enhancing 
monoaminergic transmission (Table 1.7). Substantial effort has been invested in 
attempts to identify, and exploit, novel therapeutic targets in depression. However, 
these efforts have generally not yet translated into alternative therapeutic options 
(Berton and Nestler, 2006). 
There is little to choose between different antidepressants in terms of efficacy, 
although there is a marked difference in terms of safety and side-effects (Hollon et 
al., 2002). Therefore, selection of an antidepressant for a particular patient is based 
on personal and familial history, the likelihood of particular side effects, safety in 
overdose and expense (Hollon et al., 2002). SSRIs are considered first-line, as they 
are better tolerated and safer in overdose than other classes. TCAs, for example, 
are more likely to be discontinued due to side-effects, and, moreover, can be fatally 
toxic in cases of overdose. This is an important consideration, given that patients 
suffering from depression are at a higher risk of suicide. MAOIs, on the other hand, 
have dangerous interactions with some foods and drugs (refer to Section 1.4.3), and 
they are reserved for use by specialists (Hollon et al., 2002; Joint Formulary 
Committee, 2013). 
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Table 1.7: List of currently available antidepressant treatments (adapted from Berton and Nestler, 2006; Kupfer et al., 2012; Joint Formulary 
Committee, 2013) 
Antidepressant 
class 
Drugs (subclass) Proposed mechanism of action 
Pharmacological treatments 
TCAs 
Amitriptyline, clomipramine, dosulepin, doxepin, 
Imipramine, lofepramine, nortriptyline, trimipramine 
Enhance monoaminergic transmission by non-selectively inhibiting the 
reuptake of serotonin, dopamine and noradrenaline 
TCA-related Mianserin (NaSSA), trazodone Modulation of monoaminergic system 
MAOIs 
Irreversible: phenelzine, isocarboxazid, 
tranylcypromine; Reversible: moclobemide 
Enhance monoaminergic transmission by preventing the breakdown of 
monoamines by inhibiting the monoamine oxidase enzyme 
SSRIs 
Citalopram, escitalopram, fluoxetine, fluvoxamine, 
paroxetine, sertraline 
Enhance monoaminergic transmission by selectively preventing the reuptake 
of serotonin 
Other 
Agomelatine Melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist.  
Duloxetine, Venlafaxine (SNRIs) Enhance monoaminergic transmission by preventing the reuptake of 
serotonin and noradrenaline 
Flupentixol Dopamine receptor blockade (primarily an antipsychotic) 
Mirtazapine (NaSSA) Increases central noradrenergic and serotonergic neurotransmission by 
inhibition of α2 and 5-HT2C presynaptic autoreceptors. 
Reboxetine (NRI) Enhances noradrenergic transmission by preventing its reuptake 
Tryptophan (serotonin precursor) Enhances serotonergic transmission by increasing central serotonin levels  
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Antidepressant 
class 
Drugs (subclass) Proposed mechanism of action 
Non-pharmacological treatments 
Electroconvulsive therapy (ECT) General brain stimulation 
Magnetic stimulation General brain stimulation? A magnetic field is thought to affect the brain by 
inducing electric currents and neuronal depolarization 
Vagal nerve stimulation (VNS) Unknown 
Psychotherapy Exact mechanism is uncertain, but is thought to involve learning new ways of 
coping with problems 
Deep brain stimulation In severely ill patients, stimulation of a region of the cingulate cortex found to 
function abnormally in brain imaging scans reportedly has antidepressant 
effects 
MAOIs: monoamine oxidase inhibitors; NaSSA: noradrenergic and specific serotonergic antidepressant; NRI: noradrenaline reuptake inhibitor; SNRIs: 
serotonin-noradrenaline reuptake inhibitors; SSRI: selective serotonin reuptake inhibitors; TCAs: tricyclic antidepressants 
Chapter 1: General Introduction 
 
54 
1.4.3. Side-effects of antidepressant drugs 
While all antidepressants are associated with side-effects, both central and non-
central, some are better tolerated than others. The side-effect profiles of 
antidepressants are an important clinical consideration, and can be the primary 
discriminating criterion when it comes to antidepressant choice. Further, 
antidepressant side effects can be an important factor contributing to poor 
adherence to treatment regimens among patients and, therefore, treatment failure 
(Hollon et al., 2002; Stahl, 2013). 
As mentioned in Section 1.4.2, TCAs are associated with more severe side-effects 
than SSRIs, and are resultantly more likely to be discontinued due to adverse 
reactions, with on average 30% of patients ceasing treatment for this reason 
(Hollon et al., 2002). Cardiovascular side-effects, such as arrhythmias, are a 
particular concern with TCAs, especially amitriptyline, and may be a contributory 
factor in sudden death of patients with underlying cardiovascular diseases. TCAs are 
associated with many other troublesome side-effects due to their off-target effects: 
blockade of H1 histamine receptors causes sedation and weight gain; 
anticholinergic actions at muscarinic cholinergic receptors cause dry mouth, urinary 
retention, constipation and memory disturbance; and orthostatic hypotension can 
occur due to blockade of α1 adrenoceptors in the brain (Hollon et al., 2002; Stahl, 
2013). Primarily due to these problematic side-effects, and the potentially fatal 
consequence of overdose, TCAs are no longer considered first-line options in the 
treatment of depression. 
MAOIs, on the other hand, have potentially serious interactions with a wide variety 
of other medications and foods. As a result, they have not been prescribed widely 
since the 1960s, despite their clinical efficacy, and it is advised that they should only 
be prescribed by specialists (Hollon et al., 2002). Ingestion of tyramine rich foods, 
such as mature cheese, while taking an MAOI may result in a dangerous increase in 
blood pressure as a result of a massive noradrenaline release, with potentially 
lethal consequences (Hollon et al., 2002; Stahl, 2013). Furthermore, concurrent, or 
indeed consecutive if an insufficient wash-out period is allowed, treatment with 
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MAOIs and other antidepressants may precipitate the potentially fatal serotonin 
syndrome (see Section 1.4.3.1). 
In comparison to TCAs and MAOIs, SSRI antidepressants are much better tolerated 
(Hollon et al., 2002). Nevertheless, SSRI treatment is associated with many side 
effects, mainly as a result of increased serotonergic signalling: gastrointestinal side-
effects, such as cramps and diarrhoea, via peripheral 5-HT3 and 5-HT4 receptors in 
the gut; centrally-mediated side-effects; including anxiety, appetite dysregulation, 
insomnia, sexual dysfunction, nausea and vomiting (Hollon et al., 2002; Stahl, 
2013). While the side effects of SSRIs are generally less problematic and less 
dangerous than those associated with other classes of antidepressants, they 
nonetheless represent a significant clinical problem and can result in poor patient 
adherence, with discontinuation of treatment in 10-20% of patients (Hollon et al., 
2002). Indeed, recent regulatory guidance recommended that doses of the 
commonly prescribed SSRIs citalopram and escitalopram should be minimized due 
to cardiovascular side-effects involving prolongation of the QT interval (Medicines 
and Healthcare products Regulatory Agency, 2011). Thus, any potential strategy to 
increase the selective delivery of antidepressants to their site of action in the brain, 
minimizing peripheral exposure and thereby limiting peripheral side effects, could 
be of enormous clinical benefit. However, enhancing brain concentrations of an 
antidepressant drug could result in an increased risk of centrally-mediated side-
effects, such as those listed above. 
1.4.3.1. Serotonin syndrome 
Serotonin syndrome is a potentially fatal adverse drug reaction, which occurs as a 
result of excessive serotonin signalling following ingestion of agents which enhance 
serotonergic neurotransmission (Boyer and Shannon, 2005). It is characterised by 
clinical symptoms such as tremor, clonus, muscular hypertonicity, altered mental 
state and hyperthermia in patients (Boyer and Shannon, 2005). Examples of agents 
which may precipitate serotonin syndrome are listed in Table 1.8 (Boyer and 
Shannon, 2005; Haberzettl et al., 2013). While serotonin syndrome may occur after 
ingestion of a single 5-HT enhancing agent, it is more commonly associated with 
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intake of two or more serotonergic drugs with differing mechanisms of action, such 
as SSRIs and MAOIs (Haberzettl et al., 2013). Indeed, life-threatening cases are 
generally only observed where a combination of agents have been taken (Gillman, 
2005).  
Table 1.8: List of selected compounds known to contribute to the development of 
serotonin syndrome (adapted from Boyer and Shannon, 2005; Thanacoody, 2012; 
Haberzettl et al., 2013) 
Classification Selected examples 
SSRI antidepressants Citalopram, escitalopram, fluoxetine, 
fluvoxamine, paroxetine, sertraline 
MAOI antidepressants Clorgiline, moclobemide, phenelzine, 
isocarboxazid 
Other antidepressants Buspirone, clomipramine, nefazodone, 
trazodone, venlafaxine 
Anticonvulsants Valproate 
Analgesics Fentanyl, pentazocine, pethidine, tramadol 
Anti-emetic agents Granisetron, ondansetron and metoclopramide, 
Anti-migraine drugs Sumatriptan 
Bariatric medications Sibutramine 
Antibiotics/antiretrovirals Linezolide (inhibits MAO) and ritonavir (inhibits 
CYP3A4) 
Cough remedies Dextromethorphan 
Drugs of abuse methylenedioxymethamphetamine 
(MDMA/’ecstasy’), lysergic acid diethylamide 
(LSD), cocaine 
Dietary supplements and herbal 
products 
Tryptophan, 5-hydroxy-tryptophan, Hypericum 
perforatum (St John’s Wort) 
Mood-stabilizers Lithium 
 
Owing to a lack of comprehensive epidemiological data pertaining to serotonin 
syndrome, it is not possible to definitively state its prevalence. However, estimates 
have approximated an incidence of 0.4 cases per 1,000 patient-months of 
treatment (Mackay et al., 1999). Moreover, the incidence of serotonin syndrome is 
thought to be increasing as a result of better recognition by clinicians and greater 
prescribing of serotonergic drugs in recent years (Thanacoody, 2012). Given its 
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serious and potentially lethal consequences, it is ethically unacceptable to conduct 
human experiments to investigate drug combinations which may induce serotonin 
syndrome.  
In this context, animal models of serotonin syndrome are an invaluable tool to 
investigate drug combinations which may precipitate the syndrome in humans 
(Haberzettl et al., 2013). Many of the symptoms of serotonin syndrome can be 
successfully emulated in rodent models, which exhibit high levels of predictive 
validity (Haberzettl et al., 2013). Behaviours associated with rodent models of 
serotonin syndrome include tremor, hind limb abduction and involuntary tics. 
These behaviours can be scored according to their severity, thereby facilitating 
quantitative evaluation of the impact of a drug on the manifestation of serotonin 
syndrome (Haberzettl et al., 2013). 
1.4.4. Treatment-resistant depression 
Despite the numerous drugs available for the treatment of depression (Table 1.7), 
treatment resistant depression (TRD) represents a significant clinical challenge 
(Souery et al., 2006). While the exact definition of TRD remains somewhat 
contentious, it is clear that current antidepressant therapies have unsatisfactory 
efficacy (Souery et al., 2006; Holtzheimer and Mayberg, 2011). It has been 
estimated that up to 60% of depressed patients do not achieve an adequate 
response to antidepressant treatment (Fava, 2003; Trivedi et al., 2006), with 
remission rates declining even further following successive treatment failures (Rush 
et al., 2006). Moreover, relapse occurs in a large proportion of patients who initially 
respond to treatment (Holtzheimer and Mayberg, 2011). As depression is one of 
the leading causes of disability in the developed world (Cryan and Leonard, 2010), 
there is a major impetus to determine why so many patients fail to respond to 
antidepressant treatment, and to devise novel strategies to improve treatment 
outcomes. 
Existing medication-based strategies recommended after the failure of an initial 
antidepressant trial, which has been optimized in terms of dose and duration, 
include augmentation with an adjunctive agent not thought to be an antidepressant 
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in its own right or switching to another antidepressant drug (Connolly and Thase, 
2011). A multisite, prospective, randomized, multistep clinical trial of outpatients 
with nonpsychotic major depressive disorder, the Sequenced Treatment 
Alternatives to Relieve Depression (STAR*D) study, was undertaken in recent years 
to determine the effectiveness of existing treatment strategies for people with 
major depression who did not respond to initial treatment with the SSRI 
antidepressant citalopram (Rush et al., 2004). This study found that, in the majority 
of patients, achieving remission of depressive episodes requires repeated trials of 
sufficiently sustained, vigorously dosed antidepressant therapy. Furthermore, 
switching antidepressant medication or augmenting it with another agent were 
found to be reasonable strategies in cases of initial treatment failure (Gaynes et al., 
2008).  
Numerous agents, including lithium and thyroid hormone, have been proposed to 
augment the effects of antidepressants (Thase, 2004; Connolly and Thase, 2011). 
The modes of action of these strategies are not fully understood. Augmentation 
with lithium, primarily used as a mood stabiliser, is thought to enhance the effects 
of antidepressant treatment via modulation of second messenger systems or 
increases in hippocampal proliferation, while thyroid hormone may act by ‘priming’ 
noradrenergic neurotransmission or by correcting suboptimal thyroid function in a 
subset of depressed patients (Thase, 2004; O'Leary et al., 2013). Although 
adjunctive lithium and thyroid hormone have established efficacy in the treatment 
of depression in particular circumstances, their relevance to modern practice is 
unclear. Most of the supporting evidence for these agents comes from trials when 
they were used in combination with TCAs in less severely resistant patients than 
those typically in receipt of TCAs nowadays (Connolly and Thase, 2011). As a result, 
it is impossible to confidently state their efficacy in TRD when used in combination 
with more modern antidepressants, such as SSRIs, due to a lack of data in this 
regard (Connolly and Thase, 2011). Given these issues, the troublesome side-effect 
profile of lithium treatment and its narrow therapeutic index, lithium is no longer 
widely used as an augmentation agent in TRD (Thase, 2004). The available evidence 
indicates that thyroid hormones, such as triiodothyronine (T3) are essentially 
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equivalent to lithium in terms of their efficacy as augmenters of antidepressant 
activity, and therefore may be considered a preferable option given their generally 
better tolerability and greater ease of administration (Connolly and Thase, 2011). 
Additional randomised, placebo controlled trials are needed in order to evaluate 
the efficacy of lithium or thyroid hormone in patients who have not responded to 
first-line SSRI treatment (Connolly and Thase, 2011).  
Atypical antipsychotic drugs, such as olanzapine, risperidone, quetiapine and 
aripiprazole, have also been reported to be effective augmentation agents in major 
depressive disorder (Nelson and Papakostas, 2009; Connolly and Thase, 2011). 
Atypical antipsychotics are pharmacologically diverse, with each drug having a 
distinct and complex set of receptor affinities involving dopaminergic and 
serotonergic receptors, in addition to varying effects on noradrenergic, 
histaminergic and cholinergic systems (Papakostas and Shelton, 2008).The 
proposed neuropharmacological rationale underlying the use of antipsychotic drugs 
as adjunctive agents in TRD involves their effects on various serotonin receptors, in 
particular antagonism of the 5-HT2 receptor (Papakostas and Shelton, 2008). A 
meta-analysis revealed that these agents are equally efficacious as each other as 
adjunctive agents in TRD (Nelson and Papakostas, 2009). Moreover, the evidence 
supporting their efficacy is more robust than that of lithium or T3 (Nelson and 
Papakostas, 2009). However, these atypical antipsychotic agents are associated 
with an increased risk of discontinuation due to adverse events, meaning that other 
strategies are often preferred (Nelson and Papakostas, 2009). The evidence 
supporting the efficacy other putative augmentation agents, such as buspirone, 
pindolol and psychostimulants is less than convincing (Connolly and Thase, 2011). 
In addition to augmentation, other commonly used strategies in cases of failure to 
respond to initial antidepressant treatment involve switching to another 
antidepressant drug or concurrent treatment with a combination of different 
antidepressants. While the switching approach no doubt represents a good clinical 
option, there is insufficient data to suggest that any antidepressant has a unique 
therapeutic advantage compared to others in SSRI non-response (Connolly and 
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Thase, 2011). Additional studies are needed to address this question. Similarly, the 
use of antidepressant combination therapy in non-response is understudied, 
although available data suggest that addition of mirtazapine or mianserin to SSRI 
treatment may prove to be useful in this regard (Connolly and Thase, 2011). 
As mentioned in Section 1.4.1, increasing recent evidence suggests that sub-
anaesthetic doses of ketamine may represent a potentially rapid and effective 
option in TRD (Berman et al., 2000; Zarate et al., 2006). However, certain questions 
remain to be answered before this approach is adopted into widespread clinical 
practice (Rush, 2013). Given the restrictive inclusion criteria employed in studies to 
date, whether or not these promising findings will generalize to wider populations 
of depressed patients remains unclear. Moreover, the medium-to-long term 
management required to maintain remission in ketamine-treated patients is not yet 
known. The abuse potential and side effects associated with ketamine also 
represent substantial drawbacks. Identification of the molecular pathways 
responsible for the antidepressant action of ketamine and the potential 
development of more specific, non-psychomimetic, drugs targeting these pathways 
offers hope for the future (Cryan and O'Leary, 2010). Promisingly, a novel NMDAR 
glycine-site functional partial agonist, GLYX-13, has been reported to elicit 
antidepressant-like effects in rodent models of depression, without exhibiting 
substance abuse-related or sedative side effects associated with ketamine, and is 
now undergoing Phase II clinical development programme for TRD (Burgdorf et al., 
2013). 
Other, non-pharmacological, strategies to combat TRD include vagus nerve 
stimulation, deep brain stimulation in the subgenual cingulate region of the brain, 
transcranial magnetic stimulation and electroconvulsive therapy(Holtzheimer and 
Mayberg, 2011). These approaches are reserved for severe cases of TRD, and vary 
in terms of their efficacy, with none representing a panacea in the treatment of 
depression (Holtzheimer and Mayberg, 2011). 
In summary, TRD remains a considerable clinical problem. Despite the limitations of 
the monoamine hypothesis of depression, attempts to develop improved 
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pharmacological treatment strategies based on novel mechanisms have yet to bear 
fruit (Holtzheimer and Mayberg, 2011). Further research is required to attain a 
greater understanding of the reasons why some patients respond to antidepressant 
treatment while others do not, and to develop novel approaches to overcome TRD. 
1.4.5. Animal models of depression and antidepressant-like 
activity 
One of the major challenges in elucidating the neurobiological mechanisms 
underlying depression and in developing novel treatment strategies for this 
disorder is the generation of satisfactory in vivo model systems in which to explore 
these issues (Cryan and Holmes, 2005; O'Leary and Cryan, 2013). Due to practical 
and ethical limitations, conducting studies in humans to further our knowledge of 
the neurobiology of depression is difficult. Thus, translational animal models are 
vital to develop a greater understanding of the disorder (Berton et al., 2012; 
O'Leary and Cryan, 2013). Furthermore, owing to the prohibitively large cost of 
clinical trials in pharmaceutical development, it is essential to have valid preclinical 
animal models to evaluate the potential efficacy of novel antidepressants prior to 
taking the decision to progress to clinical studies (Cryan and Holmes, 2005). 
Despite difficulties in reproducing a complex human neuropsychiatric disorder like 
depression in lower species, it is possible to model certain symptoms associated 
with human depression in rodents (Table 1.6). For example, symptoms such as 
anhedonia, weight/appetite changes, sleep disturbances and disrupted cognitive 
performance can all be modelled in rodents. More complex psychological 
symptoms, such as suicidal thoughts or feelings of worthlessness/guilt, cannot be 
modelled, however (Cryan and Holmes, 2005). Thus, it is not possible to fully 
recapitulate human depression in rodents, and it is necessary to avoid the pitfall of 
anthropromorphization of emotion-related behaviours in such lower species, 
especially in light of the substantial differences in brain anatomy between humans 
and rodents (Cryan and Holmes, 2005; O'Leary and Cryan, 2013).  
Moreover, the symptomatic heterogeneity of depression needs to be borne in mind 
when discussing animal models of depression (Berton et al., 2012). Anhedonia, for 
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example, is only present in approximately 50% of depressed patients (Berton et al., 
2012). An animal model of depression involves an inducing manipulation, such as 
stress, resulting in a behavioural or neurobiological readout (O'Leary and Cryan, 
2013). Thus, animal ‘models’ of depression which are based on particular individual 
behaviours reflecting depressive symptomatology, such as anhedonia, may be more 
accurately considered as ‘tests’ of depressive-like behaviours or of antidepressant-
like activity rather than models per se (O'Leary and Cryan, 2013). 
Despite their limitations, the use of rodent models of depression, in particular those 
involving transgenic mice, have helped to facilitate investigations of systems 
thought to be involved in depression (Cryan and Mombereau, 2004; Cryan and 
Holmes, 2005). The minimum requirements for a valid animal model of depression, 
as proposed by McKinney and Bunney (1969), are that: the symptomatology or 
manifestations are ‘reasonably analogous’ to human depression; behavioural 
changes are amenable to objective monitoring; behavioural changes are reversible 
by treatment with clinically effective antidepressant drugs; the model is 
reproducible between investigators. While these requirements act as a worthwhile 
guide in the development of animal models of depression, the need for behavioural 
changes to be reversible by clinically effective antidepressant treatments may have 
resulted in a circular situation whereby these models are primarily effective in the 
identification of novel treatments which act via the same mechanisms as already 
available antidepressants (Krishnan and Nestler, 2008). This may, in turn, have 
contributed to difficulties in successfully identifying novel treatment approaches. 
Furthermore, many compounds which have displayed antidepressant-like activity in 
rodent models of depression have not proven to be clinically useful (O'Leary and 
Cryan, 2013). Nonetheless, animal models of depression and antidepressant-like 
activity represent valuable research tools, and several such models are in use today 
(Table 1.9). 
Two of the most commonly used and conceptually similar, but not synonymous, 
rodent models of depression and antidepressant-like activity are the forced swim 
test (FST, which can be performed in rats or mice) and the tail suspension test (TST, 
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which is generally only performed in mice) (Cryan and Mombereau, 2004; Cryan 
and Holmes, 2005; O'Leary and Cryan, 2013). These so-called ‘behavioural despair’ 
tests, in which rodents are placed in an inescapable cylinder of tepid water or 
suspended upside-down by the tail, respectively, are based on the principle that the 
rodents will initially engage in vigorous, but futile, escape-oriented movements, 
followed by increasing bouts of passive immobility (Cryan and Holmes, 2005). 
Administration of various clinically effective antidepressant treatments (both 
pharmacological and non-pharmacological) prior to either the FST or TST prolong 
the duration of escape-oriented activity, with a corresponding reduction in passive 
immobility (Cryan and Holmes, 2005). Furthermore, factors which are implicated in 
depression, including genetic predisposition and exposure to stress, alter 
immobility behaviour in these tests (Cryan and Mombereau, 2004; Cryan and 
Holmes, 2005).  
Originally described as ‘behavioural despair’ (Porsolt et al., 1977a; Porsolt et al., 
1977b), the precise meaning of immobility and its relevance to depression in these 
tests is controversial (Cryan and Mombereau, 2004). Given that immobility in the 
TST or FST appears to be due to an inability or reluctance to maintain effort, as 
opposed to a manifestation of generalised hypoactivity, it is tempting to speculate 
that it may be analogous to psychomotor impairments commonly seen in 
depressed patients (as listed in Table 1.6) (Cryan and Holmes, 2005). Another 
source of contention in relation to the FST and TST is the criticism that they are 
sensitive to acute antidepressant administration, rather than the chronic treatment 
required to elicit a clinical response (as discussed in Section 1.4.2), thereby 
suggesting that they may not act via the same long-term adaptive mechanisms that 
result in antidepressant effects in humans (Cryan and Holmes, 2005). 
Notwithstanding these criticisms, the FST and TST remain useful tools in 
depression-related research, in particular when it comes to assessing strategies to 
increase the pharmacodynamic activity of existing antidepressant treatments. 
While the FST and TST are similar in their underlying principles and the main 
behavioural readout, there are some key differences between the two paradigms 
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which warrant discussion (Cryan et al., 2005a). The TST avoids possible confounding 
contribution of hypothermic exposure and swimming capability (which can be an 
issue for some mouse strains) as encountered in the FST. Furthermore, the pattern 
of immobility differs between the two tests: in the FST animals engage in rapid 
bouts of active behaviour, with immobility only emerging after the second minute 
of the test. Contrastingly, in the TST animals can become immobile much earlier 
during testing, but do not remain immobile for periods as long as those 
encountered in the FST (Cryan et al., 2005a). Moreover, the two tests offer 
differential sensitivity and divergent dose-response curves: whereas the FST may 
not be consistently sensitive in detecting SSRI activity, the TST generally is (Cryan et 
al., 2005a). Furthermore, genetic knockout of the GABAB receptor induces an 
antidepressant effect in the FST, but not the TST (Mombereau et al., 2004). 
Other animal models of depression include the learned helplessness (LH) and 
chronic mild stress (CMS) models, both of which are based on the concept of 
maladaptive coping responses to uncontrollable stresses (Cryan and Holmes, 2005; 
O'Leary and Cryan, 2013), and the olfactory bulbectomy (OB) model (Song and 
Leonard, 2005). Chronic treatment with antidepressant drugs reverses some of the 
behavioural deficits in these models, thus providing pharmacological validity (Cryan 
and Holmes, 2005; Song and Leonard, 2005). In particular, the CMS and OB models 
result in behavioural, neurochemical, neuroimmune and neuroendocrine 
alterations resembling those seen in depressed patients, some of which are 
responsive only to chronic, but not acute, antidepressant treatment (Cryan and 
Holmes, 2005; Song and Leonard, 2005). 
Additional paradigms, such as the sucrose preference test or intracranial self-
stimulation can be employed to investigate depression-related behaviours (Cryan 
and Holmes, 2005). These tests are useful in assessing anhedonic aspects of animal 
models of depression, such as LH, CMS and OB listed above. 
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Table 1.9: Current rodent models used in depression research (adapted from O'Leary and Cryan, 2013) 
Model Description 
Acute stress-based models 
Forced swim test (FST) When placed in an inescapable container of water, rats and mice will adopt an immobile posture; the duration of immobility is 
reduced by antidepressant treatment 
Modified FST As per FST, but swimming and climbing behaviours are assessed, in addition to immobility. Serotonergic antidepressants increase 
swimming behaviour, whereas noradrenergic antidepressants increase climbing behaviour. Most commonly employed in rats. 
Tail suspension test 
(TST) 
When suspended from a bar by the tail, mice will adopt an immobile posture. Like the FST, the duration of immobility is reduced 
by antidepressant treatment. 
Chronic stress-based models 
Maternal separation When separated from their mother during early postnatal life, rodents (mainly rats) can develop depression-like phenotypes in 
adulthood. 
Prenatal stress Exposure to a stressor during pregnancy induces depression-like behaviour and persistent physiological changes in the offspring. 
Unpredictable chronic 
mild stress  
Rodents are exposed to a variety of unpredictable stressors, resulting in depressive-like behaviours, which are prevented by 
antidepressant treatment. 
Social defeat stress Exposure to a novel, aggressive counterpart on a daily basis, with repeated defeat, evokes depression-like behaviours in the test 
subject. In particular, the test subject displays social avoidance behaviours when put in contact with an unfamiliar counterpart, 
and this is reversed by chronic antidepressant treatment 
Learned helplessness Rodents subjected to repeated inescapable shocks subsequently do not escape when given the opportunity, an effect reduced by 
chronic antidepressant treatment. 
Genetic predisposition studies 
Selective breeding  Independent lines of mice and rats that differ in depression-like phenotype have been generated by selective breeding based on 
depressive-like behaviours, for example Flinders sensitive line (FSL) rats and Rouen helpless mice 
Strain differences Various strains of mice and rats have been reported to exhibit differential responses in various models of depression and 
antidepressant-like activity 
Directed gene targeting Genetically modified mice have been generated with disrupted expression of proteins thought to play a role in depression 
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Model Description 
Dysfunction of limbic circuitry 
Olfactory bulbectomy 
(OB) 
Removal of the olfactory bulbs in rodents results in various neurochemical and behavioural alterations, which are reversed by 
chronic antidepressant treatment. 
Focal lesions Transient inactivation of the rat infralimbic cortex has antidepressant-like effects 
Optogenetics Inhibition or activation of specific groups of neurons in limbic areas of the brain have differential effects on depression-like 
behaviours 
Other 
Drug withdrawal In rodents, amphetamine withdrawal is characterised by anhedonia, learned helplessness and increased immobility in the FST 
and TST. 
Neonatal drug 
treatment 
Neonatal administration of clomipramine induces various depression-like behaviours in adulthood 
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1.4.6. P-gp expression and activity in depression 
A PET study using 11C-verapamil has shown that P-gp function is increased in 
patients with major depression receiving antidepressant treatment (de Klerk et al., 
2009). Using this technique, cerebral volume of distribution of 11C-verapamil, which 
is a transported P-gp substrate, was used as a surrogate measure of P-gp function. 
The reason for increased P-gp function in medicated depressed patients has not 
been fully elucidated, but there are several potential explanations that warrant 
further investigation.  
Firstly, it may be due to P-gp induction by chronic antidepressant treatment itself, 
and therefore not be related to the disease per se, as it is known that treatment 
with xenobiotics can increase P-gp expression (Bauer et al., 2004; Narang et al., 
2008). This theory is supported by both in vitro and in vivo studies demonstrating 
induction of P-gp by the antidepressant venlafaxine (Ehret et al., 2007; de Klerk et 
al., 2010).   
Secondly, various cytokines increase the expression and activity of P-gp in vitro 
(Bauer et al., 2007; Yu et al., 2007; Liptrott et al., 2009) and immune activation, 
with correspondingly increased circulating cytokine levels, has been widely 
reported in at least a subset of depressed patients (Schiepers et al., 2005; Dinan, 
2009). Therefore, immune activation may contribute to the increased P-gp function 
observed in medicated depressed patients. However, P-gp activity, as measured by 
the cerebral volume of distribution of 11C-verapamil, was reduced in rats which 
were subjected to chronic foot-shock stress as a model of human depression (de 
Klerk et al., 2010). This increase in the cerebral volume of distribution of 11C-
verapamil may be reflective of stress-mediated disruption of the BBB through non-
P-gp-mediated mechanisms, however, as no other marker was used to verify the 
integrity of the BBB independent of P-gp. In addition, the translational value of this 
rat model to processes ongoing at the BBB in depressed patients is unclear.  
Finally, functional SNPs in the ABCB1 gene may explain the altered P-gp activity 
observed in depressed patients. Indeed, certain uncommon polymorphisms in 
ABCB1 were linked to the severity of depressive symptoms in a cohort of Taiwanese 
Chapter 1: General Introduction 
 
68 
depressed patients (Lin et al., 2011). The functional impact of these particular 
polymorphisms has not yet been characterised, however. It would be of interest to 
conduct a PET study in a similar group of patients to determine if BBB P-gp function 
is related to genotype. 
1.5. Interactions between P-gp and antidepressant drugs at the 
BBB 
Antidepressant drugs need to penetrate the BBB to reach their site of action within 
the brain. Therefore, it has been suggested that drug efflux by P-gp at the BBB may 
contribute to the high prevalence of TRD. Indeed, many antidepressant drugs 
interact with P-gp in vitro and in vivo, both as substrates and inhibitors. These 
interactions have been postulated to be of clinical importance, as P-gp efflux would 
limit the distribution of these drugs in to the brain, thereby potentially resulting in 
sub-therapeutic target-site concentrations (Loscher and Potschka, 2005b) (Figure 
1.13). Interestingly, it has also been hypothesized that inhibition of P-gp may, in 
fact, be involved in the mechanism of action of antidepressant drugs (Pariante et 
al., 2004), as discussed in detail in Section 1.5.7. 
1.5.1. In vitro studies investigating the transport of 
antidepressants by P-gp 
Assays to identify P-gp inhibitors are generally more cost-effective and less labour-
intensive than studies aimed at identifying transported P-gp substrate. Therefore, 
the majority of in vitro studies investigating interactions between antidepressant 
drugs and-P-gp to date have focused on P-gp inhibition by antidepressants. 
However, a small number of studies using bidirectional transcellular transport 
assays (Rochat et al., 1999; Mahar Doan et al., 2002; Faassen et al., 2003; El Ela et 
al., 2004; Maines et al., 2005), the ATPase assay (Ejsing et al., 2006; Wang et al., 
2008) or both (Feng et al., 2008) have been conducted.  
Table 1.10 presents a summary of the available in vitro data on antidepressants as 
P-gp substrates. Column 2 indicates the conclusions drawn by the studies’ authors, 
and it is important to be aware that the interpretation of results may differ 
between groups. 
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Table 1.10: In vitro studies investigating if various antidepressants are substrates of P-gp 
Antidepressant 
P-gp substrate / 
interaction? 
Transport ratio ATPase Km (µM) Model Ref 
Bidirectional Transport Studies 
Amitriptyline N 1.34 n/a MDCK-MDR1 Mahar Doan et al., 2002 
 Y 4.51 n/a Caco-2 Faassen et al., 2003 
Citalopram N 1 1.6 n/a MDCK-MDR1 Feng et al., 2008 
 N 2 1.2 n/a MDCK-mdr1a Feng et al., 2008 
 N 1.1 n/a BMEC monolayer Rochat et al., 1999 
Clomipramine N 1.42 n/a MDCK-MDR1 Mahar Doan et al., 2002 
Desipramine N 1.03 n/a MDCK-MDR1 Mahar Doan et al., 2002 
 Y 3.983 n/a Caco-2 Faassen et al., 2003 
Doxepin N 1.15 n/a MDCK-MDR1 Mahar Doan et al., 2002 
Fluoxetine N 1.18 n/a MDCK-MDR1 Mahar Doan et al., 2002 
 N 1 0.5 n/a MDCK-MDR1 Feng et al., 2008 
 N 2 0.6 n/a MDCK-mdr1a Feng et al., 2008 
Fluvoxamine N 1.2 n/a MDCK-MDR1 Mahar Doan et al., 2002 
 N 1 0.9 n/a MDCK-MDR1 Feng et al., 2008 
 N 2 0.8 n/a MDCK-mdr1a Feng et al., 2008 
 Y 1.26 n/a Caco-2  El Ela et al., 2004 
Imipramine N 1.05 n/a MDCK-MDR1 Mahar Doan et al., 2002 
 Y 6.04 n/a Caco-2 Faassen et al., 2003  
Nortriptyline N 1.39 n/a MDCK-MDR1 Mahar Doan et al., 2002 
 N 1 1.1 n/a MDCK-MDR1 Feng et al., 2008 
 N 2 0.9 n/a MDCK-mdr1a Feng et al., 2008 
Paroxetine N 1 1 n/a MDCK-MDR1 Feng et al., 2008 
 N 2 1 n/a MDCK-mdr1a Feng et al., 2008 
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Antidepressant 
P-gp substrate / 
interaction? 
Transport ratio ATPase Km (µM) Model Ref 
Paroxetine (contd) N n/a n/a B(ovine)R(etinal)EC Maines et al., 2005 
Protriptyline Y 2 n/a MDCK-MDR1 Mahar Doan et al., 2002 
Sertraline N 1 0.4 n/a MDCK-MDR1 Feng et al., 2008 
 N 2 0.5 n/a MDCK-mdr1a Feng et al., 2008 
Trazodone N 0.94 n/a MDCK-MDR1 Mahar Doan et al., 2002 
Trimipramine N 0.92 n/a MDCK-MDR1 Mahar Doan et al., 2002 
Venlafaxine N 1 0.9 n/a MDCK-MDR1 Feng et al., 2008 
 N 2 1 n/a MDCK-mdr1a Feng et al., 2008 
ATPase assay 
Bupropion N n/a 2676 ATPase assay Wang et al., 2008 
→EB N n/a 109.3 ATPase assay Wang et al., 2008 
→HB N n/a 318.2 ATPase assay Wang et al., 2008 
→TB N n/a 2066 ATPase assay Wang et al., 2008 
Citalopram Low n/a 441 ± 140.1 ATPase assay Feng et al., 2008 
Fluoxetine Low n/a 51.6 ± 11.81 ATPase assay Feng et al., 2008 
Fluvoxamine Low n/a 180 ± 35.7 ATPase assay Feng et al., 2008 
Nortriptyline Y n/a 257.6 ATPase assay Ejsing et al., 2006 
 Low n/a 56.0 ± 15.73 ATPase assay Feng et al., 2008 
Paroxetine Moderate n/a 26.2 ± 1.02 ATPase assay Feng et al., 2008 
Sertraline High n/a 9.4 ± 1.45 ATPase assay Feng et al., 2008 
 Y n/a 4.7 ATPase assay Wang et al., 2008 
→Desmethylsert Y n/a 6.5 ATPase assay Wang et al., 2008 
Venlafaxine N n/a Neg ATPase assay Feng et al., 2008 
Km = Michaelis constant (substrate concentration at which the reaction rate is half of its maximum value) 
1, 2 Cut-off for significance: 1 1.7 or 2 1.5 (based on retrospective statistical analysis of inter-week system variability control data) 
3 Note very high donor concentration (1 mM); → denotes a metabolite 
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Of the antidepressants tested in transcellular transport assays to date, only 
protriptyline has been identified as a modest P-gp substrate, while conflicting 
findings have been reported in relation to amitriptyline, imipramine and 
fluvoxamine (Mahar Doan et al., 2002; Faassen et al., 2003; El Ela et al., 2004; Feng 
et al., 2008). However, the studies reporting positive findings in relation to 
amitriptyline, imipramine and fluvoxamine involved the use of the Caco-2 cell line, 
which expresses several other efflux and uptake transporters in addition to P-gp 
(Taipalensuu et al., 2001). Further experiments, to confirm that P-gp was the 
transporter responsible for the elevated TR observed in Caco-2 cells, were not 
conducted (Faassen et al., 2003; El Ela et al., 2004), thereby rendering the findings 
in relation to P-gp inconclusive. Similarly, there were limitations associated with the 
studies reporting negative findings. For example, it has recently been shown that 
transfection with ABCB1 in MDCK-MDR1 cells reduces the expression of 
endogenous canine P-gp relative to the wildtype MDCK cells (Kuteykin-Teplyakov et 
al., 2010). This finding may have implications for the interpretation of results from 
many of the studies reporting negative findings, which were based on the 
assumption that endogenous drug transporter expression would be the same for 
wild-type and transfected cells. 
In studies involving the ATPase assay, the SSRIs sertraline and paroxetine were 
identified as high- and moderate-affinity P-gp substrates, respectively, while the 
Michaelis constant (Km) values for nortriptyline and fluoxetine narrowly exceeded 
the threshold set for moderate-affinity (Feng et al., 2008). However, the ATPase 
assay does not determine if compounds are actually transported by P-gp. Thus, 
based on the available data from in vitro studies, it seems that some 
antidepressants interact with P-gp in vitro, but none have been robustly identified 
as high affinity P-gp substrates which are subjected to P-gp mediated transport in 
bidirectional transcellular transport assays. 
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1.5.2. In vitro studies investigating the inhibition of P-gp by 
antidepressants 
Several antidepressants inhibit P-gp in vitro (Table 1.11). In Table 1.11, it is worth 
noting that the data in the second column represent the conclusions drawn by the 
specific authors of the individual studies. Again, it must be noted that the 
interpretation of results may differ from group to group.  
Interestingly, the level of P-gp inhibition observed for several of these 
antidepressants was similar to that of established P-gp inhibitors, such as verapamil 
and quinidine (Szabo et al., 1999; Weiss et al., 2003; Feng et al., 2008). For 
example, the concentration required to reduce P-gp activity by 50% (IC50) for 
paroxetine (29.8µM) and sertraline (31.8 µM) is similar to that of quinidine (33.8 
µM) (Weiss et al., 2003). It should be noted, however, that these antidepressant 
concentrations are 250- and 500-fold higher than normal therapeutic plasma levels 
for paroxetine and sertraline respectively (Weiss et al., 2003). However, post-
mortem studies have demonstrated high brain-to-plasma concentration ratios for 
certain antidepressants (Pariante, 2008), and neuroimaging studies of fluorine-
containing antidepressants have revealed steady-state brain concentrations in the 
micromolar range (Bolo et al., 2000). Moreover, P-gp inhibition by sertraline has 
been demonstrated in vivo (Wang et al., 2006a). Nonetheless, it remains uncertain 
if P-gp-inhibitory concentrations of paroxetine or sertraline are reached at the BBB 
in clinical use. 
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Table 1.11: In vitro studies investigating if various antidepressants are inhibitors of P-gp 
Antidepressant 
P-gp 
inhibitor? 
IC50 (µM) Model Ref 
Amitriptyline Y n/a R123 uptake in Caco-2 cells Ibrahim et al., 2000 
 Y n/a R123/daunorubicin cellular uptake Szabo et al., 1999 
 Y n/a R123 efflux  Varga et al., 1996 
Citalopram Y 52.5 Calcein-AM transport in MDCK-MDR1 cells Feng et al., 2008 
Clomipramine Y n/a R123 uptake in Caco-2 cells Ibrahim et al., 2000 
 Y n/a Cell-line susceptibility to P-gp-substrate cytotoxics Jaffrezou et al., 1995 
 Y n/a Cell-line susceptibility to P-gp-substrate cytotoxics Merry et al., 1991 
Desipramine Y n/a R123 uptake in Caco-2 cells Ibrahim et al., 2000 
 Y n/a Cell-line susceptibility to P-gp-substrate cytotoxics Jaffrezou et al., 1995 
 Y n/a R123/daunorubicin cellular uptake Szabo et al., 1999 
Doxepin Y n/a R123 uptake in Caco-2 cells Ibrahim et al., 2000 
 Y n/a R123/daunorubicin cellular uptake Szabo et al., 1999 
Fluoxetine Y 31 Calcein-AM transport in MDCK-MDR1 cells Feng et al., 2008 
 Y n/a Digoxin uptake in Caco-2 cells Pariante et al., 2003b 
 Y 115.5 ± 11.7  Calcein-AM transport in L-MDR1 and pBCEC cells Weiss et al., 2003 
Fluvoxamine N > 100 Calcein-AM transport in MDCK-MDR1 cells Feng et al., 2008 
 ? 146.7 ± 1.95 Talinolol transport in Caco-2 cells El Ela et al., 2004 
Imipramine Y n/a R123 uptake in Caco-2 cells Ibrahim et al. 2000 
 Y n/a Cell-line susceptibility to P-gp-substrate cytotoxics Jaffrezou et al. 1995 
 Y n/a R123/daunorubicin cellular uptake Szabo et al. 1999 
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Antidepressant 
P-gp 
inhibitor? 
IC50 (µM) Model Ref 
Maprotiline Y n/a R123/daunorubicin cellular uptake Szabo et al. 1999 
Mianserin Y n/a Cell-line susceptibility to P-gp-substrate cytotoxics Jaffrezou et al. 1995 
Nefazodone Y 4.7 R123 uptake in Caco-2 cells Stormer et al. 2001 
Nortriptyline N > 100 Calcein-AM transport in MDCK-MDR1 cells Feng et al. 2008 
 N n/a R123 uptake in Caco-2 cells Ibrahim et al. 2000 
Paroxetine Y 27.5 Calcein-AM transport in MDCK-MDR1 cells Feng et al. 2008 
 Y n/a  [3H]Taxol uptake in bovine retinal endothelial cells Maines et al. 2005 
 Y 29.8 ± 11.1 Calcein-AM transport in L-MDR1 and pBCEC cells Weiss et al. 2003 
Protriptyline Y n/a R123 uptake in Caco-2 cells Ibrahim et al. 2000 
Sertraline Y 30 Calcein-AM transport in MDCK-MDR1 cells Feng et al. 2008 
 Y 31.8 ± 2.8 Calcein-AM transport in L-MDR1 and pBCEC cells Weiss et al. 2003 
Trazodone N n/a R123 uptake in Caco-2 cells Stormer et al. 2001 
Trimipramine Y n/a R123 uptake in Caco-2 cells Ibrahim et al. 2000 
 Y n/a Cell-line susceptibility to P-gp-substrate cytotoxics Jaffrezou et al. 1995 
 Y n/a R123/daunorubicin cellular uptake Szabo et al. 1999 
Venlafaxine N > 100 Calcein-AM transport in MDCK-MDR1 cells Feng et al. 2008 
Selected prototypical P-gp inhibitors 
Quinidine Y 30.2 Calcein-AM transport in MDCK-MDR1 cells Feng et al. 2008 
 Y 33.8 ± 11.9 Calcein-AM transport in L-MDR1 and pBCEC cells Weiss et al. 2003 
Verapamil Y 18.1 Calcein-AM transport in MDCK-MDR1 cells Feng et al. 2008 
 Y 18.9  ± 4.2 Calcein-AM transport in L-MDR1 and pBCEC cells Weiss et al. 2003 
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1.5.3. Limitations of in vitro studies investigating interactions 
between P-gp and antidepressant drugs 
It is important to consider the limitations of these in vitro studies investigating 
interactions between P-gp and antidepressant drugs; different studies have used 
the same assay for the same compound and reported contrasting results. 
Furthermore, different groups offer different interpretations of results, with 
contrasting cut-off values for significance.  
For example, the determined Km value for nortriptyline differed greatly between 
two studies using the same assay (ATPase), 257.6 µM (Ejsing et al., 2006) versus 56 
± 15.73 µM (Feng et al., 2008). Furthermore, the interpretation of these results 
conflicted between the two groups. Despite the fact that a lower Km value 
correlates with a stronger interaction, Ejsing and co-workers concluded that their 
findings confirmed an interaction which may be of clinical significance between 
nortriptyline and P-gp, while Feng and colleagues suggest that any such interaction 
is of minimal significance as they classified nortriptyline as a low-affinity P-gp-
substrate. Similarly discrepant findings were obtained in relation to the P-gp-
substrate status of amitriptyline, imipramine and fluvoxamine by different groups 
using transwell assay systems (Mahar Doan et al., 2002; Faassen et al., 2003; El Ela 
et al., 2004; Feng et al., 2008).  
Additionally, in P-gp-inhibition studies there was a marked contrast in the reported 
IC50 values for fluoxetine, 31 µM (Feng et al., 2008) versus 115.5 ± 11.7 µM (Weiss 
et al., 2003), while reported values for paroxetine and sertraline were in quite close 
agreement between the same two studies. Thus, it can be difficult to draw 
definitive conclusions from in vitro P-gp studies due to the discrepancies in results 
obtained depending on assay used and numerous other potential confounding 
factors. As a result, there remains a demand for the development of a validated and 
highly reliable predictive screening model for the accurate identification of P-gp 
substrates and inhibitors in vitro (von Richter et al., 2009).  
In addition to the discordance in results obtained from different in vitro studies, 
there has been disagreement between in vitro and in vivo findings regarding the P-
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gp-substrate status of certain antidepressant drugs. For example, citalopram 
(Rochat et al., 1999; Feng et al., 2008) and paroxetine (Maines et al., 2005; Feng et 
al., 2008) were found not to be P-gp-substrates in various cell culture models. 
However, in vivo studies using P-gp knockout mice have demonstrated increased 
brain/plasma concentration ratios in knockout mice relative to wild-type controls 
for both drugs (see Section 1.5.4), thus suggesting that they are P-gp substrates at 
the BBB in vivo (Uhr and Grauer, 2003; Uhr et al., 2003; Doran et al., 2005; Uhr et 
al., 2008). These differences may be as a result of a failure of in vitro systems to 
adequately reflect the complexity of the BBB in vivo, and therefore highlight the 
difficulty in achieving acceptable correlations between in vitro and in vivo data in 
relation to drug transport across the BBB (Avdeef, 2011), thus calling the relevance 
of any of these in vitro assays into question. As P-gp extrudes its substrates directly 
from the inner leaflet of the cellular membrane bilayer, the properties of the 
membrane used in in vitro studies impact considerably on interactions between P-
gp and the compound being tested (Romsicki and Sharom, 1999). Therefore, the 
use of epithelial cell lines such as Caco-2 and MDCK-MDR1 to predict interactions 
between drugs and P-gp expressed at the endothelial BBB in vivo may not be 
appropriate. To date, the use of BBB-derived endothelial cell lines in this regard has 
been limited, primarily due to the leakiness of such cell lines when cultured as 
monolayers in vitro (Avdeef, 2011). Alternatively, the discrepancies observed 
between in vitro and in vivo studies may highlight important species differences 
between substrate specificity of human (as measure in in vitro studies) and rodent 
P-gp, or false assumptions relating to results derived from knockout mice. Indeed, 
the relevance of marginally increased brain/plasma ratios in knockout mice, relative 
to controls, has been questioned (Feng et al., 2008). 
1.5.4. In vivo studies involving P-gp knockout rodents 
Several studies using P-gp knockout mouse models, and a recent study using P-gp 
knockout rats (Bundgaard et al., 2012), have determined that P-gp plays a major 
role in the brain penetration of several antidepressants (Table 1.12) (Uhr et al., 
2000; Uhr and Grauer, 2003; Uhr et al., 2003; Grauer and Uhr, 2004; Doran et al., 
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2005; Uhr et al., 2007; Uhr et al., 2008; Karlsson et al., 2010; Karlsson et al., 2011).It 
is important to note that the majority of studies using the P-gp knockout mouse 
models in this regard have involved acute antidepressant administration. As 
antidepressant drugs are administered chronically in clinical practice, studies 
investigating the impact of P-gp ablation on the brain distribution of antidepressant 
drugs and their metabolites following chronic administration would be of greater 
value. 
Interestingly, many of the identified P-gp-substrate-antidepressants are structurally 
unrelated and come from a variety of drug classes: including SSRIs, TCAs and SNRIs. 
Not all drugs from the same class behave similarly, however: sertraline, another 
SSRI for example, is not a P-gp substrate (Doran et al., 2005).  
Amitriptyline was found to have significantly higher brain concentrations in mice 
deficient in P-gp than in wild-type controls one hour after acute administration (Uhr 
et al., 2000). However, later studies determined that this effect was transient and 
dependent on the dosing regimen and/or the route of administration (Grauer and 
Uhr, 2004; Uhr et al., 2007). Thus, the relevance of P-gp to the CNS 
pharmacokinetics of amitriptyline following chronic administration and at steady 
state conditions is uncertain. While the exact reason for this phenomenon is 
unclear, a number of theories have been proposed (Uhr et al., 2007). For example, 
it is postulated that amitriptyline may induce changes at the BBB itself or that P-gp 
may become oversaturated with time, as certain amitriptyline metabolites are also 
P-gp substrates. Furthermore the original study used single knockout abcb1a(-/-) 
mice (Uhr et al., 2000), while subsequent studies used double knockout abcb1ab(-/-) 
mice (Grauer and Uhr, 2004; Uhr et al., 2007). Thus, the contrasting findings of the 
two studies may be explained by differences between single knockout abcb1a(-/-) 
mice and double knockout abcb1ab(-/-) mice. 
Similarly, there is also a lack of clarity in the literature regarding the status of 
fluoxetine as a P-gp substrate in vivo (Uhr et al., 2000; Doran et al., 2005). The 
original study, using single knockout abcb1a(-/-) mice, found no difference between 
the accumulation of fluoxetine in the brains of abcb1a(-/-) mice and wild type 
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controls (Uhr et al., 2000). A subsequent study, however, found increased levels of 
fluoxetine in double knockout abcb1ab(-/-) mice relative to wild type controls (Doran 
et al., 2005). Taken together, these data suggest that the brain pharmacokinetics of 
certain compounds may differ between single knockout abcb1a(-/-) mice and double 
knockout abcb1ab(-/-) mice. Indeed, a recent study has also reported that the BBB 
transport of glucocorticoids differs between single and double P-gp knockout mice 
(Mason et al., 2012). Furthermore, the data from Uhr and co-workers is from a 
single time point (one hour) following fluoxetine administration (Uhr et al., 2000); 
Doran and colleagues, on the other hand, took samples at various time points 
(Doran et al., 2005). Therefore, the impact of P-gp on fluoxetine distribution may be 
time-dependent. 
In addition to investigating the impact of P-gp ablation on venlafaxine 
pharmacokinetics, Karlsson and co-workers looked at differences in behavioural 
responses to subchronic venlafaxine treatment between wild-type and P-gp 
knockout mice (Karlsson et al., 2011). Chronic treatment with venlafaxine affected 
behaviour in the open field, with increased time spent in the centre of the arena 
and a reduced number of rears associated with venlafaxine treatment. 
Interestingly, this pharmacodynamic effect was more pronounced in P-gp knockout 
mice than wild-type controls after 7 days of venlafaxine treatment. The difference 
between the two strains was attenuated after 9 days of treatment, which may have 
been due to habituation associated with repeated testing in the open field (Thiel et 
al., 1999). While pharmacodynamic differences between P-gp knockout and wild-
type mice have previously been demonstrated following treatment with the 
antipsychotic drug, risperidone (Kirschbaum et al., 2008), this remains the only 
study demonstrating pharmacodynamic differences between the strains in 
response to treatment with an antidepressant drug, and for this reason it is 
important. However, the relevance of behaviour in the open field to antidepressant 
treatment is unclear, and future studies in this area should focus on behavioural 
pharmacodynamic readouts in established animal models of depression, such as the 
forced swim test and tail suspension test (Cryan and Holmes, 2005). 
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Table 1.12: In vivo studies in P-gp knock-out rodents investigating if various antidepressants are P-gp substrates at the BBB 
Antidepressant Dose Class Samples taken Brain/Plasma Conc. Sig Model Ref 
WT KO KO/WT 
Amitriptyline 10 mg/kg s.c. TCA 30 min post-
injection 
8.1 8.0 1.0 3 ns female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 10 mg/kg s.c. TCA 60 min post-
injection 
11.5 8.9 0.8 3 ns female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 10 mg/kg s.c. TCA 120 min post-
injection 
11.7 16.0 1.4 3,4 * female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 10 mg/kg s.c. TCA 240 min post-
injection 
12.8 12.0 0.9 3 ns female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 5 mg/kg i.p. TCA 1 h post-injection n/a n/a ~ 1.9 1,2 * female mdr1a(-/-) 
mice 
Uhr et al., 2000 
 10 mg/kg s.c. bd 
for 10 days 
TCA 4 h after final 
dose 
10.3 13.3 1.3 3 ns male mdr1ab(-/-) 
mice 
Grauer and Uhr, 
2004 
→ E-OH- AMI n/a metab 30 min post-AMI 
injection 
1.4 3.8 2.7 3 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 60 min post-AMI 
injection 
1.8 4.2 2.4 3 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 120 min post-AMI 
injection 
2.1 5.1 2.4 3 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 240 min post-AMI 
injection 
1.9 5.0 2.7 3,4 * female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 1 h post-AMI 
injection 
n/a n/a ~ 3.1 1,2 * male mdr1a(-/-) 
mice 
Uhr et al., 2000 
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Antidepressant Dose Class Samples taken Brain/Plasma Conc. Sig Model Ref 
WT KO KO/WT 
→ E-OH- AMI 
(contd) 
n/a metab 4 h after final AMI 
dose 
1.6 2.2 1.3 3,4 * male mdr1ab(-/-) 
mice 
Grauer and Uhr, 
2004 
→ Z-OH-AMI n/a metab 30 min post-AMI 
injection 
1.3 3.6 2.8 3 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 60 min post-AMI 
injection 
1.6 3.4 2.1 3 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 120 min post-AMI 
injection 
1.5 4.9 3.3 3 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 240 min post-AMI 
injection 
1.4 6.8 4.7 3,4 * female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 1 h post-AMI 
injection 
n/a n/a ~ 4.5 1,2 * male mdr1a(-/-) 
mice 
Uhr et al., 2000 
 n/a metab 4 h after final AMI 
dose 
1.5 7.4 4.9 3,4 * male mdr1ab(-/-) 
mice 
Grauer and Uhr, 
2004 
→E-OH-NOR n/a metab 30 min post-AMI 
injection 
n/a 5 0.5 n/a  3,5 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 60 min post-AMI 
injection 
n/a 5 0.6 n/a 3,5 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 120 min post-AMI 
injection 
0.5 1.0 2.2 3 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 240 min post-AMI 
injection 
0.6 1.9 3.2 3,4 * female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 1 h post-AMI 
injection 
n/a n/a ~ 2.8 1,2 * male mdr1a(-/-) 
mice 
Uhr et al., 2000 
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Antidepressant Dose Class Samples taken Brain/Plasma Conc. Sig Model Ref 
WT KO KO/WT 
 n/a metab 4 h after final AMI 
dose 
0.5 3.7 8.0 3,4 * male mdr1ab(-/-) 
mice 
Grauer and Uhr, 
2004 
→Z-OH-NOR n/a metab 30 min post-AMI 
injection 
n/a 5 0.2 n/a 3,5 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 60 min post-AMI 
injection 
n/a 5 0.2 n/a 3,5 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 120 min post-AMI 
injection 
0.2 0.5 2.5 3 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 240 min post-AMI 
injection 
0.3 0.9 2.8 3,4 * female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 1 h post-AMI 
injection 
n/a n/a ~ 2.3 1,2 * male mdr1a(-/-) 
mice 
Uhr et al., 2000 
 n/a metab 4 h after final AMI 
dose 
0.4 2.5 5.7 3,4 * male mdr1ab(-/-) 
mice 
Grauer and Uhr, 
2004 
Citalopram 1 mg/kg s.c. SSRI 1 h post-injection 4.6 15.7 3.4 3,4 * male mdr1ab(-/-) 
mice 
Uhr and Grauer, 
2003 
 60 µg/day s.c SSRI After 11 days 
treatment 
1.5 5.4 3.7 * male mdr1ab(-/-) 
mice 
Uhr et al., 2008 
 3 mg/kg s.c. SSRI Multiple time 
points 
5.1 9.7 1.9 * female mdr1ab(-/-) 
mice 
Doran et al., 
2005 
 5 mg/kg/day s.c. 
infusion 
SSRI After 3 days 
treatment 
22 44 2.0 *** mdr1a(-/-) mice Bundgaard et 
al., 2012 
 9 mg/kg/day s.c. 
infusion 
SSRI After 3 days 
treatment 
10 33 3.3 *** mdr1a(-/-) rat Bundgaard et 
al., 2012 
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Antidepressant Dose Class Samples taken Brain/Plasma Conc. Sig Model Ref 
WT KO KO/WT 
Doxepin 10 mg/kg s.c. TCA 1 h post-injection 7.1 7.6 1.1 3,4 * male mdr1ab(-/-) 
mice 
Uhr et al., 2003 
→D-Doxepin n/a metab 1 h post-DOX 
injection 
1.9 2.4 1.3 3,4 * male mdr1ab(-/-) 
mice 
Uhr et al., 2003 
Fluoxetine 1.5 mg/kg i.p SSRI 1 h post-injection n/a n/a ~ 1.1 1,2 ns male mdr1a(-/-) 
mice 
Uhr et al., 2000 
 3 mg/kg s.c. SSRI Multiple time 
points 
12.0 18.0 1.5 * female mdr1ab(-/-) 
mice 
Doran et al., 
2005 
→Norfluoxetine n/a metab 1 h post-FLX 
injection 
n/a n/a ~ 1.1 1,2 ns male mdr1a(-/-) 
mice 
Uhr et al., 2000 
Fluvoxamine 3 mg/kg s.c. SSRI Multiple time 
points 
6.1 14.0 2.3 * female mdr1ab(-/-) 
mice 
Doran et al., 
2005 
Mirtazapine 1 mg/kg s.c. NaSSA 1 h post-injection 3.1 3.0 1.0 ns male mdr1ab(-/-) 
mice 
Uhr et al., 2003 
 60 µg/day s.c NaSSA After 11 days 
treatment 
4.6 4.6 1.0 ns male mdr1ab(-/-) 
mice 
Uhr et al., 2008 
Nortriptyline 3 mg/kg s.c. TCA Multiple time 
points 
11.0 20.0 1.8 * female mdr1ab(-/-) 
mice 
Doran et al., 
2005 
 5 mg/kg s.c. TCA n/a n/a n/a 1.6 * mdr1a(-/-) mice Ejsing et al., 
2006 
→ Nortriptyline n/a metab 30 min post-AMI 
injection 
2.8 2.6 0.9 3 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 60 min post-AMI 
injection 
3.1 4.9 1.6 3 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
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Antidepressant Dose Class Samples taken Brain/Plasma Conc. Sig Model Ref 
WT KO KO/WT 
→ Nortriptyline 
(contd) 
n/a metab 120 min post-AMI 
injection 
4.8 7.3 1.5 3 n/a female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 240 min post-AMI 
injection 
8.1 11.4 1.4 3,4 * female mdr1ab(-/-) 
mice 
Uhr et al., 2007 
 n/a metab 1 h post-AMI 
injection 
n/a n/a ~ 2.4 1,2 * male mdr1a(-/-) 
mice 
Uhr et al., 2000 
 n/a metab 4 h after final AMI 
dose 
6.8 14.6 2.1 3,4 * male mdr1ab(-/-) 
mice 
Grauer and Uhr, 
2004 
Paroxetine 3 mg/kg s.c. SSRI Multiple time 
points 
3.3 7.1 2.2 * female mdr1ab(-/-) 
mice 
Doran et al., 
2005 
 1 mg/kg s.c. SSRI 1 h post-injection 1.9 3.0 1.6 3,4 * male mdr1ab(-/-) 
mice 
Uhr et al., 2003 
Sertraline 3 mg/kg s.c. SSRI Multiple time 
points 
24.0 27.0 1.1 ns female mdr1ab(-/-) 
mice 
Doran et al., 
2005 
Trimipramine 10 mg/kg s.c. TCA 1 h post-injection 7.0 9.7 1.4 3,4 * male mdr1ab(-/-) 
mice 
Uhr and Grauer, 
2003 
→D-
Trimipramine 
n/a metab 1 h post-TRIM 
injection 
2.8 3.3 1.2 3,4 * male mdr1ab(-/-) 
mice 
Uhr and Grauer, 
2003 
Venlafaxine 3 mg/kg s.c. SNRI Multiple time 
points 
4.2 7.7 1.8 * female mdr1ab(-/-) 
mice 
Doran et al., 
2005 
 5 mg/kg s.c. SNRI 1 h post-injection 4.9 8.8 1.8 3,4 * male mdr1ab(-/-) 
mice 
Uhr et al., 2003 
 300 µg /day s.c SNRI After 11 days 
treatment 
3.7 6.5 1.8 * male mdr1ab(-/-) 
mice 
Uhr et al., 2008 
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Antidepressant Dose Class Samples taken Brain/Plasma Conc. Sig Model Ref 
WT KO KO/WT 
Venlafaxine 
(contd) 
10 mg/kg i.p SNRI 1 h post-injection 4.1 8.9 2.2 3,4 ** male mdr1ab(-/-) 
mice 
Karlsson et al., 
2010 
 10 mg/kg i.p SNRI 3 h post-injection 4.3 7.4 1.7 3,4 *** male mdr1ab(-/-) 
mice 
Karlsson et al., 
2010 
 10 mg/kg i.p SNRI 6 h post-injection 3.7 5.5 1.5 3,4 * male mdr1ab(-/-) 
mice 
Karlsson et al., 
2010 
 10 mg/kg i.p SNRI 9 h post-injection 4.0 4.8 1.2 3,4 * male mdr1ab(-/-) 
mice 
Karlsson et al., 
2010 
 10 mg/kg i.p bd 
for 10 days 
SNRI 1 h after last 
injection 
4.8 8.2 1.7 3,4 *** male mdr1ab(-/-) 
mice 
Karlsson et al., 
2011 
 15 mg/kg/day s.c. 
infusion 
SSRI After 3 days 
treatment 
4.7 8.3 1.8 * mdr1a(-/-) mice Bundgaard et 
al., 2012 
 9 mg/kg/day s.c. 
infusion 
SSRI After 3 days 
treatment 
3.3 6.3 1.9 ** mdr1a(-/-) rat Bundgaard et 
al., 2012 
→D-Venlafaxine n/a metab 1 h post-VEN 
injection 
1.4 2.3 1.7 3,4 * male mdr1ab(-/-) 
mice 
Uhr et al., 2003 
 n/a metab After 11 days VEN 
treatment 
1.6 6.2 3.6 * male mdr1ab(-/-) 
mice 
Uhr et al., 2008 
 n/a metab 1 h post-VEN 
injection 
1.7 3.9 2.2 3,4 ** male mdr1ab(-/-) 
mice 
Karlsson et al., 
2010 
 n/a metab 3 h post-VEN 
injection 
5.0 12.0 2.4 3,4 ** male mdr1ab(-/-) 
mice 
Karlsson et al., 
2010 
 n/a metab 6 h post-VEN 
injection 
6.2 23.8 3.9 3,4 *** male mdr1ab(-/-) 
mice 
Karlsson et al., 
2010 
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Antidepressant Dose Class Samples taken Brain/Plasma Conc. Sig Model Ref 
WT KO KO/WT 
→D-Venlafaxine 
(contd) 
n/a metab 9 h post-VEN 
injection 
5.3 15.9 3.0 3,4 ** male mdr1ab(-/-) 
mice 
Karlsson et al., 
2010 
 n/a metab 1 h after last VEN 
injection 
1.8 3.5 1.9 3,4 *** male mdr1ab(-/-) 
mice 
Karlsson et al., 
2011 
KO: P-gp knockout mice; KO/WT: ratio of brain/plasma ratios between KO and WT mice; metab: metabolite; NaSSA: noradrenergic and 
selective serotonergic antidepressant; SNRI: serotonin-noradrenaline reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; TCA: 
tricyclic antidepressant; WT: wild-type mice 
→ denotes a metabolite 
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It is important to consider the inherent limitations of the P-gp knockout mouse 
model’s utility in the assessment of the impact of P-gp mediated efflux on drug 
distribution into the brain. For example, the expression of BCRP mRNA in the 
cerebral microvessels of abcb1a(-/-) mice is increased threefold relative to wild-type 
animals (Cisternino et al., 2004). Furthermore, this increase in BCRP mRNA 
expression is associated with a greater export of two of its substrates, prazosin and 
mitoxantrone, from the brain of abcb1a(-/-) mice versus wild-type controls 
(Cisternino et al., 2004). Importantly, other ABC transporters, including BCRP, 
demonstrate overlapping drug specificities with P-gp (Litman et al., 2001; Sharom, 
2008), and the expression of ABC drug transporters at the BBB may become 
upregulated following exposure to xenobiotics (Miller, 2010). Therefore, potential 
upregulation of alternative drug efflux transporters, such as BCRP, in P-gp knockout 
mice must be considered before valid conclusions can be drawn regarding in vivo P-
gp-drug interactions using this model.  
In addition, following a comparison of in vitro and in vivo data for 23 compounds, it 
has been recommended that a threshold ratio of four-fold increase in brain/plasma 
drug concentration ratios between P-gp knockout and wild-type mice (KO:WT B/P 
ratio) should be set to assess P-gp-drug interactions in vivo (Feng et al., 2008). For 
example, risperidone, despite having a KO:WT B/P ratio of 10, indicating that it is 
heavily subjected to P-gp efflux, is still a reasonably efficacious antipsychotic agent 
(Doran et al., 2005). This might reflect the potency of risperidone, meaning that 
high brain concentrations are not required for it to exert its clinical effect. To date, 
no antidepressant drug has been shown to have a KO:WT B/P ratio greater than 3.6 
(Table 1.12). Thus, it seems that no antidepressant has yet been identified as a high 
affinity transported P-gp substrate in vivo, and therefore the overall influence of P-
gp efflux on the effectiveness of antidepressants has been questioned (Doran et al., 
2005). Furthermore, in many studies using knockout mice, brain antidepressant 
concentrations were not normalized against plasma levels (i.e. a brain/plasma 
concentration ratio was not used). Despite plasma drug concentrations being 
considerably higher in P-gp knockout than wild-type mice in some these studies, in 
certain cases with statistically significant differences in plasma drug levels between 
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the strains (Uhr et al., 2003), brain drug concentrations were compared directly 
between strains (Uhr et al., 2003; Uhr et al., 2007). Thus statistically significant 
differences in brain drug concentrations identified between these two strains in 
such studies may have been partially due to variations in plasma pharmacokinetics, 
rather than solely as a result of altered drug transport across the BBB due to a lack 
of P-gp. 
1.5.5. In vivo studies involving P-gp inhibition in wild-type 
rodents 
Other in vivo studies have made use of established P-gp inhibitors, such as 
verapamil and cyclosporin A (CsA), to investigate if inhibition of P-gp results in 
altered antidepressant drug penetration in to the brain (Table 1.13).  
Using this method, nortriptyline was shown to have significantly higher brain/serum 
ratios in rats treated with a P-gp-inhibitor than in untreated controls (Ejsing and 
Linnet, 2005). However, this increase was relatively small, equating to a c. 25% 
increase in the brain-serum ratio, compared to an 80% increase in the brains of P-
gp knockout compared to wild-type mice (Doran et al., 2005). 
The use of whole brain in the analysis above may have obscured potentially greater 
region-specific central increases in drug concentration. In order to address this 
issue, the effect of P-gp inhibition on imipramine and desipramine concentrations 
in various brain regions was determined, and it was found that there was a region-
specific effect (Clarke et al., 2009). For example, the frontal cortex/serum 
imipramine concentration ratio was significantly increased to 2.4, compared to a 
non-significant ratio of 1.1 in the hypothalamus (Clarke et al., 2009). Similarly for 
desipramine, a significant effect was observed in the frontal cortex but not for 
other brain areas (Clarke et al., 2009). Thus, it seems that the effect of P-gp on drug 
penetration into the CNS is not uniform, and region-specific effects should be taken 
in to account when interpreting data in P-gp-interaction studies, as potentially 
significant results may be obscured or missed entirely.  
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Interestingly, it has been demonstrated that pharmacological induction of P-gp 
using any one of three different inducing agents (rifampicin, dexamethasone or 5-
pregnene-3beta-ol-20-on-16alpha-carbonitrile) results in reduced brain distribution 
of risperidone and its active metabolite, 9-hydroxyrisperidone (Holthoewer et al., 
2010). Similar investigations in relation to antidepressant drugs would help to 
further clarify the role played by P-gp in their BBB transport. 
A study evaluating pharmacokinetic interactions between the antipsychotic drug 
risperidone and the antidepressant sertraline in CF1 mice demonstrated P-gp 
inhibition by sertraline, resulting in significantly increased brain risperidone levels 
(Wang et al., 2006a). This in vivo finding supports in vitro studies reporting P-gp 
inhibition by sertraline (Weiss et al., 2003; Feng et al., 2008). As the plasma 
sertraline levels achieved in this study approximate those observed in patients 
treated with the drug, this finding suggests that sertraline may induce clinically 
significant P-gp inhibitory effects in therapeutic use. Whether these preclinical 
findings can translate into therapeutic potential of P-gp inhibitors as adjunctive 
therapies in the treatment of schizophrenia remains to be determined.
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Table 1.13: In vivo studies using P-gp inhibition to investigate if various antidepressants are P-gp substrates at the BBB 
Antidepressant Dose Class 
Species 
(strain) 
P-gp inhibitor 
Brain 
Region 
Brain/Serum Conc. 
Sig Ref Control P-gp 
I 
P-gp I / 
Control 
Imipramine 15 mg/kg i.p. TCA Rat (Sprague 
Dawley) 
Verapamil  
(20 mg/kg i.p.) 
HYPO 21.5 23.6 1.1 ns Clarke et al., 
2009 
 15 mg/kg i.p. TCA Rat (Sprague 
Dawley) 
Verapamil  
(20 mg/kg i.p.) 
FC 11.9 28.4 2.4 * Clarke et al., 
2009 
 15 mg/kg i.p. TCA Rat (Sprague 
Dawley) 
Verapamil  
(20 mg/kg i.p.) 
HIPPO 17.4 26.0 1.5 * Clarke et al., 
2009 
 15 mg/kg i.p. TCA Rat (Sprague 
Dawley) 
Verapamil  
(20 mg/kg i.p.) 
BS 12.2 25.2 2.1 *** Clarke et al., 
2009 
→ Desipramine IMI 15 
mg/kg i.p. 
meta
bolite 
Rat (Sprague 
Dawley) 
Verapamil  
(20 mg/kg i.p.) 
HYPO 31.5 32.3 1.0 ns Clarke et al., 
2009 
 IMI 15 
mg/kg i.p. 
meta
bolite 
Rat (Sprague 
Dawley) 
Verapamil  
(20 mg/kg i.p.) 
HIPPO 13.8 15.1 1.1 ns Clarke et al., 
2009 
 IMI 15 
mg/kg i.p. 
meta
bolite 
Rat (Sprague 
Dawley) 
Verapamil  
(20 mg/kg i.p.) 
FC 13.2 19.0 1.4 ** Clarke et al., 
2009 
 IMI 15 
mg/kg i.p. 
meta
bolite 
Rat (Sprague 
Dawley) 
Verapamil  
(20 mg/kg i.p.) 
BS 10.0 13.4 1.3 ns Clarke et al., 
2009 
Nortriptyline 5 mg/kg i.p. TCA Rat Verapamil  
(50 mg/kg i.p.) 
Whole 
brain 
n/a n/a 1.6 ** Ejsing et al., 
2006 
 various i.p. 
(pooled) 
TCA Rat Cyclosporin  
(200 mg/kg i.p.) 
Whole 
brain 
n/a n/a 1.3 * Ejsing et al., 
2006 
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Antidepressant Dose Class 
Species 
(strain) 
P-gp inhibitor 
Brain 
Region 
Brain/Serum Conc. 
Sig Ref Control P-gp 
I 
P-gp I / 
Control 
Nortriptyline 
(contd) 
25 mg/kg 
p.o. 
TCA Rat (Wistar 
Hanover 
GALAS) 
Cyclosporin  
(200 mg/kg p.o.) 
Whole 
brain 
16.2 22.5 1.4 * Ejsing and 
Linnet, 2005 
 10 mg/kg i.p TCA Rat (Wistar 
Hanover 
GALAS) 
Cyclosporin  
(200 mg/kg i.p) 
Whole 
brain 
17.0 22.0 1.3 * Ejsing and 
Linnet, 2005 
 25 mg/kg i.p TCA Rat (Wistar 
Hanover 
GALAS) 
Cyclosporin  
(200 mg/kg i.p) 
Whole 
brain 
23.0 27.0 1.2 ns Ejsing and 
Linnet, 2005 
 various 
(pooled) 
TCA Rat (Wistar 
Hanover 
GALAS) 
Cyclosporin  
(200 mg/kg p.o.) 
Whole 
brain 
20.0 25.0 1.3 ** Ejsing and 
Linnet, 2005 
→ E-OH-NT NOR 25 
mg/kg p.o. 
meta
bolite 
Rat (Wistar 
Hanover 
GALAS) 
Cyclosporin  
(200 mg/kg p.o.) 
Whole 
brain 
1.2 2.0 1.7 ns Ejsing and 
Linnet, 2005 
 NOR 10 
mg/kg i.p 
meta
bolite 
Rat (Wistar 
Hanover 
GALAS) 
Cyclosporin  
(200 mg/kg i.p) 
Whole 
brain 
~ 1.7 ~1.9 1.1 ns Ejsing and 
Linnet, 2005 
 NOR 25 
mg/kg i.p 
meta
bolite 
Rat (Wistar 
Hanover 
GALAS) 
Cyclosporin  
(200 mg/kg i.p) 
Whole 
brain 
~ 0.9 ~ 1.1 1.2 ns Ejsing and 
Linnet, 2005 
 NOR various 
(pooled) 
meta
bolite 
Rat (Wistar 
Hanover 
GALAS) 
Cyclosporin  
(200 mg/kg p.o.) 
Whole 
brain 
1.3 1.6 1.3 ns Ejsing and 
Linnet, 2005 
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Antidepressant Dose Class 
Species 
(strain) 
P-gp inhibitor 
Brain 
Region 
Brain/Serum Conc. 
Sig Ref Control P-gp 
I 
P-gp I / 
Control 
Risperidone1 1 mg/kg i.p. n/a 
(APD) 
Mouse (CF1) Sertraline (SSRI; 
10 µg/g i.p.) 
Whole 
brain 
1.6 2.3 1.4 ** Wang et al., 
2006a 
→ 9-OH-Risp n/a meta
bolite 
Mouse (CF1) Sertraline (SSRI; 
10 µg/g i.p.) 
Whole 
brain 
0.9 2.5 2.8 ** Wang et al., 
2006a 
P-gp I = group treated with P-gp inhibitor 
BS: brain stem; FC: frontal cortex; HIPPO: hippocampus; HYPO: hypothalamus 
1 Risperidone is an antipsychotic drug (APD) known to be a P-gp substrate. This study demonstrates P-gp inhibition by sertraline in vivo. 
 * p < 0.05; ** p < 0.01; *** p < 0.001; ns = non-significant 
→ denotes a metabolite 
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1.5.6. Pharmacogenetic studies in humans 
Given that preclinical findings have identified many antidepressants as P-gp 
substrates (Sections 1.5.4 and 1.5.5), and that medicated depressed patients have 
been reported to have increased P-gp activity (de Klerk et al., 2009) (discussed in 
Section 1.4.6), it is plausible that P-gp efflux of antidepressants may be clinically 
relevant in resistance to the treatment of depression (as outlined in relation to 
other brain disorders in Section 1.3.5).  
Co-administration of a P-gp inhibitor, itraconazole, has been reported to increase 
the bioavailability of paroxetine in humans (Yasui-Furukori et al., 2007), while 
fluvoxamine and citalopram plasma pharmacokinetics were found to be dependent 
on polymorphisms in the ABCB1 gene (Fukui et al., 2007; Nikisch et al., 2008), 
indicating that these antidepressants are P-gp substrates in humans.  
As outlined in Section 1.3.4, the functional significance of any of the many SNPs in 
the ABCB1 gene is unclear and remains controversial. Nonetheless, similar links 
have also been reported between ABCB1 genotype and the frequency of side 
effects following antidepressant treatment (Roberts et al., 2002; de Klerk et al., 
2013).  
Moreover, several studies have reported associations between ABCB1 SNPs and 
response to treatment with antidepressants, including paroxetine, citalopram and 
escitalopram (Gex-Fabry et al., 2008; Kato et al., 2008; Nikisch et al., 2008; 
Sarginson et al., 2010; Lin et al., 2011; Singh et al., 2012). In contrast, no links were 
found between these ABCB1 SNPs and treatment response for amitriptyline, 
fluoxetine or nortriptyline (Roberts et al., 2002; Laika et al., 2006). Importantly, 
there has been little consensus regarding the involvement of particular SNPs in 
pharmacogenetic studies reporting positive results. Moreover, reported 
associations for paroxetine and citalopram have not been replicated in subsequent 
studies (Mihaljevic Peles et al., 2008; Peters et al., 2008), thereby raising concerns 
over the validity of these observations.  
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The majority of clinical studies in this area have focused on a small number of 
ABCB1 SNPs, mostly at the 3435 and 2677 sites. An early study found postural 
hypotension to be significantly more common following treatment with 
nortriptyline in patients carrying the C3435T SNP (Roberts et al., 2002). It was 
hypothesized that this may have been due to a relative increase in the 
accumulation of nortriptyline, or its metabolites, in the brain due to reduced P-gp 
function. Clinical response to nortriptyline (or fluoxetine) was not associated with 
the C3435T SNP in this study, however (Roberts et al., 2002). In contrast, paroxetine 
treatment-response has been reported to have a significant association with ABCB1 
genotype (Gex-Fabry et al., 2008; Kato et al., 2008). However, the SNPs that were 
linked to paroxetine treatment-response differed between these two studies. Kato 
and colleagues reported a significant positive association between the G2677T/A 
SNP and paroxetine treatment-response. Furthermore, a link between the ABCB1 
haplotype combination 3435C–2677G–1236T and a poor therapeutic response to 
paroxetine was identified (Kato et al., 2008). These associations did not reach 
significance in the other above-mentioned study, however, in which a link was 
found between a SNP at the 61 position in the ABCB1 gene and the therapeutic 
response to paroxetine (Gex-Fabry et al., 2008). In addition, a later study failed to 
replicate the findings of Kato and colleagues (Mihaljevic Peles et al., 2008). It 
should, however, be noted that these studies were undertaken in patient cohorts 
from different ethnic backgrounds (Japanese vs. Caucasians) 
Furthermore, the associations reported between ABCB1 SNPs and paroxetine 
treatment response have not been observed with other antidepressants. In fact, 
Nikisch and colleagues (2008) reported directly conflicting findings with regard to 
citalopram, with the 2677T genotype being significantly more common in non-
responders to citalopram treatment. This correlated with significantly lower plasma 
and cerebrospinal fluid citalopram concentrations in patients with the 2677T 
genotype relative to carriers of the wild-type allele, while no difference was 
observed in the same study for the C3435T polymorphism (Nikisch et al., 2008). 
However, the small number of subjects in this pilot study (n=15) is a limitation. In 
addition, no significant correlation was found between the G2677T/A 
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polymorphism and therapeutic response or side effect severity in patients treated 
with amitriptyline (Laika et al., 2006).  
Another study failed to find any correlation between the C3435T polymorphism and 
the frequency of antidepressant-induced mania in bipolar patients, treated with 
various serotonergic antidepressants (De Luca et al., 2003). However, the wide 
range of antidepressants involved in the study, some of which have been reported 
to be P-gp substrates in vivo (paroxetine, venlafaxine, fluoxetine etc.) and others 
which have not (sertraline, nefazodone, moclobemide), and the focus on an 
independent polymorphism, as opposed to its role as part of a haplotype, are major 
confounding factors (De Luca et al., 2003). 
The often contradictory literature surrounding the role of genetic differences in 
ABCB1 in antidepressant response is complicated by several factors, not least the 
focus on individual SNPs, as opposed to haplotypes, in the majority of studies and 
the lack of clarity regarding the functional impact of these SNPs. In addition, in 
many cases it has not been clear if the antidepressants in question are transported 
substrates of human P-gp.  
Rather than focusing on individual, previously described SNPs, Uhr and co-workers 
undertook a comprehensive fine-mapping of the ABCB1 gene to identify variants 
which may be associated with antidepressant response (Uhr et al., 2008). 
Moreover, in this study, antidepressants were classified as P-gp substrates (namely 
venlafaxine, citalopram, paroxetine and amitriptyline) or non-P-gp substrates 
(mirtazapine), albeit based on findings from studies in P-gp knockout mice rather 
than data pertaining to human P-gp. 
In this study, no association was found between antidepressant treatment response 
and the G2677T or C3435T SNPs (Uhr et al., 2008). This finding in relation to the 
G2677T or C3435T SNPs was subsequently replicated for citalopram, following 
analysis of data from the large Sequenced Treatment Alternatives to Relieve 
Depression (STAR*D) sample of depressed patients (Peters et al., 2008).  
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In contrast, two key intronic ABCB1 SNPs, rs2032583 and rs2235015, were 
identified as strong predictors of remission when patients were treated with 
antidepressants that were P-gp substrates (Uhr et al., 2008). Patients carrying the 
rare alleles of these intronic SNPs and receiving treatment with P-gp substrate 
antidepressants had a 7.7-fold higher chance to remit after 5 weeks than carriers of 
the other alleles (Uhr et al., 2008). This association was not due to differences in 
dosing or plasma levels, thus suggesting a role for P-gp function at the BBB. 
Moreover, no such association was determined in patients treated with 
mirtazapine, which is not a P-gp substrate (Uhr et al., 2008), thus supporting the P-
gp-related hypothesis. A later study partially replicated these findings for 
paroxetine (P-gp substrate) and mirtazapine (non-substrate) in geriatric depression, 
finding rs2032583, but not rs2235015, to be associated with response to paroxetine 
treatment (Sarginson et al., 2010). However, in their retrospective analysis of data 
from the large STAR*D clinical trial population, Peters and colleagues failed to 
replicate the findings of Uhr and co-workers with regard to an association between 
certain ABCB1 SNPs and citalopram response (Peters et al., 2008). While the 
original focus of their study involved investigating potential links between three 
common ABCB1 variants (C1236T, G2677T/A, and C3435T) and citalopram 
response, two ABCB1 SNPs reported to be in tight linkage disequilibrium with 
rs2032583 in the first haplotype block reported to be significant by Uhr and 
colleagues were also genotyped. Neither of these SNPs were associated with 
citalopram response in the STAR*D population (Peters et al., 2008; Peters et al., 
2009). However, it must be stressed that the authors did not have genotype data 
on the actual SNPs reported to be at play by Uhr and co-workers. 
In contrast to Uhr and colleagues’ findings in relation to P-gp substrate 
antidepressants, no association was found between duloxetine response and 
rs2032583 (Perlis et al., 2010). Bearing in mind that there are no published in vitro 
or in vivo studies indicating that duloxetine is a transported P-gp substrate, this 
finding does not necessarily contradict the previous study. Further research is 
required to establish if duloxetine is a transported substrate of P-gp to facilitate 
informed interpretation of this study’s finding in relation to rs2032583. 
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Significant links were also found between escitalopram response and uncommon 
ABCB1 SNPs in Taiwanese depressed patients (Lin et al., 2011). However, the loci 
associated with remission in this patient cohort were different to those identified 
by Uhr and co-workers. Moreover, a recent study has reported that the C3435T SNP 
predicts the dose of escitalopram required to achieve remission, with significantly 
higher doses required in carriers of the C allele (Singh et al., 2012). Although 
citalopram, a racemic mixture of R- and S-enantiomers, has been identified as a P-
gp substrate in vivo, no study has yet investigated the effect of P-gp on the brain 
distribution of escitalopram, the pharmacologically active S-enantiomer of 
citalopram. This is a key consideration given that P-gp is known to exhibit 
enantioselectivity for several drugs (de Lagerie et al., 2004; Wang et al., 2004b; 
Sakugawa et al., 2009; Akamine et al., 2012). Thus, further studies are needed to 
ascertain if escitalopram is a transported substrate of P-gp. 
In summary, while several studies have highlighted potential pharmacogenetic 
interactions between ABCB1 and antidepressant treatment, there has been little 
consistency regarding the involvement of particular SNPs and most studies have not 
been successfully replicated. However, recent findings regarding the rs2032583 SNP 
offer much promise. Further studies investigating interactions between this SNP 
and response to antidepressants which are transported substrates of human P-gp 
are now warranted. However, it should be noted that efflux transporters other than 
P-gp, such as breast cancer resistance protein (BCRP) and the multidrug resistance-
associated proteins (MRPs), are also expressed at the BBB. The role of these 
transporters in the brain distribution and treatment response to antidepressants 
has been under-investigated, especially in light of a study linking response to 
citalopram treatment with a SNP in ABCC1, the gene encoding MRP1 (Lee et al., 
2010). Future studies should be conducted to address this issue. 
1.5.7. Stress, the HPA axis, depression and P-gp 
Stress is thought to play a major role in the development of depression (Gold and 
Chrousos, 2002). The hypothalamic-pituitary-adrenal (HPA) axis controls the 
physiological response to stress through the secretion of corticosteroid hormones 
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such as cortisol, the main glucocorticoid in humans. As discussed in Section 1.4.1, 
dysregulation of the HPA axis has been implicated in the pathogenesis of 
depression (Holsboer, 2000; Julio-Pieper and Dinan, 2010). The HPA axis is 
regulated by negative feedback inhibition, whereby secreted corticosteroid 
hormones act on the hypothalamus and pituitary gland to suppress further HPA axis 
activation by reducing corticotrophin-releasing factor (CRF) and adrenocorticotropic 
hormone (ACTH) secretion, respectively.  
Hyperactivity of the HPA axis is one of the most consistent biological findings in 
depressed patients (Pariante and Lightman, 2008). Depressives often have elevated 
plasma cortisol (Halbreich et al., 1985) and ACTH (Carroll et al., 2007) levels, and fail 
to respond to the dexamethasone suppression test (Carroll, 1982a; Carroll, 1982b), 
whereby administration of the synthetic glucocorticoid dexamethasone should 
suppress the secretion of cortisol. This is indicative of central HPA axis overdrive, 
with compromised negative feedback inhibition at the hypothalamic level of the 
HPA axis, in depressed patients. 
The effect of P-gp on the brain penetration of glucocorticoids is unclear and 
somewhat controversial. Several early studies reported that many important 
endogenous and synthetic glucocorticoids are P-gp-substrates (Ueda et al., 1992; 
Vankalken et al., 1993; Schinkel et al., 1995; Meijer et al., 1998; Karssen et al., 
2001; Karssen et al., 2002; Uhr et al., 2002). However, subsequent evidence, from 
experiments involving double knockout abcb1ab(-/-) mice, suggests that 
corticosterone (the main glucocorticoid in rodents) and cortisol (the main 
glucocorticoid in humans) are not P-gp substrates at the BBB in vivo (Mason et al., 
2008; Mason et al., 2010), despite initial reports to the contrary (Uhr et al., 2002). 
Moreover, recent studies have revealed that the brain accumulation of the 
glucocorticoids cortisol, corticosterone and dexamethasone is greater in single 
knockout abcb1a(-/-) mice than wild-types, thereby further confusing the issue 
(Mason et al., 2012). 
Regardless of this controversy, it has been reported that double P-gp knockout 
abcb1ab(-/-) mice have consistently lower plasma ACTH and corticosterone levels 
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than control animals, thus indicating that P-gp may play a key role in the regulation 
of the HPA axis, and that absence of P-gp results in sustained suppression of the 
HPA axis (Muller et al., 2003; Yau et al., 2007). Furthermore, treatment with the 
tricyclic antidepressant desipramine reduced both basal and activated HPA axis 
activity in wild-type comparator mice, while the same treatment only reduced an 
activated HPA axis in abcb1ab(-/-) mice (Yau et al., 2007). This difference observed 
between P-gp knockout and wild-type mice further indicates that there may be a P-
gp-dependent mechanism at play in the regulation of the HPA axis. However, the 
uncertainty regarding the involvement of P-gp in the BBB transport of endogenous 
glucocorticoids makes it difficult to explain this phenomenon. The original 
hypothesis, which proposed that an absence of P-gp at the BBB resulted in a 
suppression of the HPA by increased negative feedback inhibition axis due to 
enhanced corticosterone entry into the brain (Muller et al., 2003; Yau et al., 2007), 
is contingent on corticosterone being a transported substrate of P-gp at the BBB. 
Further investigations are therefore needed to fully explain these observations.  
While hyperactivity of the HPA axis is associated with depression, successful 
antidepressant therapy results in normalization of the HPA axis (Herr et al., 2003; 
Kunzel et al., 2003). Antidepressant-mediated enhancement of glucocorticoid 
receptor function has been demonstrated in vitro (Pariante et al., 1997; Pariante et 
al., 2001; Herr et al., 2003; Pariante et al., 2003a; Pariante et al., 2003b). 
Interestingly, this effect has been observed following antidepressant co-incubation 
with certain glucocorticoids, such as dexamethasone and cortisol, but was not 
evident with others, such as corticosterone (Pariante et al., 1997). Given the lack of 
clarity regarding the role of P-gp in glucocorticoid transport, it is tempting to 
speculate that these differences are due to differential transport of glucocorticoids 
by P-gp. Further experiments are required to substantiate or disprove this 
hypothesis. Interestingly, co-incubation with the P-gp-inhibitor verapamil 
attenuated or reduced the glucocorticoid-enhancing effect of the antidepressants 
clomipramine and fluoxetine (Pariante et al., 2001; Pariante et al., 2003a; Pariante 
et al., 2003b), thus indicating that antidepressant-mediated P-gp-inhibition may be 
the underlying mechanism at play. Therefore, it has been suggested that 
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antidepressant drugs may increase the access of cortisol to the brain by inhibition 
of P-gp at the BBB, thereby enhancing glucocorticoid-mediated negative feedback 
on the HPA-axis, and that this may contribute to the clinical mechanism of action of 
antidepressants (Figure 1.12) (Pariante et al., 2004). 
This theory has, however, been challenged (Weber et al., 2005; Weber et al., 2006). 
Firstly, it has been questioned if P-gp inhibition by antidepressants could be 
clinically relevant given that it is only seen at concentrations above therapeutically 
relevant plasma levels (Weber et al., 2005). Furthermore, it seems that P-gp is 
present in excess in brain capillaries (Miller, 2010), which may influence the 
concentration of P-gp inhibitor needed to meaningfully increase substrate transport 
across a membrane (Kannan et al., 2009). As a result, for antidepressants to exert 
clinically significant P-gp inhibition at the BBB, concentrations several times higher 
than their IC50 would need to be achieved (Kalvass and Pollack, 2007). Therefore, it 
remains unclear if P-gp inhibitory concentrations of antidepressants are reached at 
the BBB in clinical use. 
In the second study challenging the relevance of P-gp inhibition to HPA axis 
normalising ability of antidepressants (Weber et al., 2006), a potentially sub-
effective dose of amitriptyline was used (Yau et al., 2007). Moreover, it involved the 
comparison of corticosterone levels in the brain and plasma, and it has 
subsequently been reported that corticosterone may not a P-gp substrate in vivo 
(Mason et al., 2008), thus undermining conclusions drawn from the study. 
Nonetheless, despite ample in vitro data demonstrating P-gp inhibition and P-gp-
mediated enhancement of glucocorticoid function by antidepressants, there is a 
paucity of in vivo data to support the hypothesis that antidepressants inhibit P-gp, 
resulting in enhanced glucocorticoid entry into the brain. In fact, the most recent 
publication from the Pariante group (the original proposers of this hypothesis) in 
relation to this question has failed to demonstrate that either acute or chronic 
administration of the antidepressant drug desipramine results in enhanced brain 
levels of glucocorticoids in an in situ mouse model (Mason et al., 2011). This study, 
in conjunction with another reporting enhanced P-gp function following chronic 
Chapter 1: General Introduction 
 
100 
antidepressant treatment (de Klerk et al., 2010) undermines the hypothesis, and 
therefore it seems unlikely that antidepressant mediated inhibition of P-gp 
contributes to the clinical mechanism of action of antidepressant drugs. 
In summary, the theory suggesting that P-gp inhibition at the BBB by some 
antidepressants may contribute to their mechanism of action is certainly 
interesting, but there is an increasing body of evidence undermining the 
hypothesis. The single study demonstrating P-gp inhibition by an antidepressant in 
vivo (Wang et al., 2006a) has not yet been replicated. Furthermore, it has yet to be 
proven that P-gp-inhibitory concentrations of antidepressants are reached at the 
BBB in the clinical setting. It is also necessary to clarify the role of P-gp in the brain 
accumulation of glucocorticoids, and the underlying mechanism behind the 
reduced corticosterone levels observed in P-gp knockout mice relative to controls. 
In addition, P-gp function has been shown to be increased in medicated depressed 
patients, chronically treated with antidepressants, relative to healthy controls (de 
Klerk et al., 2009). This would seem to contradict the theory that antidepressant 
treatment inhibits P-gp function at the BBB. However, the antidepressants used by 
the patients in this study were not listed. Therefore, it is not possible to determine 
if patients were treated with antidepressant medications that are thought to inhibit 
P-gp. Most importantly, a relatively recent study failed to demonstrate that 
administration of the antidepressant desipramine resulted in P-gp inhibition leading 
to enhanced glucocorticoid entry into the brain, thereby questioning the validity of 
the original hypothesis (Mason et al., 2011). Therefore, on balance, evidence to 
support the theory that P-gp inhibition by antidepressants at the BBB contributes to 
their mechanism of action is controversial and not supported by the most recent in 
vivo studies. More research in this area is needed to prove whether such negative 
effects generalise to other antidepressants. 
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Figure 1.12: Potential interaction between regulation of the HPA axis and antidepressants as P-gp inhibitors* (O'Brien et al., 2012b). 
A. Stress activates the HPA axis by triggering the release of CRH from the hypothalamus, which in turn acts on the anterior pituitary gland to 
secrete ACTH. ACTH stimulates the release of glucocorticoid hormones from the adrenal cortex. These glucocorticoid hormones, including 
cortisol, the main glucocorticoid in humans, inhibit the release of CRH and ACTH from the hypothalamus and pituitary gland respectively, thus 
exerting negative feedback control on the system. However, control of the HPA axis is often dysregulated in depressed patients, who may 
exhibit elevated levels of circulating cortisol and ACTH due to hyperactivity of the HPA axis.  
B. Many glucocorticoids are P-gp substrates. Therefore, in depressed patients, P-gp may limit the entry of glucocorticoids into the brain at the 
BBB, thus resulting in reduced negative feedback inhibition of the HPA axis. 
C. Successful treatment of depression results in normalisation the HPA axis, and many antidepressant drugs have been shown to enhance GR 
activity in vitro - an effect attenuated or reduced by co-incubation with a P-gp inhibitor. Therefore, it has been hypothesized that part of the 
mechanism of action of these antidepressant drugs may be to facilitate the access of glucocorticoids to the hypothalamus by inhibiting P-gp, 
thereby restoring central negative feedback control of the HPA axis. 
* It should be noted that this hypothesis is undermined by the most recent in vivo study with the antidepressant desipramine (Mason et al., 
2011) 
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1.5.8. Inhibition of P-gp as a putative antidepressant 
augmentation strategy? 
While several preclinical studies have robustly identified various antidepressants as 
transported P-gp substrates in rodents, these findings have generally not been 
supported by investigations using in vitro bidirectional transport assays. From a 
clinical perspective, interactions between antidepressant drugs and P-gp could 
potentially lead to altered dose-to-plasma relationships and/or frequency of side 
effects with altered P-gp function. In particular, P-gp-mediated efflux of 
antidepressants at the BBB would limit the access of these drugs to their site of 
action within the brain, therefore potentially contributing to the high rate of 
treatment failure (Figure 1.13).  
Further preclinical studies are required to more fully elucidate the role of P-gp in 
determining the brain levels and effect of antidepressant drugs in vivo. To date, no 
antidepressant has been robustly identified as a transported P-gp substrate both in 
vitro and in vivo. In particular, it is difficult to draw definitive conclusions from the 
available in vitro studies investigating if antidepressants are transported substrates 
of human P-gp. Thus, there is a major need for additional research in this regard. In 
addition, there is a paucity of studies demonstrating that brain concentrations of an 
antidepressant can be augmented by pharmacological inhibition of P-gp. Indeed, 
the only antidepressant drugs for which this has been reported are imipramine and 
nortriptyline, both of which are seldom used TCA antidepressants. Given that 
previous studies reported substantially smaller increases in the brain levels of 
nortriptyline following P-gp inhibition than similar experiments involving P-gp 
knockout mice (Doran et al., 2005; Ejsing and Linnet, 2005), it is important to 
investigate the potential for modulation of P-gp as a strategy to enhance brain 
delivery. Moreover, the pharmacodynamic impact of increasing brain 
concentrations of P-gp substrate antidepressants has not been adequately 
investigated to date. 
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Figure 1.13: Antidepressants as transported substrates of P-gp at the BBB (O'Brien 
et al., 2012b). Based on numerous in vitro and in vivo studies, it is thought that 
many antidepressant drugs may be transported P-gp substrates at the BBB, thereby 
limiting their brain distribution. Therefore, therapeutically effective brain 
concentrations might not be achieved in some cases, which in turn may play a role 
in treatment resistant depression.  
 
Many studies have reported associations between SNPs in ABCB1 and 
antidepressant treatment response. However, there appears to be little consensus 
among the reported results, with numerous publications claiming antithetical 
findings. Nonetheless, the report of Uhr and colleagues in 2008 is extremely 
promising (Uhr et al., 2008), especially considering that some of their findings were 
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subsequently replicated (Sarginson et al., 2010); although it must also be noted that 
others have failed to replicate certain aspects of these findings (Peters et al., 2008). 
Thus, the importance of the putative role of ABCB1 variants in the clinical efficacy 
of antidepressants remains controversial, and well-powered, prospective clinical 
trials are needed to definitively resolve this issue (Peters et al., 2009).  
Until such time as these trials have taken place, it remains plausible that P-gp 
inhibitors may augment the effects of certain antidepressants, particularly in 
treatment-resistant situations. Indeed, anecdotal evidence indicates a beneficial 
effect of adjunctive verapamil treatment in severely depressed patients who are 
refractory to SSRI treatment (Clarke et al., 2009). Clinical trials, exercising caution to 
avoid potential unwanted side effects due to putative pharmacokinetic or 
pharmacodynamic interactions, investigating this possibility may now be 
warranted. 
As outlined in Section 1.4.2, one common approach used in the treatment of TRD is 
the augmentation of a failed antidepressant therapy with another agent, such as 
the antipsychotics aripiprazole, olanzapine, quetiapine or risperidone (Philip et al., 
2010). Interestingly, some of these antipsychotics inhibit P-gp in vitro (Wang et al., 
2006b; Zhu et al., 2007; Feng et al., 2008); it is tempting to speculate that this 
property may contribute to their therapeutic efficacy as adjunctive treatments. 
Indeed, co-administration of risperidone with sertraline has been shown to result in 
a trend for increased sertraline concentrations in the brain of CF1 mice in vivo 
(Wang et al., 2006a). Therefore, one could hypothesize that the mechanistic 
explanation for this augmentation strategy involves the inhibition of P-gp by the 
antipsychotic drug, leading to increased central antidepressant concentrations. 
However, further studies (both in vitro and in vivo) are needed to establish if there 
is any merit to this hypothesis. 
In conclusion, recent studies suggest that a complex, and as yet not fully 
understood, relationship exists between antidepressants and drug efflux pumps, 
such as P-gp, at the BBB, and that this relationship may impact on the therapeutic 
efficacy of antidepressant treatment. TRD represents a major challenge in the 
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treatment of depression, and there is a huge unmet medical need for novel 
approaches to overcome this challenge. Advances in pharmacogenomics, 
neuroimaging and animal studies, coupled with more sophisticated in vitro assay 
technology, are sure to shed light on the interaction between antidepressants and 
P-gp in the coming years, thus potentially resulting in new strategies for adjunctive 
therapies for TRD.  
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1.6. Aims of the thesis 
This thesis aims to further investigate interactions between P-gp and 
antidepressants at the BBB by addressing some key outstanding questions. In 
particular, the role played by P-gp in the brain distribution of certain 
antidepressants, such as escitalopram, has yet to be investigated. Moreover, it 
remains unclear if antidepressants which have been identified as transported P-gp 
substrates in rodents are also transported substrates of human P-gp. Most 
importantly in the context of P-gp inhibition as a putative strategy to augment 
antidepressant treatment, the effect of blocking P-gp on an antidepressant’s 
activity in a relevant animal model remains to be elucidated.  
1.6.1. Aim 1: Establish an integrated intracerebral microdialysis 
approach to determine the effect of P-gp inhibition on 
antidepressant levels in the brain  
The intracerebral microdialysis approach offers several advantages as a means to 
assess the impact of P-gp on the brain distribution of drug compounds, as outlined 
in Section 1.2.5.4. Furthermore, by combining intracerebral microdialysis with 
peripheral jugular vein and carotid artery catheterizations, it would be possible to 
administer the drug of interest intravenously, thereby removing differences in drug 
absorption as a confounding factor, as well as taking parallel serial blood samples, 
thereby facilitating simultaneous monitoring of brain and plasma drug levels. Thus, 
it would be possible to determine the effect of administration of a P-gp inhibitor on 
the blood-brain barrier transport of antidepressant drugs in conscious freely 
moving animals over a period of time. We aimed to develop such a model and to 
apply it to different antidepressants to investigate the role of P-gp in their BBB 
transport (Chapters 2 and 4). 
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1.6.2. Aim 2: Establish and employ an in vitro model to identify 
antidepressants which are transported substrates of 
human P-gp 
Due to reports of species differences in P-gp activity and specificity (Yamazaki et al., 
2001; Katoh et al., 2006; Baltes et al., 2007; Syvanen et al., 2009), and indeed 
differences in the identification of P-gp substrates between single and double P-gp 
knockout mice, the clinical relevance of preclinical studies demonstrating that P-gp 
restricts the brain concentrations of various antidepressants in rodents is unclear. 
The establishment and consistent, rational application of an in vitro bidirectional 
transport model involving cells expressing human P-gp was therefore a priority, 
given the paucity and inconsistency of the available data pertaining to the transport 
of antidepressants by human P-gp. We aimed to establish such a model, and to use 
it to screen a number of antidepressant in relation to their status as transported P-
gp substrates (Chapters 3 and 4).  
1.6.3. Aim 3: Investigate the impact of P-gp inhibition on the 
pharmacodynamic activity of antidepressants which are P-
gp substrates 
While numerous studies have demonstrated that P-gp inhibition or P-gp knockout 
results in increased brain levels of various antidepressants, it has not yet been 
determined if enhancing brain levels of antidepressants in this way results in an 
augmentation in their antidepressant-like activity. We aimed to address this 
question, using appropriate animal models to investigate behavioural responses to 
antidepressant treatment, as outlined in Section 1.4.5 (Chapters 4, 5 and 6). 
Furthermore, we aimed to adapt our microdialysis model to investigate the impact 
of P-gp inhibition on antidepressant-induced increases in extracellular serotonin 
concentrations (Chapter 5). 
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1.6.4. Aim 4: Determine the effect of chronic treatment with a P-
gp inhibitor and an antidepressant on the brain 
distribution and behavioural and molecular responses to 
antidepressant treatment 
To date, studies investigating the effect of P-gp inhibition on the brain distribution 
of antidepressants have exclusively involved acute treatments. Given that 
antidepressants are prescribed on a chronic basis in clinical practice and considering 
that the expression of P-gp, as well as other ABC transporters, can be up-regulated 
in response to certain xenobiotics (Miller, 2010), it is essential to determine if P-gp 
inhibition will result in enhanced brain levels of a P-gp substrate antidepressant 
after chronic treatment. Moreover, there is typically a therapeutic delay of several 
weeks in the onset of action of antidepressants clinically (Krishnan and Nestler, 
2008). Therefore, the impact of P-gp inhibition on responses to chronic 
antidepressant treatment is a key question (Chapter 6). 
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Abstract 
Background: Recent studies indicate that efflux of antidepressants by the multidrug 
resistance transporter P-glycoprotein (P-gp) at the blood-brain barrier (BBB) may 
contribute to treatment resistant depression (TRD) by limiting intracerebral 
antidepressant concentrations. In addition, clinical experience shows that 
adjunctive treatment with the P-gp inhibitor verapamil may improve the clinical 
outcome in TRD. Therefore, the present study aimed to investigate the impact of P-
gp inhibition on the BBB transport of the tricyclic antidepressant imipramine and its 
active metabolite desipramine. 
Methods: Intracerebral microdialysis was used to monitor brain levels of 
imipramine and desipramine following intravenous imipramine administration, with 
or without pre-treatment with one of the P-gp inhibitors verapamil or cyclosporin A 
(CsA). Plasma drug levels were also determined at regular intervals. 
Results: Pre-treatment with either verapamil or CsA resulted in significant increases 
in imipramine concentrations in the microdialysis samples, without altering 
imipramine plasma pharmacokinetics. Furthermore, pre-treatment with verapamil, 
but not CsA, led to a significant elevation in plasma and brain levels of desipramine. 
Conclusions: The present study demonstrates that P-gp inhibition can enhance 
intracerebral imipramine concentrations, thus supporting the hypothesis that P-gp 
restricts brain levels of certain antidepressants, including imipramine. These 
findings may help to explain reports of a beneficial response to adjunctive therapy 
with verapamil in TRD. 
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2.1. Introduction 
Recent pre-clinical studies indicate that several antidepressant drugs may be 
substrates of the multidrug resistance transporter P-glycoprotein (P-gp) at the 
blood-brain barrier (BBB) (O'Brien et al., 2012b). P-gp, encoded by the ABCB1 gene 
in humans, is expressed at multiple sites within the body, including the luminal 
membrane of the brain capillary endothelial cells which form the BBB (Cordoncardo 
et al., 1989). Drug efflux by P-gp at the BBB represents a major obstacle in the 
delivery of pharmacological compounds which are P-gp substrates to the brain, and 
has been linked to treatment failure in various brain disorders, such as epilepsy and 
brain cancer (Siddiqui et al., 2003; Pauwels et al., 2007).  
Several functional single nucleotide polymorphisms (SNPs) in the ABCB1 gene have 
been identified which impact on P-gp expression and/or function (Cascorbi, 2006). 
These functional SNPs may therefore have an impact on the ability of P-gp 
substrate drugs to reach the brain. Emerging clinical evidence indicates that the 
response rate to treatment with antidepressants, particularly those which have 
been shown to be P-gp substrates at the BBB in vivo, may be associated with ABCB1 
genotype (Uhr et al., 2008; Sarginson et al., 2010; Lin et al., 2011). This suggests 
that P-gp-mediated efflux may contribute to the high prevalence of treatment 
resistant depression (TRD) by limiting antidepressant concentrations at their 
intracerebral site of action (O'Brien et al., 2012b). In addition, preliminary clinical 
studies have suggested that co-administration of the P-gp inhibitor verapamil may 
be beneficial in TRD (Clarke et al., 2009). However, despite numerous in vivo studies 
demonstrating enhanced brain levels of several antidepressants in P-gp knockout 
mice compared to wild-type controls, the relative contribution of P-gp-mediated 
efflux and passive permeability on the BBB transport of these antidepressant drugs 
has yet to be definitively determined, and the significance of putative P-gp efflux to 
the BBB transport of antidepressants remains contentious (O'Brien et al., 2012b). 
Not all antidepressants are P-gp substrates, however. Mirtazapine is one such 
example (Uhr et al., 2003; Uhr et al., 2008), and interestingly clinical response to 
mirtazapine is not associated with ABCB1 genotype (Uhr et al., 2008). Furthermore, 
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the complexity of the relationship between antidepressants and P-gp should be 
noted, as well as the difficulties in extrapolating results from one experimental 
context to another (O'Brien et al., 2012b). This point is illustrated by work from the 
Pariante group, where in vitro studies led to the proposal that activity of P-gp at the 
BBB may itself be a target of antidepressant action (Pariante et al., 2003b; Pariante 
et al., 2004), whereas recent in vivo results appear to contradict this hypothesis 
(Mason et al., 2011). 
While several studies have investigated the distribution of antidepressants into the 
brain in P-gp knockout mice relative to wild-type controls, there is a paucity of 
research investigating the impact of pharmacological P-gp inhibition on the ability 
of antidepressants to penetrate the BBB, with only three such studies published to 
date to our knowledge (Ejsing and Linnet, 2005; Ejsing et al., 2006; Clarke et al., 
2009). We have previously shown that pre-treatment with verapamil leads to 
enhanced brain-to-serum ratios of the tricyclic antidepressant imipramine and its 
active metabolite, desipramine, in certain brain regions (Clarke et al., 2009). 
However, in vitro transport studies using different P-gp expressing cell-lines have 
yielded conflicting findings regarding the P-gp substrate status of imipramine 
(Mahar Doan et al., 2002; Faassen et al., 2003). Therefore, it remains unclear 
whether P-gp limits the ability of imipramine to penetrate the BBB. These previous 
studies in normal animals have only investigated brain-to-serum ratios at a single 
(terminal) time-point post-antidepressant administration, and therefore have not 
elucidated the time-dependent impact of P-gp inhibition on the distribution of 
these antidepressants into the brain. 
The present study utilises an integrated intracerebral microdialysis technique to 
investigate the impact of pre-treatment with one of two distinct P-gp inhibitors, 
verapamil or cyclosporin A (CsA), on free imipramine and desipramine 
concentrations in brain extracellular fluid (ECF) over time in wild-type Sprague 
Dawley rats. Intracerebral microdialysis represents a useful investigational tool 
which can be used to assess drug permeability across the BBB as a function of time, 
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particularly when applied to the study of drug transporters in the central nervous 
system (CNS) (Sawchuk and Elmquist, 2000).   
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2.2. Methods 
2.2.1. Drugs and chemicals 
High performance liquid chromatography (HPLC) grade acetonitrile, potassium 
dihydrogen phosphate and orthophosphoric acid (OPA) were obtained from Fisher 
Scientific (Ireland). Heparin sodium solution (Wockhardt UK Ltd, UK) and CsA 
(Sandimmun; Novartis Pharmaceuticals UK Ltd, UK) were purchased from Uniphar 
Group (Ireland). Imipramine, desipramine, trimipramine and verapamil were 
obtained from Sigma-Aldrich as were all other chemicals unless otherwise stated. 
2.2.2. Animals 
Male Sprague Dawley rats (Harlan Laboratories, UK), weighing 255-290 g, were 
used in this study (total n = 18). Animals were group-housed 4-6 animals per cage 
and maintained on a 12 hour light/dark cycle (lights on at 08:00 h) with food and 
water ad libitum. Room temperature was controlled at 22 ± 1°C. All procedures 
were carried out in accordance with EU directive 89/609/EEC and approved by the 
Animal Experimentation & Ethics Committee of University College Cork. 
2.2.3. Surgical procedures 
Animals were anaesthetized prior to surgery with a ketamine/xylazine mixture 
(90/10 mg.kg-1 i.p.), with maintenance of anaesthesia achieved by repeating 20-25% 
of the induction dose at 30-40 minute intervals, as required. Analgesia was 
provided by pre-operative administration of carprofen (3 mg.kg-1 s.c.). Throughout 
surgical procedures, the body temperature of each rat was maintained using a 
heating pad. 
2.2.3.1. Catheterization surgery 
Two indwelling catheters were surgically implanted in each rat using standard 
surgical techniques: one in the carotid artery for collection of serial blood samples 
and one in the external right jugular vein to facilitate intravenous drug 
administration (Thrivikraman et al., 2002; Huang et al., 2006; Heiser, 2007). All 
catheters were pyrogen-free polyethylene tubing (Instech Laboratories, Plymouth 
Meeting, PA). The arterial and venous catheters consisted of BPE-T25 tubing 
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(0.018"ID x 0.036"OD) and BPE-T50 tubing (0.023"ID x 0.038"OD), respectively. The 
catheters were subcutaneously tunnelled to the back of the neck of the rat, where 
they were exteriorized and connected to three-way Discofix® stopcocks (B. Braun). 
To prevent clotting the catheters were filled with a heparinised saline solution (20 
IU.ml-1).  
2.2.3.2. Microdialysis surgery 
Immediately after completion of catheterization surgery, while still anaesthetized, 
rats were placed in a stereotaxic frame (Model 900 Small Animal Stereotaxic 
Instrument, David Kopf Instruments, Bilaney Consultants, St Julians, Sevenoaks, UK) 
with the skull flat. A small burr hole was made in the skull, centred 2.7 mm anterior 
and 0.7 mm lateral to bregma. The microdialysis probe was slowly lowered 5 mm 
from dura into the prefrontal cortex (PFC) (Paxinos and Watson, 1998) and secured 
with skull screws and dental acrylic. The inlet of the probe was connected to a fluid 
swivel (Instech Laboratories, Plymouth Meeting, PA) and the rats were single-
housed in cylindrical plexiglass containers (Instech Laboratories, Plymouth Meeting, 
PA) filled with bedding and food pellets. The venous and arterial catheters were 
secured to the swivel in the cage to prevent the rats from interfering with them, 
while at the same time enabling free movement. Artificial cerebrospinal fluid (aCSF: 
147 mM NaCl, 1.7 mM CaCl2, 0.9 mM MgCl2, and 4mM KCl) was continuously 
perfused through each microdialysis probe at a rate of 1.5 μl.min-1 by a microlitre 
‘Pico Plus’ syringe pump (Harvard Apparatus, Fircroft Way, Edenbridge, Kent UK) 
and the rats allowed to recover overnight prior to sampling on the following day 
during the optimal post-surgical period (de Lange et al., 2000).  
2.2.4. Dialysis probe construction and calibration 
Vertical concentric microdialysis probes were constructed as described elsewhere 
(Page and Lucki, 2002). Briefly, a piece of fused silica (ID 75 ± 3 µm, OD 150 ± 6 µm; 
CM Scientific Ltd, UK) was inserted through PE10 tubing (Instech Laboratories, 
Plymouth Meeting, PA). A Spectra/Por® Micro-dialysis Hollow Fiber regenerated 
cellulose semipermeable membrane with a 13 kD molecular weight cut-off 
(Spectrum Laboratories, Inc.) was placed over the fused silica and into the PE10 
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tubing, and fixed in place using epoxy adhesive. The open end of the 
semipermeable membrane was sealed with a 0.5 mm epoxy plug, and the active 
area of the fibre, where diffusion takes place across the membrane, was limited to 
3 mm in length by coating regions outside this range with epoxy adhesive. To 
determine the in vitro probe recovery rate, each probe was immersed in a well of 
aCSF containing a known concentration (100 ng.ml-1) of imipramine and 
desipramine. The recovered concentration of imipramine and desipramine in the 
perfusate was expressed as a percentage of the known concentration in the well. 
Probes used in the in vivo studies had in vitro recovery rates between 6.8-12.2% for 
imipramine and 7.0-13.5% for desipramine. As imipramine is known to bind to 
plastic tubing (Friedl and Propping, 1984), it was not possible to calibrate the 
probes in vivo using standard techniques such as the no-net-flux or retrodialysis 
methods, due to imipramine binding to inlet (polyethylene) tubing in the probes 
(unpublished observations). As the diffusion properties of compounds in brain 
tissue are likely different from in vitro conditions, dialysate values were not 
corrected to account for the in vitro recovery rate of the probe. However, it was 
possible to directly compare the uncorrected dialysate concentrations between the 
groups as there was no statistical difference between in vitro probe recovery rates 
across the groups (Table 2.1), thus ensuring comparisons were valid as per 
numerous previous reports (Sato et al., 1994; Evrard et al., 1998; Page and Lucki, 
2002; Page et al., 2010).  
2.2.5. Experimental design 
Rats were separated into three groups: imipramine only (IMI only), imipramine plus 
verapamil (IMI+VER) and imipramine plus CsA (IMI+CsA; n=6 per group) (Figure 2.1). 
Imipramine (5 mg.kg-1 i.v.) was administered to all rats via the jugular vein catheter, 
with or without pre-treatment with either verapamil or CsA, both of which are P-gp 
inhibitors. Rats in the IMI+VERAP group were pre-treated with verapamil (20 mg.kg-
1 i.p.) 90 minutes before imipramine administration. Rats in the IMI+CsA group 
were pre-treated with CsA (25 mg.kg-1 i.v.) 30 minutes before imipramine 
administration. The doses, routes of administration and timing of P-gp inhibitor 
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administration used were based on those previously published in P-gp inhibition 
studies (Tsai et al., 2002; Bart et al., 2003; Syvanen et al., 2006; Liow et al., 2007; 
Clarke et al., 2009). Microdialysis samples (dialysates) from the PFC were collected 
at 20 minute intervals for 1 hour before (blanks) and for 4 hours post-imipramine 
administration. Dialysates were stored at -80oC until analysed by HPLC. Blood 
samples were taken at 8 time-points, one before imipramine administration (blank) 
and one at 5, 15, 30, 60, 120, 180 and 240 minutes post-imipramine administration. 
Blood samples (~ 250 µl) were immediately centrifuged at 5000 rpm for 5 minutes, 
plasma taken and stored at -80oC until extraction for analysis by HPLC with 
electrochemical detection. At the conclusion of the experiment, rats were deeply 
anaesthetized using intravenous ketamine/xylazine mixture, and bromophenol blue 
dye was then infused through the probe to mark its location. The rats were 
subsequently decapitated while under anaesthesia, and the brains removed for 
histological verification of probe placement. Data were discarded if the probe 
placement was outside of the PFC.  
 
 
2.2.6. Plasma extraction 
Imipramine and its active metabolite desipramine were extracted from plasma 
using a liquid-liquid extraction technique as described previously (Clarke et al., 
2009), with some modifications. Briefly, 98 µl of plasma was spiked with 2 µl of the 
internal standard, trimipramine, to yield a final concentration of 20 ng.ml-1 
trimipramine. To this trimipramine-spiked plasma, 1 ml of sodium hydroxide (2 M) 
and 3 ml of water were added. Extraction was carried out in 7.5 ml of 1.5% isoamyl 
alcohol in n-heptane by vortexing for 30 seconds, followed by agitation on a 
mechanical shaker for 15 min and then centrifugation at 5000 RPM for 15 min at 
Figure 2.1: Schematic illustrating experimental design and timelines (refer to text 
in Section 2.2.5 for full details). 
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20°C. The upper solvent layer was transferred to a tube containing 200 µl of 25 mM 
OPA, vortexed for 30 seconds, then agitated on a mechanical shaker for 15 min 
followed by centrifugation at 5000 rpm for 15 min at room temperature.  Twenty 
microlitres of the lower aqueous phase was injected onto the HPLC system for 
analysis. 
2.2.7. HPLC analysis 
2.2.7.1. HPLC equipment 
The HPLC with electrochemical detection (HPLC-ECD) system consisted of a 
Shimadzu LC-20AD XR Prominence Pump, CBM-20A communication bus module, 
SIL-20AC XR Prominence Autosampler, CTO-20A Prominence Column oven (all 
supplied by Mason Technology, Cork, Ireland). System components were used in 
conjunction with Shimadzu LC solutions software (Mason Technology). The detector 
used was ESA Coulochem III with the 5041 Amperometric Cell (Supplied by ESA 
Analytical, Ltd., Brook Farm, Dorton, Aylesbury, Buckinghamshire, HP18 9NH 
England). All samples were injected onto a reversed phase Luna 3 µm C18(2) 150 x 
2 mm column (Phenomenex), which was protected by Krudkatcher Ultra in-line 
filters (Phenomenex). 
2.2.7.2. HPLC conditions 
The HPLC-ECD method was adapted from previously described methods (Sato et al., 
1994; Frahnert et al., 2003). Briefly, the mobile phase which was used on the HPLC 
system consisted of a mixture of potassium dihydrogen phosphate (25 mM, pH 7 
with 4N NaOH) and HPLC grade acetonitrile (56:44). Mobile phase was filtered 
through Millipore 0.22 µm Durapore filters (Millipore, Ireland) and vacuum 
degassed prior to use. Compounds were eluted isocratically over a 30 min runtime 
at a flow rate of 0.4 ml.min-1 after a 20 µl injection. The column was maintained at a 
temperature of 30oC and samples/standards were kept at 8oC in the cooled 
autoinjector prior to analysis. The glassy carbon working electrode combined with a 
platinum reference electrode (ESA) was operated at a potential of 600 mV and a 
range of 50 nA. 
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2.2.7.3. Analyte identification and quantification 
Imipramine, desipramine, verapamil and trimipramine (internal standard) were 
identified by their characteristic retention times as determined by standard 
injections which were run at regular intervals during sample analysis. For the 
extracted plasma samples, analyte:internal standard peak height ratios were 
measured and compared with standard injections, and results were expressed as 
nanograms of analyte per ml of plasma. As no extraction procedure was necessary 
for microdialysis samples, analyte peak heights from undiluted samples were 
compared directly with standard injections and expressed as nanograms of analyte 
per ml of dialysate. The limit of detection (S/N ratio of 2) was 0.22 ng/ml and 0.28 
ng/ml for desipramine and imipramine respectively, while the limit of quantification 
(S/N ratio of 5) was 0.56 ng/ml for desipramine and 0.71 ng/ml for imipramine. The 
co-efficient of variation (% CV) for the HPLC method was 2% for desipramine and 
3% for imipramine (n=8). The accuracy of the technique was determined by carrying 
out the extraction procedure on plasma samples spiked with known concentrations 
of imipramine and desipramine followed by HPLC analysis. The mean (± SEM) 
concentration determined for extracted desipramine and impramine samples were 
96 ± 1 % and 102 ± 1 % of the known spiked concentration respectively (n = 4). 
2.2.8. Data analysis and statistical procedures 
Pharmacokinetic (PK) parameters were calculated from the observed data by non-
compartmental analysis. The area under the concentration-time curve (AUC) for 
imipramine and desipramine in plasma and dialysate samples was calculated using 
the linear trapezoidal method from the first to the last measured plasma 
concentration in all cases. The elimination rate constant (kel) for imipramine in 
plasma was calculated by log-linear regression of the last four plasma concentration 
time-points. The apparent terminal elimination half-life (t1/2) of imipramine in 
plasma was obtained from the kel. Imipramine clearance from plasma (Cl) after i.v. 
bolus dose administration was calculated by dividing the i.v. dose by the AUC. All 
statistical analyses were carried out using standard commercial software (PASW 
Statistics, version 17.0.2; SPSS, Inc., Chicago, IL). Plasma and dialysate concentration 
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versus time profiles were compared using one-way repeated measures ANOVA. 
Statistical analyses of all other parameters were carried out using one-way ANOVA. 
Where a significant overall group effect was observed, the two-sided Dunnett’s 
post-hoc test was used to elucidate differences between the IMI only group and the 
other two groups. All data are reported as mean ± SEM.  The criterion for statistical 
significance was p ≤ 0.05.  
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2.3. Results 
2.3.1. Plasma imipramine and desipramine pharmacokinetics 
There was no significant difference between the groups in terms of imipramine 
levels in plasma over time (F(2, 15) = 0.696, p > 0.05; Figure 2.2A). Furthermore, 
there was no significant difference in mean plasma imipramine AUC values 
between the groups (F(2, 15) = 0.726, p > 0.05; Table 2.1). Plasma pharmacokinetic 
parameters for imipramine are listed in Table 2.1. No statistically significant 
differences between the groups were observed in any of the plasma 
pharmacokinetic parameters.  
Due to transient technical difficulties with baseline stabilisation pertaining to the 
electrochemical detection technique, it was not possible to determine plasma 
desipramine concentrations at certain time-points for 2 of the 18 animals in the 
study. As a result of these missing individual data-points, these animals could not 
be included in repeated measures analysis of plasma desipramine levels, thus 
reducing our group numbers to n= 5 for both the IMI only and IMI+CsA groups for 
the repeated measures ANOVA. Nonetheless, there was a significant overall group 
effect on plasma desipramine levels over time (F(2, 13) = 53.311, p < 0.001; Figure 
2.2B), with significantly higher plasma desipramine concentrations in the 
IMI+VERAP group than the IMI only group at every time-point (Figure 2.2B). In 
addition, there was a significant group effect on mean plasma desipramine AUC 
values (F(2, 15) = 40.689, p < 0.001; Table 2.1), with post-hoc analysis revealing that 
the mean plasma desipramine AUC was significantly higher in the IMI+VERAP group 
than the IMI only group (p < 0.001), with no difference between the IMI only and 
IMI+CsA groups (Table 2.1).  
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Figure 2.2: Plasma imipramine and desipramine profiles 
A. Imipramine concentrations in plasma as measured at different time points. There 
was no statistical difference in imipramine plasma profiles between the 3 groups. B. 
Desipramine concentrations in plasma as measured at different time points. There 
was a significant overall difference between the groups in terms of desipramine 
plasma profiles (p < 0.001). Desipramine levels were markedly increased in the 
IMI+VERAP group relative to the IMI only group at all time points (** p < 0.01; *** p 
<0.001).  
Data are represented as mean ± SEM from 5-6 animals per group. Red square 
symbols with solid line represent IMI only group; green triangular symbols with 
dashed line represent IMI+VERAP group; blue diamond-shaped symbols with dotted 
line represent IMI+CsA group. 
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Table 2.1: Summary of key pharmacokinetic (PK) parameters and probe recovery 
values 
 
IMI only  
mean ± SEM 
IMI+VERAP  
mean ± SEM 
IMI+CsA  
mean ± SEM 
Overall p-
value 
Plasma AUC 
(ng.ml-1 .min) 
IMI 101 635 ± 18 370 88 002 ± 7876 81 041 ± 7350 0.500 
DMI 11 137 ± 2393 46 050 ± 4984 *** 7990 ± 1 527 < 0.001*** 
Imipramine 
plasma PK 
parameters 
kel (min
-1 
x 10-3) 
9.5 ± 1.1 7.9 ± 0.6 8.8 ± 0.7 0.426 
t1/2 
(min) 
79.8 ± 12.3 90.2 ± 7.0 81.5 ± 6.0 0.681 
Cl 
(ml.min-1) 
15.43 ± 2.13 16.05 ± 1.55 17.69 ± 2.21 0.713 
In vitro 
probe 
recovery (%) 
IMI 8.23 ± 0.80 8.91 ± 0.48 8.92 ± 0.66 0.703 
DMI 8.62 ± 0.98 9.56 ± 0.68 9.18 ± 0.57 0.701 
Dialysate 
AUC  
(ng.ml-1 .min) 
IMI 1322 ± 98 1802 ± 144* 2108 ± 169** 0.004** 
DMI n/a1 158.4 ± 14 n/a1 n/a 
Ratio of imipramine 
dialysate AUC: plasma 
AUC 
0.0149 ± 0.0024 0.0215 ± 0.0028 
0.0274 ± 
0.0038* 
0.035* 
AUC, area under the concentration curve; Cl, drug clearance from plasma; DMI, 
desipramine; IMI, imipramine kel, elimination rate constant; t1/2, half-life of drug in 
plasma. 
* p ≤ 0.05; ** p < 0.01; *** p < 0.001 (relative to IMI only group) 
n/a = not available 
1 Below limit of quantification 
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2.3.2. Dialysate imipramine and desipramine pharmacokinetics 
There was a significant overall group effect on dialysate imipramine concentrations 
over time (F(2, 15) = 8.361, p < 0.01; Figure 2.3A), with significantly greater 
dialysate imipramine concentrations observed in the IMI+CsA group than the IMI 
only group between the second and fifth samples inclusive (Figure 2.3A). In 
addition, there was a significant overall difference between the groups in terms of 
dialysate imipramine AUC values (F(2, 15) = 7.533, p < 0.01; Table 2.1). The 
increases in imipramine dialysate AUC values observed in the IMI+VERAP group 
(36% increase; p = 0.05) and IMI+CsA group (59% increase; p < 0.01) relative to the 
IMI only group were statistically significant. Desipramine levels in the dialysate 
samples proved to be below the limit of quantification in the IMI only and IMI+CsA 
groups. However, it was possible to quantify desipramine levels in the dialysate 
from rats in the IMI+VERAP group (Figure 2.3B; Table 2.1), thus suggesting that the 
levels were higher in this group although statistical analysis was precluded by the 
lack of quantifiable samples from the other two groups. 
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Figure 2.3: Dialysate imipramine and desipramine profiles 
A. Imipramine concentrations in the dialysate samples as measured at different time 
intervals. Samples were continually collected and taken for analysis at 20 minute 
intervals. There was a significant overall group effect on dialysate imipramine 
concentrations over time (p < 0.05). Imipramine concentrations were significantly 
higher in the IMI+CsA group than the IMI only group between the second and fifth 
samples, inclusive (* p < 0.05; ** p < 0.01). B. Dialysate desipramine concentrations 
as measured at different time intervals. Note: Desipramine concentrations in 
dialysate samples from the IMI only and IMI+CsA groups were below the limit of 
quantification. The first 5 time-points shown represent mean values of 3-5 animals 
per time-point. At these early time-points, values for the excluded animal(s) were 
below the limit of quantification and were therefore omitted. 
Mean ± SEM; n = 6. Red square symbols with solid line represent IMI only group; 
green triangular symbols with dashed line represent IMI+VERAP group; blue 
diamond-shaped symbols with dotted line represent IMI+CsA group. 
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2.3.3. Comparison of dialysate:plasma imipramine AUC ratios 
The dialysate:plasma imipramine AUC ratio gives an indication of BBB transport as it 
accounts for any variations in plasma imipramine levels which might explain 
observed differences in dialysate concentration. There was a significant overall 
group effect on the ratio of dialysate:plasma imipramine AUC (F(2, 15) = 4.210, p < 
0.05; Table 2.1). Post-hoc analysis revealed that the 84% increase observed in the 
IMI+CsA group relative to IMI only group was statistically significant (p < 0.05), 
while the 44% increase observed in the IMI+VERAP group relative to the IMI only 
group was not statistically significant (Figure 2.4).  
 
  
Figure 2.4: Comparison of dialysate:plasma imipramine AUC ratio 
Dialysate:plasma imipramine area under the curve (AUC) ratio for each 
group, normalised to IMI only group. There was a significant overall group 
effect (p < 0.05), with post-hoc analysis showing that the 84% increase 
evident in the IMI+CsA group is statistically significant (* p < 0.05). The 44% 
increase observed in the IMI+VERAP group did not reach statistical 
significance. 
Data are represented as mean ± SEM from 6 animals per group.  
Horizontally dotted red bar represents IMI only group; diagonally striped 
green bar represents IMI+VERAP group; black and blue checked bar 
represents IMI+CsA group. 
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2.4. Discussion 
Despite some conflicting reports in the literature, much recent evidence highlights a 
potential link between therapeutic response to antidepressants which have been 
shown to be P-gp substrates and functional SNPs in the ABCB1 gene which encodes 
P-gp in humans (Gex-Fabry et al., 2008; Kato et al., 2008; Nikisch et al., 2008; Uhr et 
al., 2008; Sarginson et al., 2010; Lin et al., 2011). The present study demonstrates 
that pre-treatment with either verapamil or CsA, both of which are well-established 
P-gp inhibitors, significantly increases levels of the tricyclic antidepressant 
imipramine in brain ECF without affecting imipramine levels in plasma. This offers 
the intriguing possibility of adjunctive treatment with P-gp inhibitors to enhance 
the BBB penetrating ability of certain antidepressant therapies, which may be 
particularly relevant to TRD.  
Furthermore, the potential to lower the dose of the antidepressant required to 
achieve the same clinical effect when administered in combination with a P-gp 
inhibitor may help to negate some of the problematic peripheral side-effects 
associated with antidepressant therapy. Both verapamil and CsA are first 
generation P-gp inhibitors with other pharmacological activities aside from P-gp 
inhibition (Colabufo et al., 2010). Verapamil is primarily used as a calcium channel 
blocker, while CsA is an immunosuppressive agent. Therefore, unwanted side-
effects associated with other pharmacological actions would likely preclude the 
widespread use of these drugs to achieve adjunctive P-gp inhibition in the 
management of depression. More specific second and third generation P-gp 
inhibitors may represent viable alternatives due to reduced off-target effects. 
However, it is important to be cautious when extrapolating results from preclinical 
rodent studies to the clinical setting due to potential species differences in terms of 
P-gp substrate specificity (Yamazaki et al., 2001; Baltes et al., 2007). 
The P-gp-inhibition-mediated increases in brain antidepressant levels occurred 
independently of any significant alteration in the plasma pharmacokinetics of 
imipramine. Clinical investigations have demonstrated that co-administration of 
verapamil increased imipramine bioavailability following oral administration in 
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healthy volunteers, and it was speculated that this effect was due to reduced oral 
clearance of imipramine (Hermann et al., 1992). In the present study, pre-
treatment with verapamil did not alter the plasma clearance of imipramine (Table 
2.1). We previously reported a significant, but small, increase in serum imipramine 
concentration at a single (terminal) time-point following verapamil pre-treatment 
(Clarke et al., 2009). This effect was not observed in the present study, possibly due 
to the different routes of imipramine administration employed in the two studies 
(i.p. previously versus i.v. in the present study) or the different methods of sampling 
(trunk blood collection following decapitation previously versus sampling from 
indwelling catheter in the present study).  
The ratio of dialysate:plasma imipramine AUC for animals in the IMI+CsA group was 
84% higher than for animals in the IMI only group. This observed difference was 
statistically significant, which strongly suggests enhanced imipramine transport 
across the BBB in CsA-treated animals. Although dialysate imipramine AUC was 
significantly higher in the IMI+VERAP group than the IMI only group, the 44% 
difference in the dialysate:plasma imipramine AUC ratio observed between these 
groups did not reach statistical significance, likely due to the increased variability 
observed when plasma concentrations were taken into account. As both CsA and 
verapamil are well characterised as P-gp inhibitors (Baumert and Hilgeroth, 2009), 
these data corroborate our previous findings (Clarke et al., 2009) and further 
support the hypothesis that P-gp limits the ability of certain antidepressants, 
including imipramine, to cross the BBB (O'Brien et al., 2012b). Moreover, it is worth 
noting that the greater increase in brain imipramine levels observed in the CsA pre-
treated group compared with verapamil pre-treated animals is in agreement with 
CsA being a more potent P-gp inhibitor than verapamil (Hsiao et al., 2008).  
To our knowledge, the present study is the first to employ the microdialysis 
technique to investigate the effect of P-gp inhibition on the ability of 
antidepressants to cross the BBB and enter the brain. The microdialysis approach 
offers several advantages over traditional methods which involve the analysis of 
drug concentrations in brain homogenate samples (de Lange et al., 2000; 
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Hammarlund-Udenaes, 2010). Firstly, samples obtained using the microdialysis 
technique only contain drug which has penetrated the BBB, whereas samples 
obtained from brain homogenates are confounded by the presence of a network of 
blood capillaries throughout the brain. Secondly, microdialysis measures only free 
drug molecules in the brain ECF, whereas the traditional brain homogenate method 
does not typically differentiate between pharmacologically inactive bound and 
active unbound drug. Thirdly, using the microdialysis technique it is possible to 
track fluctuations in brain drug concentrations in individual animals over time with 
or without P-gp inhibition, thus providing temporal resolution which is not possible 
with homogenate-based approaches. In addition, microdialysis enables us to 
investigate the impact of P-gp inhibition on drug concentrations in a specific brain 
region of interest, such as the PFC. While region-specific analysis can be carried out 
using brain homogenate techniques (Clarke et al., 2009), previous studies have 
almost exclusively focused on whole brain antidepressant drug concentrations 
rather than investigating region-specific effects. This is a major limitation of such 
studies considering that there are differences in P-gp expression and function 
between different anatomical regions in the brain (Kwan et al., 2003; Clarke et al., 
2009). Therefore, the use of whole brain analysis previously may have obscured 
important region-specific differences in drug concentrations.  
When comparing dialysate concentrations which have not been corrected to 
account for in vivo probe recovery in microdialysis studies investigating the impact 
of P-gp efflux on the BBB transport of a drug, it is important to consider that 
altering drug clearance by P-gp inhibition will likely have an impact on probe 
recovery (Sawchuk and Elmquist, 2000). However, using mathematical modelling, it 
has been predicted that in vivo probe recovery would be lower in situations where 
efflux processes have been reduced, such as P-gp inhibition (Bungay et al., 1990). 
Moreover, this has proven to be the case experimentally (de Lange et al., 1998; Xie 
et al., 1999). Therefore, it is likely that if it were possible to correct our dialysate 
concentrations for in vivo recovery, and thereby calculate actual brain ECF 
imipramine concentrations, we would in fact see an even more exaggerated 
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increase in brain imipramine levels in the verapamil and CsA pre-treated animals 
relative to the untreated controls.  
Given the different methodology employed in the present study, it is difficult to 
compare the magnitude of the increases in brain imipramine concentrations 
reported here with those reported previously in other studies which have 
investigated the impact of P-gp inhibition on the BBB transport of antidepressants. 
Moreover, it will be of interest to assess how these findings will relate to human 
patients treated chronically with antidepressants.  
Interestingly, verapamil pre-treatment markedly enhanced the concentrations of 
desipramine, an active metabolite of imipramine and an antidepressant in its own 
right, in plasma. The mean AUC for desipramine in plasma in the IMI+VERAP group 
was over 4-fold greater than the corresponding value in the IMI only group and 
almost 6 times greater than the desipramine plasma AUC in the CsA pre-treated 
group. We previously reported a 1.3-fold, non-significant increase in serum 
desipramine levels in verapamil pre-treated rats relative to controls (Clarke et al., 
2009). The greater difference observed in the present study is likely due to 
differences in the experimental protocol (i.e. dosing regimen and sampling 
methods) as discussed previously. The mechanism underlying this verapamil-
mediated increase in plasma desipramine concentrations is unclear at present. 
However, it seems unlikely that it is mediated by P-gp inhibition, as there was no 
increase in plasma desipramine levels in CsA pre-treated animals. In addition to its 
primary pharmacological role as a calcium channel antagonist and its ability to 
inhibit P-gp, verapamil interacts with various other transporters, receptors and 
metabolic enzymes (Auguet et al., 1986; Cole et al., 2000; Polasek et al., 2004; 
Wang et al., 2004d). Moreover, verapamil has been shown to alter the 
pharmacokinetics of several drugs (Backman et al., 1994; Kantola et al., 1998; 
Fleishaker et al., 2000; Kovarik et al., 2005). Thus, it seems likely that the increase in 
plasma desipramine levels might be mediated via one of these alternative 
interactions rather than by inhibition of P-gp.  
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In particular, verapamil has been described as an inhibitor of cytochrome P450 
enzymes (Wang et al., 2004d), and these enzymes play the predominant role in 
imipramine and desipramine metabolism in humans (Lemoine et al., 1993). While 
co-administration of verapamil did not alter imipramine plasma clearance (Table 
2.1), one could speculate that the increase in plasma desipramine levels observed 
in the IMI+VERAP group may be due to verapamil-mediated inhibition of 
desipramine metabolism. In addition, it is worth noting that a functional 
cytochrome P450 monooxygenase system exists in the brain (Ravindranath, 1998). 
Therefore, putative inhibition of these enzymes by verapamil could impact on drug 
levels in the brain.  
The increased desipramine levels in plasma observed in the IMI+VERAP group were 
reflected in the brain, where desipramine levels in microdialysis samples could only 
be reliably quantified in animals pre-treated with verapamil, thus indicating higher 
brain levels in these animals. Whether this increase in brain desipramine 
concentrations plays a role in the putative therapeutic benefit of verapamil 
augmentation in TRD, as anecdotally reported (Clarke et al., 2009), remains to be 
clarified. However, it should be noted that a human study in healthy volunteers 
found that verapamil co-administration had no effect on desipramine 
concentrations in plasma following oral administration of imipramine (Hermann et 
al., 1992). Therefore, the increase in desipramine levels following verapamil pre-
treatment in rats treated with i.v. imipramine observed here might not be relevant 
in humans receiving oral imipramine treatment. As it was not possible to quantify 
desipramine concentrations in dialysate samples from the IMI only or IMI+CsA 
groups, it was not possible to determine whether pre-treatment with either P-gp 
inhibitor had any impact on the BBB transport of desipramine. 
In conclusion, the present study clearly demonstrates that pre-treatment with 
either verapamil or CsA, both of which are P-gp inhibitors, results in increased brain 
levels of the antidepressant imipramine in wild-type rats. This shows that P-gp 
efflux limits the ability of imipramine to cross the BBB. These findings support the 
increasing body of clinical evidence which indicates that P-gp mediated restriction 
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of the ability of certain antidepressants to reach their site of action within the brain 
could potentially be a contributing factor to the high prevalence of TRD. In light of 
these findings, it is tempting to speculate that adjunctive therapy with P-gp 
inhibitors may offer clinical benefits in the treatment of depression. 
 
 134 
Chapter 3:  
Human P-glycoprotein Differentially  
Affects Antidepressant Drug Transport: 
Relevance to Blood-Brain Barrier Permeability 
 
Fionn E. O’Brien1,2,3, Gerard Clarke1,4, Timothy G. Dinan1,4,  
John F. Cryan1,3# and Brendan T. Griffin2,# 
 
1 Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland 
2 School of Pharmacy, University College Cork, Cork, Ireland 
3 Department of Anatomy & Neuroscience, University College Cork, Cork, Ireland 
4 Department of Psychiatry, University College Cork, Cork, Ireland 
 
 
 
 
 
 
 
 
 
 
 
Published in: 
The International Journal of Neuropsychopharmacology (2013) 16(10):2259-2272  
Chapter 3: Antidepressant efflux by human P-gp 
135 
Abstract 
The pharmacological concept that inhibition of the drug efflux pump P-glycoprotein 
(P-gp) enhances brain distribution of the antidepressant imipramine in the rat has 
recently been demonstrated. To determine if these findings are relevant to 
humans, the present studies investigate if imipramine is a transported substrate of 
human P-gp. Furthermore, additional experiments were carried out to determine if 
findings in relation to imipramine and human P-gp would apply to other 
antidepressants from a range of different classes. To this end, bidirectional 
transport experiments were carried out in the ABCB1-transfected MDCKII-MDR1 
cell line. Transported substrates of human P-gp are subjected to net efflux in this 
system, exhibiting a transport ratio (TR) ≥ 1.5, and directional efflux is attenuated 
by co-incubation of a P-gp inhibitor. Imipramine was identified as a transported 
substrate of human P-gp (TR = 1.68, attenuated by P-gp inhibition). However, the 
antidepressants amitriptyline, duloxetine, fluoxetine and mirtazapine were not 
transported substrates of human P-gp (TR ≤ 1.16 in all cases). The present findings 
offer insight into the role of P-gp in the distribution of antidepressants, revealing 
that rodent findings pertaining to imipramine may translate to humans. Moreover, 
the present results highlight that other antidepressants may not be transported 
substrates of human P-gp. 
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3.1. Introduction 
Overcoming treatment resistant depression represents a major challenge in 
psychiatry, with up to 50-60% of depressed patients not achieving adequate 
response following antidepressant treatment (Fava, 2003). Increasing preclinical 
evidence suggests that the multidrug resistance transporter P-glycoprotein (P-gp), 
expressed at the blood-brain barrier (BBB), plays an important role in the brain 
distribution of several, but not all, antidepressants (O'Brien et al., 2012b). These 
findings may be of considerable clinical importance given that drug efflux by P-gp 
can prevent therapeutic brain concentrations of centrally acting drugs from being 
achieved, thereby resulting in treatment failure (Loscher and Potschka, 2005b). 
 Indeed, several gene association studies have recently reported links between 
single nucleotide polymorphisms (SNPs) in ABCB1, the gene which encodes P-gp in 
humans, and treatment response to certain antidepressants (Gex-Fabry et al., 2008; 
Kato et al., 2008; Nikisch et al., 2008; Uhr et al., 2008; Sarginson et al., 2010; Lin et 
al., 2011; Singh et al., 2012). These findings indicate that P-gp efflux at the BBB may 
contribute to the high failure rate of treatment with these antidepressants by 
preventing therapeutic brain levels from being achieved in some patients. However, 
similar pharmacogenetic associations have not been observed for other 
antidepressants (Roberts et al., 2002; Laika et al., 2006; Perlis et al., 2010), 
indicating that P-gp efflux may not be clinically important for all antidepressant 
drugs. It is therefore important to determine if individual antidepressants are 
transported substrates of human P-gp to facilitate prediction of clinically relevant 
interactions with P-gp at the BBB. 
P-gp is a 170-kDa membrane-bound broad-spectrum unidirectional efflux pump, 
also known as multidrug resistance protein 1 (MDR1). As a member of the 
adenosine triphosphate binding-cassette (ABC) superfamily of efflux transporters, 
P-gp uses ATP hydrolysis to power the active efflux of substrate molecules against a 
concentration gradient (Figure 3.1A). Owing to the diverse composition of its 
substrate-binding pocket, which contains distinct drug-binding sites consisting of 
different individual residues, P-gp exhibits remarkably broad polyspecificity and is 
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renowned for its substrate promiscuity (Aller et al., 2009). P-gp is expressed at 
various sites in the body, including the apical membrane of the intestinal epithelial 
cells, the biliary canalicular membrane of hepatocytes and the luminal membrane 
of proximal tubular epithelial cells in the kidney (Marzolini et al., 2004). In addition, 
P-gp is expressed at the luminal membrane of the endothelial cells in the cerebral 
vasculature, where it acts as a “gatekeeper at the BBB” (Schinkel, 1999). 
Despite the abundance of studies which have reported that P-gp restricts brain 
concentrations of various structurally unrelated antidepressants from different 
classes in rodents (Uhr et al., 2000; Uhr and Grauer, 2003; Uhr et al., 2003; Doran et 
al., 2005; Ejsing and Linnet, 2005; Uhr et al., 2008; Clarke et al., 2009; Karlsson et 
al., 2010; Bundgaard et al., 2012; O'Brien et al., 2012a; Karlsson et al., 2013; O'Brien 
et al., 2013b), there has been a paucity of studies which have investigated whether 
these antidepressants are also transported substrates of human P-gp. This is a 
major concern in light of well-documented interspecies differences in terms of P-gp 
substrate specificity and activity (Yamazaki et al., 2001; Katoh et al., 2006; Baltes et 
al., 2007; Syvanen et al., 2009). Of the few in vitro studies which have investigated 
interactions between human P-gp and antidepressants, many have used 
approaches which offer little information regarding drug transport, such as the 
ATPase assay, rather than adopting the gold-standard bidirectional transport 
approach (Balimane et al., 2006; O'Brien et al., 2012b). Furthermore, some of the 
bidirectional transport studies which have included antidepressants to date have 
reported conflicting results, which may be explained by differences in 
methodological approach and highlights well-documented problems associated 
with inter-lab variability (Balimane et al., 2006; O'Brien et al., 2012b). Therefore, it 
is imperative that additional research is carried out in this area to facilitate critical 
evaluation of the role P-gp plays in antidepressant distribution in humans. 
To this end, in vitro bidirectional transport studies were conducted in the ABCB1-
transfected MDCKII-MDR1 cell line (Figure 3.1B) to build on our recent rodent data 
in relation to the tricyclic antidepressant imipramine (Clarke et al., 2009; O'Brien et 
al., 2012a, Chapter 2) by ascertaining if it is also a transported substrate of human 
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P-gp. Furthermore, we investigated if findings in relation to imipramine and human 
P-gp would apply to other structurally distinct antidepressants.  
Five antidepressants were included in the present study, with representatives from 
each of the major antidepressant classes (Table 3.1). Despite their structural 
differences and different classes, these drugs have broadly similar physicochemical 
characteristics, with comparable molecular weights, lipophilicities and dissociation 
constants (Table 3.1). However, the selected antidepressants differ in terms of 
available information regarding their transport by P-gp from in vivo and in vitro 
studies (Table 3.1). We aimed to determine if previous in vivo findings in rodents 
would translate to studies involving human P-gp and to determine if previous in 
vitro findings would be replicated for the selected antidepressants, thereby 
enhancing our understanding of the role P-gp may play in the transport of these 
antidepressant drugs across the BBB in humans. 
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Table 3.1: Antidepressants investigated in the present studies, including their structures, antidepressant classes, physicochemical properties 
and results from previous in vivo and in vitro P-gp studies 
Drug name and 
structurea 
Antidepressant 
Class 
Physicochemical properties  P-gp substrate? 
Refs 
MW Log P pKa In vivo Human P-gp 
Amitriptyline 
TCA 277.4a 4.9a 9.4a Y? Y/N 
(Uhr et al., 2000; Mahar Doan et al., 
2002; Faassen et al., 2003; Grauer and 
Uhr, 2004; Uhr et al., 2007) 
Duloxetine 
SNRI 297.4a 4.0a 9.3b n/a n/a n/a 
Fluoxetine 
SSRI 309.3a 4.6a 8.7b Y/N N 
(Uhr et al., 2000; Mahar Doan et al., 
2002; Doran et al., 2005; Feng et al., 
2008) 
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Drug name and 
structurea 
Antidepressant 
Class 
Physicochemical properties  P-gp substrate? 
Refs 
MW Log P pKa In vivo Human P-gp 
Imipramine 
TCA 280.4a 3.9a 9.4a Y Y/N 
(Mahar Doan et al., 2002; Faassen et 
al., 2003; Clarke et al., 2009; O'Brien 
et al., 2012a) 
Mirtazapine 
NaSSA 265.4a 2.9a 7.7c N n/a (Uhr et al., 2003; Uhr et al., 2008) 
Log P: partition co-efficient; MW: molecular weight; NaSSA: noradrenergic and specific serotonergic antidepressant; pKa: acid dissociation 
constant; SNRI: serotonin and noradrenaline reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant 
a www.drugbank.ca; b MSDS (ehs.lilly.com); c Remeron RDTM Monograph (www.remeronrd.ca) 
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3.2. Methods 
3.2.1. Drugs and chemicals 
High performance liquid chromatography (HPLC) grade acetonitrile, potassium 
dihydrogen phosphate and orthophosphoric acid (OPA) were obtained from Fisher 
Scientific (Ireland). Mirtazapine, duloxetine hydrochloride and fluoxetine 
hydrochloride were purchased from Discovery Fine Chemicals (Dorset, UK). 
Verapamil hydrochloride, imipramine hydrochloride and amitriptyline 
hydrochloride were obtained from Sigma-Aldrich (Ireland), as were all other 
chemicals and materials unless otherwise stated. 
3.2.2. Cell-lines and materials 
MDCKII-WT and MDCKII-MDR1 cells were obtained from the Piet Borst Laboratory 
(Netherlands Cancer Institute, Amsterdam, The Netherlands). Transport 
experiments were carried out using Costar 3414 Polycarbonate Membrane 
Transwell® Inserts (24 mm diameter, 3 µm pore size). 
3.2.3. Cell culture 
Cells were grown in 75 cm2 culture flasks using Dulbecco's Modified Eagle's 
Medium, supplemented with 10% fetal bovine serum and 1% Penicillin-
Streptomycin. Cells were split twice weekly at a dilution of 1:12, and incubated at 
37°C in a humidified 5% CO2 and 95% air atmosphere.  
3.2.4. Western blot analysis 
Expression of P-gp was confirmed by western blot analysis once a month (Figure 
3.1C). The western blot procedure was performed as described previously (Gosselin 
et al., 2010). MDCKII-MDR1 and MDCKII-WT monolayers were grown as per 
transport experiments. Cells were washed with ice-cold phosphate-buffered saline, 
then lysed in lysis buffer (HEPES 20 mM; Np-40 (1%); DTT 0.5 mM; Na3VO4 0.1 mM; 
PMSF 0.1 mM; aprotinin 2 µg/ml; leupeptin 2 µg/ml; NaF 0.02 mM) for 15 min at 
4°C. Cell lysate was centrifuged at 4°C for 10 min at 10 000 rpm. The supernatant 
was stored at -80°C for later analysis. Five micrograms of cell protein were loaded in 
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10-12% SDS-PAGE gel and run at 60-100 V for 120 min. After transfer onto a 0.2-µm 
nitrocellulose membrane and blocking with 5% skimmed milk and 0.1% Tween 20 in 
PBS, blots were probed overnight at 4°C with the C219 primary monoclonal P-gp 
antibody (1:100 dilution in 2% skimmed milk) (Enzo Life Sciences (UK) Ltd, Exeter, 
UK). Reprobing was conducted for 1 h at room temperature using a goat anti-
mouse IgG-HRP conjugate, diluted 1:2000 (Jackson Immunoresearch Europe Ltd). 
Images were obtained using a luminescent image analyzer (LAS-3000; Fujifilm, 
Ireland). For the detection of β-actin, the membranes were incubated with 
Monoclonal Anti-β-Actin−Peroxidase antibody produced in mouse (1:15000). 
Immunoblots were quantified using ImageJ software. 
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Figure 3.1: A Mechanism of efflux by P-gp. P-gp substrates enter the P-gp substrate-
binding pocket (SBP) via portals which are open to the cytoplasm and inner leaflet of 
the lipid bilayer. Binding of ATP to the nucleotide-binding domain (NBD), stimulated 
by interactions between the substrate and residues in the SBP, results in 
dimerization of the NBDs. This triggers a conformational change which sterically 
occludes transport of the substrate into the cytoplasm or the inner leaflet of the 
bilayer. Hence, when the substrate is released, it partitions into the outer leaflet of 
the bilayer or to the extracellular space, thereby preventing transport of the 
substrate across the lipid bilayer (Aller et al., 2009). B Schematic representation of 
the in vitro bidirectional transport model. A monolayer of MDCKII-MDR1 cells, 
cultured on a semi-permeable membrane at the base of a transwell insert, 
separates distinct apical and basolateral chambers. As human P-gp is expressed on 
the apical membrane of MDCKII-MDR1 cells only, it restricts the transport of P-gp 
substrates in the apical-to-basolateral (A→B) direction, but not in the basolateral-
to-apical (B→A) direction. Therefore, transported substrates of human P-gp will 
exhibit lower permeability in the A→B than B→A direction, while non-substrates will 
have similar permeabilities in both directions. C Representative image of western 
blot, confirming greater expression of P-gp in MDCKII-MDR1 cells than MDCKII-WT 
cells. 
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3.2.5. Transport experiments 
The MDCKII-MDR1 cell line is stably transfected with ABCB1 and expresses human 
P-gp on the apical membrane in a polarised fashion when cultured on an 
appropriate transwell support (Pastan et al., 1988). Therefore, transported 
substrates of human P-gp will have lower permeability in the apical-to-basolateral 
(A→B) direction than in the basolateral-to-apical direction (B→A), due to the effect 
of P-gp efflux at the apical membrane, exhibiting a (B→A)/(A→B) transport ratio 
(TR) ≥ 2, while a TR between 1.5 and 2 is inconclusive (Polli et al., 2001; Zhang et al., 
2006). As the MDCKII-MDR1 cell line also expresses endogenous canine kidney 
transporters, the TR in MDCKII-MDR1 cells can be compared to the TR in wild-type 
MDCKII-WT cells to yield a corrected transport ratio (cTR), which in theory isolates 
the effect of human P-gp. A cTR value of ≥ 1.5 indicates the test compound may be 
a transported substrate of human P-gp (Schwab et al., 2003). However, transfection 
with ABCB1 may alter the expression of endogenous transporters (Kuteykin-
Teplyakov et al., 2010). Therefore it is important to repeat transport experiments 
with inhibition of P-gp to confirm that P-gp is responsible for net efflux in MDCKII-
MDR1 cells. In the present studies, where initial transport experiments indicated an 
antidepressant may be a transported P-gp substrate, experiments were repeated 
with co-incubation of the P-gp inhibitors verapamil (200 µM) and CsA (25 µM) as 
previously described (Tang et al., 2002; Taub et al., 2005). For transport 
experiments, cells (passage number: 8-30) were seeded at a density of 2x106 cells 
per well. Cells were allowed to grow to confluency over 4 days with 1.5 ml of 
medium in the apical compartment and 2.6 ml of medium in the basolateral 
compartment. The medium was changed daily and trans-epithelial electrical 
resistance (TEER) measurements were taken each day using an Endohm meter 
(World Precision Instruments, Sarasota, FL) to monitor the development and 
integrity of the cell monolayer. On the days of experiments, the mean (± SD) TEER 
value for MDCKII-WT cells was 194 (± 43) .cm2 and for MDCKII-MDR1 cells was 
387 (± 36) .cm2. Fresh cell culture medium was added two hours before the 
transport experiment. One hour later, cell culture medium was removed and 
monolayers were rinsed twice with transport buffer (Hank’s Balanced Salt Solution 
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[HBSS] with 10mM HEPES). All transport experiments were carried out 
independently in three different transwells (n = 3). Transport experiments were 
conducted by adding the test drug (freshly prepared in transport buffer) to the 
donor chamber and measuring the appearance of drug at 30 minute intervals in the 
receiver chamber over a two hour incubation period at 37°C. Apical and basolateral 
chamber volumes were maintained at 1.5 and 2.6 ml, respectively, throughout the 
transport experiment by replacing the volume (100 µl) removed from the receiver 
chamber at each sampling point with an equal volume of blank transport buffer. In 
addition, a 100 µl sample was taken from the donor chamber at the beginning of 
the experiment, to confirm the initial donor concentration (C0), and at the end of 
the experiment, to facilitate mass balance calculations. For apical-to-basolateral 
(A→B) transport, the apical chamber is the donor chamber and the basolateral 
chamber is the receiver chamber. Conversely, for basolateral-to-apical (B→A) 
transport, the basolateral chamber is the donor chamber and the apical chamber is 
the receiver chamber. For P-gp inhibition studies, the MDCKII-MDR1 cells were pre-
incubated with the P-gp inhibitor on both sides of the monolayer for 30 min before 
addition of the antidepressant, and transport experiments were carried out in the 
presence of the P-gp inhibitor in both chambers throughout the experiment. Fresh 
transport buffer containing the appropriate P-gp inhibitor was replaced in the 
receiver side after sampling. 
3.2.6. Transport experiment calculations 
The apparent permeability coefficient (Papp; unit: cm.s
-1) of antidepressant in each 
individual well was calculated using equation (3.1) (Youdim et al., 2003). 
Importantly, this equation accounts for cellular retention of the test compound, 
which may influence the results obtained from in vitro transport studies and 
therefore needs to be taken into consideration.  
     
  
               
 
   
  
     (3.1) 
where, VD = donor chamber volume (cm
3), A = surface area of the cell monolayer 
(4.67 cm2), MD = initial amount of drug in the donor chamber (mol), Mcells = amount 
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of drug retained by the membrane/cells (mol) and  
   
  
 = change in the amount of 
drug in the receiver chamber over time (mol.s-1).  
The transport ratio (TR), which compares drug permeability in the B→A direction to 
drug permeability in the A→B direction, was calculated using equation (3.2). A TR 
greater than 1 indicates that net efflux of the drug is occurring. A TR value of ≥ 2 
indicates that the test compound is a transported P-gp substrate, while a TR 
between 1.5 and 2 is inconclusive (Polli et al., 2001; Zhang et al., 2006). 
   
       
       
       (3.2) 
The corrected transport ratio (cTR), calculated using equation (3.3), takes the 
effects of endogenous transporters on drug transport across MDCK cells into 
account. Hence, in theory, the effect of human P-gp is evaluated specifically. 
However, transfection with ABCB1 may alter the expression of endogenous 
transporters (Kuteykin-Teplyakov et al., 2010). Therefore, a cTR value of ≥ 1.5, in 
conjunction with a reduction in TR in MDCKII-MDR1 cells on co-incubation of a P-gp 
inhibitor, is required for confirmation that the test compound is a transported P-gp 
substrate (Polli et al., 2001; Schwab et al., 2003). 
    
               
             
     (3.3) 
3.2.7. Analytical procedures 
Samples were analysed by HPLC on a system consisting of a Shimadzu LC-20AD XR 
Prominence Pump, CBM-20A communication bus module, SIL-20AC XR Prominence 
Autosampler, CTO-20A Prominence Column oven, SPD-10A UV detector and RF-10A 
XL fluorescence detector (all supplied by Mason Technology, Cork, Ireland) or ESA 
Coulochem III with 5041 Amperometric Cell electrochemical detector (supplied by 
ESA Analytical, Ltd., Aylesbury, Bucks, England). All samples were injected onto a 
reversed phase Luna 3 µm C18 (2) 150 x 2 mm column (Phenomenex), which was 
protected by Krudkatcher Ultra in-line filters (Phenomenex). 
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The HPLC methods were adapted from previously described methods (Frahnert et 
al., 2003; Rao et al., 2011; O'Brien et al., 2012a). Briefly, the mobile phase which 
was used on the HPLC system consisted of a mixture of 25 mM potassium 
dihydrogen phosphate (25 mM, pH 7 with 4N NaOH) and HPLC grade acetonitrile 
(56:44). Mobile phase was filtered through Millipore 0.22 µm Durapore filters 
(Millipore, Ireland) and vacuum degassed prior to use. Samples in transport buffer 
were diluted 50:50 with mobile phase prior to injection. Compounds were eluted 
individually using an isocratic method over a 15 min runtime at a flow rate of 0.4 
ml.min-1 after 20-40 µl injections. The column was maintained at a temperature of 
30oC and samples/standards were kept at 8oC in the cooled autoinjector prior to 
analysis. The detector used and detection conditions for each antidepressant are 
listed in Table 3.2, along with limits of detection (LOD) and limits of quantification 
(LOQ) for each drug. 
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Table 3.2: HPLC detection conditions and limits of quantification/detection for 
each of the five antidepressants 
Drug Method of 
detection 
Detection 
conditions 
Injection 
volume (µl) LOD (nM) LOQ (nM) 
Amitriptyline UV 230 nm 40 6.6 32.9 
Duloxetine UV 230 nm 40 3.2 15.9 
Fluoxetine UV 230 nm 40 4.7 23.3 
Imipramine ECD 
Potential: 600 
mV; Range: 50 
nA 
20 0.4 1.9 
Mirtazapine FLD 
Excitation: 
290 nm; 
Emission:  
370 nm 
20 35.4 177.7 
C0 = initial concentration in the donor chamber; ECD: electrochemical detection; FLD: 
fluorescent detection; LOD: limit of detection; LOQ: limit of quantification; UV: ultraviolet 
detection 
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3.3. Results 
3.3.1. Imipramine is a transported substrate of human P-gp in 
vitro 
Initial experiments, carried out at 5 µM donor concentration, indicated that 
imipramine may have been a transported substrate of human P-gp. Imipramine 
permeability was greater in the B→A than A→B direction in MDCKII-MDR1 cells (TR 
= 1.35; Table 3.3; Figure 3.2), while there was no net efflux in MDCKII-WT cells (TR = 
0.90; Table 3.3; Figure 3.2). These results yielded a cTR of 1.51, which is in excess of 
the cut-off for identification of a potential P-gp substrate (Figure 3.2). However, the 
results were not conclusive as the TR in MDCKII-MDR1 cells was below 1.5.  
Therefore, additional transport experiments were undertaken at a lower donor 
concentration (1 µM) of imipramine to further investigate its potential efflux by 
human P-gp. At 1µM donor concentration of imipramine, a greater net efflux effect 
was observed in MDCKII-MDR1 cells (TR = 1.63; Table 3.3; Figure 3.2), while there 
remained no difference between imipramine permeability across monolayers of 
MDCKII-WT cells in the A→B and B→A directions (TR = 0.97; Table 3.3; Figure 3.3), 
resulting in a cTR of 1.68 (Figure 3.3).  
As the TR in MDCKII-MDR1 cells was above 1.5 and the cTR indicated that P-gp 
efflux of imipramine was taking place, transport experiments were repeated in the 
presence of the P-gp inhibitors verapamil (200 µM) or CsA (25 µM). Co-incubation 
with verapamil attenuated the directional efflux effect, reducing the TR in MDCKII-
MDR1 cells to 1.11 (Table 3.3; Figure 3.3). Similarly, co-incubation with CsA 
attenuated the directional efflux effect, reducing the TR in MDCKII-MDR1 cells to 
1.05 (Table 3.3; Figure 3.3). Taken together, these results indicate that imipramine 
is a transported substrate of human P-gp.  
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3.3.2. Human P-gp had no effect on the permeability of 
amitriptyline, duloxetine, fluoxetine or mirtazapine in 
vitro 
3.3.2.1. Amitriptyline 
The permeability of amitriptyline was equivalent in A→B and B→A directions in 
both MDCKII-WT (TR = 0.97) and MDCKII-MDR1 cells (TR = 0.87; Table 3.3; Figure 
3.2), thus yielding a cTR of 0.90 (Figure 3.2). These results indicate that human P-gp 
had no impact on amitriptyline transport in this model.  
3.3.2.2. Duloxetine 
The permeability of duloxetine was equivalent in both directions in MDCKII-WT cells 
(TR = 0.93; Table 3.3; Figure 3.2). However, in MDCKII-MDR1 cells, the permeability 
of duloxetine was greater in the A→B direction than in the B→A direction (TR = 
0.72; Table 3.3; Figure 3.2), resulting in a cTR of 0.78 (Figure 3.2). These results 
indicate that human P-gp had no impact on duloxetine transport in this model, but 
may be subject to uptake processes in MDCKII-MDR1 cells.  
3.3.2.3. Fluoxetine 
The permeability of fluoxetine across both MDCKII-WT (TR = 0.80) and MDCKII-
MDR1 (TR = 0.63) cells was greater in the A→B direction than in the B→A direction 
(Table 3.3; Figure 3.2), respectively, resulting in a cTR of 0.78 (Figure 3.2). These 
results indicate that fluoxetine is not a transported substrate of human P-gp in this 
model, but may be subject to uptake processes by endogenous canine kidney 
transporters in both MDCKII-WT and MDCKII-MDR1 cells. 
3.3.2.4. Mirtazapine 
The permeability of mirtazapine was marginally greater in the B→A than A→B 
direction in both MDCKII-WT and MDCKII-MDR1 cells. However, the TRs were 
equivalently low in both cases (1.12 and 1.16, respectively; Table 3.3; Figure 3.2), 
yielding a cTR of 1.04 (Figure 3.2). These results indicate that mirtazapine is not a 
transported substrate of human P-gp in this model.  
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Table 3.3: Permeability values calculated for each antidepressant drug from in 
vitro bidirectional transport studies 
Drug 
Donor 
concentration 
Cell type 
P-gp  
inhibitor 
Papp A→B  
(cm.s-1 x 
10-5) 
Papp B→A  
(cm.s-1 x 
10-5) 
Amitriptyline 5 µM 
MDCKII-WT - 2.47 ± 0.09 2.40 ± 0.04 
MDCKII-MDR1 - 2.10 ± 0.33 1.83 ± 0.18 
Duloxetine 5 µM 
MDCKII-WT - 2.18 ± 0.14 2.02 ± 0.08 
MDCKII-MDR1 - 1.48 ± 0.17 1.07 ± 0.10 
Fluoxetine 5 µM 
MDCKII-WT - 2.32 ± 0.16 1.87 ± 0.19 
MDCKII-MDR1 - 1.91 ± 0.12 1.20 ± 0.07 
Imipramine 
5 µM 
MDCKII-WT - 1.94 ± 0.22 1.74 ± 0.26 
MDCKII-MDR1 - 1.56 ± 0.11 2.11 ± 0.19 
1 µM 
MDCKII-WT - 2.04 ± 0.00 1.98 ± 0.40 
MDCKII-MDR1 - 1.40 ± 0.21 2.28 ± 0.07 
MDCKII-MDR1 Verapamil 1.48 ± 0.12 1.65 ± 0.10 
MDCKII-MDR1 CsA 1.62 ± 0.03 1.70 ± 0.14 
Mirtazapine 5 µM 
MDCKII-WT - 2.05 ± 0.11 2.29 ± 0.08 
MDCKII-MDR1 - 1.96 ± 0.05 2.29 ± 0.01 
Papp: apparent permeability (n = 3; mean ± SD); TR: transport ratio; cTR: corrected transport 
ratio 
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Figure 3.2: Transport ratios (TR) in MDCKII-WT (white bars) and MDCKII-MDR1 cells 
(black bars), as well as corrected transport ratio (cTR) values (black bars with white 
diagonal stripes), for each drug at 5 µM donor concentration (mean ± SD; n = 3). 
Imipramine was the only drug to exhibit net efflux in MDCKII-MDR1 cells (TR = 1.35 
and cTR = 1.51), indicating that it may be a transported substrate of human P-gp. 
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Figure 3.3: Transport ratios (TR) in MDCKII-WT (white bar) and MDCKII-MDR1 cells 
(black bar), as well as the corrected transport ratio (cTR) value (black bar with white 
diagonal stripes), for imipramine at 1 µM donor concentration (mean ± SD; n = 3). 
Imipramine exhibited net efflux in MDCKII-MDR1 cells (TR = 1.63 and cTR = 1.68). 
Transport experiments were repeated in the presence of the P-gp inhibitors verapamil 
(grey bar with horizontal black lines) or CsA (grey bar with black squares) to 
determine if P-gp efflux was responsible for its elevated TR. 
a A compound with a TR of 1.5–2.0 is classified as a P-gp substrate if the directional 
efflux is attenuated by the presence of a P-gp inhibitor (Polli et al., 2001) 
b Above pre-defined cTR threshold for identification of a P-gp substrate (Schwab et al., 
2003) 
c Directional efflux is attenuated by the presence of a P-gp inhibitor 
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3.4. Discussion 
Rodent studies have recently demonstrated that brain levels of the tricyclic 
antidepressant (TCA) imipramine can be augmented in rats by pre-treatment with a 
P-gp inhibitor (Clarke et al., 2009; O'Brien et al., 2012a, Chapter 2). The present 
study using the MDCKII-MDR1 cell-line has revealed that imipramine is also a 
transported substrate of human P-gp. Taken together, these findings indicate that 
P-gp may restrict imipramine transport across the BBB in humans. In addition, the 
present findings serve to clarify conflicting evidence from previous studies as to 
whether imipramine is a transported substrate of human P-gp (Mahar Doan et al., 
2002; Faassen et al., 2003).  
Regarding the previous studies, a TR of 6.04 has been reported for imipramine in 
transport experiments in the Caco-2 cell line, indicating that active efflux processes 
were limiting imipramine transport in the A→B direction (Faassen et al., 2003). 
However, no further experiments to elucidate the transporter(s) responsible for 
this effect were reported, which is vital as the Caco-2 cell line expresses a wide 
variety of transporters in addition to P-gp (Taipalensuu et al., 2001). In contrast, a 
TR of 1.05 was previously reported for imipramine in the MDCKII-MDR1 cell-line 
(Mahar Doan et al., 2002). The discrepancy with present findings may be related to 
differences in the methodological approaches between the two studies. For 
example, the use of an appropriate donor concentration is a key factor in obtaining 
accurate results using in vitro bidirectional transport studies. At higher donor 
concentrations, P-gp may become saturated, leading to functional knockout of P-gp 
activity (Balimane et al., 2006). This may result in false negative findings, even for 
well-known P-gp substrates (Balimane et al., 2006). To avoid this pitfall, it has been 
recommended that donor concentrations of 5 µM or less should be used where the 
sensitivity of the analytical assay permits (Balimane et al., 2006). Whereas the 
previous work of Mahar Doan and colleagues consisted of experiments involving a 
10 µM donor concentration of imipramine, two different lower concentrations of 
imipramine were used in the present study (5 µM and 1 µM). At 5 µM donor 
concentration we observed a trend towards P-gp efflux for imipramine, leading us 
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to carry out further experiments at 1 µM. At this lower donor concentration of 
imipramine (1 µM = 280 ng.ml-1), which reflects therapeutic plasma levels (175-350 
ng.ml-1) (Perry et al., 1994), a clear P-gp efflux effect was observed. In addition, the 
previous transport experiment was conducted over a shorter timeframe, with 
permeability calculations based on samples taken a single time-point at one hour 
(Mahar Doan et al., 2002), whereas the present study involved samples taken at 
several time-points over two hours. It is also important to note that monolayer 
TEER values were not reported in the previous paper (Mahar Doan et al., 2002). As 
a result, it is not possible to compare the confluencies of the monolayers between 
the earlier work and our present studies. 
In contrast to imipramine (TR = 1.35 in MDCKII-MDR1 cells and cTR = 1.51 at 5 µM 
donor concentration), there was no indication that any of the other antidepressants 
included in the present study may be subjected to efflux by human P-gp when 
tested at a 5 µM donor concentration (TR ≤ 1.16 in MDCKII-MDR1 cells and cTR ≤ 
1.04 in each case). These results suggest that none of these antidepressant drugs 
are meaningfully transported substrates of human P-gp. Therefore, further 
transport experiments using additional donor concentrations for each of these 
antidepressants were not carried out. 
The observation that amitriptyline, another TCA which is structurally very similar to 
imipramine (Table 3.1), was not a transported substrate of human P-gp in our in 
vitro bidirectional transport model reveals that findings in relation to imipramine do 
not generalize to other antidepressants, even those from the same class with very 
similar molecular structures. This emphasizes the need to experimentally determine 
interactions between P-gp and drugs, as attempts at prediction based on structural 
and physicochemical properties alone can be fraught with difficulties. Historically, 
efforts to develop quantitative structure-activity relationships for P-gp substrates 
have been challenging (Sharom, 2008). However, recent developments, involving 
larger datasets and taking a complex range of parameters into consideration, have 
yielded more promising results, and may prove to be useful screening tools in the 
early stages of drug development (Desai et al., 2013). The number of hydrogen 
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bond acceptors (HBAs) in a molecule has been identified as one of the key 
properties involved, with an increased number of HBAs associated with a higher 
likelihood of being a P-gp substrate (Desai et al., 2013). Therefore, it is plausible 
that the additional HBA provided by the nitrogen atom in the middle ring of the 
imipramine structure, as opposed to the carbon atom in the analogous position of 
the amitriptyline structure (Table 3.1), may explain why imipramine was found to 
be a transported substrate of human P-gp in the present studies, but amitriptyline 
was not. 
The existing rodent data in relation to the influence of P-gp on amitriptyline brain 
distribution is inconclusive. While it seems that P-gp does limit brain levels of 
amitriptyline in mice (Uhr et al., 2000), this effect appears to be transient and 
dependent on the dosing regimen used (Grauer and Uhr, 2004; Uhr et al., 2007). 
Furthermore, previous in vitro transport investigations pertaining to the efflux of 
amitriptyline by human P-gp have yielded antithetical findings. In common with 
imipramine, it has been reported that amitriptyline may be a transported substrate 
of human P-gp in Caco-2 cells (TR = 4.51) (Faassen et al., 2003), while others 
concluded that it was not following transport experiments in MDCKII-MDR1 cells 
(TR = 1.34) (Mahar Doan et al., 2002). Therefore, the present finding that 
amitriptyline was not a transported substrate of human P-gp helps to bring clarity 
to the role of P-gp in amitriptyline distribution.  
In common with several other antidepressant drugs, most notably paroxetine and 
sertraline (Weiss et al., 2003), the serotonin and noradrenaline reuptake inhibitor 
(SNRI) duloxetine has been reported to be an inhibitor of P-gp (Ruike et al., 2010). 
However, to our knowledge, there has been no study to date, either in vivo or in 
vitro, which has investigated if duloxetine is subject to P-gp efflux. Therefore, the 
finding that human P-gp had no effect on duloxetine permeability in our in vitro 
model offers novel insight into the interaction between duloxetine and P-gp. This 
finding is particularly important given duloxetine’s increasing clinical importance 
and its role in a wide range of indications in addition to depression. Interestingly, in 
vivo studies found that P-gp limits brain levels of another SNRI, venlafaxine (Doran 
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et al., 2005; Karlsson et al., 2010). However, in common with duloxetine, 
venlafaxine was not a transported substrate of human P-gp in vitro (Feng et al., 
2008). This highlights potential species differences and again underlines the 
importance of analysis involving human P-gp such as that reported in the present 
study. 
There are directly conflicting reports in the literature pertaining to the role of P-gp 
in the transport of the selective serotonin reuptake inhibitor (SSRI) fluoxetine 
across the BBB in mice (Uhr et al., 2000; Doran et al., 2005). This discrepancy may 
be attributable to differences between single P-gp knockout strains [e.g. abcb1a(-/-)] 
and double P-gp knockout strains [i.e. abcb1ab(-/-)), as recently highlighted in 
relation to the brain accumulation of glucocorticoids (Mason et al., 2012). However, 
two in vitro transport studies have concurred, reporting that fluoxetine was not a 
transported substrate of human P-gp in MDCKII-MDR1 cells (Mahar Doan et al., 
2002; Feng et al., 2008). The present study corroborates these earlier in vitro 
transport studies, indicating that P-gp is unlikely to influence the brain distribution 
of fluoxetine in patients.  
The present finding that mirtazapine was not a transported substrate of human P-
gp in our in vitro model correlates well with in vivo studies, in which there was no 
difference in brain levels of mirtazapine between wild-type and P-gp knockout mice 
(Uhr et al., 2003; Uhr et al., 2008). While several studies have highlighted potential 
pharmacogenetic interactions between single nucleotide polymorphisms (SNPs) in 
ABCB1 and response to antidepressant treatment (Gex-Fabry et al., 2008; Kato et 
al., 2008; Nikisch et al., 2008; Lin et al., 2011; Singh et al., 2012), there has been 
little consistency regarding the involvement of particular SNPs. Moreover, attempts 
to replicate some of these positive studies have failed (Mihaljevic Peles et al., 2008; 
Peters et al., 2008). In addition, no similar pharmacogenetic association has been 
found for other antidepressants (Roberts et al., 2002; Laika et al., 2006; Perlis et al., 
2010). The often contradictory literature surrounding the role of genetic variations 
of ABCB1 in antidepressant response is complicated by several factors, including the 
lack of clarity regarding the P-gp substrate status of the antidepressants involved in 
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many of the studies. In two recent investigations, the antidepressants involved 
were categorised as P-gp substrates or non-substrates (Uhr et al., 2008; Sarginson 
et al., 2010). These studies reported significant associations between one particular 
SNP (rs2032583) and response to treatment with antidepressants that were P-gp 
substrates, while there was no such association for non-substrates of P-gp (Uhr et 
al., 2008; Sarginson et al., 2010). Based on findings from experiments involving P-gp 
knockout mice (Uhr et al., 2003; Uhr et al., 2008), mirtazapine was used as the non-
P-gp-substrate control in these studies. However, to our knowledge, there were no 
data pertaining to human P-gp available for mirtazapine prior to the present study. 
In light of well-documented species differences in P-gp activity and substrate 
specificity (Yamazaki et al., 2001; Katoh et al., 2006; Baltes et al., 2007; Syvanen et 
al., 2009), it was vital that further experiments to confirm that mirtazapine is not a 
transported substrate of human P-gp were conducted to facilitate informed 
interpretation of these clinical studies. In addition, the finding that amitriptyline, 
duloxetine and fluoxetine were not transported substrates of human P-gp in our in 
vitro bidirectional transport model may help to explain why no association was 
found between ABCB1 SNPs and response to these antidepressants in previous 
clinical studies (Roberts et al., 2002; Laika et al., 2006; Perlis et al., 2010). In 
contrast, two studies have reported pharmacogenetic associations between ABCB1 
SNPs and response to the SSRI escitalopram (Lin et al., 2011; Singh et al., 2012), and 
we have recently identified escitalopram as a transported substrate of human P-gp 
in the same in vitro model as used in the present study (O'Brien et al., 2013b, 
Chapter 4). Moreover, we also demonstrated that inhibition of P-gp enhances the 
brain distribution and antidepressant-like activity of escitalopram in rodents 
(O'Brien et al., 2013b, Chapter 4). Taken together, these data indicate that the P-gp 
inhibition strategy may represent a novel approach to augment escitalopram 
treatment clinically. In light of the present results, it is tempting to speculate that 
the same might apply to imipramine. However, further preclinical and clinical 
studies are required to evaluate the safety and efficacy of this potential strategy. 
In vitro bidirectional transport studies represent the gold standard approach for the 
identification of transported substrates of human P-gp (Balimane et al., 2006). 
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Nonetheless, this approach has its limitations, and it is necessary to be cognisant of 
these when interpreting results from such studies. In particular, the present studies 
involve canine kidney MDCKII cells transfected with human P-gp. The morphological 
properties of this epithelial cell line differ from those of the endothelial cell-type 
found at the BBB (Hellinger et al., 2012). Therefore, the present approach does not 
represent a model of P-gp interactions at the BBB per se. Despite this limitation, 
bidirectional transport experiments using MDCKII-MDR1 cells have been reported 
to be more effective than an in vitro BBB model for the identification of P-gp 
substrates (Hellinger et al., 2012). In addition, in vitro bidirectional transport studies 
are often subject to inter-lab variability, as differences in methodological approach 
may influence the results obtained (Balimane et al., 2006). Therefore, independent 
replication of findings is crucial before definitive conclusions can be safely drawn 
regarding the transport of drugs by human P-gp, in particular where in vitro results 
contradict in vivo findings. In this context, the present study offers value as it 
corroborates previous in vitro reports in relation to fluoxetine and helps to bring 
clarity to conflicting evidence from previous in vitro studies involving imipramine 
and amitriptyline. To further confirm the present findings, additional studies may 
now be warranted. In particular, studies utilising the concentration equilibrium 
transport assay approach, recently described in relation to anti-epileptic drugs 
(Luna-Tortos et al., 2008; Zhang et al., 2010), would be of interest.  
In conclusion, the present in vitro bidirectional transport studies offer valuable 
insights into the role of P-gp in the distribution of antidepressants in humans. The 
results indicate that findings from previous in vivo studies demonstrating that the 
brain distribution of imipramine can be augmented by co-administration of a P-gp 
inhibitor in rats (Clarke et al., 2009; O'Brien et al., 2012a, Chapter 2) may translate 
to humans. Moreover, the present findings emphasize that results relating to 
imipramine and P-gp cannot be readily generalized to other antidepressants, even 
ones from the same class with similar structure. In addition, the present study 
highlights that results from studies using P-gp knockout mice may not translate to 
studies involving human P-gp. It is therefore important to screen individual 
compounds, using appropriate experimental approaches, in order to evaluate 
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interactions with human P-gp. Finally, results from the present studies may help to 
facilitate informed interpretation of previous clinical studies which have 
investigated links between SNPs in ABCB1 and therapeutic response to different 
antidepressants. 
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Abstract 
Despite the clinical prevalence of the antidepressant escitalopram, over 30% of 
escitalopram-treated patients fail to respond to treatment. Recent gene association 
studies have highlighted a potential link between the drug efflux transporter P-
glycoprotein (P-gp) and response to escitalopram. The present studies investigated 
pharmacokinetic and pharmacodynamic interactions between P-gp and 
escitalopram. In vitro bidirectional transport studies revealed that escitalopram is a 
transported substrate of human P-gp. Microdialysis-based pharmacokinetic studies 
demonstrated that administration of the P-gp inhibitor cyclosporin A (CsA) resulted 
in increased brain levels of escitalopram without altering plasma escitalopram 
levels in the rat, thereby showing that P-gp restricts escitalopram transport across 
the blood-brain barrier (BBB) in vivo. The tail suspension test (TST) was carried out 
to elucidate the pharmacodynamic impact of P-gp inhibition on escitalopram effect 
in a mouse model of antidepressant activity. Pre-treatment with the P-gp inhibitor 
verapamil enhanced the response to escitalopram in the TST. Taken together, these 
data indicate that P-gp may restrict the BBB transport of escitalopram in humans, 
potentially resulting in sub-therapeutic brain concentrations in certain patients. 
Moreover, by verifying that increasing escitalopram delivery to the brain by P-gp 
inhibition results in enhanced antidepressant-like activity, we suggest that 
adjunctive treatment with a P-gp inhibitor may represent a beneficial approach to 
augment escitalopram therapy in depression. 
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4.1. Introduction 
Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is among the most 
commonly prescribed and clinically important antidepressants. However, over 30% 
of escitalopram-treated depressed patients fail to respond to treatment, with a full 
remission achieved in only 50% of cases (Kennedy et al., 2006). Recent clinical 
studies have found associations between single nucleotide polymorphisms (SNPs) in 
ABCB1, the gene encoding the multidrug efflux transporter P-glycoprotein (P-gp) in 
humans, and escitalopram response (Lin et al., 2011; Singh et al., 2012). Given that 
drug efflux by P-gp at the blood-brain barrier (BBB) can prevent therapeutic 
concentrations of centrally-acting drugs from being achieved in the brain (Loscher 
and Potschka, 2005b), this genetic association may indicate that escitalopram efflux 
by P-gp at the BBB contributes to the high prevalence of treatment failure (O'Brien 
et al., 2012b). 
Therefore, findings from these clinical studies raise the intriguing possibility that 
augmentation of failed escitalopram treatment with adjunctive P-gp inhibition 
therapy may represent a novel approach to overcome treatment-resistant 
depression in certain patients. Furthermore, in light of recent regulatory guidance, 
which has recommended the limitation of escitalopram doses used clinically due to 
the risk of QT prolongation, especially in the elderly (Medicines and Healthcare 
products Regulatory Agency, 2011), it would be advantageous if it were possible to 
selectively enhance escitalopram delivery to the brain by P-gp inhibition. This could 
facilitate escitalopram dose reduction while maintaining therapeutic response, 
thereby helping to minimise problems associated with peripheral side-effects. 
However, several questions remain to be answered before this potential 
therapeutic strategy becomes realised. For example, it is unknown if escitalopram is 
a transported substrate of human P-gp or if P-gp efflux restricts the transport of 
escitalopram across the BBB. Moreover, it is unknown if any putative enhancement 
of escitalopram brain levels by P-gp inhibition would result in an augmentation of 
its pharmacodynamic activity. While several studies have demonstrated that P-gp 
restricts the brain distribution of various antidepressants in vivo (Uhr et al., 2000; 
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Uhr and Grauer, 2003; Uhr et al., 2003; Grauer and Uhr, 2004; Ejsing and Linnet, 
2005; Uhr et al., 2007; Uhr et al., 2008; Clarke et al., 2009; Karlsson et al., 2010; 
Bundgaard et al., 2012; O'Brien et al., 2012a), it has not yet been determined if 
increasing brain levels of any antidepressant due to P-gp knockout or P-gp 
inhibition results in an augmentation of pharmacodynamic effect in an appropriate 
animal model of antidepressant activity. 
The present study was designed to address these outstanding questions, using a 
combination of in vitro and in vivo approaches to investigate pharmacokinetic and 
pharmacodynamic interactions between P-gp and escitalopram.  
In vitro bidirectional transport studies, using cell-lines which express human P-gp 
(Figure 4.1A), represent the gold standard for the identification of transported 
substrates of human P-gp (Balimane et al., 2006; O'Brien et al., 2012b). This is 
particularly important considering well-established species differences in P-gp 
specificity (Yamazaki et al., 2001; Katoh et al., 2006; Baltes et al., 2007; Syvanen et 
al., 2009). The integrated microdialysis approach adopted in the present 
pharmacokinetic studies facilitated the simultaneous and repeated monitoring of 
plasma and brain levels of escitalopram before and after administration of a P-gp 
inhibitor under steady-state conditions. This approach gives a unique insight into 
the effect of P-gp inhibition on escitalopram transport across the BBB. 
Pharmacodynamic studies were carried out to determine if increasing the delivery 
of escitalopram to the brain by inhibition of P-gp would result in enhanced 
antidepressant-like activity. To this end, the tail suspension test (TST), which is 
among the most commonly used and well-validated preclinical models for the 
assessment of antidepressant activity (Cryan et al., 2005a), was conducted.  
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4.2. Materials and methods 
4.2.1. Drugs and chemicals 
Acetonitrile, potassium dihydrogen phosphate and orthophosphoric acid were 
obtained from Fisher Scientific (Ireland). Heparin sodium solution (Wockhardt UK 
Ltd, UK) and cyclosporin A (CsA; Sandimmun) were purchased from Uniphar Group 
(Ireland). Escitalopram oxalate was purchased from Discovery Fine Chemicals 
(Dorset, UK). Verapamil hydrochloride and imipramine hydrochloride were 
obtained from Sigma-Aldrich (Ireland), as were all other chemicals, reagents and 
materials unless otherwise stated. 
4.2.2. In vitro bidirectional transport studies 
Transport experiments were conducted in MDCKII-WT and MDCKII-MDR1 cells, 
obtained from the Laboratory of Prof. Piet Borst (Netherlands Cancer Institute, 
Amsterdam, The Netherlands), as described in detail in the supplementary 
information (Section 4.5.1). The MDCKII-MDR1 cell line is transfected with ABCB1 
and expresses human P-gp on the apical membrane in a polarised fashion when 
cultured on an appropriate transwell support (Pastan et al., 1988). Therefore 
transported substrates of human P-gp will have lower permeability in the apical-to-
basolateral (A→B) direction than in the basolateral-to-apical direction (B→A) due to 
the effect of P-gp efflux at the apical membrane, exhibiting a (B→A)/(A→B) 
transport ratio (TR) ≥ 2 (Polli et al., 2001; Zhang et al., 2006). 
 As the MDCKII-MDR1 cell line also expresses endogenous canine kidney 
transporters, the TR in MDCKII-MDR1 cells can be compared to the TR in wild-type 
MDCKII-WT cells to yield a corrected transport ratio (cTR), which in theory isolates 
the effect of human P-gp. A cTR value of ≥ 1.5 indicates the test compound is a 
transported substrate of human P-gp (Schwab et al., 2003). However, transfection 
with ABCB1 may alter the expression of endogenous transporters (Kuteykin-
Teplyakov et al., 2010). Therefore it is important to repeat transport experiments 
with inhibition of P-gp to confirm that P-gp is responsible for net efflux in MDCKII-
MDR1 cells. The P-gp inhibitors verapamil (200 µM) and CsA (25 µM) were used in 
the present study as previously described (Tang et al., 2002; Taub et al., 2005). 
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Expression of P-gp was confirmed by western blot as described in the 
supplementary information (Section 4.5.1.3). 
4.2.3. In vivo pharmacokinetic studies 
4.2.3.1. Animals 
Male Sprague Dawley rats (Harlan Laboratories, UK), weighing 250-320 g, were 
used in this study (total n = 10). Animals were group-housed 4-6 animals per cage 
and maintained on a 12 hour light/dark cycle (lights on at 08:00 h) with food and 
water ad libitum. Room temperature was controlled at 22 ± 1°C. All procedures 
were carried out in accordance with EU directive 89/609/EEC and approved by the 
Animal Experimentation & Ethics Committee of University College Cork. 
4.2.3.2. Microdialysis probe construction and calibration 
Microdialysis probes were constructed as previously described (O'Brien et al., 
2012a, Chapter 2). In vitro probe recovery values ranged from 5.64 to 8.28% for 
escitalopram. Dialysate values were not corrected to account for in vitro recovery, 
as the diffusion properties of compounds in brain tissue are likely different from in 
vitro conditions. Rather, dialysate values are expressed as a percentage of steady 
state concentration, calculated independently for each individual animal. 
4.2.3.3. Surgical procedures 
To facilitate intravenous and intra-arterial drug administration, as well as the 
collection of serial blood samples, the jugular vein and carotid artery of each rat 
were catheterised using standard surgical techniques, and microdialysis probes 
were inserted into the prefrontal cortex (PFC: 2.7 mm anterior and 0.7 mm lateral 
to bregma, lowered 5 mm from dura (Paxinos and Watson, 1998), as described 
previously (O'Brien et al., 2012a, Chapter 2). Post-surgery, rats were single-housed 
in cylindrical plexiglass containers with the probe inlet connected to a fluid swivel 
(Instech Laboratories, Plymouth Meeting, PA). Artificial cerebrospinal fluid (aCSF: 
147 mM NaCl, 1.7 mM CaCl2, 0.9 mM MgCl2, and 4mM KCl) was perfused through 
each microdialysis probe at a rate of 1.5 μl.min-1. Rats were allowed to recover 
overnight prior to sampling on the following day during the optimal post-surgical 
period (de Lange et al., 2000).  
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4.2.3.4. Experimental design 
Rats were separated into two groups: Escitalopram plus vehicle (Escit+VEH) and 
escitalopram plus CsA (Escit+CsA; n = 5 per group). To achieve and maintain steady 
state levels of escitalopram (Bundgaard et al., 2007), a bolus dose of escitalopram 
(6 mg.kg-1 i.v.) was administered to all rats at time (t) = 0 min, followed by a 
continuous escitalopram infusion (4 mg.kg-1.h-1 i.v.). Rats in the Escit+CsA group 
were treated with the P-gp inhibitor CsA (25 mg.kg-1 intra-arterial) (O'Brien et al., 
2012a, Chapter 2) after steady state escitalopram levels had been achieved at t = 
120 min. Rats in the Escit+VEH group received the same volume (2 ml.kg-1) of 
vehicle (1/12 ethanol: 2/12 Cremophor EL: 9/12 saline) at t = 120 min. Microdialysis 
samples were collected at 20 min intervals, and stored at -80oC until analysed by 
HPLC. Plasma samples (~ 250 µl) were collected at seven time-points: one before 
escitalopram administration (blank) and one at 10, 40, 80, 120, 160 and 220 min 
post-escitalopram bolus administration, and stored at -80oC until extraction for 
HPLC analysis. At the conclusion of the experiment (t = 220 min), rats were 
euthanized by intra-arterial administration of sodium pentobarbital. Brains were 
subsequently removed and dissected. The right hemisphere was taken for 
histological verification of probe placement. The PFC and hippocampus were taken 
from the contralateral hemisphere to determine escitalopram concentration in 
brain tissue at the termination of the experiment. Escitalopram was extracted from 
plasma and brain tissue using a liquid-liquid extraction technique described in 
supplementary information (Section 4.5.2).  
4.2.4. In vivo pharmacodynamic studies 
4.2.4.1. Tail suspension test 
The tail suspension test (TST), one of the most widely used assays for assessing 
antidepressant activity in rodents (Cryan et al., 2005a), was carried out using male 
C57BL/6JOlaHsd mice (Harlan Laboratories, UK; 6-8 weeks old; total n= 67), as 
described previously (O'Connor and Cryan, 2013). This allowed an assessment of 
the pharmacodynamic impact of pre-treatment with the P-gp inhibitor verapamil 
on escitalopram activity. Briefly, after a 5-7 day acclimation period, mice were pre-
treated with either the P-gp inhibitor verapamil (20 mg.kg-1 i.p.) or saline one hour 
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before administration of either escitalopram (0.1 mg.kg-1 or 1 mg.kg-1 i.p.) or saline. 
Thirty minutes after the second injection, mice were individually suspended by the 
tail from a horizontal bar using adhesive tape. Six minute test sessions were 
recorded by a video camera and subsequently scored by a trained observer blind to 
the treatment groups. The amount of time spent immobile by the animal was 
recorded. Brain tissue (PFC and hippocampus) was harvested from each animal 10 
min after commencement of the TST and brain escitalopram and verapamil levels 
were determined using the extraction procedure described in the supplementary 
information (Section 4.5.2). 
4.2.4.2. Locomotor activity 
To investigate potential locomotor effects, which would confound analysis of 
behavioural data from the TST, the impact of drug treatment on locomotor activity 
was assessed as previously described (O'Connor and Cryan, 2013). A separate 
cohort of mice were pre-treated with either the P-gp inhibitor verapamil (20 mg.kg-
1 i.p.) or saline one hour before administration of either escitalopram (0.1 mg.kg-1 
i.p.) or saline, thus resulting in 4 groups. Thirty minutes after the second injection, 
mice were individually placed in activity monitoring units (27 cm X 21 cm). Activity 
was then monitored via beam breaks for 60 minutes.  
4.2.5. HPLC analysis 
Samples were analysed by HPLC using a reversed phase Luna 3 µm C18(2) 150 x 2 
mm column (Phenomenex). The HPLC method was adapted from previously 
described methods (Frahnert et al., 2003; Unceta et al., 2011). Briefly, the mobile 
phase consisted of a mixture of 25 mM potassium dihydrogen phosphate (25 mM, 
pH 7 with 4N NaOH) and HPLC grade acetonitrile (56:44). Compounds were eluted 
isocratically over a 15 min runtime at a flow rate of 0.4 ml.min-1 after a 20 µl 
injection. The UV detector was set to 230 nm and the fluorescent detector was set 
to 249 nm excitation and 302 nm emission. Escitalopram, imipramine (internal 
standard) and verapamil were identified and quantified based on their 
characteristic retention times and peak heights as determined by standard 
injections which were run at regular intervals during sample analysis. The limit of 
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quantification (LOQ) for escitalopram was 6.25 ng.ml-1. The coefficients of variation 
(% CV) for the HPLC method were 9.02%, 2.04% and 0.34% at 6.25 ng.ml-1 (LOQ), 20 
ng.ml-1 (typical of microdialysis samples) and 1000 ng.ml-1 (typical of extracted 
plasma or brain samples), respectively. 
4.2.6. Data analysis and statistical procedures 
All statistical analyses were carried out using standard commercial software (SPSS 
Statistics, version 20.0.0; SPSS, Inc., Chicago, IL). Plasma and dialysate concentration 
versus time profiles were analyzed using one-way repeated measures ANOVA. 
Where significant overall group or time effects were observed, unpaired t-test or 
LSD post-hoc test were used to elucidate differences between or within the groups, 
respectively. Statistical analyses of differences between the two groups for all other 
parameters pertaining to in vivo pharmacokinetic studies were carried out using 
unpaired t-test. Results from the TST and locomotor studies were analysed 
statistically by one-way ANOVA with LSD post-hoc. The strength of the association 
between immobility in the TST and brain escitalopram concentrations was 
evaluated using the Spearman rank-order correlation analysis. The criterion for 
statistical significance was p ≤ 0.05. 
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4.3. Results 
4.3.1. In vitro bidirectional transport studies 
4.3.1.1. Western blot analysis 
Western blot analysis confirmed that expression of P-gp in ABCB1-transfected 
MDCKII-MDR1 cells was higher than endogenous P-gp expression in MDCKII-WT 
cells (Figure 4.1B). 
4.3.1.2. Human P-gp limited escitalopram transport across MDCKII-
MDR1 cells 
The transport ratio (TR) compares drug permeability across the cell monolayer in 
the basolateral-to-apical (B→A) direction to drug permeability in the apical-to-
basolateral direction (A→B). Drugs which are transported substrates of human P-gp 
will have greater permeability in the B→A than A→B direction (i.e. TR > 1) in 
MDCKII-MDR1 cells, due to P-gp efflux restricting drug transport in the A→B 
direction only (Figure 4.1A). To account for the potential impact of endogenous 
transporters of MDCK cells, a corrected transport ratio (cTR) is determined relative 
to wild-type cells.  
In MDCKII-WT cells, which are not transfected with ABCB1 and therefore do not 
express human P-gp, the apparent permeability (Papp) of escitalopram was greater 
in the B→A than A→B direction, with a TR of 2.32 (Figure 4.1C and Table 4.1). This 
indicates that endogenous MDCK transporters exert a net efflux effect on 
escitalopram.  
In MDCKII-MDR1 cells, which express human P-gp on the apical membrane only 
(Figure 4.1A), the difference between B→A and A→B Papp was greater than in 
MDCKII-WT cells, as evidenced by the TR of 7.22 and cTR of 3.11 (Figure 4.1D and 
Table 4.1). Therefore, both the TR and cTR for escitalopram substantially exceeded 
the recommended TR and cTR thresholds of 2 and 1.5, respectively, for the 
identification of transported substrates of human P-gp (Polli et al., 2001; Schwab et 
al., 2003; Zhang et al., 2006). Moreover, co-incubation of the P-gp inhibitor 
verapamil (200 µM) reduced the TR in MDCKII-MDR1 cells to 1.51 (Figure 4.1E and 
Table 4.1). Similarly, co-incubation of another P-gp inhibitor, CsA (25 µM), reduced 
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the TR to 3.33 in MDCKII-MDR1 cells (Figure 4.1F and Table 4.1). Taken together, 
the data from this series of in vitro bidirectional transport experiments 
demonstrate that escitalopram is a transported substrate of human P-gp.  
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Figure 4.1: In vitro bidirectional transport studies A Schematic illustrating the in vitro bidirectional transport assay. MDCKII-MDR1 cells 
express human P-gp in a polarised fashion at the apical membrane only when cultured on a transwell support. When substrates of human P-
gp are added to the apical chamber, their transport across the monolayer of cells is restricted by P-gp efflux, thereby reducing their apical-
to-basolateral (A→B) permeability. When substrates of human P-gp are added to the basolateral chamber, P-gp does not limit their 
transport across the monolayer as it is not expressed at the basolateral membrane. Therefore, human P-gp substrates will have greater 
permeability in the basolateral-to-apical (B→A) direction than in the A→B direction, and directional efflux is attenuated by co-incubation of 
a P-gp inhibitor. Bidirectional transport studies are also carried out in MDCKII-WT cells, which do not express human P-gp, to determine the 
influence of endogenous transporters, including canine P-gp, on drug permeability. B Representative image of western blot demonstrating 
over 4.5-fold greater expression of P-gp in MDCKII-MDR1 cells than MDCKII-WT cells. C-D Escitalopram accumulation in receiver chamber 
over time in MDCKII-WT and MDCKII-MDR1 cells. Escitalopram crossed the monolayer to a greater extent in the B→A direction than A→B 
direction in both MDCKII-WT (C) and MDCKII-MDR1 (D) cells, indicating net efflux in both cell lines. However, the magnitude of the efflux 
effect was substantially greater in MDCKII-MDR1 cells, highlighting a role for human P-gp. E-F Escitalopram accumulation in receiver 
chamber over time in MDCKII-MDR1 cells with co-incubation of the P-gp inhibitors verapamil (E) or CsA (F). Co-incubation with either P-gp 
inhibitor attenuated the directional efflux of escitalopram, thereby confirming that escitalopram is a transported substrate of human P-gp 
(mean ± SEM; n = 3 in all experiments). 
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Table 4.1: Apparent permeability (Papp), transport ratio (TR) and corrected transport ratio (cTR) values from in vitro bidirectional transport 
studies 
Cell-type 
Treatment  
(P-gp inhibitor) 
Papp A→B 
(x10-6 cm.s-1) 
Papp B→A 
(x10-6 cm.s-1) 
TR cTR 
MDCKII-WT None 7.75 ± 0.33 18.00 ± 0.51 2.32 n/a 
MDCKII-MDR1 None 2.11 ± 0.10 15.23 ± 0.51 7.221 3.111 
MDCKII-MDR1 
Verapamil  
(200 µM) 
4.87 ± 0.65 7.36 ± 1.13 1.51 n/a 
MDCKII-MDR1 
CsA   
(25 µM) 
3.35 ± 0.39 11.12 ± 0.42 3.33 n/a 
1 Exceeds pre-defined threshold for identification of a transported P-gp substrate (Polli et al., 2001; 
Schwab et al., 2003; Zhang et al., 2006) 
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4.3.2. In vivo pharmacokinetic studies 
4.3.2.1. P-gp inhibition had no effect on plasma escitalopram 
pharmacokinetics 
Both CsA- and vehicle-treated groups exhibited similar plasma escitalopram 
pharmacokinetics, with no group effect on plasma escitalopram levels over time 
(F(1, 8) = 0.104, p = 0.756; Figure 4.2A). Steady-state plasma escitalopram levels 
were reached within 120 min. However, after administration of either vehicle or 
CsA at t = 120 min, an equivalent 15-20% increase in plasma escitalopram 
concentrations, compared to steady-state levels, was evident in both groups. As 
there was no difference between the groups in terms of plasma escitalopram 
pharmacokinetics, any differences in brain escitalopram concentrations observed 
between the groups can be attributed to altered BBB transport. 
4.3.2.2. P-gp inhibition increased escitalopram concentration in 
microdialysis samples 
Steady-state dialysate levels of escitalopram were achieved within 120 min in all 
cases. There was a statistically significant difference between the groups in terms of 
dialysate escitalopram profiles (F(1, 8) = 11.569, p = 0.009; Figure 4.2B). There was 
also a significant overall time effect (F(7, 56) = 24.763, p < 0.001), in addition to a 
significant group x time interaction (F(1,56) = 10.160, p < 0.001).  
In the Escit+VEH group, administration of vehicle resulted in an increase in dialysate 
escitalopram levels relative to steady-state. This increase mirrored the 15-20% 
increase evident in plasma levels and reached a maximum 17.08% at the 200 min 
time-point, thereby indicating that administration of vehicle had no effect on the 
transport of escitalopram across the BBB. The increase from steady-state was 
statistically significant from 180 min onwards (Figure 4.2B). 
In the Escit+CsA group, treatment with the P-gp inhibitor CsA resulted in an 
increase from steady state levels, reaching a maximum increase of 66.94% at t = 
220 min with a statistically significant elevation relative to steady-state from t = 160 
min onwards (Figure 4.2B). Moreover, the increase in the Escit+CsA group was 
significantly greater than that observed in the Escit+VEH group from t = 160 min 
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onwards (Figure 4.2B). Taken together, these in vivo plasma and microdialysis 
pharmacokinetic data demonstrate that inhibition of P-gp results in enhanced BBB 
transport of escitalopram. 
4.3.2.3. Brain tissue escitalopram concentrations were increased 
following P-gp inhibition 
At termination of the microdialysis experiment, PFC brain tissue escitalopram 
concentrations were over three times greater in CsA-treated animals than vehicle-
treated controls (t(8) = 8.602, p < 0.001; Figure 4.2C). Moreover, the PFC brain 
tissue:plasma escitalopram concentration ratio was also elevated over three-fold in 
CsA-treated animals relative to controls (t(5.617) = 5.617, p = 0.004; Table 4.2), thus 
demonstrating that escitalopram transport across the BBB is significantly increased 
by P-gp inhibition. 
Similarly, hippocampal brain tissue escitalopram concentrations were more than 
2.5 times greater in CsA-treated animals than vehicle-treated controls (t(8) = 
11.047, p < 0.001; Figure 4.2D). In addition, the hippocampal brain tissue:plasma 
escitalopram concentration ratio was elevated more than 2.75-fold in CsA-treated 
animals relative to vehicle-treated controls (t(8) = 5.458, p = 0.001; Table 4.2). 
These findings corroborate the microdialysis results, and demonstrate that 
inhibition of P-gp results in enhanced transport of escitalopram across the BBB. 
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Figure 4.2: In vivo pharmacokinetic studies A Plasma escitalopram pharmacokinetics. There was no difference in escitalopram 
plasma pharmacokinetics between vehicle- and CsA-treated animals. Steady state plasma escitalopram levels were achieved within 
120 min in both groups. Administration of vehicle or the P-gp inhibitor CsA resulted in an equivalent 15-20% increase in plasma 
escitalopram levels from steady state in both groups. B Dialysate escitalopram pharmacokinetics. Steady state dialysate 
concentrations of escitalopram were also achieved in both groups within 120 min. Administration of vehicle resulted in a significant 
17% increase in dialysate escitalopram concentration from steady state levels, which mirrored increases observed in plasma. 
Administration of the P-gp inhibitor CsA resulted in a 67% increase from steady state, which was significantly greater than that 
observed in the vehicle-treated group. C-D Brain tissue escitalopram concentrations. Escitalopram concentrations in brain tissue at 
termination of in vivo pharmacokinetic studies were significantly greater in CsA-treated animals than vehicle-treated animals in 
both the prefrontal cortex (C) and the hippocampus (D) (mean ± SEM; n = 5 per group for all graphs). 
* p < 0.05; ** p < 0.01; *** p < 0.001 between the groups 
# p < 0.05; ## p < 0.01; ### p < 0.001 compared to steady-state levels 
  
 178 
 
 179 
Table 4.2: Escitalopram concentrations in plasma and brain tissue, and brain tissue:plasma escitalopram concentration ratios at termination 
of in vivo pharmacokinetic studies 
Group  Plasma  Prefrontal Cortex  Hippocampus 
  (ng.ml-1)  (ng.g-1) B:P1 Ratio  (ng.g-1) B:P1 Ratio 
Escit+VEH  709 ± 26  7 074 ± 438 10.09 ± 0.87  7 999 ± 638 11.43 ± 1.19 
Escit+CsA  678 ± 76  21 827 ± 1658 33.59 ± 4.09  20 432 ± 927 31.48 ± 3.48 
p-value  0.709  < 0.001*** 0.004**  < 0.001*** 0.001** 
1 Brain region:plasma ratio 
n = 5 per group; ** p < 0.01; *** p < 0.001 
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4.3.3. In vivo pharmacodynamic studies 
4.3.3.1. Verapamil augmented escitalopram response in tail suspension 
test 
The tail suspension test (TST) is one of the most widely used models for the 
assessment of antidepressant activity in mice (Cryan et al., 2005a). When subjected 
to the short term inescapable stress of suspension by the tail, mice adopt an 
immobile posture. Treatment with antidepressant medications, including 
escitalopram (Zomkowski et al., 2010), reduces the time spent immobile in this 
paradigm in a dose-responsive manner (Cryan et al., 2005a).  
In the present study, it was found that pre-treatment with the P-gp inhibitor 
verapamil augmented the antidepressant response at both doses of escitalopram 
investigated (Figure 4.3A). There was a significant overall difference between the 
groups in immobility in the TST (F(5, 61) = 6.964, p < 0.001; Figure 4.3A). Post-hoc 
analysis revealed that the 23 second reduction in immobility, compared to control 
animals, observed in mice treated with the lower dose of escitalopram (0.1 mg.kg-1) 
without verapamil pre-treatment was not statistically significant (p = 0.168). Pre-
treatment with verapamil augmented the response to this lower dose of 
escitalopram by over 60%, resulting in a statistically significant 38 second reduction 
in immobility versus controls (p = 0.01). Moreover, while treatment with the higher 
dose of escitalopram (1 mg.kg-1) led to a significant reduction in immobility with or 
without pre-treatment with verapamil (p = 0.001 and p < 0.001 respectively), the 
magnitude of the reduction was augmented by almost 40% following pre-treatment 
with verapamil (Figure 4.3A). These results demonstrate that inhibition of P-gp 
augments the antidepressant-like effect of escitalopram in the TST. 
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4.3.3.2. Effects of escitalopram and verapamil in the TST were not a 
function of increased locomotor activity 
Treatments which lead to increased locomotor activity could cause a reduction in 
immobility in the TST unrelated to antidepressant-like activity. To investigate this 
potential confounding factor, the effects of the present drug treatments on 
locomotor activity were assessed. There was a significant difference in locomotor 
activity between the groups (F(3, 23) = 4.605, p = 0.012; Figure 4.3B). Post-hoc 
analysis revealed that mice in receipt of pre-treatment with verapamil exhibited 
decreased locomotion relative to saline-treated controls, whether subsequently 
treated with saline (p = 0.016) or escitalopram (p = 0.002). Administration of 
escitalopram without verapamil pre-treatment had no effect on locomotor activity 
(p = 0.252). As locomotor activity was not increased by treatment with verapamil 
and/or escitalopram, the decreases in immobility observed in the TST can be 
attributed to the antidepressant-like activity of escitalopram, as opposed to being 
an artefact of increased locomotion. 
4.3.3.3. Brain tissue concentrations of escitalopram were increased 
following verapamil pre-treatment 
Brain tissue escitalopram concentrations were significantly greater in mice pre-
treated with the P-gp inhibitor verapamil than control mice at both doses of 
escitalopram treatment (Figure 4.3C). Pre-treatment with verapamil resulted in a 
greater than two-fold increase in brain escitalopram levels in mice treated with 0.1 
mg.kg-1 of escitalopram (t(17) = -3.010, p = 0.008) and a greater than 1.75-fold 
increase in brain escitalopram levels in mice treated with 1 mg.kg-1 of escitalopram 
(t(10) = -6.516, p < 0.001). Verapamil concentration in brain tissue was consistent 
across the three verapamil-treated groups (1 163 ± 53 ng.ml-1). These results 
confirm that administration of verapamil as a P-gp inhibitor resulted in increased 
brain levels of escitalopram in the mice during the TST. 
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4.3.3.4. Correlation between brain escitalopram concentration and 
immobility in the TST 
There was a moderately strong and statistically significant negative correlation 
between escitalopram concentration in brain tissue and immobility in the TST (rs = -
0.594, n = 56, p < 0.001; Figure 4.3D). This indicates that the decreased immobility 
observed in escitalopram-treated mice in receipt of verapamil pre-treatment was 
related to the increased delivery of escitalopram to the brains of these animals. 
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Figure 4.3: In vivo pharmacodynamic studies A Tail suspension test. Treatment with escitalopram reduced the time spent immobile in the TST 
in a dose dependent manner. Treatment with verapamil without escitalopram had no impact on immobility. However, pre-treatment with 
verapamil augmented the antidepressant-like effect of escitalopram in the TST, further reducing the time spent immobile at both doses of 
escitalopram (mean ± SEM; n = 8-17 per group). B Locomotor activity. Treatment with verapamil, escitalopram or both did not increase 
locomotor activity, indicating that the reductions in immobility observed in the TST were due to antidepressant-like effects. In fact, treatment 
with verapamil reduced locomotor activity, with or without escitalopram treatment (mean ± SEM; n = 6-7 per group). C Brain tissue 
escitalopram concentrations. Pre-treatment with the P-gp inhibitor verapamil before administration of escitalopram significantly increased 
brain concentrations of escitalopram in mice used in the TST at both doses of escitalopram treatment (mean ± SEM; n = 6-12 per group). D 
Correlation between brain escitalopram concentration and immobility in the TST. There was a moderately strong negative correlation 
between escitalopram concentration in brain tissue and immobility in the TST (rs = -0.594, n = 56, p < 0.001). 
* p < 0.05; ** p < 0.01; *** p < 0.001 relative to saline-saline control group (or between two groups where indicated in Figure 4.3C) 
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4.4. Discussion 
The present findings clearly demonstrate that P-gp modulates the pharmacokinetics 
and pharmacodynamics of the widely prescribed antidepressant escitalopram. In 
showing that escitalopram is a transported substrate of human P-gp, and that 
pharmacological inhibition of P-gp results in enhanced escitalopram transport 
across the BBB in vivo, we open up the concept that P-gp inhibition may be a viable 
and potentially safe strategy to augment the effects of escitalopram. Moreover, we 
bolster this hypothesis by showing a pharmacodynamic consequence of elevated 
brain levels of escitalopram by P-gp inhibition in a relevant animal model of 
antidepressant activity. These novel findings are especially important in light of 
recent clinical studies which have found associations between SNPs in ABCB1 and 
response to escitalopram treatment  (Lin et al., 2011) and the dose of escitalopram 
required to achieve remission in major depression (Singh et al., 2012). While there 
is generally no clear correlation between antidepressant plasma levels and 
therapeutic efficacy (Perry et al., 1987; Spina et al., 1997; Normann et al., 2004), it 
has been proposed that inter-individual variability in BBB transport, due to genetic 
differences in P-gp functionality, may lead to clinically relevant differences in the 
brain distribution of certain antidepressants (Kato et al., 2008). 
The present results, in conjunction with previously reported pharmacogenetic 
associations between ABCB1 genotype and treatment response (Lin et al., 2011; 
Singh et al., 2012), support this hypothesis in relation to escitalopram, indicating 
that P-gp may prevent therapeutic brain concentrations from being achieved in 
certain patients with elevated P-gp activity due to functional SNPs in ABCB1.  
To our knowledge, the behavioural studies included in the present work 
demonstrate for the first time that the pharmacodynamic activity of an 
antidepressant can be augmented by inhibition of P-gp. In addition, analysis of the 
correlation between time spent immobile in the TST and brain escitalopram 
concentrations indicated that the reduction in immobility was related to the 
enhanced delivery of escitalopram to the brain following P-gp inhibition. These 
novel findings are especially exciting as they indicate that this approach to increase 
Chapter 4: Escitalopram and P-gp 
186 
escitalopram concentrations in the brain may prove to be therapeutically beneficial 
in patients. In previous preclinical studies, escitalopram has been shown to reduce 
immobility in the TST in a dose responsive manner up to a maximal response at 1 
mg.kg-1 (Zomkowski et al., 2010). At higher doses of escitalopram, the time spent 
immobile increased, likely due to peripheral side effects, resulting in a U-shaped 
dose response curve (Zomkowski et al., 2010). In the present study, it was found 
that pre-treatment with the P-gp inhibitor verapamil augmented the antidepressant 
response at both doses of escitalopram investigated, including an enhanced 
response to a 1 mg.kg-1 dose (Figure 4.3A). This highlights that the P-gp inhibition 
strategy may facilitate augmentation of the central effects of escitalopram while 
avoiding peripheral side effects associated with higher doses of escitalopram. 
However, it should be noted that this approach could potentially result in increased 
risk of unwanted central side effects. This risk could be offset by selectively 
employing the P-gp inhibition augmentation strategy in patients shown to have 
enhanced P-gp functionality or in conjunction with low dose escitalopram, thereby 
serving to normalize brain levels of escitalopram rather than resulting in toxic brain 
concentrations.  
Our finding that administration of a P-gp inhibitor increased brain concentrations of 
escitalopram without altering plasma levels conclusively demonstrates that 
inhibition of P-gp enhances escitalopram transport across the BBB. Importantly, the 
intracerebral microdialysis technique employed to monitor brain levels of 
escitalopram measures only unbound drug levels in brain extracellular fluid (de 
Lange et al., 2000). Given that drugs are active in the unbound form and that 
escitalopram acts within the brain by inhibiting the serotonin reuptake transporter 
in the extracellular synaptic cleft, the present findings are of particular 
pharmacological relevance. Furthermore, the steady-state approach adopted in the 
present study enabled the confirmation of microdialysis findings by determining 
brain tissue concentrations from the same animals at termination of the 
experiment, when differences between the groups were maximal. To our 
knowledge, there are no data available in relation brain levels of escitalopram in 
humans in clinical practice. Therefore, it is not possible to discuss the brain 
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concentrations observed in the present studies in the context of those encountered 
clinically. Future imaging or post-mortem studies may offer further information in 
this regard. Nonetheless, our finding that brain tissue levels of escitalopram were 
increased three-fold by P-gp inhibition compares favourably with recently reported 
results from studies using P-gp knockout mice, which were published online as this 
paper was being finalised (Karlsson et al., 2013). Given that it has proven difficult to 
reproduce effects observed in P-gp knockout mice by P-gp inhibition in the past 
(Ejsing and Linnet, 2005), it remained vital to demonstrate that P-gp inhibition 
would result in similarly increased brain levels of escitalopram before proposing 
that co-administration of a P-gp inhibitor may represent a promising approach to 
enhance escitalopram delivery to the brain. Considering that patients are treated 
chronically with antidepressants in clinical practice, future studies are required to 
investigate if escitalopram concentrations in the brain can be enhanced and 
maintained by repeated P-gp inhibition. 
Well-documented interspecies differences in P-gp substrate specificity (Yamazaki et 
al., 2001; Katoh et al., 2006; Baltes et al., 2007; Syvanen et al., 2009) mean that 
findings in relation to P-gp transport obtained from animal models cannot be 
readily extrapolated to humans. Therefore, appropriate in vitro bidirectional 
transport studies involving human P-gp are necessary to enable evaluation of the 
clinical relevance of results from rodent studies. Indeed, this is a very pertinent 
point in light of our recent findings that the antidepressants amitriptyline and 
fluoxetine, both of which have been identified as P-gp substrates in mice (Uhr et al., 
2000; Doran et al., 2005), are not transported substrates of human P-gp (O'Brien et 
al., 2013a, Chapter 3). Therefore, the present finding that escitalopram is a 
transported substrate of human P-gp indicates that findings from our in vivo studies 
may translate to humans. 
While the present studies have exclusively involved escitalopram, it is possible that 
our findings may extend to certain other antidepressant drugs, as there is a growing 
body of evidence to suggest that efflux by P-gp may influence treatment response 
to several antidepressants (reviewed in O'Brien et al., 2012b). There is limited 
information available in relation to antidepressant transport by human P-gp per se. 
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However, in common with escitalopram, pharmacogenetic studies have revealed an 
association between SNPs in ABCB1 and response to other antidepressants (Gex-
Fabry et al., 2008; Kato et al., 2008; Nikisch et al., 2008; Sarginson et al., 2010). 
These antidepressants, including citalopram and paroxetine, are thought to be P-gp 
substrates based on results from studies in P-gp knockout mice (Uhr and Grauer, 
2003; Uhr et al., 2003; Doran et al., 2005; Uhr et al., 2008). However, it has been 
reported that similar pharmacogenetic associations do not exist for other 
antidepressants, including amitriptyline, duloxetine, fluoxetine and mirtazapine 
(Roberts et al., 2002; Laika et al., 2006; Uhr et al., 2008; Perlis et al., 2010; 
Sarginson et al., 2010). Emerging data from our lab, indicating that these four 
antidepressants are not transported substrates of human P-gp, despite 
aforementioned preclinical findings in relation to amitriptyline and fluoxetine (Uhr 
et al., 2000; Doran et al., 2005), may offer an explanation for these observations. 
(O'Brien et al., 2013a, Chapter 3). Further studies are now warranted to determine 
if the present findings in relation to escitalopram generalise to other 
antidepressants.  
It should be noted that transporters other than P-gp, such as breast cancer 
resistance protein (BCRP) and the multidrug resistance-associated proteins (MRPs), 
also play an important role at the BBB. Given the significant overlap in substrate 
specificity between P-gp, BCRP and the MRPs (Sharom, 2008), it is possible that 
these alternative transporters may also influence the distribution of escitalopram 
across the BBB. Indeed, racemic citalopram has been reported to be an MRP1 
substrate, while the same study found an association between polymorphisms in 
the MRP1 gene and citalopram response (Lee et al., 2010). Nonetheless, the range 
of approaches adopted in the present studies, not least the in vitro study involving 
MDCKII-MDR1 cells transfected with human P-gp, highlight an important role for P-
gp in escitalopram pharmacokinetics and pharmacodynamics independent of any 
potential involvement of other transporters. 
In summary, the present studies indicate that P-gp may restrict the BBB transport of 
escitalopram in humans, potentially resulting in sub-therapeutic brain 
concentrations in certain patients, particularly those with elevated P-gp 
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functionality due to SNPs in ABCB1. Moreover, the novel finding that increasing 
escitalopram delivery to the brain by P-gp inhibition results in enhanced 
antidepressant-like activity indicates that adjunctive treatment with a P-gp inhibitor 
may represent a beneficial approach to augment escitalopram therapy in 
depression in such patients. This approach could potentially have the added benefit 
of reducing the administered dose required to achieve escitalopram response, 
which is particularly desirable following recent guidance recommending the 
limitation of escitalopram doses used clinically due to the risk of QT prolongation 
(Medicines and Healthcare products Regulatory Agency, 2011). The P-gp inhibitors 
verapamil and CsA, used as tool compounds in the present proof-of-concept study, 
have the advantage of being clinically available for non-CNS indications. However, it 
is unlikely that these drugs would be appropriate for clinical use as P-gp inhibitors 
due to their lack of specificity and potency, thereby requiring high doses to 
adequately inhibit P-gp. Verapamil is primarily used as a calcium channel blocker, 
while CsA is an immunosuppressant agent which also modulates other drug 
transporters (Qadir et al., 2005). The use of more selective second or third 
generation P-gp inhibitors may represent a more acceptable alternative for 
potential clinical use. Additional studies, both preclinical and clinical, are now 
warranted to further evaluate the safety and efficacy of this strategy to augment 
treatment response to escitalopram. 
  
Chapter 4: Escitalopram and P-gp 
190 
4.5. Supplementary information: supplementary materials and 
methods 
4.5.1. In vitro bidirectional transport studies 
4.5.1.1. Cell-lines and materials 
MDCKII-WT and MDCKII-MDR1 cells were obtained from the Piet Borst Laboratory 
(Netherlands Cancer Institute, Amsterdam, The Netherlands). Transport 
experiments were carried out using Costar 3414 Polycarbonate Membrane 
Transwell® Inserts (24 mm diameter, 3 µm pore size), purchased from Sigma 
Aldrich, as were all other materials and chemicals unless otherwise stated. 
4.5.1.2. Cell culture 
Cells were grown in 75 cm2 culture flasks using Dulbecco's Modified Eagle's 
Medium, supplemented with 10% fetal bovine serum and 1% Penicillin-
Streptomycin. Cells were split twice weekly at a dilution of 1:12, and incubated at 
37°C in a humidified 5% CO2 and 95% air atmosphere.  
4.5.1.3. Western blot analysis 
Expression of P-gp was confirmed by western blot analysis. Briefly, MDCKII-MDR1 
and MDCKII-WT monolayers were grown as per transport experiments. Cells were 
washed with ice-cold phosphate-buffered saline, then lysed in lysis buffer (HEPES 
20 mM; Np-40 (1%); DTT 0.5 mM; Na3VO4 0.1 mM; PMSF 0.1 mM; aprotinin 2 µg.ml
-
1; leupeptin 2 µg.ml-1; NaF 0.02 mM) for 15 min at 4°C. Cell lysate was centrifuged 
at 4°C for 10 min at 10 000 rpm. The supernatant was stored at -80°C for later 
analysis. Five micrograms of cell protein were loaded in 10-12%SDS-PAGE gel and 
run at 60-100 V for 120 min. After transfer onto a 0.2-µm nitrocellulose membrane 
and blocking with 5% skimmed milk and 0.1% Tween 20 in PBS, blots were probed 
overnight at 4°C with the C219 primary monoclonal P-gp antibody (1:100 dilution in 
2% skimmed milk; Enzo Life Sciences (UK) Ltd, Exeter, UK). Reprobing was 
conducted for 1 h at room temperature using a goat anti-mouse IgG-HRP conjugate, 
diluted 1:2000 (Jackson Immunoresearch Europe Ltd). Images were obtained using 
a luminescent image analyzer (LAS-3000; Fujifilm, Ireland). For the detection of β-
actin, the membranes were incubated with Monoclonal Anti-β-Actin−Peroxidase 
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antibody produced in mouse (1:15000). Immunoblots were quantified using ImageJ 
software. 
4.5.1.4. Transport Experiments 
For transport experiments, cells (passage number: 23-25) were seeded at a density 
of 2x106 cells per well. Cells were allowed to grow to confluence over four days 
with 1.5 ml of medium in the apical compartment and 2.6 ml of medium in the 
basolateral compartment. The medium was changed daily and trans-epithelial 
electrical resistance (TEER) measurements were taken each day using an Endohm 
meter (World Precision Instruments, Sarasota, FL) to monitor the development and 
integrity of the cell monolayer. On the day of experiment, the mean (± SEM) TEER 
value for MDCKII-WT cells was 184 (± 7) .cm2 and for MDCKII-MDR1 cells was 533 
(± 10) .cm2.Fresh cell culture medium was added to the cells two hours before the 
transport experiment. One hour prior to the commencement of the transport 
experiment, cell culture medium was removed and monolayers were rinsed twice 
with transport buffer (Hank’s Balanced Salt Solution [HBSS] with 10 mM HEPES). 
Transport experiments were carried out by adding escitalopram (5 µM, freshly 
prepared in transport buffer) to the donor chamber and measuring the 
concentration of escitalopram in the receiver chamber at 30 minute intervals over a 
two hour incubation period at 37°C. Apical and basolateral chamber volumes were 
maintained at 1.5 and 2.6 ml, respectively, throughout the transport experiment by 
replacing the volume (100 µl) removed from the receiver chamber at each sampling 
point with an equal volume of blank transport buffer. In addition, a 100 µl sample 
was taken from the donor chamber at the beginning of the experiment, to confirm 
the initial concentration (C0), and at the end of the experiment, to facilitate mass 
balance calculations. For apical-to-basolateral (A→B) transport, the apical chamber 
is the donor chamber and the basolateral chamber is the receiver chamber. 
Conversely, for basolateral-to-apical (B→A) transport, the basolateral chamber is 
the donor chamber and the apical chamber is the receiver chamber. To confirm the 
identification of P-gp substrates in bidirectional transport studies using MDCKII-WT 
and MDCKII-MDR1 cells, it is recommended that transport experiments are 
repeated in the presence of at least two P-gp inhibitors (Zhang et al., 2006). If P-gp 
Chapter 4: Escitalopram and P-gp 
192 
transport is the mechanism net efflux in MDCKII-MDR1 cells, inhibition of P-gp will 
attenuate the efflux. For this reason, transport experiments were also carried out in 
the presence either verapamil (200 µM in transport buffer) or CsA (25 µM in 
transport buffer), both of which are P-gp inhibitors. The concentration chosen for 
each P-gp inhibitor was based on studies in the literature (Tang et al., 2002; Taub et 
al., 2005). For P-gp inhibition studies, the MDCKII-MDR1 cells were pre-incubated 
with the P-gp inhibitor on both sides of the monolayer for 30 min before addition of 
escitalopram (5 µM), and transport experiments were carried out in the presence of 
the P-gp inhibitor in both chambers throughout the experiment. Fresh transport 
buffer containing the appropriate P-gp inhibitor was replaced in the receiver side 
after sampling. All transport experiments were carried out in triplicate. 
4.5.1.5. Transport experiment calculations 
The apparent permeability coefficient (Papp; unit: cm.s
-1) of escitalopram in each 
individual well was calculated using equation (4.1) (Youdim et al., 2003). 
 
 (4.1)   
 
where, VD = donor volume (cm
3), A = surface area of the cell monolayer (4.67 cm2), 
MD = initial amount of escitalopram in the donor chamber (mol), Mcells = amount of 
escitalopram retained by the membrane/cells (mol) and  
   
  
 = change in the 
amount ofe scitalopram in the receiver chamber over time (mol.s-1). 
The transport ratio (TR), which compares drug transport in the B→A direction to 
drug transport in the A→B direction, was calculated using equation (4.2). A ratio 
greater than 1 indicates that net efflux is taking place, and a TR value of ≥ 2 
indicates that the test compound is a transported P-gp substrate, while a TR 
between 1.5 and 2 is inconclusive (Polli et al., 2001; Zhang et al., 2006). 
  
 𝑎𝑝𝑝 =
𝑉𝐷
[𝐴 × (𝑀𝐷 − 𝑀 𝑒𝑙𝑙𝑠 )]
×
 𝑀 
 𝑡
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(4.2) 
The corrected transport ratio (cTR), calculated using equation (4.3), takes the 
effects of endogenous transporters on drug transport across MDCK cells into 
account. Hence, in theory, the effect of human P-gp, is evaluated specifically. 
However, transfection with ABCB1 may alter the expression of endogenous 
transporters (Kuteykin-Teplyakov et al., 2010). Therefore, a cTR value of ≥ 1.5, in 
conjunction with a reduction in TR in MDCKII-MDR1 cells on co-incubation of a P-gp 
inhibitor, is required for confirmation that the test compound is a P-gp substrate 
(Polli et al., 2001; Schwab et al., 2003). 
    
 
(4.3)  
 
4.5.2. Escitalopram extraction from plasma and brain tissue 
Escitalopram was extracted from plasma and brain tissue obtained from in vivo 
pharmacokinetic studies using a liquid-liquid extraction technique described 
previously (Clarke et al., 2009), with some modifications. Briefly, 48 µl of plasma 
was spiked with 2 µl of the internal standard, verapamil, to yield a final 
concentration of 1 µg.ml-1 verapamil. To this verapamil-spiked plasma, 1 ml of 
sodium hydroxide (2 M) and 3 ml of water were added. Extraction was carried out 
in 7.5 ml of 1.5% isoamyl alcohol in n-heptane by vortexing for 30 seconds, followed 
by agitation on a mechanical shaker for 15 min and then centrifugation at 5000 rpm 
for 15 min at 20°C. The upper solvent layer was transferred to a tube containing 
200 µl of 25 mM OPA, vortexed for 30 seconds, then agitated on a mechanical 
   =
  (𝑀𝐷𝐶𝐾𝐼𝐼−𝑀𝐷 1)
  (𝑀𝐷𝐶𝐾𝐼𝐼−𝑊 )
 
  =
 𝑎𝑝𝑝 ,𝐵 𝐴
 𝑎𝑝𝑝 ,𝐴 𝐵
   
Chapter 4: Escitalopram and P-gp 
194 
shaker for 15 min followed by centrifugation at 5000 rpm for 15 min at room 
temperature. Twenty microlitres of the lower aqueous phase was injected onto the 
HPLC system for analysis. Brain tissue samples were weighed prior to 
homogenization in 500 µl of verapamil-spiked (1 µg.ml-1) homogenization buffer 
(i.e. HPLC mobile phase). Homogenized brain tissue was centrifuged at 14 000 rpm 
at 8°C for 15 min, and escitalopram was extracted from 200 µl of the supernatant as 
described above. As verapamil was used as a P-gp inhibitor in pharmacodynamic tail 
suspension test (TST) studies, imipramine was used as an internal standard for 
extractions from samples obtained following the TST. Due to technical difficulties 
during this extraction procedure in brain samples from the TST, 2-4 samples per 
group were lost during the extraction process, meaning that drug levels could not 
be ascertained for these animals.  
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Abstract 
Recent studies have raised the possibility that P-glycoprotein (P-gp) inhibition may 
represent a putative augmentation strategy for treatment with certain 
antidepressants. Indeed, we have previously shown that administration of the P-gp 
inhibitor verapamil increased the brain distribution and behavioural effects of the 
antidepressant escitalopram. The aim of the current study was to investigate if 
similar effects occur with another P-gp inhibitor, cyclosporin A (CsA). CsA pre-
treatment exacerbated the severity of behaviours in an escitalopram-induced 
mouse model of serotonin syndrome, a potentially life-threatening adverse drug 
reaction associated with serotonergic drugs. P-gp inhibition by CsA enhanced the 
brain distribution of escitalopram by 70-80%. Serotonin (5-HT) turnover in the 
prefrontal cortex was reduced by escitalopram, and this effect was augmented by 
CsA. However, CsA pre-treatment did not augment the effect of escitalopram in the 
tail suspension test (TST) of antidepressant-like activity. Microdialysis experiments 
revealed that pre-treatment with CsA failed to augment, but blunted, the increase 
in extracellular 5-HT in response to escitalopram administration. This blunting effect 
may contribute to the lack of augmentation in the TST. Taken together the present 
studies demonstrate that co-administration of CsA and escitalopram produces 
differential effects depending on the behavioural and neurochemical assays 
employed. Thus the results highlight the need for further studies involving more 
selective pharmacological tools to specifically evaluate the impact of P-gp inhibition 
on behavioural responses to antidepressants which are subject to efflux by P-gp. 
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5.1. Introduction 
Currently available drug treatments for depression have unsatisfactory efficacy, 
with an estimated 50-60% of patients failing to adequately respond to 
antidepressant treatment (Fava, 2003). Hence, there is a major impetus to 
elucidate, and overcome, the mechanisms underlying resistance to antidepressant 
drug treatment. Increasing evidence from preclinical and clinical studies has 
highlighted a key role for the multidrug resistance efflux transporter P-glycoprotein 
(P-gp), expressed at the blood-brain barrier (BBB), in limiting the brain distribution, 
and therefore efficacy, of several antidepressant drugs (Uhr et al., 2008; Clarke et 
al., 2009; O'Brien et al., 2012b; Karlsson et al., 2013; O'Brien et al., 2013a). 
We have recently demonstrated that the selective serotonin reuptake inhibitor 
(SSRI) escitalopram, one of the most commonly prescribed antidepressants, is a 
transported substrate of human P-gp in vitro (O'Brien et al., 2013b, Chapter 4). 
Moreover, pre-treatment with the P-gp inhibitor verapamil enhanced the brain 
distribution of escitalopram and augmented its antidepressant-like activity in mice 
(O'Brien et al., 2013b, Chapter 4), as measured in the tail suspension test (TST), one 
of the most widely used models for assessing antidepressant activity in rodents 
(Cryan et al., 2005a). In addition, microdialysis studies revealed that administration 
of another P-gp inhibitor, cyclosporin A (CsA), also resulted in enhanced brain levels 
of escitalopram in rats, thereby confirming the involvement of P-gp in its BBB 
transport (O'Brien et al., 2013b, Chapter 4). These results raise the possibility that 
treatment with escitalopram, and potentially other antidepressants which are 
transported P-gp substrates, could be augmented by adjunctive therapy with a P-gp 
inhibitor.  
Notwithstanding the potential of P-gp inhibition to enhance antidepressant brain 
distribution and therapeutic efficacy, the possibility that adjunctive P-gp inhibitor 
therapy may elicit unwanted side effects merits further consideration. Indeed, 
there is evidence to suggest that concurrent administration of serotonin (5-HT) 
enhancing antidepressants and CsA, which is a clinically used immunosuppressant 
as well as an inhibitor of P-gp, can result in serious adverse drug reactions. Three 
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case studies describing incidences of serotonin syndrome, a potentially life-
threatening adverse drug reaction associated with excessive serotonergic 
neurotransmission (Boyer and Shannon, 2005), in patients treated with CsA and 5-
HT enhancing antidepressants, including escitalopram, have been published (Wong 
et al., 2002; Lang et al., 2008; Newey et al., 2011). In addition, there have been over 
30 reports of CsA-related serotonin syndrome since 2001, according to the FDA 
Adverse Event Reporting System 
(http://www.ehealthme.com/ds/cyclosporine/serotonin+syndrome; Accessed 
29/09/13).  
In the present studies, the effect of CsA administration in an escitalopram-induced 
mouse model of serotonin syndrome was investigated to determine if CsA impacts 
on the severity of behaviours associated with this model. In addition, further 
behavioural studies were undertaken to determine if CsA pre-treatment would 
augment the antidepressant-like activity of escitalopram in the TST, as previously 
reported for another P-gp inhibitor (verapamil) (O'Brien et al., 2013b, Chapter 4). 
Finally, the neurochemical effects of this drug combination were assessed by 
measuring brain tissue levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid, 
and by conducting intracerebral microdialysis studies to investigate the effect of 
pre-treatment with CsA on the increase in extracellular 5-HT in response to 
escitalopram administration. 
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5.2. Material and methods 
5.2.1. Drugs and chemicals 
Cyclosporin A (CsA; Sandimmun Concentrate for Solution for Infusion) was 
purchased from Uniphar Group (Ireland). Escitalopram oxalate was purchased from 
Discovery Fine Chemicals (Dorset, UK). 5-hydroxytryptophan (5-HTP) was obtained 
from Sigma-Aldrich (Ireland), as were all other chemicals, reagents and materials 
unless otherwise stated. 
5.2.2. Animals 
Male C57BL/6JOlaHsd mice (6-8 weeks old) and male Sprague Dawley rats 
(weighing 265-315 g), purchased from Harlan Laboratories, UK, were used in these 
studies. All animals were group-housed 4 animals per cage and maintained on a 12 
hour light/dark cycle (lights on at 08:00 h) with food and water ad libitum. Room 
temperature was controlled at 22 ± 1°C. All procedures were carried out in 
accordance with EU directive 2010/63/EU and approved by the Animal 
Experimentation & Ethics Committee of University College Cork. 
5.2.3. Effect of CsA administration in a mouse model of serotonin 
syndrome 
Serotonin syndrome was evoked in male C57BL/6JOlaHsd mice by adapting 
previously described methods involving co-administration of the serotonin 
precursor 5-HTP and the SSRI escitalopram (Sanchez et al., 2003; Kreilgaard et al., 
2008). These agents act to increase serotonergic neurotransmission by enhancing 
serotonin synthesis and preventing its reuptake, respectively (Haberzettl et al., 
2013). Together, these treatments induced a syndrome characterised by a number 
of specific behaviours, as outlined in Table 5.1 (Diaz and Maroteaux, 2011; 
Haberzettl et al., 2013). Mice were pre-treated with CsA (37.5, 75 or 150 mg/kg i.p.) 
or its vehicle (1/12 ethanol: 2/12 Cremophor EL: 9/12 saline), one hour prior to co-
administration of 5-HTP (100 mg/kg i.p.) and escitalopram (2 mg/kg i.p.) (n = 7 per 
group). Fifteen minutes later, mice were placed into a plexiglass arena (27 cm X 21 
cm), and serotonin syndrome-related behaviours were scored by an observer blind 
to the treatment groups for six one-minute periods at five-minute intervals (Figure 
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5.1A; Table 5.1). The sum of scores for each behaviour over the course of the 
experiment was totalled for each animal as a measurement of the severity of each 
behaviour. In addition, an overall serotonin syndrome score was calculated by 
adding the sum of scores for each behaviour. Doses of 5-HTP and escitalopram 
were chosen based on pilot studies and reports that treatment with 5-HTP (100 
mg/kg) induces serotonin syndrome behaviours only when administered in 
combination with another serotonin enhancing agent such as escitalopram 
(Sanchez et al., 2003; Kreilgaard et al., 2008). 
Table 5.1: Table listing the intermittent and continuous behaviours, and scoring 
systems, associated with the mouse model of serotonin syndrome used in the 
present study (adapted from Diaz and Maroteaux, 2011; Haberzettl et al., 2013) 
Intermittent 
behaviours Scoring 
Continuous 
Behaviours Scoring 
Backward gait 0 Absent Flat body position 0 Absent 
Tics 1 Once Piloerection 1 Perceptible 
Hunched back 2 Several times Straub tail 2 Weak 
Head weaving 3 Frequently Hind limb abduction 3 Medium 
Forepaw treading 4 Permanently Tremor 4 Maximal 
 
5.2.4. Influence of CsA pre-treatment on the brain distribution 
and neurochemical and behavioural effects of 
escitalopram 
5.2.4.1. Tail suspension test 
The tail suspension test (TST), one of the most widely used models for assessing 
antidepressant activity in rodents (Cryan et al., 2005a), was carried out using male 
C57BL/6JOlaHsd mice (6-8 weeks old; total n= 64 from Harlan, UK), as described 
previously (O'Brien et al., 2013b). This facilitated investigation of the impact of pre-
treatment with the P-gp inhibitor CsA on the antidepressant-like activity of 
escitalopram. Briefly, after a 5-7 day acclimation period, mice were pre-treated 
with either the P-gp inhibitor CsA (75 mg/kg i.p.) or its vehicle one hour before 
administration of either escitalopram (0.1 or 1 mg/kg i.p.) or saline (n = 9-14 per 
group). Thirty minutes after the second injection, mice were individually suspended 
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by the tail from a horizontal bar using adhesive tape. Six minute test sessions were 
recorded by video camera and the amount of time spent immobile by each animal 
was subsequently scored by a trained observer blind to the treatment groups. 
Doses of escitalopram and CsA were selected based on previous studies 
(Zomkowski et al., 2010; O'Brien et al., 2012a; O'Brien et al., 2013b). Moreover, 
pilot studies revealed that treatment with a higher dose of CsA (150 mg/kg) 
resulted in a substantial increase in immobility in the TST, likely due to sedative 
side-effects (data not shown). 
5.2.4.2. Brain concentrations of escitalopram, 5-HT and 5-HIAA 
Brain tissue (prefrontal cortex (PFC) and hippocampus) was harvested from each 
animal 10 min after commencement of the TST. Hippocampal escitalopram levels 
were determined using an extraction procedure and high performance liquid 
chromatography (HPLC) method as described previously (O'Brien et al., 2013b). 
Briefly, escitalopram was extracted from brain tissue using an acid-base liquid-liquid 
extraction technique, with imipramine as an internal standard, prior to analysis by 
HPLC with fluorescent detection (excitation wavelength: 249 nm; emission: 302 
nm). Due to the low levels of escitalopram present in the brains of mice treated 
with the lower dose of escitalopram (0.1 mg/kg), it was necessary to pool 
hippocampal samples from two animals in these groups to successfully measure 
escitalopram concentrations. In addition, levels of 5-HT and its metabolite, 5-
hydroxyindoleacetic acid (5-HIAA), were measured in the PFC, using previously 
described tissue extraction and HPLC analysis methods (Browne et al., 2011; 
Browne et al., 2013). Briefly, brain tissue was homogenized in ice cold mobile phase 
with N-methyl-5-HT as an internal standard prior to analysis of the supernatant by 
HPLC with electrochemical detection. This facilitated investigation of the effect of 
escitalopram and/or CsA treatment on 5-HT turnover (i.e. the 5-HIAA:5-HT ratio). 
5.2.4.3. Locomotor activity 
To investigate potential locomotor effects, which could confound analysis of 
behavioural data from the TST, the impact of drug treatment on locomotor activity 
was assessed as previously described (O'Brien et al., 2013b). A separate cohort of 
mice were pre-treated with either the P-gp inhibitor CsA (75 mg/kg i.p.) or vehicle 
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one hour before administration of either escitalopram (0.1 mg/kg i.p.) or saline (n = 
6-7 per group). Thirty minutes after the second injection, mice were individually 
placed in activity monitoring units (27 cm X 21 cm). Activity was then monitored via 
beam breaks for 60 minutes.  
5.2.5. Microdialysis studies to investigate the effect of CsA pre-
treatment on escitalopram-induced increases in 
extracellular levels of 5-HT  
5.2.5.1. Microdialysis probe construction and calibration 
Microdialysis probes were constructed as previously described (O'Brien et al., 
2012a, Chapter 2). In vitro probe recovery values ranged from ~11 – 14% for 5-HT. 
Dialysate values were not corrected to account for in vitro recovery, as the diffusion 
properties of compounds in brain tissue are likely different from in vitro conditions 
(Anderzhanova and Wotjak, 2013). Rather, dialysate 5-HT values are expressed as a 
percentage of basal concentration, calculated independently for each individual 
animal based on a minimum of three samples prior to drug administration, thereby 
facilitating comparison of relative changes in extracellular 5-HT levels following 
treatment (Anderzhanova and Wotjak, 2013). 
5.2.5.2. Surgical procedures 
Microdialysis studies were undertaken in male Sprague Dawley rats. The jugular 
vein of each rat was catheterised using standard surgical techniques, to facilitate 
intravenous drug administration, and microdialysis probes were inserted into the 
prefrontal cortex (PFC) (2.7 mm anterior and 0.7 mm lateral to bregma, lowered 5 
mm from dura (Paxinos and Watson, 1998)), as described previously (O'Brien et al., 
2012a; O'Brien et al., 2013b). Post-surgery, rats were single-housed in cylindrical 
plexiglass containers with the probe inlet connected to a fluid swivel (Instech 
Laboratories, Plymouth Meeting, PA). Artificial cerebrospinal fluid (147 mM NaCl, 
1.7 mM CaCl2, 0.9 mM MgCl2, and 4mM KCl) was perfused through each 
microdialysis probe at a rate of 1.5 μl.min-1. Rats were allowed to recover overnight 
prior to sampling on the following day during the optimal post-surgical period (de 
Lange et al., 2000). 
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5.2.5.3. Experimental design 
CsA (25 mg/kg i.v.) or vehicle were administered 30 minutes prior to escitalopram 
administration (0.25 mg/kg i.v. at t = 0 min) (n = 4 per group). The dose of CsA 
chosen was based on a previously described dosing regimen shown to result in P-gp 
inhibition (O'Brien et al., 2012a; O'Brien et al., 2013b). Microdialysis samples were 
collected at 20 min intervals before and after drug administration, and stored at -
80oC until analysed by HPLC with electrochemical detection (HPLC-ECD). At the 
conclusion of the experiment (t = 240 min), rats were euthanized by intravenous 
administration of sodium pentobarbital. Brains were subsequently removed for 
histological verification of probe placement.  
5.2.5.4. HPLC analysis of 5-HT in microdialysis samples 
The HPLC with electrochemical detection (HPLC-ECD) system consisted of a 
Shimadzu LC-20AD XR Prominence Pump, CBM-20A communication bus module, 
SIL-20AC XR Prominence Autosampler, CTO-20A Prominence Column oven (all 
supplied by Mason Technology, Cork, Ireland). System components were used in 
conjunction with Shimadzu LC solutions software (Mason Technology). The detector 
used was ESA Coulochem III with the 5041 Amperometric Cell (Supplied by ESA 
Analytical, Ltd., UK). All samples were injected onto a reversed phase KinetexTM 2.6 
µm C18 100 Å (100 x 2.1 mm) column (Phenomenex, Ireland), which was protected 
by Krudkatcher Ultra in-line filters (Phenomenex). 
The mobile phase consisted of 0.1 M citric acid, 0.1 M sodium dihydrogen 
phosphate, 0.01 mM EDTA (Alkem/Reagecon, Ireland), 5.6 mM octane-1-sulphonic 
acid and 9% (v/v) methanol (Alkem/Reagecon), adjusted to pH 2.8 with 4 N sodium 
hydroxide (Alkem/Reagecon), and was filtered prior to use (Millipore 0.22 µm 
Durapore filters, Millipore, Ireland). Compounds were eluted isocratically over a 20 
minute runtime at a flow rate of 0.4 ml/min after a 20 µl injection. The samples 
were kept at 8˚C in the cooled autoinjector prior to injection and the column was 
maintained at 30˚C. The glassy carbon working electrode, combined with a 
platinum reference electrode (ESA Analytical, Ltd), was operated at a potential of 
200 mV and a range of 100 pA. 5-HT was identified and quantified based on its 
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characteristic retention time and peak height, as determined by standard injections 
which were run at regular intervals during sample analysis.  
5.2.6. Data analysis and statistical procedures 
Statistical analysis of data was carried out using standard commercial software 
(SPSS Statistics, version 20.0.0; SPSS, Inc., Chicago, IL). The differences in brain 
levels of escitalopram between two groups were analysed using unpaired t-test. 
Results from 5-HT turnover, TST and serotonin syndrome studies were analysed 
statistically by one-way ANOVA, with LSD post-hoc where an overall group effect 
was determined. Differences in locomotor activity were analysed by two-way 
ANOVA with LSD post-hoc to elucidate statistically significant differences between 
treatment groups. Comparison of increases in extracellular levels of 5-HT following 
escitalopram administration with and without pre-treatment with CsA were 
analysed by repeated measures ANOVA, with parameter estimates analysis 
highlighting time points where significant differences existed between the groups. 
The criterion for statistical significance was p ≤ 0.05.  
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5.3. Results 
5.3.1. Effect of CsA administration in a mouse model of serotonin 
syndrome 
5.3.1.1. Pre-treatment with CsA exacerbated the severity of behaviours 
associated with a mouse model of serotonin syndrome  
A statistically significant difference in overall serotonin syndrome score was 
observed between the groups (F(3, 24) = 24.351, p < 0.001; Figure 5.1B). In 
addition, statistically significant differences between the groups for each of the 
three most prominent behaviours were observed (Figure 5.1C-E): tics (F(3, 24) = 
14.762, p < 0.001), tremor (F(3, 24) = 7.838, p = 0.001) and hind limb abduction (F(3, 
24) = 14.257, p < 0.001).  
For the overall score, as well as for each of these individual behaviours, pre-
treatment with any of the three doses of CsA used resulted in a more severe 
manifestation of the serotonin syndrome, as evidenced by the significantly higher 
scores, relative to vehicle-pre-treated controls (p < 0.05, 0.01 or 0.001 in each case; 
Figure 5.1B-E). 
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Figure 5.1: Effect of cyclosporin A (CsA) pre-treatment in a mouse model of 
serotonin syndrome. A Schematic illustrating the dosing regimen and scoring 
protocol used. B Overall serotonin syndrome score. Pre-treatment with any of the 3 
doses of CsA significantly increased the overall serotonin syndrome score, relative to 
vehicle-treated mice. This increase was significantly lower in mice treated with 75 
mg/kg CsA compared to the other two doses of CsA. C Cumulative scores for tics 
behaviour. Pre-treatment with any of the 3 doses of CsA resulted in a significantly 
greater number of tics during the observation periods compared to vehicle-treated 
mice, and this effect was more substantial in mice pre-treated with 150 mg/kg than 
75 mg/kg of CsA. D Cumulative scores for tremor behaviour. Pre-treatment with any 
of the 3 doses of CsA significantly increased the severity of tremors in the mouse 
model of serotonin syndrome during the observation periods, relative to the vehicle-
treated group. E Cumulative hind limb abduction score. Hind limb abduction was 
more pronounced in mice pre-treated with CsA than vehicle. This effect was greater 
in mice in receipt of CsA 37.5 or 150 mg/kg than 75 mg/kg (n = 7 per group). 
* p < 0.05; ** p < 0.01; *** p < 0.001 relative to vehicle-pre-treated group 
# p < 0.05; # # p < 0.01 between indicated groups in receipt of different doses of CsA 
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5.3.2. Influence of CsA pre-treatment on the brain distribution 
and neurochemical and behavioural effects of 
escitalopram 
5.3.2.1. CsA pre-treatment increased hippocampal concentrations of 
escitalopram  
Hippocampal escitalopram concentrations were significantly greater in mice pre-
treated with the P-gp inhibitor CsA than control mice at both doses of escitalopram 
treatment (Figure 5.2A+B). Pre-treatment with CsA resulted in a 71.4% increase in 
brain escitalopram levels in mice treated with 0.1 mg/kg of escitalopram (t(4.474) = 
-10.147, p < 0.001; Figure 5.2A) and a 79.8% increase in brain escitalopram levels in 
mice treated with 1 mg/kg of escitalopram (t(16) = -7.385, p < 0.001; Figure 5.2B). 
 
Figure 5.2: Effect of cyclosporin A (CsA) pre-treatment on brain concentrations of 
escitalopram. A Pre-treatment with CsA (75 mg/kg) resulted in a 71.4% increase in 
hippocampal concentrations of escitalopram at a dose of 0.1mg/kg (n = 5 pooled 
samples per group). B Pre-treatment with CsA (75 mg/kg) resulted in a 79.8% 
increase in hippocampal concentrations of escitalopram at a dose of 1mg/kg (n = 9 
per group). 
# # # p < 0.001 between groups 
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5.3.2.2. Pre-treatment with CsA augmented the effect of escitalopram on 
serotonin turnover in the PFC  
The treatment groups differed significantly in terms of 5-HT turnover in the PFC 
(F(5, 60) = 13.961, p < 0.001; Figure 5.3A). There was no difference in PFC 5-HT 
levels between the treatment groups (F(5, 60) = 1.494, p = 0.205; Figure 5.3B), but 
there was a significant difference in PFC 5-HIAA levels (F(5, 60) = 2.513, p = 0.039; 
Figure 5.3C). 
In vehicle-pre-treated animals, escitalopram had no effect on either 5-HT or 5-HIAA 
levels in the PFC, but reduced 5-HT turnover at the higher dose of escitalopram only 
(1 mg/kg; p < 0.001).  
CsA administration, without escitalopram treatment, had no impact on 5-HT levels, 
5-HIAA levels or 5-HT turnover (p > 0.05). However, when CsA pre-treatment was 
followed by escitalopram administration, 5-HIAA levels were significantly reduced 
compared to control mice (p = 0.019 and 0.012 for escitalopram 0.1 and 1 mg/kg, 
respectively). Interestingly, at both low (0.1 mg/kg) and high (1 mg/kg) doses of 
escitalopram, CsA pre-treatment resulted in statistically significant reductions in 5-
HT turnover relative to the control group (p < 0.001). Moreover, 5-HT turnover was 
reduced to a greater extent after CsA pre-treatment than observed following 
administration of the same dose of escitalopram on its own (p < 0.01 for both doses 
of escitalopram).  
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Figure 5.3: Effect of escitalopram and cyclosporin A (CsA) on 5-HT turnover, as well 
as 5-HT and 5-HIAA levels, in the PFC. A Escitalopram treatment reduced 5-HT 
turnover (i.e. the 5-HIAA:5-HT ratio) in a dose-dependent manner, with a significant 
reduction at 1 mg/kg, but not at 0.1 mg/kg. CsA treatment without escitalopram did 
not alter 5-HT turnover. However, when both CsA and escitalopram were 
administered, 5-HT turnover was reduced to a greater extent than at the equivalent 
dose of escitalopram without CsA pre-treatment. B Treatment with escitalopram 
and/or CsA had no significant impact on 5-HT concentrations in the PFC. C 
Escitalopram or CsA treatment alone did not cause a significant change in 
concentrations of the 5-HT metabolite, 5-HIAA, in the PFC. However, when 
escitalopram and CsA treatments were combined, 5-HIAA concentrations were 
significantly reduced, to the same extent, in comparison to the control group at 
each dose of escitalopram investigated (n = 9-14 per group). 
* p < 0.05; *** p < 0.001 relative to vehicle- and saline-treated control group 
# # p < 0.01 between indicated groups in receipt of the same dose of escitalopram 
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5.3.2.3. CsA pre-treatment did not augment escitalopram activity in the 
tail suspension test 
There was a significant difference between the groups in terms of immobility in the 
TST (F(5, 58) = 9.859, p < 0.001; Figure 5.4A). In vehicle-pretreated mice, 
escitalopram reduced the time spent immobile. Treatment with the higher (1 
mg/kg) dose of escitalopram resulted in a statistically significant 40% reduction in 
immobility compared to the saline-treated control group (p = 0.001), whereas 
treatment with the lower (0.1 mg/kg) dose of escitalopram did not elicit a 
significant reduction in immobility (p = 0.394). 
Pre-treatment with CsA had no impact on immobility in saline-treated mice (p = 
0.272). In common with vehicle-pre-treated mice, administration of the higher dose 
of escitalopram significantly reduced the time spent immobile in the TST in CsA-pre-
treated mice (p < 0.001 vs controls). There was no difference in immobility 
following administration of the higher dose of escitalopram between vehicle- and 
CsA-pre-treated animals (p = 0.430). However, in mice treated with the lower dose 
of escitalopram, there was a statistically significant difference between vehicle- and 
CsA-pre-treated animals (p = 0.017), with CsA pre-treatment resulting in 37% 
increase in the duration of immobility in the TST. 
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5.3.2.4. CsA treatment significantly reduced locomotor activity 
Escitalopram treatment had no effect on locomotor activity (F(1, 23) = 0.165, p = 
0.689; Figure 5.4B). In contrast, CsA did have a significant effect on this parameter 
(F(1, 23) = 23.78, p < 0.001), but there was no interaction between the two 
treatments (F(1, 23) = 0.727, p = 0.403). Post-hoc analysis revealed that CsA 
treatment significantly diminished locomotor activity, with a 40-45% reduction in 
the distance travelled in the activity monitoring unit, regardless of whether saline (p 
= 0.01) or escitalopram (p = 0.005) was subsequently administered.  
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Figure 5.4: Effect of escitalopram and cyclosporin A (CsA) on immobility in the tail 
suspension test (TST) and locomotor activity. A Escitalopram reduced immobility in 
the TST in a dose-dependent manner, with a significant 40% reduction in mice 
treated with 1 mg/kg but no significant reduction in mice treated with 0.1 mg/kg of 
escitalopram. CsA treatment, without escitalopram, had no significant impact on 
immobility in the TST nor did CsA augment the antidepressant-like effects of 
escitalopram in the TST. On the contrary, pre-treatment with CsA before the 0.1 
mg/kg dose of escitalopram caused a significant increase in the time spent immobile 
compared to mice in receipt of the same dose of escitalopram without CsA pre-
treatment (n = 9-14 per group). B CsA treatment significantly reduced locomotor 
activity by 40-45%, with or without escitalopram administration. Escitalopram had 
no effect on locomotor activity (n = 6-7 per group).  
* p < 0.05; ** p < 0.01; *** p < 0.001 relative to vehicle- and saline-treated control 
group 
 # p < 0.05 between indicated groups in receipt of the same dose of escitalopram 
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5.3.3. Microdialysis studies to investigate the effect of CsA pre-
treatment on escitalopram-induced increases in 
extracellular levels of 5-HT  
5.3.3.1. Pre-treatment with CsA attenuated the increase in extracellular 
5-HT in the PFC in response to escitalopram administration 
Pre-treatment with CsA attenuated the increase in extracellular 5-HT following 
escitalopram administration, relative to the vehicle-pre-treated group (F(1, 6) = 
6.899, p = 0.039; Figure 5.5). In addition, there was a significant group x time 
interaction (F(15, 90), p < 0.001), indicating that the time-profile of 5-HT increase 
differed between the groups.  
In vehicle pre-treated rats, dialysate 5-HT levels rose to ~300-400% of basal levels 
directly after administration of escitalopram, with a maximal increase to 411% of 
basal levels at t = 80 min preceding a drop to ~250% at t = 240 min. In contrast, in 
CsA pre-treated rats, escitalopram-induced increases in dialysate 5-HT levels rose 
gradually and consistently to a maximum of ~223% at t = 200 min, and this increase 
was significantly smaller than that observed in the vehicle-treated group up to 100 
min post-escitalopram administration (Figure 5.5). 
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Figure 5.5: Effect of cyclosporin A (CsA) pre-treatment on escitalopram-induced 
increases in extracellular 5-HT in the PFC. Compared to the vehicle-treated control 
group, pre-treatment with CsA transiently blunted the increases in extracellular 5-HT 
in response to escitalopram treatment, with significantly lower increases from 20 – 
100 minutes post-escitalopram administration, inclusive (n = 4 per group). 
* p < 0.05; ** p < 0.01; *** p < 0.001 relative to vehicle-treated group 
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5.4. Discussion 
Increasing preclinical evidence indicates that inhibition of the drug efflux 
transporter P-gp at the BBB may represent a putative strategy to augment therapy 
with certain antidepressants by increasing their brain delivery (Ejsing and Linnet, 
2005; Clarke et al., 2009; O'Brien et al., 2012a; O'Brien et al., 2012b; O'Brien et al., 
2013b). However, the potential clinical consequences of this strategy in terms of 
increased side effects merit careful consideration. The prospect of increasing the 
risk of serious side effects is a particular concern in light of case studies reporting 
serotonin syndrome in patients treated with both 5-HT enhancing antidepressants 
and CsA, which is a P-gp inhibitor in addition to its primary pharmacological action 
as an immunosuppressant (Wong et al., 2002; Lang et al., 2008; Newey et al., 2011). 
Indeed our data, using an animal model of serotonin syndrome, show for what is to 
our knowledge the first time that CsA can augment the behavioural effects of the 
SSRI escitalopram. In addition, CsA pre-treatment augmented the effect of 
escitalopram on 5-HT turnover in the prefrontal cortex (PFC). Intriguingly, CsA failed 
to enhance the effects of escitalopram in the TST, and actually blunted its 
neurochemical effect in terms of increases in extracellular 5-HT concentrations in 
the prefrontal cortex.   
Serotonin syndrome is a potentially fatal adverse drug reaction, which occurs as a 
result of excessive 5-HT signalling following ingestion of agents which enhance 
serotonergic neurotransmission (Boyer and Shannon, 2005). It is characterised by 
clinical symptoms such as tremor, clonus, muscular hypertonicity, altered mental 
state and hyperthermia in patients (Boyer and Shannon, 2005). Examples of agents 
which may precipitate serotonin syndrome include SSRIs and other antidepressants, 
especially monoamine oxidase inhibitors (MAOIs), some antiemetics (e.g. 
ondansetron, granisetron and metoclopraminde), certain drugs of abuse (e.g. 
MDMA and LSD) and 5-HT precursors such as tryptophan (Boyer and Shannon, 
2005; Haberzettl et al., 2013). While serotonin syndrome may occur after ingestion 
of a single 5-HT enhancing agent, it is more commonly associated with intake of two 
or more serotonergic drugs with differing mechanisms of action, such as SSRIs and 
MAOIs (Haberzettl et al., 2013). Indeed, life-threatening cases are generally only 
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observed where a combination of agents has been taken (Gillman, 2005). 
Importantly, the incidence of serotonin syndrome is thought to be rising with 
increased prescribing of serotonergic drugs (Thanacoody, 2012). Considering the 
serious and potentially fatal outcomes associated with serotonin syndrome, it is not 
possible to conduct human experiments to investigate drug combinations which 
may induce the syndrome. However, many of the symptoms of serotonin syndrome 
can be successfully emulated in rodent models (Haberzettl et al., 2013). Thus, due 
to their high level of predictive validity, such rodent models of serotonin syndrome 
represent a valuable tool to assess drug combinations suspected of eliciting cases of 
serotonin syndrome in humans (Haberzettl et al., 2013). In this context, the present 
study offers confirmation that CsA may cause or exacerbate serotonin syndrome 
when combined with serotonergic antidepressants, such as escitalopram, as per 
previous case studies reported in humans treated with CsA in combination with 
escitalopram, venlafaxine or sertraline (Wong et al., 2002; Lang et al., 2008; Newey 
et al., 2011). 
In addition to inhibiting P-gp, CsA has other pharmacological actions that may be 
responsible for the effects seen in the present study. For example, CsA is a potent 
calcineurin inhibitor and immunosuppressant. Interestingly, CsA has been reported 
to potentiate tremors induced by harmine, a naturally occurring plant alkaloid 
which inhibits the monoamine oxidase enzyme, thereby implicating the 
monoaminergic system in its pharmacology (Shuto et al., 1998). Indeed, the present 
data point to pharmacodynamic interactions between CsA and escitalopram 
affecting serotonin transmission that may be either P-gp dependent or 
independent. It is worth noting that the intermediate dose of CsA used in this study 
(75 mg/kg) elicited a significantly milder exacerbation of the mouse model of 
serotonin syndrome than the other two doses used (37.5 and 150 mg/kg). The 
mechanism underlying this dose-dependent effect is unclear. However, pilot studies 
revealed that the 75 and 150 mg/kg doses of CsA resulted in similar increases in 
brain tissue concentrations of escitalopram (71% vs 62% increase, respectively; data 
not shown). These findings indicate that a P-gp independent mechanism may be at 
play, as the dose-dependent effect of CsA on serotonin syndrome behaviours 
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cannot be attributed to differences in brain levels of escitalopram. Further studies 
are needed to ascertain whether findings in relation to the effect of CsA in this 
model of serotonin syndrome occurred as a result of increased brain levels of 
escitalopram at key sites involved in the regulation of serotonin syndrome due to P-
gp inhibition, or reflect an intrinsic effect of CsA on the serotonergic system. 
We have recently demonstrated that pre-treatment with the P-gp inhibitor 
verapamil results in increased escitalopram levels in brain homogenates (O'Brien et 
al., 2013b, Chapter 4). In the present study, the impact of pre-treatment with CsA in 
the same paradigm was investigated to determine if observations in relation to 
verapamil extend to other P-gp inhibitors. Similar increases in escitalopram brain 
concentrations were observed following pre-treatment with CsA as previously 
reported for verapamil, thereby further confirming the key role played by P-gp in 
the brain distribution of escitalopram.  
In line with data from previous reports using different antidepressants (Connor et 
al., 2000; Stenfors and Ross, 2002; Miura et al., 2005; Miura et al., 2007), 
escitalopram treatment was found to reduce 5-HT turnover in the PFC in a dose-
dependent manner in the present study. Pre-treatment with CsA augmented this 
effect. Despite there being a ~5-fold difference in brain levels of escitalopram 
between the two groups (70 vs 349 ng/g, respectively), 5-HT turnover was reduced 
to the same extent in mice treated with CsA and the lower dose of escitalopram as 
those treated with the higher dose of escitalopram without CsA pre-treatment. 
Therefore, the augmentation of escitalopram’s effect on 5-HT turnover by CsA pre-
treatment cannot be fully attributed to the increased brain levels of escitalopram 
due to P-gp inhibition. Moreover, significant reductions in the PFC concentration of 
the 5-HT metabolite, 5-HIAA, were only observed when both CsA and escitalopram 
were administered together, regardless of brain concentrations of escitalopram.  
Taken together, these observations indicate that CsA and escitalopram may work in 
concert to reduce 5-HT turnover by reducing 5-HT metabolism via a P-gp-
independent mechanism, likely related to other pharmacological actions of CsA. 
Interestingly, CsA administration on its own had no effect on 5-HT turnover, 
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suggesting that these effects are dependent on states where alterations in 5-HT 
signalling are already present, as is the case following SSRI treatment. 
In contrast to previous findings in relation to the P-gp inhibitor verapamil (O'Brien 
et al., 2013b, Chapter 4), pre-treatment with CsA did not result in an augmentation 
of escitalopram’s antidepressant-like activity in the TST. On the contrary, CsA pre-
treatment significantly increased the time spent immobile in mice treated with the 
lower dose of escitalopram. The suppression of locomotor activity by CsA may 
preclude meaningful interpretation of its influence on behaviour in the TST, as this 
paradigm is sensitive to changes in locomotor activity unrelated to antidepressant-
like activity. It is worth noting, however, that verapamil treatment resulted in a 
similar reduction in locomotion in the above-mentioned study in which it was found 
to augment the antidepressant-like activity of escitalopram (O'Brien et al., 2013b, 
Chapter 4). Importantly, intracerebral administration of calcineurin inhibitors, 
including CsA, has been reported to induce depressive-like behaviour in rodent 
models of depression (Zhu et al., 2011; Yu et al., 2013), thus underlining the 
difficulties encountered when conducting behavioural P-gp inhibition studies using 
relatively non-selective inhibitors. The divergence between the effects of CsA and 
verapamil pre-treatment on escitalopram activity in the TST, despite comparable 
reductions in locomotor activity and similar increases in brain levels of escitalopram 
for both P-gp inhibitors, highlights the need for further studies involving more 
selective P-gp inhibitors, such as the CsA analogue valspodar or tariquidar, to 
specifically elucidate the impact of P-gp inhibition on the antidepressant-like 
activity of escitalopram.   
In light of the behavioural data observed, where CsA increased the severity of an 
escitalopram-induced mouse model of serotonin syndrome but did not augment 
the antidepressant-like activity of escitalopram in the TST, and the combined effect 
of CsA and escitalopram in reducing 5-HT turnover, intracerebral microdialysis 
studies were undertaken to investigate the pharmacodynamic effect of co-
administration of CsA and escitalopram on extracellular 5-HT. These experiments 
were of particular interest considering a previous microdialysis study reported that 
CsA administration reduced extracellular 5-HT levels in the PFC in mice by over 50% 
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relative to basal concentrations (Sato et al., 2007). To our knowledge, the present 
study represents the first time that the impact of CsA administration on SSRI-
induced increases in extracellular 5-HT has been investigated. These experiments 
revealed that CsA markedly blunted the increase in extracellular 5-HT in response 
to escitalopram administration. These microdialysis findings may help to explain 
why CsA differed to verapamil in terms of its impact on escitalopram activity in the 
TST, as depletion of 5-HT attenuates the response to SSRIs in this paradigm (O'Leary 
et al., 2007). However, it must be noted that, for technical reasons, microdialysis 
experiments were undertaken in the rat, as opposed to mice used in behavioural 
studies. Thus, potential inter-species differences between rats and mice in terms of 
serotonergic responses to CsA need to be taken into consideration when 
attempting to compare results from behavioural and microdialysis experiments. 
Further studies, investigating the impact of CsA on serotonergic signalling in an 
SSRI-induced animal model of serotonin syndrome, will offer additional insight into 
the mechanism underlying the differential effects of CsA on behavioural responses 
to escitalopram. In addition, future intracerebral microdialysis experiments should 
be conducted to determine the effect of treatment with more selective P-gp 
inhibitors (Colabufo et al., 2010), as opposed to CsA or verapamil, on escitalopram-
induced increases in extracellular 5-HT. 
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5.5. Conclusion 
In conclusion, the present data reveal novel, but complex, pharmacokinetic and 
pharmacodynamic interactions between CsA and the SSRI escitalopram. Firstly, we 
demonstrate that CsA pre-treatment exacerbates the severity of symptoms 
associated with a mouse model of serotonin syndrome. This finding, in conjunction 
with previously published case studies (Wong et al., 2002; Lang et al., 2008; Newey 
et al., 2011), indicates that caution should be exercised if CsA is to be administered 
concurrently with a serotonergic antidepressant in clinical practice. The mechanism 
underlying this effect remains elusive. Further studies are required to determine if 
it is due to altered escitalopram pharmacokinetics as a result of P-gp inhibition, or 
as a result of a combined effect of CsA and escitalopram on serotonergic 
transmission related to other pharmacological actions of CsA, such as calcineurin 
inhibition Furthermore, a novel pharmacodynamic interaction between CsA and 
escitalopram was revealed, whereby these drugs acted in concert to reduce 
serotonin turnover in the prefrontal cortex. Finally, these studies highlight the need 
for further investigations using more selective pharmacological tools to specifically 
elucidate the effect of P-gp inhibition on the activity of antidepressants which are 
transported substrates of P-gp. Such experiments will serve to discriminate 
between pharmacokinetic effects, due to P-gp inhibition per se, and potential 
pharmacodynamic interactions related to alternative pharmacological effects which 
may be encountered when using non-specific P-gp inhibitors. 
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Abstract 
Recent preclinical studies have revealed a functionally important role for the drug 
efflux pump P-glycoprotein (P-gp) at the blood-brain barrier (BBB) in limiting brain 
levels and antidepressant-like activity of certain antidepressant drugs. Specifically, 
acute administration of P-gp inhibitors, such as verapamil and CsA, have been 
shown to augment brain concentrations and functional activity of the 
antidepressant escitalopram in rodents. However, depression is a chronic disorder 
and current treatments require prolonged administration to elicit their full 
therapeutic effect. Thus, it is important to investigate whether acute findings in 
relation to P-gp inhibition translate to chronic paradigms. To this end, the present 
study investigates whether chronic treatment with the P-gp inhibitor verapamil and 
the antidepressant escitalopram results in enhanced brain distribution and 
antidepressant-like effects of escitalopram. Verapamil (10 mg/kg i.p.) and 
escitalopram (0.1 mg/kg i.p.) were administered once daily for 22 days. On the final 
day of treatment, brain regions and plasma were collected for analysis of cortical 
and plasma concentrations of escitalopram and verapamil, and to determine the 
hippocampal expression of genes previously reported to be altered by chronic 
antidepressant treatment. Verapamil treatment resulted in a greater than two-fold 
increase in brain levels of escitalopram, without altering plasma levels. Gene 
expression analysis did not reveal an augmentation of molecular responses to 
escitalopram treatment as a result of verapamil administration. Taken together, 
these data demonstrate for the first time that P-gp inhibition can yield elevated 
brain concentrations of an antidepressant after chronic treatment, but the 
functional relevance of these increased brain levels remains unclear.  
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6.1. Introduction 
Increasing data have revealed that the multidrug efflux transporter P-glycoprotein 
(P-gp), expressed at the blood-brain barrier (BBB), restricts brain levels of several 
clinically important antidepressant drugs, thereby potentially contributing to the 
high prevalence of treatment failure (Uhr et al., 2008; O'Brien et al., 2012a; O'Brien 
et al., 2012b; O'Brien et al., 2013a). Moreover, we have recently demonstrated that 
acute inhibition of P-gp by verapamil enhances the behavioural effects of the 
antidepressant escitalopram in the tail suspension test (TST) (O'Brien et al., 2013b), 
one of the most widely used and well-validated animal models to assess 
antidepressant-like activity (Cryan et al., 2005a). Taken together, these findings 
raise the possibility that adjunctive treatment with a P-gp inhibitor may represent a 
potentially beneficial augmentation strategy in treatment resistant depression. 
Most studies investigating the effect of P-gp on antidepressant distribution into the 
brain have focused on acute drug administration (O'Brien et al., 2012b). While a 
limited number of studies have reported that brain levels of certain antidepressants 
are elevated in P-gp knockout mice relative to wild-type controls after subchronic 
(10-11 days) treatment (Grauer and Uhr, 2004; Uhr et al., 2008; Karlsson et al., 
2011; Karlsson et al., 2013), no study to date has investigated the effect of chronic 
P-gp inhibition on antidepressant distribution into the brain in wild-type animals, to 
our knowledge. This is a key consideration, as currently available antidepressants 
are associated with a delayed response, typically requiring chronic treatment in 
order to achieve their therapeutic effect in patients (Krishnan and Nestler, 2008). 
Moreover, certain xenobiotics are known to upregulate the expression and activity 
of P-gp (Miller, 2010). Indeed, the antidepressant venlafaxine, which is known to be 
a transported P-gp substrate (O'Brien et al., 2012b), has been reported to increase 
P-gp function in vitro and in vivo (Ehret et al., 2007; de Klerk et al., 2010). Thus, 
even though acute P-gp inhibition can result in increased brain levels of certain 
antidepressants, this effect could be negated following chronic exposure due to the 
hypothetical counteractive upregulation of P-gp activity. 
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The primary goal of the present study is to determine whether chronic treatment 
with the P-gp inhibitor verapamil and escitalopram would increase the brain 
distribution of escitalopram. Recent studies, both in P-gp knockout (acute and 
subchronic) (Karlsson et al., 2013) and wild-type (acute only) (O'Brien et al., 2013b) 
rodents, have identified that escitalopram, a commonly prescribed selective 
serotonin reuptake inhibitor (SSRI) antidepressant, is a transported P-gp substrate 
at the BBB. In addition, putative behavioural and molecular effects of chronic 
treatment with a P-gp inhibitor and a P-gp substrate antidepressant are 
investigated. In particular, the expression of several genes involved in the 
regulation of monoaminergic signalling, neurogenesis, responses to stress and gene 
transcription and which have been reported to be sensitive to chronic 
antidepressant treatment was assessed (Table 6.1). 
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Table 6.1: Target genes selected for mRNA expression analysis 
Gene 
name 
Protein product Function Studies implicating gene in 
antidepressant response 
Nr3c1 Glucocorticoid 
receptor (GR) 
Receptor for 
glucocorticoids, such as 
corticosterone in mice 
(Peiffer et al., 1991; Seckl and 
Fink, 1992; Johansson et al., 
1998; Bjartmar et al., 2000; 
Guidotti et al., 2013) 
Nr3c2 Mineralocorticoid 
receptor (MR) 
Cytosolic receptor for 
mineralocorticoids, such 
as aldosterone, as well as 
glucocorticoids 
(Brady et al., 1991; Seckl and 
Fink, 1992; Johansson et al., 
1998; Bjartmar et al., 2000) 
Fkbp5 FK506 binding 
protein (FKBP5) 
Immunophilin protein 
involved in 
immunoregulation and 
protein folding/trafficking 
(Guidotti et al., 2013) 
 
Egr1 Early growth 
response protein 1 
(EGR1; aka Zif268 
or NGFI-A) 
Transcription factor  (Morinobu et al., 1997; 
Johansson et al., 1998; 
Bjartmar et al., 2000; Sillaber et 
al., 2008) 
Nr4a1 Nerve growth 
factor IB (NGFI-B) 
Transcription factor (Bjartmar et al., 2000) 
Slc6a4 Serotonin 
transporter (SERT) 
Reuptake if 5-HT from 
synaptic space 
(Lesch et al., 1993; Lopez et al., 
1994; Benmansour et al., 1999) 
Tph2 Tryptophan 
hydroxylase 2 
(TPH2) 
Rate limiting enzyme in 
the synthesis of 5-HT in 
CNS 
(Abumaria et al., 2007; 
Shishkina et al., 2007; 
Heydendael and Jacobson, 
2009) 
Htr1a 5-HT1A receptor 5-HT autoreceptor 
involved in regulation of 
5-HT signalling 
(Burnet et al., 1994; Abumaria 
et al., 2007) 
Kcnk2 Trek-1 Potassium channel  (Heurteaux et al., 2006) 
Bdnf Brain derived 
neurotrophic 
factor (BDNF) 
Neurotrophin (Nibuya et al., 1995; Martinez-
Turrillas et al., 2005; Sillaber et 
al., 2008; Alboni et al., 2010) 
Creb cAMP response 
element-binding 
protein (CREB) 
Transcription factor  (Nibuya et al., 1996; Thome et 
al., 2000; Blom et al., 2002; 
Alboni et al., 2010) 
S100a10 p11 Involved in regulation of 
5-HT signalling in brain 
(Svenningsson et al., 2006; 
Melas et al., 2012) 
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6.2. Material and methods 
6.2.1. Drugs and chemicals 
Escitalopram oxalate was purchased from Discovery Fine Chemicals (Dorset, UK). 
Verapamil was obtained from Sigma-Aldrich (Ireland), as were all other chemicals, 
reagents and materials unless otherwise stated. 
6.2.2. Animals 
Male C57BL/6JOlaHsd mice (6-8 weeks old at the beginning of the study), 
purchased from Harlan Laboratories, UK, were used in this study. All animals were 
group-housed 4 animals per cage and maintained on a 12 hour light/dark cycle 
(lights on at 08:00 h) with food and water ad libitum. Room temperature was 
controlled at 22 ± 1°C. All procedures were carried out in accordance with EU 
directive 2010/63/EU and approved by the Animal Experimentation & Ethics 
Committee of University College Cork. 
6.2.3. Experimental design 
Verapamil (10 mg/kg i.p.) or saline were administered at least 30min before 
escitalopram (0.1 mg/kg i.p.) or saline each morning for 22 days (n = 9-10 per 
group). Body weight was measured daily to monitor for potential adverse reactions 
to treatment. On the penultimate day of treatment (day 21), mice were subjected 
to the tail suspension test to assess the effect of chronic verapamil pre-treatment 
on the antidepressant-like activity of escitalopram. On the final day of treatment, 
mice were sacrificed 40 min after escitalopram and 100 minutes post-verapamil 
administration. Timings were based on previous acute experiments (O'Brien et al., 
2013b, Chapter 4). Brain regions were immediately dissected out in ice-cold PBS 
and trunk plasma was collected. All samples were snap frozen in isopentane on dry 
ice, and stored at -80˚C until further processing. The dose of escitalopram was 
selected based on our previous study, where 0.1 mg/kg of escitalopram was found 
to elicit a behavioural effect in the TST only when administered in conjunction with 
verapamil (O'Brien et al., 2013b). However, a lower dose of verapamil was used in 
the present study (10 mg/kg rather than 20 mg/kg) due to concerns about potential 
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systemic side effects that may have arisen with prolonged high dose verapamil 
treatment. 
6.2.4. Tail suspension test 
The tail suspension test (TST), one of the most widely used models for assessing 
antidepressant activity in rodents (Cryan et al., 2005a), was carried out on the 21st 
day of treatment, as described previously (O'Brien et al., 2013b). This facilitated 
investigation of the impact of pre-treatment with the P-gp inhibitor verapamil on 
the antidepressant-like activity of escitalopram after chronic administration of each 
drug. Briefly, on the day of the TST, the P-gp inhibitor verapamil (10 mg/kg i.p.) or 
saline was administered one hour before escitalopram (0.1 mg/kg i.p.) or saline 
treatment. Thirty minutes after the second injection, mice were individually 
suspended by the tail from a horizontal bar using adhesive tape. Six minute test 
sessions were recorded by video camera and the amount of time spent immobile by 
each animal was subsequently scored by a trained observer blind to the treatment 
groups.  
6.2.5. Determination of escitalopram and verapamil in brain and 
plasma samples 
Escitalopram and verapamil were extracted from cortical brain tissue and plasma 
using a liquid-liquid extraction technique described previously (Clarke et al., 2009; 
O'Brien et al., 2013b). Briefly, 48 µl of plasma was spiked with 2 µl of the internal 
standard, imipramine, to yield a final concentration of 1 µg/ml imipramine. To this 
imipramine-spiked plasma, 1 ml of sodium hydroxide (2 M) and 3 ml of water were 
added. Extraction was carried out in 7.5 ml of 1.5% isoamyl alcohol in n-heptane by 
vortexing for 30 seconds, followed by agitation on a mechanical shaker for 15 min 
and then centrifugation at 5000 rpm for 15 min at 20°C. The upper solvent layer 
was transferred to a tube containing 200 µl of 25 mM OPA, vortexed for 30 
seconds, then agitated on a mechanical shaker for 15 min followed by 
centrifugation at 5000 rpm for 15 min at room temperature. Twenty microlitres of 
the lower aqueous phase was injected onto a HPLC system for analysis of 
escitalopram and verapamil, using a previously described HPLC method (O'Brien et 
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al., 2013b). Brain tissue samples were weighed prior to homogenization in 500 µl of 
imipramine-spiked (1 µg/ml) homogenization buffer (i.e. HPLC mobile phase). 
Homogenized brain tissue was centrifuged at 14000 rpm at 8°C for 15 min, and 
escitalopram and verapamil were extracted from 200 µl of the supernatant as 
described above. 
6.2.6. Gene expression analysis  
The hippocampal expression of twelve genes, which have been shown to be 
responsive to chronic antidepressant treatment or implicated in the antidepressant 
response (Table 6.1), was analysed using real-time quantitative polymerase chain 
reaction (qPCR). To our knowledge, p11, brain-derived neurotrophic factor (BDNF) 
and cAMP-responsive element binding protein (CREB) are the only gene targets 
which have been shown to be altered by chronic escitalopram treatment in the (rat) 
brain (Jacobsen and Mork, 2004; Alboni et al., 2010; Melas et al., 2012). Total RNA 
was extracted from hippocampal tissue using a commercially available kit 
(mirVanaTM PARISTM Kit, Applied Biosystems, USA), as per the manufacturer’s 
instructions. RNA purity and quantity was measured by spectrophotometric analysis 
(NanoDrop® ND-1000 Spectrophotometer, NanoDrop Technologies, Inc., USA). 
mRNA was reverse transcribed from 1 µg total RNA using a G-storm thermocycler 
(G-storm, Surrey, UK). PCR primers and probes were purchased from Integrated 
DNA Technologies (Belgium). Assays were designed for murine genes, as detailed in 
Table 6.1. Analysis of gene expression was performed in triplicate on 384-well 
plates using the LightCycler 480 System (Roche, Ireland), and the expression of each 
gene was normalised to that of β-actin. The 2−ΔΔCT method was used to calculate 
relative changes in gene expression determined from qPCR experiments (Livak and 
Schmittgen, 2001). Gene expression values are expressed relative to the control 
group. 
6.2.7. Data analysis and statistical procedures 
Statistical analysis of data was carried out using standard commercial software 
(SPSS Statistics, version 20.0.0; SPSS, Inc., Chicago, IL). The differences in brain and 
plasma levels of escitalopram between the two escitalopram-treated groups were 
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analysed using an unpaired Student’s t-test. Similarly, verapamil concentrations in 
brain tissue and plasma were compared by unpaired Student’s t-test. Differences in 
gene expression between the groups were analysed by two-way ANOVA, with 
verapamil and escitalopram as factors, and the LSD post-hoc was used to elucidate 
statistically significant differences between treatment groups. Differences in 
changes in body weight over time were analysed by two-way repeated measures 
ANOVA, with escitalopram and verapamil as factors. The criterion for statistical 
significance was p ≤ 0.05.  
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6.3. Results 
6.3.1. Concomitant chronic treatment with the P-gp inhibitor 
verapamil and escitalopram increased the brain levels of 
escitalopram, without affecting plasma levels  
The concentrations of escitalopram in cortical brain tissue were significantly greater 
in mice pre-treated with the P-gp inhibitor verapamil compared to saline-
pretreated mice, whereas there was no significant difference in plasma 
escitalopram levels (Figure 6.1A+B). Pre-treatment with verapamil resulted in a 
110% increase in cortical escitalopram levels (t(17) = -5.903, p < 0.001; Figure 6.1A), 
but had no effect on plasma levels of escitalopram (t(17) = -0.98, p = 0.341); Figure 
6.1B). Thus, the increase in brain concentrations of escitalopram can be attributed 
to enhanced BBB transport due to P-gp inhibition, rather than a reflection of 
elevated plasma concentrations. 
Plasma (t(17) = 0.274, p = 0.787) and brain (t(14) = -0.810, p = 0.937) levels of 
verapamil were equivalent in both verapamil-treated groups, with mean (± SEM) 
concentrations of 390 (± 37) ng/ml in plasma and 202 (±15) ng/g in cortical tissue. 
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6.3.2. Body weight 
Neither drug treatment, nor a combination of both drugs, had an effect on body 
weight during the course of the 22 day of drug administration: escitalopram 
(F(1,35) = 0.376, p = 0.544); verapamil (F(1, 35) = 0.096, p = 0.759); and 
escitalopram x verapamil (F(1, 35) = 0.195, p = 0.661). 
6.3.3. Tail suspension test 
Neither escitalopram (F(1, 35) = 0.885, p = 0.353) nor verapamil (F(1, 35) = 0.004, p 
= 0.950) had a significant impact on the duration of immobility in the TST, nor was 
there an interaction between the two factors (F(1, 35) = 1.505, p = 0.228). In 
comparison to previously reported acute experiments performed in our laboratory 
Figure 6.1: Effect of verapamil pre-treatment on brain and plasma 
concentrations of escitalopram after chronic administration. A Pre-treatment 
with verapamil resulted in a 110% increase in concentrations of escitalopram in 
cortical brain tissue. B Pre-treatment with verapamil did not significantly alter 
plasma levels of escitalopram (n = 9-10 per group). 
*** p < 0.001 between groups 
Chapter 6: Chronic verapamil and escitalopram 
232 
(O'Brien et al., 2013b), chronic administration reduced the time spent immobile in 
saline-treated mice by 35% (97s vs 150s).  
6.3.4. Gene expression analysis 
For technical reasons, it was not possible to include all animals in gene expression 
analysis. The total numbers of samples included for each gene are listed in Table 
6.2. Two-way ANOVA analysis of PCR results revealed a verapamil, escitalopram or 
verapamil x escitalopram effect on the expression of four of the twelve genes 
analysed (Table 6.2).  
The only target for which a significant escitalopram x verapamil interaction was 
detected was the serotonin transporter (SERT). Treatment with verapamil or 
escitalopram individually resulted in a trend towards increased SERT mRNA 
expression, but this trend was reversed when both verapamil and escitalopram 
were administered together, resulting in a significant reduction in SERT mRNA 
levels compared to mice treated with escitalopram only (Figure 6.2A).  
Escitalopram treatment had an effect on the expression of early growth response 
protein 1 (EGR1) mRNA, resulting in increased expression of this gene. Post-hoc 
analysis revealed that this increase was only statistically significant in mice treated 
with both verapamil and escitalopram. However, there was no significant 
interaction between the two treatments (Table 6.2; Figure 6.2B). 
Verapamil treatment affected the expression of mRNA for p11 and nerve growth 
factor IB (NGFI-B), increasing p11 expression to a similar extent with or without 
escitalopram treatment (Figure 6.2C). NGFI-B mRNA expression was also increased 
by verapamil treatment. Similar to EGR1, post-hoc analysis revealed that this 
increase was only statistically significant in mice treated with both verapamil and 
escitalopram, but there was no significant interaction between the two treatments 
(Table 6.2; Figure 6.2D).  
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Table 6.2: Two-way ANOVA of the effects of verapamil, escitalopram and verapamil 
x escitalopram interaction on mRNA expression in the hippocampus (n= 7-10). 
Target Total n Verapamil effect Escitalopram 
effect 
Verapamil x 
escitalopram 
interaction 
GR 32 F(1, 28) = 0.15,  
p = 0.904 
F(1, 28) = 4.132, 
p = 0.052 
F(1, 28) = 2.337, 
p = 0.138 
MR 31 F(1, 27) = 1.530,  
p = 0.227 
F(1, 27) = 0.004, 
p = 0.952 
F(1, 27) = 0.059, 
p = 0.810 
FKBP5 34 F(1, 30) = 0.810, 
 p = 0.375 
F(1, 30) = 0.669, 
p = 0.420 
F(1, 30) = 1.385, 
p = 0.249 
EGR1 34 F(1, 30) = 3.795,  
p = 0.061 
F(1, 30) = 5.854, 
p = 0.022 
F(1, 30) = 0.011, 
p = 0.917 
NGFI-B 31 F(1, 27) = 5.336,  
p = 0.029 
F(1, 27) = 1.838, 
p = 0.186 
F(1, 27) = 0.389, 
p = 0.538 
SERT 33 F(1, 29) = 0.408,  
p = 0.528 
F(1, 29) = 0.009, 
p = 0.925 
F(1, 29) = 5.385, 
p = 0.028 
TPH2 33 F(1, 29) = 0.284,  
p = 0.598 
F(1, 29) = 1.258, 
p = 0.271 
F(1, 29) = 3.342, 
p = 0.078 
5-HT1A 33 F(1, 29) = 0.008,  
p = 0.930 
F(1, 29) = 1.091, 
p = 0.305 
F(1, 29) = 0.414, 
p = 0.525 
TREK-1 33 F(1, 29) = 1.568,  
p = 0.221 
F(1, 29) = 0.091, 
p = 0.765 
F(1, 29) = 2.216, 
p = 0.147 
BDNF 34 F(1, 30) = 0.000,  
p = 0.990 
F(1, 30) = 0.918, 
p = 0.346 
F(1, 30) = 0.062, 
p = 0.805 
CREB 32 F(1, 28) = 2.163,  
p = 0.153 
F(1, 28) = 0.008, 
p = 0.930 
F(1, 28) = 0.477, 
p = 0.496 
p11 34 F(1, 30) = 10.182, 
p = 0.003 
F(1, 30) = 0.076, 
p = 0.785 
F(1, 30) = 0.127, 
p = 0.724 
Bold font denotes statistically significant effect 
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Figure 6.2: Relative expression of genes for which significant effects were 
observed. A. A significant interaction between verapamil and escitalopram was 
observed for SERT expression. SERT mRNA levels were significantly lower in mice 
treated with both verapamil and escitalopram than those treated with escitalopram 
only. B. Escitaloram treatment was found to exert a significant effect on EGR1 
mRNA expression. The increase in EGR1 mRNA levels, compared to the control 
group, was only statistically significant in mice treated with both verapamil and 
escitalopram. However, there was no significant interaction between the two 
treatments. C. Verapamil exerted a significant effect on p11 expression, resulting in 
a significant increase in mice treated with verapamil only compared to control mice, 
and a trend towards increased expression in mice treated with both verapamil and 
escitalopram (p = 0.054). D. Verapamil also exerted a significant effect on NGFI-B 
expression. A statistically significant elevation in NGFI-B mRNA was only observed in 
mice treated with both verapamil and escitalopram, but there was no interaction 
between the two treatments (n = 7-10 per group). 
* p < 0.05; ** p < 0.01 compared to control group 
# p < 0.05 between the indicated groups 
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6.4. Discussion 
Recent evidence from preclinical studies has highlighted an important role for the 
efflux transporter P-gp at the BBB in limiting the brain distribution of several 
antidepressants (O'Brien et al., 2012b). Here, we demonstrate, for what is to our 
knowledge the first time, that chronic treatment with a P-gp inhibitor and a P-gp 
substrate antidepressant results in increased brain levels of the antidepressant 
drug. We recently demonstrated that acute pre-treatment with the P-gp inhibitor 
verapamil augmented the brain concentrations and functional activity of the SSRI 
escitalopram in mice. However, prior to the present study, it remained unclear if 
such findings would translate to chronic treatment paradigms. Considering that 
antidepressant drugs are administered chronically in clinical practice, this is an 
important consideration, especially given that the antidepressant venlafaxine has 
been reported to induce P-gp in vitro and in vivo (Ehret et al., 2007; de Klerk et al., 
2010). Thus, the present results indicate that P-gp inhibition may represent a 
promising strategy to augment the brain delivery of certain antidepressants during 
chronic treatment. 
Verapamil, the P-gp inhibitor used in the present study, is a clinically used calcium 
channel blocker, indicated for the treatment of cardiovascular conditions such as 
angina, supraventricular tachycardia and essential hypertension. At higher doses, 
which it is thought may be required to inhibit P-gp due to its lack of specificity and 
relatively low potency, verapamil can elicit toxicity, characterized by symptoms 
such as hypotension and bradycardia (DeWitt and Waksman, 2004). In the present 
study, in which verapamil was found to inhibit P-gp, no overt signs of toxicity were 
detected during daily observations or in terms of alterations in body weight. 
Furthermore, the plasma concentrations of verapamil measured in the present 
study (390 ng/ml) are within the clinical therapeutic range (50 - 500 ng/ml) 
(Regenthal et al., 1999). Notwithstanding the potential for verapamil to inhibit P-gp, 
it is likely that its other pharmacological actions, including cardiovascular effects 
and inhibition of cytochrome P450 enzymes, would preclude its widespread use as 
a P-gp inhibitor in clinical practice. Several more specific second and third 
generation P-gp inhibitors have been developed which may be more appropriate 
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for this purpose (Colabufo et al., 2010). Nonetheless, verapamil represents a 
valuable pharmacological tool to investigate the effects of P-gp inhibition on drug 
distribution in preclinical studies. 
Despite observing a greater than 2-fold increase in escitalopram concentrations in 
cortical tissue in mice treated with the P-gp inhibitor verapamil, no enhancement of 
behavioural or gene expression responses to chronic escitalopram treatment was 
detected. Indeed, chronic treatment with escitalopram elicited no robust effect on 
the behavioural or molecular parameters investigated in the present study. This is 
perhaps not too surprising, given that we chose a relatively low dose (0.1 mg/kg) of 
escitalopram so as to be able to unmask any augmentation effects of verapamil. 
Nonetheless, in previous acute studies, we had observed a behavioural effect in the 
TST at this dose of escitalopram, but only when mice were pre-treated with 
verapamil (O'Brien et al., 2013b, Chapter 4). No such effect was evident here after 
chronic administration of both drugs. However, the results from the TST are 
inconclusive: when compared to our previous acute experiments (cf. O'Brien et al., 
2013b, Chapter 4), the baseline immobility in the control group was reduced by 
35%. This may have resulted in a floor effect, thereby potentially obscuring any 
putative behavioural impact of the increased brain concentrations of escitalopram 
due to P-gp inhibition. Although there have been a limited number of reports of the 
TST being responsive to chronic antidepressant administration, it is predominantly 
used to assess behavioural responses to acute antidepressant treatment (Cryan et 
al., 2005a). Interestingly, studies which have yielded positive results in the TST 
following chronic antidepressant administration have generally involved quite high 
doses of the antidepressant, for example 20 mg/kg of fluoxetine (Ukai et al., 1998). 
Hence, increasing the dose of escitalopram may represent a viable strategy to 
overcome the floor effect seen here. Future investigations of the effect of P-gp 
inhibition on antidepressant-like activity should make use of other paradigms, 
which are responsive to chronic antidepressant treatment, such as the social defeat 
stress or learned helplessness models (O'Leary and Cryan, 2013). 
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Similar to our behavioural studies, gene expression analysis did not reveal an 
augmentation of molecular responses to escitalopram administration in verapamil 
pre-treated mice. However, reports of alterations in mRNA expression in response 
to antidepressant treatment are often inconsistent, and may not be universal 
among different antidepressants, as evidenced by the variable findings in relation 
to BDNF expression (Tardito et al., 2006; Groves, 2007). Thus, genes which have 
been reported to be altered by treatment with other antidepressants may not be 
influenced by escitalopram administration. To our knowledge, p11, BDNF and CREB 
are the only gene targets which have been shown to be affected by chronic 
escitalopram treatment (Jacobsen and Mork, 2004; Alboni et al., 2010; Melas et al., 
2012). However, the expression of these genes was not altered by escitalopram 
treatment in the present study, further underlining the inconsistency of the effects 
of antidepressant treatment on mRNA expression. Moreover, our finding that 
chronic escitalopram treatment exerted a significant effect on mRNA levels of the 
transcription factor EGR1 is the first time that this has been reported, to our 
knowledge. Interestingly, the combination of verapamil and escitalopram 
treatment, but neither in isolation, resulted in a statistically significant increase in 
EGR1 mRNA expression relative to control mice. Similar findings were observed in 
relation to another transcription factor, NGFI-B. While there was not a significant 
interaction between escitalopram and verapamil treatment for either of these 
genes, indicating that this could merely reflect an additive effect of the two 
treatments, these targets warrant further investigation in future studies. 
It is also worth noting that antidepressant-induced changes in gene expression can 
be dependent on the brain region analysed and the antidepressant dose used 
(Tardito et al., 2006). In relation to the dose, the drug administration regimen used 
in the present study yielded plasma concentrations of escitalopram (23 ng/ml) 
within the therapeutic range (15 – 80 ng/ml) (Baumann et al., 2004), albeit at the 
lower end of that range. However, most studies which have reported significant 
alterations in mRNA expression following antidepressant treatment have involved 
the administration of much higher doses of the antidepressant (10 mg/kg 
escitalopram daily, for example (Jacobsen and Mork, 2004; Alboni et al., 2010)). 
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Thus, the doses of escitalopram used in the present study may have been 
insufficient to reproduce previously reported changes in mRNA expression. 
Furthermore, it is possible that there may have been functionally relevant 
alterations in protein expression, activation or cellular localization in response to 
antidepressant treatment, without changes in mRNA levels. Future studies should 
investigate these possibilities.  
Even though our analysis did not reveal any augmentation of escitalopram’s effects 
on mRNA expression by verapamil administration, a statistically significant 
interaction between the two treatments was observed in terms of serotonin 
transporter (SERT) mRNA levels. Interestingly, this effect constituted an attenuation 
of a trend towards increased SERT mRNA levels following verapamil or escitalopram 
on their own. It is important to note that, while studies have shown that SERT 
mRNA expression can be altered in response to antidepressant treatment, these 
findings have been somewhat inconsistent. SERT mRNA levels have been variously 
reported to be increased, decreased or not affected by chronic antidepressant 
treatment (Lesch et al., 1993; Lopez et al., 1994; Benmansour et al., 1999; 
Abumaria et al., 2007), indicating that the effect of antidepressant drugs on SERT 
expression is complex and variable.  
Due to the inconclusive nature of our findings in relation to the effect of chronic P-
gp inhibition on behavioural and molecular responses to antidepressant treatment, 
further studies are required to investigate this question. Such future studies should 
ideally utilise more specific inhibitors of P-gp, thereby limiting the contribution of P-
gp independent factors to alterations in gene expression, and helping to specifically 
elucidate antidepressant-related changes. For example, two-way ANOVA analysis 
revealed that verapamil itself exerted a significant effect on the expression of 
mRNA for NGFI-B and p11, thus making it difficult to identify any potential influence 
of P-gp inhibition on putative escitalopram effects in relation to these targets. In 
addition, future studies should use different dosing regimens of escitalopram and 
investigate other parameters, such as protein expression, rather than focusing on 
mRNA expression exclusively. 
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In conclusion, the present study demonstrates that inhibition of P-gp results in 
elevated brain levels of an antidepressant drug in a chronic drug administration 
paradigm. This finding indicates that P-gp inhibition may represent a viable strategy 
to enhance the brain distribution of P-gp substrate antidepressants after repeated 
dosing. In addition, these data reveal that chronic escitalopram administration can 
influence mRNA expression of the transcription factor EGR1. Further studies are 
required to fully elucidate the functional consequences, if any, of increasing the 
brain levels of an antidepressant drug by P-gp inhibition on a prolonged basis. 
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7.1. Overview and Summary 
In this thesis, we have demonstrated that the drug efflux pump P-glycoprotein (P-
gp) restricts the blood-brain barrier (BBB) transport of the antidepressants 
imipramine and escitalopram in rodents. Inhibition of P-gp, by either verapamil or 
cyclosporin A (CsA), resulted in a significant increase in brain concentrations of both 
of these antidepressants following acute administration. Further studies revealed 
that the acute effect of P-gp inhibition on the brain distribution of escitalopram is 
also relevant to chronic treatment scenarios. Moreover, we have shown that both 
imipramine and escitalopram are transported substrates of human P-gp, using an in 
vitro bidirectional transport approach, indicating that our findings in rodents may 
also apply to humans. In contrast, we found that the antidepressants amitriptyline, 
duloxetine, fluoxetine and mirtazapine are not transported substrates of human P-
gp in vitro, demonstrating that it is necessary to assess the P-gp substrate status of 
antidepressant drugs on a case-by-case basis. Furthermore, we investigated 
functional consequences of increasing brain levels of antidepressants by 
modulating P-gp function, demonstrating that P-gp inhibition by verapamil 
augmented the antidepressant-like activity of escitalopram, as measured in the tail 
suspension test (TST) in mice, and that CsA exacerbated behavioural responses to 
escitalopram in a mouse model of serotonin syndrome, indicating that adjunctive P-
gp inhibition may potentially increase the risk of serious adverse reactions to 
antidepressant treatment.  
It should also be noted that, unlike verapamil, CsA pre-treatment did not augment 
the effect of escitalopram in the TST, despite similar increases in brain 
concentrations of escitalopram. Thus, further studies are needed to fully 
characterise the functional relevance of P-gp inhibition on the effects of 
antidepressant treatment.  
Nonetheless, the studies outlined in this thesis advance our understanding of the 
role of P-gp in the pharmacokinetics and pharmacodynamics of antidepressant 
drugs, and support the concept that modulation of P-gp could represent a 
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beneficial therapeutic approach to augment antidepressant treatment, especially in 
cases of treatment resistant depression (TRD). 
7.2. The need for more effective strategies to improve response 
to antidepressant treatment 
With the possible exception of agomelatine, currently available antidepressant 
medications act primarily by modulating monoaminergic function in the brain 
(Section 1.4.2). While these antidepressant drugs fail to achieve an adequate 
response in up to 60% of patients, and require prolonged treatment to elicit a 
clinical effect in those who do respond, they remain the best therapeutic option 
available at present (Hollon et al., 2002; Fava, 2003). Much effort has been directed 
at attempts to unravel the neurobiological mechanisms of depression beyond the 
monoamine hypothesis, in the hope that a greater understanding of the 
pathophysiology the disorder may reveal novel therapeutic targets, resulting in 
more rapid and more efficacious antidepressant treatments (Krishnan and Nestler, 
2008). Although this research has led to the identification of numerous systems, in 
addition to the monoaminergic system, which contribute to the aetiology of 
depression, a ‘universal theory of depression’ has not been elucidated. Moreover, 
this work has not resulted in the successful development of more efficacious 
antidepressant drugs (Krishnan and Nestler, 2008). Indeed, such is the lack of 
success in the development of novel antidepressant treatments that it is widely 
acknowledged that those in use in the present day are no more effective in 
relieving the devastating symptomatology of depression than imipramine, which 
was serendipitously discovered over 50 years ago. However, recent findings in 
relation to glutamatergic involvement in depression offer much promise, and the 
results of clinical trials focused on drugs targeting this mechanism are awaited with 
interest (Burgdorf et al., 2013).  
In the absence of more effective drugs targeting novel mechanisms, clinicians 
endeavour to maximise the therapeutic benefit attainable with currently available 
antidepressant drugs (Connolly and Thase, 2011). Several pharmacological options 
are available in cases of treatment failure, including dose optimisation, switching to 
another antidepressant or augmentation of antidepressant treatment with another 
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agent, in addition to other, non-pharmacological, interventions, such as 
electroconvulsive therapy (Connolly and Thase, 2011). The recent STAR*D study 
found that applying these (pharmacological) options in a stepwise fashion, 
according to a defined algorithm, resulted in remission in approximately 70% of 
patients, but that it required repeated trials of sufficiently sustained, vigorously 
dosed antidepressant therapy to achieve this response (Gaynes et al., 2008). 
Furthermore, the authors concluded that “should the first treatment fail, either 
switching treatment or augmenting the current treatment” are reasonable options 
(Gaynes et al., 2008). However, the STAR*D study was not placebo controlled, and 
it is important to note that the evidence base supporting the efficacy of currently 
used augmentation strategies is far from convincing, especially in the context of the 
more modern and most commonly used SSRI antidepressant drugs (Connolly and 
Thase, 2011). Moreover, the mechanisms of action of these augmentation agents 
are poorly defined. Thus, there remains scope to develop new strategies to increase 
the efficacy of currently available antidepressants, in addition to a clear need for 
more efficacious drugs which exploit novel mechanisms for the treatment of 
depression. 
In this context, targeted inhibition of P-gp efflux represents a promising alternative 
to currently accepted augmentation strategies. The research outlined in this thesis 
builds on previous studies which initially revealed the key role played by P-gp in 
limiting the BBB transport of several antidepressants. Prior to the research 
conducted in this thesis, with the exception of three studies (Ejsing and Linnet, 
2005; Ejsing et al., 2006; Clarke et al., 2009), the existing literature demonstrating 
that P-gp limited brain levels of antidepressant drugs had focused exclusively on 
investigations involving P-gp knockout mice.  
7.3. Limitations of studies in P-gp knockout mice 
While P-gp knockout mice without doubt represent an invaluable investigational 
tool in determining the role of P-gp in drug distribution, there are several 
limitations associated with studies involving their use.  
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Firstly, studies in P-gp knockout mice do not offer information regarding the 
capacity to target P-gp as a strategy to increase brain concentrations of its 
transported substrates. Indeed, a previous study has reported a failure to 
reproduce observations in P-gp knockout mice by pharmacological inhibition of P-
gp (Ejsing and Linnet, 2005). Similarly, this limitation extends to studies involving 
the effect of P-gp on antidepressant distribution into the brain following chronic 
treatment. Given that the expression and activity of ABC transporters can be 
modulated by administration of certain xenobiotics, including the P-gp substrate 
antidepressant venlafaxine (Ehret et al., 2007; de Klerk et al., 2010), it is plausible 
that chronic treatment with a P-gp inhibitor and an antidepressant could result in 
an upregulation of P-gp activity. Considering that P-gp knockout mice do not 
express P-gp at the BBB, the effect of chronic drug treatment on the expression and 
function of P-gp, and by extension the BBB transport of P-gp substrate drugs, 
cannot be investigated in P-gp knockout mice. Moreover, P-gp knockout mice are 
developmentally different to their wild-type counterparts; there is evidence to 
suggest that the expression and function of other ABC efflux transporters, such as 
breast cancer resistance protein (BCRP), is upregulated in the absence of P-gp 
(Cisternino et al., 2004). Given the extensive overlap in substrate specificity 
between the different transporters in the ABC superfamily (Sharom, 2008), this is a 
potentially crucial confounding factor.  
The apparent discrepancy in findings between studies utilising single knockout 
abcb1a(-/-) mice (i.e. those lacking the abcb1a homologue only) and double 
knockout abcb1ab(-/-) mice is another important consideration in relation to P-gp 
knockout mice. For reasons which remain unclear, discrepant findings about the P-
gp substrate status of several glucocorticoids, as well as the antidepressants 
fluoxetine and amitriptyline, have been reported in studies using the two strains, 
thereby leading to uncertainty regarding the role of P-gp in their brain distribution 
(Uhr et al., 2000; Doran et al., 2005; Uhr et al., 2007; Mason et al., 2012). Given 
that abcb1a is thought to be the predominant isoform of P-gp at the BBB in 
rodents, it is difficult to rationalise these findings.  
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Another limitation of many of the previously existing studies regarding the role of 
P-gp in the brain distribution of antidepressants is the focus on brain 
concentrations at a particular, individual timepoint after drug administration. As 
demonstrated in studies by Uhr and colleagues in relation to amitriptyline, the time 
of sampling can influence the results obtained (Uhr et al., 2007). Thus, potentially 
significant differences between P-gp knockout and wild-type mice may not have 
been detected in some studies due to the sampling time. 
Finally, P-gp deficient mice have been reported to behave abnormally in relation to 
their wild-type comparators in commonly used animal models of antidepressant 
activity, such as the forced swim test (FST) and the tail suspension test (TST) 
(Schoenfelder et al., 2012). Thus, it may not be possible to assess the impact of P-gp 
knockout on responses to antidepressant treatment using these commonly used 
and well-validated models.  
Due to these limitations, there remained a need for further studies in wild-type 
animals to further investigate the potential for pharmacological manipulation of P-
gp to modulate antidepressant pharmacokinetics and pharmacodynamics.  
7.4. An adaptable, integrated intracerebral microdialysis 
approach to assess drug transport across the BBB in vivo 
To allow us to address some of the issues highlighted in the previous section, we 
developed an integrated intracerebral microdialysis technique to facilitate the 
assessment drug transport across the BBB in vivo in the conscious, freely moving 
rat. This approach involved catheterization of the jugular vein and carotid artery, 
and implantation of a microdialysis probe into the brain. While technically 
challenging, this technique offered several advantages over more simplistic 
methods of assessing BBB transport.  
The advantages of the intracerebral microdialysis have already been outlined in 
Section 1.2.5.4, and are summarised in Table 7.1. Jugular vein catheterization 
facilitated intravenous drug administration without a need to handle or restrain the 
animal, thereby minimising pharmacokinetic variability by eliminating the drug 
absorption step associated with other routes of administration (such as 
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intraperitoneal, subcutaneous or oral), while also avoiding stress associated with 
handling or restraint. Catheterization of the carotid artery in this model facilitated 
repeated blood sampling from the animal while simultaneously monitoring 
fluctuations in free drug concentrations in the extracellular space in the brain. 
Again, using the catheterization approach, it was possible to do this without a need 
to handle or restrain the animal. The simultaneous and repeated sampling from the 
carotid artery and microdialysis probe allowed us to measure drug concentrations 
in the blood and the brain with a high level of temporal resolution. Thus, it was 
uniquely possible to determine the effect of P-gp inhibition on the BBB transport of 
antidepressant drugs over time by adopting this approach.  
Table 7.1: Advantages and limitations of intracerebral microdialysis technique (de 
Lange et al., 2000; Anderzhanova and Wotjak, 2013) 
Advantages 
Facilitates the monitoring of changes in the extracellular concentration of various 
compounds of interest in conscious freely animals 
Only free, unbound, physiologically and pharmacologically active concentrations of the 
compound are monitored 
Amenable to studies investigating neurotransmission as well as drug pharmacokinetics 
Minimal disruption of tissue homeostasis  
Efficient spatial and temporal resolution 
Samples do not require purification or work-up prior to analysis 
Limitations 
Physiological stress associated with the invasive surgical procedure required 
Physical damage caused by implantation of the microdialysis probe 
Requirement for highly sensitive analytical assays to facilitate determination of 
compounds in small volume, low concentration samples 
Challenges in achieving quantitative analysis of actual brain ECF concentrations  
Potential changes in probe recovery due to manipulations which dramatically change the 
extracellular concentrations of the analyte of interest 
Unsuitable for highly lipophilic compounds 
Temporal resolution is restricted to several minutes (e.g. 20 min), thereby unsuitable for 
the measurement of rapid changes in analyte concentration 
 
Using this technique, we demonstrated that P-gp inhibition results in increased 
brain levels of the antidepressants imipramine and escitalopram. Furthermore, we 
were able to investigate the effect of pre-treatment with the P-gp inhibitor CsA on 
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increases in extracellular serotonin in response to escitalopram treatment, thereby 
offering unique insight into the pharmacodynamic effects of this drug combination. 
The possibility to administer a drug as a continuous intravenous infusion, due to the 
presence of the indwelling jugular vein catheter, allowed us to achieve and 
maintain steady state concentrations of escitalopram in plasma and brain tissue. 
This proved to be a particularly useful strategy when investigating the influence of 
P-gp inhibition on drug transport across the BBB, as demonstrated in Chapter 4, 
where a striking increase in brain levels of escitalopram were observed immediately 
after administration of the P-gp inhibitor CsA (O'Brien et al., 2013b). Furthermore, 
this approach enabled us to cease the experiment at a point when the elevation in 
brain levels was maximal, thereby facilitating confirmation of microdialysis findings 
by measuring escitalopram concentrations in brain tissue harvested at termination 
of the experiment. This was not possible in our earlier studies involving a one-off, 
bolus administration of imipramine; brain levels of imipramine, as measured by 
microdialysis, were no longer different between the groups at the end of the 
experiment. Thus, it is advisable that future studies investigating the effect of drug 
efflux transporters on BBB transport should avail of the steady state approach. 
Indeed, recent work in our lab has adapted this strategy to investigate the effect of 
OAT3 inhibition on the BBB transport of bumetanide, with promising results to date 
(Donovan, O’Brien et al., unpublished data). 
One of the major challenges in successfully implementing the intracerebral 
microdialysis technique is the requirement to develop a high sensitivity analytical 
method to facilitate detection of the analyte of interest. For this purpose, we were 
able to successfully adapt methods described in the literature for the 
antidepressant drugs investigated in the present study. In addition, it was possible 
to modify our microdialysis technique to measure extracellular serotonin 
concentrations, both at basal levels and in response to escitalopram treatment, 
thereby facilitating investigation of the effect pre-treatment with the P-gp inhibitor 
CsA on escitalopram-induced increases in extracellular serotonin. The analytical 
challenge presented by microdialysis studies highlights another advantage of 
conducting drug transport experiments at steady state with continuous intravenous 
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drug infusion. When using this approach, drug concentrations can be maintained at 
higher, and therefore more readily detectable, levels compared to bolus 
administration studies. After bolus administration, drug concentrations rapidly 
decline to low levels from an initial peak, thereby potentially presenting an 
insurmountable analytical challenge. Thus, by using the steady state approach, our 
integrated intracerebral microdialysis technique could be applied to drugs for which 
highly sensitive analytical assays do not exist. The numerous applications to which 
this integrated intracerebral microdialysis model has already been successfully 
employed highlight its flexibility and utility, and indicate that it may be possible to 
extend its use to address other research questions.  
7.5. The importance of in vitro studies to identify drugs which 
are transported substrates of human P-gp  
Despite the abundance of preclinical evidence demonstrating that P-gp limits the 
brain distribution of antidepressants in rodents, the existing data from in vitro 
studies investigating interactions between antidepressants and human P-gp were 
inconclusive (O'Brien et al., 2012b; Chapter 1). While several studies reported 
significant interactions between certain antidepressants and human P-gp using the 
ATPase assay, the relevance of these findings to drug transport is unclear. In 
contrast, the in vitro bidirectional transport approach represents the ‘gold 
standard’ approach for the identification of transported substrates of P-gp 
(Balimane et al., 2006).  
However, bidirectional transport studies investigating if antidepressant drugs are 
transported substrates of human P-gp have reported inconsistent, but generally 
negative, findings. Confident interpretation of the results from these studies is 
difficult, however, mostly due to methodological limitations of the two studies 
which have provided most of the data in this regard (Mahar Doan et al., 2002; Feng 
et al., 2008). For example, one of these studies, which investigated the effects of 
human P-gp on the permeability of 39 compounds in the MDCKII-MDR1 cell line, 
found that none of the seven antidepressants included in the study were 
transported substrates of P-gp (Feng et al., 2008). Presumably to facilitate high 
throughput screening of the large number of compounds included in the study, the 
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effect of P-gp on drug transport was only determined at a single, 5-hour time-point. 
While this approach was sufficient to identify very high affinity substrates of P-gp, 
such as ritonavir, it may have lacked the sensitivity to detect less avid substrates. 
Indeed, the transport ratio for verapamil, a well-established P-gp substrate, in 
addition to being an inhibitor of P-gp, was marginally above the threshold for 
identification of a transported P-gp substrate in this study (Feng et al., 2008). 
Another study reported that 10 of 11 antidepressants investigated were not 
transported substrates of P-gp (Mahar Doan et al., 2002). However, the donor 
concentration used in this work was twice the recommended upper limit of 5 µM 
for these types of studies and samples were only taken at single timepoint one hour 
after commencing the experiment (see Balimane et al., 2006, for a discussion of 
methodological considerations). Similarly, two of the three in vitro bidirectional 
transport studies which have reportedly identified antidepressant drugs as 
transported substrates of P-gp were carried out in the Caco-2 cell line, without 
conducting additional experiments to confirm that P-gp was the transporter 
responsible for the net efflux effect observed (Faassen et al., 2003; El Ela et al., 
2004). Thus, there was a lack of definitive and reliable data pertaining to the 
transport of antidepressants by human P-gp. This was a major limitation when 
attempting to evaluate the relevance of findings from rodent studies to humans in 
receipt of antidepressant treatment, considering reports of species differences in P-
gp specificity and activity (Yamazaki et al., 2001; Katoh et al., 2006; Baltes et al., 
2007; Syvanen et al., 2009). It was in this context that we established and utilised 
an in vitro bidirectional transport model to assess if various antidepressants are 
transported substrates of P-gp. 
In the in vitro model employed in our work (Chapters 3 and 4), drug transport was 
measured at several time points throughout the experiments, rather than taking a 
single measurement at the end, thus enabling us to determine the rate of transport 
more accurately (Youdim et al., 2003). Moreover, cellular retention of the 
compound, an often overlooked factor when calculating permeability values based 
on experimental observations, was accounted for in our studies (Youdim et al., 
2003). Using this approach, we determined that P-gp substantially limited the 
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ability of escitalopram to traverse the cell monolayer, while it also restricted 
imipramine permeability, albeit to a lesser extent. Moreover, we found that P-gp 
exerted no effect on the permeability of amitriptyline, duloxetine, fluoxetine or 
mirtazapine. Thus, the in vitro model was sensitive enough to discriminate between 
antidepressants which were subjected to P-gp mediated efflux and those which 
were not. The data from these studies suggest that P-gp may play a role in the brain 
distribution of escitalopram and imipramine in humans, but is unlikely to affect the 
BBB transport of amitriptyline, duloxetine, fluoxetine or mirtazapine. This 
information in regard to amitriptyline and fluoxetine is particularly interesting, as 
there had been ambiguity about the role of P-gp in their brain distribution based on 
somewhat inconsistent findings from studies involving P-gp knockout mice (Uhr et 
al., 2000; Doran et al., 2005; Uhr et al., 2007).  
Knowing which antidepressants are transported substrates of P-gp would be 
essential in rationally designing any potential future clinical studies with the aim of 
evaluating P-gp inhibition as an antidepressant augmentation strategy. This 
knowledge will help to avoid potential flaws in study design similar to those which 
may have contributed to the failure of large scale clinical trials investigating P-gp 
inhibitors as adjunctive agents in oncology (as outlined in Section 1.3.5). Similarly, 
information regarding the transport of antidepressants by human P-gp is important 
when planning or critically evaluating pharmacogenetic studies investigating 
potential links between SNPs in ABCB1 and antidepressant response. 
7.6. Determining the functional relevance of increasing brain 
levels of antidepressant drugs by P-gp inhibition: 
behavioural studies 
While several studies had reported that the brain pharmacokinetics of certain 
antidepressants were enhanced by P-gp inhibition or P-gp knockout, no published 
study had investigated the functional effect of increased brain distribution of 
antidepressants in a relevant animal model of antidepressant activity. Indeed, it had 
been proposed that a 4-fold increase in brain levels of a drug in P-gp knockout mice 
relative to wild-type controls was required in order to consider P-gp efflux to be 
functionally relevant (Feng et al., 2008); the greatest increase reported for an 
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antidepressant to date is a 3.6-fold increase (O'Brien et al., 2012b). Thus, it was 
unclear whether the differences in brain pharmacokinetics of antidepressant drugs 
due to P-gp inhibition or P-gp knockout would result in a meaningful difference in 
the pharmacodynamic effects of the antidepressant.  
One previous study had reported altered behaviour in the open field in P-gp 
knockout mice, compared to wild-type controls, when treated with the P-gp 
substrate antidepressant venlafaxine (Karlsson et al., 2011). While this finding was 
certainly interesting, as it revealed a differential response to antidepressant 
treatment between the two strains, its relevance to the antidepressant effects of 
venlafaxine were unclear. Thus, there remained a major impetus to carry out 
further experiments to elucidate the impact of a reduction in P-gp function, either 
due to pharmacological intervention or genetic ablation, on the pharmacodynamic 
activity of P-gp substrate antidepressants. The related, but subtly different, forced 
swim test (FST) and tail suspension test (TST) are two of the most widely used and 
well validated rodent models for assessing antidepressant-like activity (Cryan and 
Holmes, 2005), and would therefore represent ideal paradigms in which to address 
this issue. However, it may not be possible to conduct such experiments in the P-gp 
knockout mice, as they have been reported to display aberrant behaviour in these 
tests, with significantly lower immobility in the FST and significantly greater 
immobility in the TST, relative to their wild-type counterparts (Schoenfelder et al., 
2012). Therefore, P-gp knockout mice may not respond normally to antidepressant 
drugs in these tests; indeed, this seems to be the case (Schmitt et al., 2009).  
In light of the aberrant responses of P-gp knockout mice in these commonly used 
animal models of antidepressant activity, it was necessary to conduct 
pharmacodynamic studies involving P-gp inhibition in wild-type animals to assess 
the functional relevance of increased brain levels of antidepressants as a result of 
reduced P-gp function. Our experiment demonstrating that pre-treatment with 
verapamil augmented the antidepressant-like activity of escitalopram in the TST 
was the first such study (Chapter 4). However, subsequent investigations using an 
alternative P-gp inhibitor, CsA, yielded conflicting results (Chapter 5). CsA itself was 
found to exert an effect on the serotonergic system, as demonstrated by its 
Chapter 7: General Discussion 
252 
attenuating effect on escitalopram-induced increased in extracellular serotonin and 
its effect on serotonin turnover when administered in combination with 
escitalopram. In addition, it significantly reduced locomotor activity in the open 
field, which may explain why it did not augment the effect of escitalopram in the 
TST. Thus, it is difficult to draw any firm conclusions from pharmacodynamic studies 
involving CsA. Further experiments, involving more specific P-gp inhibitors, are 
required to definitively elucidate the impact of P-gp inhibition on behavioural 
responses to antidepressant drugs which are transported substrates of P-gp. 
We also investigated the impact of P-gp inhibition on an escitalopram-induced 
mouse model of serotonin syndrome, finding that CsA pre-treatment significantly 
exacerbated the manifestation of behaviours associated with this model (Chapter 
5). This finding highlights the potential for increased risk of side-effects when 
increasing brain levels of antidepressants by P-gp inhibition. Further studies are 
required to confirm the mechanism underlying this interaction between CsA and 
escitalopram, given that CsA was found to modulate escitalopram-induced changes 
in the serotonergic system as outlined above. 
7.7. Do findings from acute experiments in relation to the 
impact of P-gp inhibition on antidepressant transport 
across the BBB translate to chronic studies? 
One of the main unresolved questions regarding studies demonstrating that P-gp 
limited the BBB transport of certain antidepressants, and that inhibition of P-gp 
resulted in increased brain levels of these drugs, was whether these findings would 
translate to chronic drug administration scenarios which are more analogous to the 
clinical use of antidepressants. This is a key consideration when contemplating P-gp 
inhibition as a potential adjunctive strategy for treatment with P-gp substrate 
antidepressants, given that repeated exposure to xenobiotics, including the 
antidepressant venlafaxine (Ehret et al., 2007; de Klerk et al., 2010), can result in 
increased P-gp expression and function (Miller, 2010).  
A number of studies had gone some way to addressing this issue by conducting 
longer term studies in P-gp knockout compared to wild-type mice. However, these 
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studies could be more aptly described as ‘subchronic’ rather than chronic per se, as 
they involved drug administration for a maximum of 11 days. Moreover, studies in 
P-gp knockout mice do not yield information that indicates whether long term 
administration of a P-gp inhibitor in conjunction with a P-gp substrate 
antidepressant will result in increased brain levels of the antidepressant. Thus, we 
conducted a chronic experiment in which the P-gp inhibitor verapamil and the P-gp 
substrate antidepressant escitalopram were administered daily for 22 days (Chapter 
6). This study revealed that brain levels of a P-gp substrate antidepressant were 
indeed increased by P-gp inhibition in a chronic paradigm. This finding indicates 
that long term treatment with a P-gp inhibitor may represent a viable strategy to 
achieve enhanced brain delivery of P-gp substrate antidepressants in clinical 
practice.  
In addition, the behavioural and neurochemical effects of antidepressant treatment 
have been reported to differ between acute and chronic drug administration 
paradigms (Cryan et al., 2005b; Gaska et al., 2012). Therefore, as a secondary goal 
of our chronic study, we investigated potential behavioural and molecular 
consequences of chronically increased brain levels of escitalopram by P-gp 
inhibition. These experiments did not detect any augmentation of escitalopram’s 
effects by P-gp inhibition. However, there are several potential explanations for this 
lack of effect, as outlined in Section 6.4, not least the low dose (0.1 mg/kg) of 
escitalopram administered in the study. Studies which have reported significant 
effects of chronic antidepressant administration on the mRNA expression of the 
targets investigated in Chapter 6 have involved much higher doses than that used in 
our experiment. The rationale underlying the choice of dose for our chronic study 
was based on our findings in acute studies, whereby this dose of escitalopram did 
not elicit a significant antidepressant-like effect when administered on its own, but 
did when administered in combination with the P-gp inhibitor verapamil. Thus, it 
seemed rational to investigate the effect of P-gp inhibition on the 
pharmacodynamic activity of this dose following chronic administration, as using a 
higher dose of escitalopram would have risked encountering a ceiling effect. Future 
studies should explore the question of the pharmacodynamic effect of chronic P-gp 
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inhibitor and antidepressant treatment using a different dosing regimen of 
escitalopram. 
7.8. Limitations of the work outlined in this thesis 
No experimental approach is without its limitations, and it is necessary to be 
cognisant of this fact when interpreting our results. The in vivo and in vitro 
techniques used in the work described in this thesis have several limitations, as 
outlined in the following sections. 
7.8.1. Limitations of in vivo studies 
7.8.1.1. Intracerebral microdialysis 
There are several advantages associated with the intracerebral microdialysis 
technique (see Table 7.1), including the ability to continuously monitor fluctuations 
in extracellular concentrations of unbound, pharmacologically and physiologically 
active compounds in specific brain regions, thus offering a unique level of spatial 
and temporal resolution. However, there are also several important limitations 
associated with this approach (Table 7.1). For example, stereotaxic implantation of 
the microdialysis probe causes unavoidable damage to the surrounding tissue, 
which may in turn affect the integrity of the BBB. The impact of this damage on 
studies investigating BBB drug transport can be minimised by conducting 
experiments during the optimal post-surgical period, between 1 and 2 days after 
probe implantation; after recovery from early tissue reactions and before the start 
of long term reactions (de Lange et al., 2000). Importantly, in our BBB transport 
studies, we were able to detect changes in the brain levels of our target compounds 
as a result of P-gp inhibition, thereby demonstrating that the BBB was exerting a 
functional effect on drug transport; had the BBB been substantially compromised 
by the insertion of the microdialysis probe, it is likely that such differences would 
not have been evident. 
Another important limitation associated with our microdialysis studies is that we 
did not perform quantitative analyses, meaning that we did not determine actual 
concentrations of the analytes of interest in brain extracellular fluid. Rather, we 
compared relative changes in analyte concentrations between different treatment 
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groups. As a result, it was not possible to definitively calculate the actual magnitude 
of increases in brain concentrations of the antidepressant due to P-gp inhibition. 
This is a particular concern considering that inhibition of P-gp could alter probe 
recovery (de Lange et al., 2000). However, both predictions, based on theoretical 
modelling (Bungay et al., 1990), and experimental evidence (de Lange et al., 1998; 
Xie et al., 1999) indicate that inhibition of P-gp would result in a reduction in probe 
recovery of P-gp substrate compounds. Therefore, it is likely that our findings may 
underestimate the effect of P-gp inhibition on brain levels of antidepressants. 
7.8.1.2. Non-selective nature of P-gp inhibitors used 
Perhaps the most important limitation of the present work is the non-selective 
nature of the P-gp inhibitors used, verapamil and CsA. Each of these compounds 
has an extensive range of pharmacological actions in addition to their inhibition of 
P-gp. Verapamil is primarily known as a calcium channel blocker, while CsA is a 
calcineurin inhibitor. Both are clinically used; verapamil for cardiovascular 
indications, and CsA as an immunosuppressant. The rich pharmacology of these 
compounds makes isolation of P-gp mediated effects somewhat challenging, 
especially when investigating pharmacodynamic effects.  
The integrated approach adopted in microdialysis-based pharmacokinetic studies 
allowed us to confirm that increases in brain concentrations following 
administration of these P-gp inhibitors were not merely a reflection of elevations in 
circulating blood levels, thereby confirming increased BBB transport. Furthermore, 
the converging effect of both verapamil and CsA, in enhancing the brain 
concentrations of imipramine and escitalopram, strongly indicates that this 
enhancement was mediated via P-gp inhibition, an effect common to both drugs. 
Moreover, the involvement of P-gp was confirmed by in vitro studies, which offered 
the advantage of elucidating the mechanism at play, in addition to demonstrating 
that these antidepressants are substrates of human P-gp (as discussed in Section 
7.5). 
While it was possible to overcome potential problems associated with the non-
selective nature of the P-gp inhibitors in pharmacokinetic studies, it is more difficult 
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to discriminate between P-gp-dependent and P-gp-independent effects in relation 
to pharmacodynamic studies. We found that verapamil augmented the 
antidepressant-like activity of escitalopram in the TST, resulting in a reduction in 
immobility. Moreover, this reduction in immobility was statistically correlated with 
brain levels of escitalopram, thereby indicating that this effect was likely as a result 
of increased brain concentrations of escitalopram following P-gp inhibition, as 
opposed to, for example, verapamil’s ability to block calcium channels (Cohen et al., 
1997; Busquet et al., 2010). In contrast, inhibition of P-gp by CsA did not augment 
the antidepressant-like activity of escitalopram in the TST. The effects of CsA on the 
serotonergic system, as demonstrated by microdialysis studies, and its effect on 
serotonin turnover in prefrontal cortex brain tissue, in addition to its effects on 
locomotor activity, indicate that the pharmacodynamic effects of CsA may be acting 
to suppress any potential enhancement of escitalopram activity due to increased 
brain levels. Similarly, it is not possible to definitively attribute the exacerbating 
effects of CsA in an escitalopram-induced mouse model of serotonin syndrome to 
P-gp dependent or independent mechanisms. Further studies, using more specific 
P-gp inhibitors (Colabufo et al., 2010), are required to conclusively determine the 
effect of P-gp inhibition on the pharmacodynamic activity of P-gp substrate 
antidepressants. 
7.8.1.3. Caution extrapolating findings in rodents to humans 
As with any in vivo preclinical studies, it is important to avoid over-interpretation of 
our findings in rodents when evaluating their potential relevance to humans. 
Therefore, the pharmacokinetic differences between rodents and humans need to 
be highlighted and taken into consideration.  
Studies have shown that the capacity of P-gp at the BBB differs between species, 
requiring different doses of a P-gp inhibitor to elicit the same effect in terms of 
increased brain distribution of P-gp substrates (Cutler et al., 2006; Syvanen et al., 
2009). Thus, it may not be possible to replicate our findings in rodents in human 
subjects. Indeed, a recent paper, published on behalf of the International 
Transporter Consortium, has questioned whether clinical modulation of efflux 
transport at the BBB is likely for these reasons (Kalvass et al., 2013). 
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Another important consideration, especially relevant to our chronic study, is the 
difference in drug clearance between rodents and humans. Typically, the half life of 
a drug is much shorter in rodents than in humans. Owing to their long half lives, 
most antidepressants accumulate until steady state levels are achieved following 
chronic once daily administration in humans. In contrast, steady state levels may 
not be achieved with once, or even more frequent, daily dosing in mice (Frazer and 
Benmansour, 2002). Thus, it is necessary to be cautious when drawing conclusions 
from chronic studies involving daily injections in mice. This could be especially 
relevant when investigating pharmacodynamic effects, as it may be necessary for 
antidepressant levels to remain consistently above a certain concentration in order 
to elicit their long term effects (Frazer and Benmansour, 2002). This problem could 
be overcome with future studies involving continuous drug infusion over a 
prolonged period of time, for example by using an osmotic minipump. 
Similarly, animal models of antidepressant activity, such as the TST used in the 
present work, have their limitations. The pharmacodynamic findings in these 
studies do not necessarily mean that similar effects will be observed in patients, as 
evidenced by the fact that many compounds which have shown antidepressant-like 
effects in these models have failed to gain clinical approval (O'Leary and Cryan, 
2013). Thus, it is necessary to be cautious when interpreting results from our 
behavioural studies. 
7.8.2. Limitations of in vitro studies 
To ensure accurate identification of antidepressants which are subjected to efflux 
by P-gp, every effort was made in our in vitro work to adopt a rational and 
consistent methodological approach, based on published guidelines and best 
practice (Polli et al., 2001; Youdim et al., 2003; Balimane et al., 2006; Zhang et al., 
2006). However, it remains a possibility that aspects of our approach may have 
resulted in misleading results. It is necessary to consider such potential sources of 
error, as discussed in the following sections. 
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7.8.2.1. Non-BBB characteristics of cells used for in vitro studies 
Due to limitations of BBB-derived systems, as outlined in Section 1.2.5.2, we chose 
to use cells from a non-cerebral origin for our in vitro work. This is not ideal, given 
that the properties of the endothelium/epithelium are known to influence P-gp 
activity at the BBB (Romsicki and Sharom, 1999; Hellinger et al., 2012). However, 
the available data indicate that the MDCKII-MDR1 model we employed is at least as 
effective, if not more so, at identifying transported P-gp substrates at the BBB than 
alternative, BBB-derived, in vitro approaches (Hellinger et al., 2012). Nonetheless, it 
is important to bear in mind that our in vitro system is not a model of the BBB per 
se, and therefore does not reflect the complexity of uptake, efflux and metabolic 
processes ongoing at the BBB in vivo. Rather, our model represents a tool for the 
identification of P-gp substrates in general, and this caveat needs to be borne in 
mind when considering the relevance of in vitro findings to BBB transport in vivo. 
Our approach, whereby rodent studies to assess the role of P-gp in the BBB 
transport of imipramine and escitalopram in vivo were combined with in vitro 
studies involving human P-gp, helps to offset this limitation. 
7.8.2.2. Concentration-dependence of in vitro studies 
The donor concentration used in in vitro studies is known to influence the results 
obtained (Balimane et al., 2006). Using too high a donor concentration may result in 
saturation of the efflux transporter and a resultant overwhelming of the efflux 
effect. Conversely, it has been reported that the antiepileptic drug phenobarbital 
was detected as a P-gp substrate when higher, but not lower, donor concentrations 
were used (Zhang et al., 2010). Thus, it is possible that the antidepressants which 
we did not find to be affected by P-gp efflux may have been identified as P-gp 
substrates had we used a different donor concentration. As a result, further studies 
are required before these antidepressant drugs can be definitively categorised as 
non-P-gp substrates.  
When attempting to conduct traditional bidirectional transport studies at low 
donor concentrations, the small amount of the compound of interest that has 
accumulated in the receiver chamber, in particular at earlier time-points, can 
present a substantial analytical challenge. The concentration-equilibrium-transport-
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assay (CETA) approach may represent a useful means to circumvent this problem in 
future studies (Luna-Tortos et al., 2008; Zhang et al., 2011). The CETA approach 
involves simultaneously adding equal concentrations of the compound of interest 
to both the apical and basolateral chambers. If the compound is a transported P-gp 
substrate, it will preferentially accumulate in the apical chamber, due to the 
influence of P-gp efflux at the apical membrane. Thus, due to the addition of the 
compound to each chamber, the same level of sensitivity in the analytical technique 
is not required as would be the case for traditional bidirectional transport studies 
involving the same initial concentration. 
7.9. Is P-gp inhibition a potentially viable option to augment 
antidepressant treatment clinically? 
Our work has shown that P-gp inhibition results in increased brain levels of certain 
antidepressants, and can lead to an augmentation of their antidepressant-like 
activity, in rodents. This has raised the possibility that adjunctive therapy with a P-
gp inhibitor could represent a potential strategy to augment antidepressant 
treatment in treatment-resistant depression. However, despite recent advances, 
several outstanding questions remain to be answered before this strategy can be 
considered a viable clinical option. Some of these questions will be outlined in the 
following sections. 
7.9.1. Which antidepressants are transported substrates of P-gp? 
To rationally choose which antidepressant drugs may be amenable to augmentation 
with a P-gp inhibitor, it is necessary to know which antidepressants are transported 
P-gp substrates and which are not. In a recent review paper (Zhang et al., 2012), a 
set of criteria for defining the P-gp substrate status of compounds was proposed in 
relation to antiepileptic drugs (Table 7.2). 
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Table 7.2: Definitions of substrate status classifications (Zhang et al., 2012) 
Substrate status Definition 
Definite P-gp substrate Evidence from both in vivo (animal model or human data) and in 
vitro bidirectional transport studies demonstrating transport by 
P-gp 
Probable P-gp 
substrate 
Drug is a transported substrate of P-gp in vitro but no (or 
inconclusive) in vivo data is available, or vice versa 
Possible P-gp substrate Inconsistent results from in vitro and in vivo studies 
Unlikely to be a P-gp 
substrate 
Drug is not transported by P-gp in vitro, but no (or inconclusive) 
in vivo data is available, or vice versa 
Not a P-gp substrate Both in vivo and in vitro studies have demonstrated that the 
drug is not transported by P-gp 
 
By adapting these criteria and applying them to antidepressant drugs, it is evident 
that the P-gp substrate status of most antidepressant drugs remains unclear (Table 
7.3). Due to a paucity of data from studies which have investigated if 
antidepressant drugs are P-gp substrates in humans, we have included 
pharmacogenetic associations showing alterations in antidepressant 
pharmacokinetics or treatment response as a surrogate indicator of interactions 
with human P-gp. Furthermore, we have subdivided animal studies into those using 
P-gp knockout mice and those involving P-gp inhibition in wild-type animals.  
Based on the research outlined in this thesis, in conjunction with recent work 
carried out by others (Karlsson et al., 2013), escitalopram is the only antidepressant 
which can be classified as a ‘definite’ P-gp substrate. In all likelihood, several other 
antidepressants, including the commonly prescribed citalopram, paroxetine and 
venlafaxine, are also P-gp substrates, but further studies are required in order to 
state this with confidence. The lack of clarity in this regard is due, in large part, to 
deficiencies in relation to in vitro studies of antidepressant transport by P-gp. Most 
of the currently available data from in vitro experiments come from only two 
studies, and there are certain limitations associated with the methodologies 
employed in these studies (as outlined in Section 7.5). Interestingly, based on the 
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available data, it seems unlikely that amitriptyline is a transported substrate of P-
gp, despite its inclusion as one of four ‘P-gp substrate antidepressants’ in the 
landmark pharmacogenetic study demonstrating associations between SNPs in 
ABCB1 and treatment response to antidepressants (Uhr et al., 2008). Thus, further 
research is required in order to definitively determine the P-gp substrate status of 
commonly used antidepressant drugs before the use of P-gp inhibitors as adjunctive 
agents can be advocated.  
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Table 7.3: Antidepressants as P-gp substrates in research models (adapted from studies summarised in Chapter 1 and the research outlined in 
this thesis) 
AD 
Substrate 
status 
In vitro1 
Animals 
Humans 
Pharmacogenetic associations2 
P-gp 
knockout 
P-gp 
inhibition 
Pharmacokinetic Response/side effects 
Escitalopram Definite Y Y Y - - Y 
Fluvoxamine Probable ? Y - - Y - 
Imipramine Probable ? - Y - - - 
Protriptyline Probable Y - - - - - 
Citalopram Possible N Y - - Y ? 
Desipramine Possible N - Y - - - 
Doxepin Possible N Y3 - - - - 
Nortriptyline Possible N Y Y - - ? 
Paroxetine Possible N Y - Y - ? 
Trimipramine Possible N Y - - - - 
Venlafaxine Possible N Y - - - Y 
Amitriptyline Unlikely N ? - - - ? 
Clomipramine Unlikely N - - - - - 
Duloxetine Unlikely N - - - - N 
Fluoxetine Unlikely N ? - - - N 
Trazodone Unlikely N - - - - - 
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AD 
Substrate 
status 
In vitro1 
Animals 
Humans 
Pharmacogenetic associations2 
P-gp 
knockout 
P-gp 
inhibition 
Pharmacokinetic Response/side effects 
Mirtazapine Not N N - - - N 
Sertraline Not N N - - - - 
Agomelatine Unknown - - - - - - 
Dosulepin Unknown - - - - - - 
Lofepramine Unknown - - - - - - 
Y = yes; N = no; - = not reported; ? = inconclusive evidence 
1 Most of the in vitro data comes from only two studies which reported almost universally negative data. Due to methodological 
limitations of these studies, further investigations are needed 
2 Surrogate indicator of interactions with P-gp in humans 
3 The increase in P-gp knockout mice relative to WT controls was marginal (10%), but statistically significant 
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7.9.2. Would adjunctive treatment with a P-gp inhibitor result in 
increased brain levels of a P-gp substrate antidepressant 
in patients? 
Due to documented species differences in the ability of P-gp inhibitors to enhance 
brain distribution of P-gp substrates (Cutler et al., 2006; Syvanen et al., 2009), 
human studies are needed to demonstrate that P-gp inhibition would result in 
enhanced brain distribution of antidepressants which are proven to be P-gp 
substrates. Given that it is generally not possible to directly measure brain levels of 
a drug in human brain tissue (with the exception being in rare brain biopsy cases), 
imaging approaches may represent the best approach to assess the impact of P-gp 
inhibition on the brain distribution of an antidepressant. Ideally, such studies would 
involve direct measurement of a radiolabelled antidepressant by PET. However, 
logistical reasons may preclude the generation of such radiolabelled compounds. 
Measuring serotonin transporter (SERT) occupancy by means of imaging, using 
selective ligands such as 123I-ADAM, could represent an alternative approach to 
address this question. Interestingly, this technique has been shown to be 
sufficiently sensitive to detect a 2-fold difference in the dose of escitalopram 
treatment, meaning that it may be suitable for this purpose (Klein et al., 2006). 
Furthermore, the effect of chronic treatment with a P-gp inhibitor and P-gp 
substrate antidepressant would need to be investigated in man, due to potential 
species differences as outlined in Section 7.8.1.3. 
7.9.3. How significant is the contribution of P-gp efflux to 
antidepressant resistance? 
The causes of treatment resistant depression (TRD) are, in all probability, 
multifactorial. As such, it is not likely that P-gp inhibition will represent an 
appropriate augmentation strategy for all refractory depressed patients. However, 
P-gp mediated restriction of brain levels of antidepressants may contribute to the 
aetiology of TRD in a subset of patients, especially considering the robust 
association between P-gp genotype and response to treatment with P-gp substrate 
antidepressants reported by Uhr and colleagues (Uhr et al., 2008). However, given 
that the functional effects of SNPs in the ABCB1 gene are unknown, the exact 
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mechanism underlying this pharmacogenetic association is unclear. Future imaging 
studies may serve to elucidate the functional effect of ABCB1 genotype, thereby 
helping to inform decisions regarding which patients are likely to benefit from 
adjunctive P-gp inhibition. Moreover, imaging studies could help to determine if P-
gp activity is elevated in patients who fail to respond to antidepressant treatment. 
Such studies could serve to experimentally evaluate the contribution of P-gp efflux 
to treatment failure, as current evidence is inconclusive. 
7.9.4. Clinical promise and limitations of increasing brain 
distribution of P-gp substrate antidepressants: Towards an 
antidepressant augmentation strategy? 
We have demonstrated that P-gp inhibition by verapamil enhances the 
antidepressant-like activity of escitalopram in the tail suspension test, thereby 
raising the possibility that P-gp inhibition may represent a potential strategy to 
augment treatment with P-gp substrate antidepressant. However, further 
preclinical studies are required to more thoroughly investigate the effect of P-gp 
inhibition on antidepressant-like activity in different animal models and using more 
specific P-gp inhibitors. Such studies will facilitate informed prediction of expected 
effects in patients. However, should preclinical investigations yield positive results, 
it will remain necessary to conduct clinical studies to confirm whether findings from 
animal models will translate to humans. At present, despite one promising result 
from our preclinical studies (O'Brien et al., 2013b; Chapter 4), there is insufficient 
data available to conclusively state whether increasing the brain distribution of a P-
gp substrate antidepressant by P-gp inhibition would be expected to result in an 
augmentation of its efficacy as an antidepressant. 
Despite the normal viability of P-gp knockout mice (Schinkel et al., 1997) and the 
tolerability of certain P-gp inhibitors in humans (Kreisl et al., 2010), there are likely 
to be myriad problems associated with long term clinical use of P-gp inhibitors. P-gp 
fulfils an important function in several organs in the body, not only at the BBB 
(Marzolini et al., 2004). Thus, inhibition of P-gp activity could have undesirable 
effects on the distribution and metabolism of various endogenous and exogenous 
P-gp substrates. This would be a particular problem in patients taking other 
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medications which are P-gp substrates, in addition to the antidepressant and P-gp 
inhibitor. Moreover, although increasing brain levels of an antidepressant drug by 
P-gp inhibition may facilitate dose reduction while maintaining therapeutic effect, 
thereby minimising peripheral side-effects, this could prove to be problematic. For 
example, inceasing brain levels of the antidepressant may lead to an increased risk 
of centrally-mediated side effects of antidepressant treatment, such as nausea, 
vomiting and appetite dysregulation, as outlined in Section 1.4.3. Indeed, our 
research revealed that co-administration of the P-gp inhibitor CsA exacerbated the 
manifestation of an escitalopram-induced mouse model of serotonin syndrome, 
thereby highlighting the potential for serious adverse interactions between a P-gp 
inhibitor and an SSRI (Chapter 5). However, additional research is required to 
determine if this effect was due to P-gp inhibition or an alternative effect of CsA. 
Regardless, there would be genuine cause for concern about the potential for 
adverse reactions in patients treated chronically with a P-gp inhibitor. Further 
studies are needed to evaluate the risk:benefit ratio associated with any putative 
augmentation of antidepressant treatment by P-gp inhibition. 
Furthermore, while the P-gp inhibitors used in our research, verapamil and CsA, 
have the advantage of being clinically approved and widely available, they lack the 
requisite potency and specificity to represent viable agents for achieving P-gp 
inhibition in clinical use (Kalvass et al., 2013). More selective second or third 
generation P-gp inhibitors, such as the CsA analogue valspodar or tariquidar (which 
have been used in clinical trials), may represent better alternatives. However, the 
high cost of more selective P-gp inhibitors such as these may preclude their 
widespread use in clinical practice. Furthermore, it is unclear whether 
pharmaceutical companies would be interested in supporting the large scale clinical 
trials that would be needed in order to investigate the benefit, or lack thereof, of 
adjunctive P-gp inhibitor treatment in depression, given the previous failures of 
similar studies in the field of oncology (Szakacs et al., 2006). 
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7.10. Overall conclusions and future perspectives 
In this thesis, we have conducted research which has furthered our understanding 
of the role played by P-gp in the brain distribution and antidepressant-like activity 
of antidepressant drugs. To build on this work, further studies are now needed to 
address unanswered questions regarding the role of P-gp in the pharmacokinetics 
and pharmacodynamics of antidepressant drugs. For the majority of 
antidepressants, the available data are inadequate to allow definitive classification 
as transported substrates of P-gp or not. Further preclinical studies, with a 
particular focus on in vitro approaches involving human P-gp, are required to 
provide more conclusive information in this regard. Furthermore, additional studies 
assessing the impact of P-gp inhibition on the effects of antidepressants in animal 
models of depression are needed to elucidate the pharmacodynamic effect of 
increasing brain concentrations of P-gp substrate antidepressants. Moreover, 
clinical studies are required to investigate potential associations between TRD and 
P-gp efflux of antidepressants. Taken together, the results from such studies will 
facilitate an informed evaluation of the potential of P-gp inhibition as a novel 
augmentation strategy in the treatment of depression. Given the potential 
difficulties associated with therapeutic use of P-gp inhibitors in clinical practice, 
tailoring the choice or dose of antidepressant based on information relating to P-gp 
function may represent a more feasible option. Indeed, a pilot clinical study has 
recently reported that antidepressant treatment can be optimized by the clinical 
application of ABCB1 genotyping (Breitenstein et al., 2013). Further investigations 
of the benefits of this approach will be of interest. 
In conclusion, we have demonstrated that the antidepressants imipramine and 
escitalopram are transported substrates of human P-gp in vitro and that acute 
inhibition of P-gp increases the brain distribution of these antidepressants in 
rodents. In addition, a further study revealed that findings from acute in vivo P-gp 
inhibition experiments also apply after chronic administration for escitalopram. In 
contrast, the antidepressants amitriptyline, duloxetine, fluoxetine and mirtazapine 
were not found to be transported substrates of human P-gp in vitro. Moreover, we 
have shown, for the first time, that inhibition of P-gp can result in an augmentation 
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of the behavioural effects of an antidepressant. Taken together these findings 
indicate that P-gp inhibition may represent a potential strategy to augment 
treatment with certain antidepressants, such as escitalopram. The promise of this 
approach now requires clinical validation. 
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5-HIAA: 5-hydroxyindoleacetic acid  
5-HT: serotonin  
5-HTP: 5-hydroxytryptophan  
A→B: apical-to-basolateral permeability  
ABC: adenosine triphosphate binding-cassette  
ACTH: adrenocorticotropic hormone  
AF6: afadin  
ATP: adenosine triphosphate  
AUC: area under the concentration-time curve  
B→A: basolateral-to-apical permeability   
BBB: blood-brain barrier BCEC: brain capillary endothelial cell  
BCEC: brain capillary endothelial cell 
BCRP: breast cancer resistance protein  
BCSFB: blood-cerebrospinal fluid barrier 
C0: initial concentration following bolus intravenous administration (Chapter 2) or 
initial donor concentration used in in vitro studies (Chapters 3 and 4) 
Caco-2: human colorectal adenocarcinoma cells  
Calcein AM: calcein acetoxymethyl ester  
CAR: coxsackie- and adenovirus receptor 
Cl: drug clearance from plasma 
CNS: central nervous system 
 cTR: corrected (B→A)/(A→B) transport ratio  
CRF: corticotrophin-releasing factor  
CsA: cyclosporin A 
CYP: cytochrome P450  
DBS: deep brain stimulation 
ECF: extracellular fluid 
ECT: electroconvulsive therapy 
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ESAM: endothelial selective adhesion molecules 
FST: forced swim test 
HPA axis: hypothalamic-pituitary-adrenal axis  
HPLC: high performance liquid chromatography  
HPLC-ECD: HPLC with electrochemical detection 
IC50: half maximal inhibitory concentration  
ICV: intracerebroventricular 
JAM: junctional adhesion molecules 
JACOP: junction associated coiled-coil protein 
kel: elimination rate constant 
Km: Michaelis constant  
KO:WT B/P ratio: brain/plasma drug concentration ratios between P-gp knockout 
and wild-type mice  
MAOI: monoamine oxidase inhibitor  
MDCK: Madine-Darby canine kidney cells 
MDCK-MDR1: ABCB1-transfected MDCK cells which overexpress human P-gp  
MDCK-WT: wild-type Madine-Darby canine kidney cells 
MDR1: multidrug resistance 1 gene  
MRP: multidrug resistance-associated proteins  
MUPP1: multi-PDZ-protein 1 
NaSSA: noradrenergic and specific serotonergic antidepressant 
NBD: nucleotide binding domain  
NSCLC: non-small cell lung cancer 
OB: olfactory bulbectomy 
OPA: orthophosphoric acid  
Papp: apparent permeability coefficient (cm.s
-1) 
PECAM: platelet-endothelial cell adhesion molecule 
PFC: prefrontal cortex  
P-gp: P-glycoprotein  
PK: pharmacokinetic 
SBP: substrate-binding pocket  
SNP: single nucleotide polymorphism  
Appendix A: Abbreviations 
306 
SNRI: serotonin–noradrenaline reuptake inhibitor  
SSRI: selective serotonin reuptake inhibitor  
STAR*D: Sequenced Treatment Alternatives to Relieve Depression study  
t1/2: half-life of drug in plasma 
TCA: tricyclic antidepressant  
TEER: trans-epithelial electrical resistance 
TR: (B→A)/(A→B) transport ratio  
TRD: treatment resistant depression 
TST: tail suspension test 
Vd: volume of distribution 
VE-cadherin: vascular endothelial cadherin 
VNS: vagus nerve stimulation 
ZO: zona occludens proteins 
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C.1. Introduction 
In order to evaluate the BBB transport of a compound using microdialysis, it was 
necessary to develop an integrated technique which enables the simultaneous 
determination of drug levels in the brain and the blood (Bundgaard et al., 2007). 
This integrated technique involves concomitant intracerebral microdialysis and 
peripheral catheterizations. To facilitate intravenous drug administration (thereby 
avoiding variability in drug absorption) and serial blood sampling (to determine 
plasma drug pharmacokinetics), in-dwelling catheters are surgically inserted into 
the jugular vein and carotid artery respectively, while a microdialysis probe is 
inserted into the brain to monitor fluctuations in drug concentrations in the brain 
extracellular fluid (ECF).  
It was decided that achieving proficiency at each of these intricate surgical 
procedures individually was necessary before attempting to combine them in the 
same animal. To this end, imipramine, a tricyclic antidepressant drug, was selected 
as the model drug during method development. Imipramine was chosen as it has 
previously been sampled using the microdialysis technique (Sato et al., 1994), and 
the ability of antidepressants such as imipramine to cross the BBB has come under 
scrutiny of late (O'Brien et al., 2012b). It was therefore also necessary to develop a 
highly sensitive analytical assay to facilitate detection of the very low levels of 
imipramine that were anticipated to be recovered in the microdialysis samples. In 
addition, imipramine has an active metabolite, desipramine, which we aimed to 
detect and quantify using the same analytical technique. 
The present study had several goals. Firstly, it was aimed to develop and optimise a 
highly sensitive analytical assay which would enable detection and quantification of 
imipramine down to the nanograms per millilitre concentration range. High 
performance liquid chromatography with electrochemical detection (HPLC-ECD) 
was chosen as an appropriate analytical technique for this purpose based on 
previous reports in the literature (Sato et al., 1994). It was necessary to determine 
the optimal electrochemical detector settings for the determination of 
concentrations of imipramine, desipramine and the internal standard trimipramine. 
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Using these optimised settings, calibration curves for these drugs at low and high 
concentration ranges, as would be expected in microdialysis and plasma samples 
respectively, were generated to determine if a linear relationship exists between 
analyte concentration and detector response. Secondly, once the HPLC method had 
been established, it was aimed to validate the success of peripheral catheterization 
surgeries by administering imipramine intravenously followed by serial blood 
sampling. Using this method, we aimed to generate imipramine and desipramine 
plasma pharmacokinetic profiles in dual-catheterized rats following intravenous 
administration and determine an optimal intravenous dose for use in further 
studies. In order to do this, it was necessary to optimise a plasma extraction 
technique and to validate that imipramine, desipramine and trimipramine could be 
reliably and efficiently extracted from plasma samples, and that these compounds 
in the extracted plasma samples could be determined using the HPLC-ECD system. 
Initial catheterization surgeries were carried out on a non-recovery basis. Therefore 
the plasma pharmacokinetics of imipramine were initially determined in 
anaesthetized animals. Once greater surgical proficiency was achieved, imipramine 
plasma pharmacokinetics were determined in conscious freely moving animals 
which had recovered post-operatively. Thirdly, we measured plasma corticosterone 
concentrations over time in one conscious freely moving catheterized animal 
following post-operative recovery to ascertain that it was possible to monitor 
diurnal variations in plasma corticosterone levels using our technique and to 
determine if plasma corticosterone levels were elevated above expected normal 
values on the day following surgery. Finally, we aimed to validate the success of our 
microdialysis technique by detecting fluctuations in imipramine levels in 
microdialysis samples in the conscious, freely moving rat following intraperitoneal 
imipramine administration in animals which had received microdialysis surgery 
only. 
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C.2. Methods 
C.2.1. Drugs and chemicals 
High performance liquid chromatography (HPLC) grade acetonitrile, potassium 
dihydrogen phosphate and orthophosphoric acid (OPA) were obtained from Fisher 
Scientific (Ireland). Heparin sodium solution (Wockhardt UK Ltd, UK) was purchased 
from Uniphar Group (Ireland). Imipramine, desipramine, trimipramine and 
verapamil were obtained from Sigma-Aldrich as were all other chemicals unless 
otherwise stated. 
C.2.2. HPLC method development 
C.2.2.1. HPLC equipment 
The HPLC with electrochemical detection (HPLC-ECD) system consisted of a 
Shimadzu LC-20AD XR Prominence Pump, CBM-20A communication bus module, 
SIL-20AC XR Prominence Autosampler, CTO-20A Prominence Column oven (all 
supplied by Mason Technology, Cork, Ireland). System components were used in 
conjunction with Shimadzu LC solutions software (Mason Technology). The detector 
used was ESA Coulochem III with the 5041 Amperometric Cell (Supplied by ESA 
Analytical, Ltd., Brook Farm, Dorton, Aylesbury, Buckinghamshire, HP18 9NH 
England). All samples were injected onto a reversed phase Luna 3 µm C18(2) 150 x 
2 mm column (Phenomenex), which was protected by Krudkatcher Ultra in-line 
filters (Phenomenex).  
C.2.2.2. HPLC optimisation and validation 
Standard solutions of imipramine, desipramine, verapamil and trimipramine were 
injected onto the HPLC system at different voltages to determine the optimal 
voltage. Response (as measured by peak height) was plotted against applied 
voltage to facilitate identification of the optimal voltage. Calibration curves were 
generated to investigate if a linear relationship exists between analyte 
concentration and peak height across the concentration ranges to be investigated.  
C.2.2.3. HPLC conditions 
The HPLC-ECD method was adapted from previously described methods (Sato et al., 
1994; Frahnert et al., 2003). Briefly, the mobile phase which was used on the HPLC 
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system consisted of a mixture of 25mM potassium dihydrogen phosphate (25 mM, 
pH 7 with 4N NaOH) and HPLC grade acetonitrile (56:44). Mobile phase was filtered 
through Millipore 0.22 µm Durapore filters (Millipore, Ireland) and vacuum 
degassed prior to use. Compounds were eluted isocratically over a 30 min runtime 
at a flow rate of 0.4 ml.min-1 after a 20 µl injection. The column was maintained at a 
temperature of 30oC and samples/standards were kept at 8oC in the cooled 
autoinjector prior to analysis. The glassy carbon working electrode combined with a 
platinum reference electrode (ESA) was operated at a potential of 600mV and a 
range of 50nA. 
C.2.2.4. Analyte identification and quantification 
Imipramine, desipramine and trimipramine (internal standard) were identified by 
their characteristic retention times as determined by standard injections which 
were run at regular intervals during sample analysis. For the extracted plasma 
samples, analyte:internal standard peak height ratios were measured and 
compared with standard injections, and results were expressed as nanograms of 
analyte per ml of plasma. As no extraction procedure was necessary for 
microdialysis samples, analyte peak height ratios were compared directly with 
standard injections and expressed as nanograms of analyte per ml of dialysate 
C.2.3. In vivo experiments 
Male and female Sprague Dawley rats (Harlan Laboratories, UK) were used for 
these preliminary in vivo experiments. Animals were group-housed 4-6 animals per 
cage and maintained on a 12 hour light/dark cycle (lights on at 08:00 h) with food 
and water ad libitum. Room temperature was controlled at 22 ± 1°C. All procedures 
were carried out in accordance with EU directive 89/609/EEC and approved by the 
Animal Experimentation & Ethics Committee of University College Cork. 
C.2.3.1. Development of surgical procedures 
Animals were anaesthetized prior to surgery with a ketamine/xylazine mixture 
(90/10 mg.kg-1 i.p.), with maintenance of anaesthesia achieved by repeating 20-25% 
of the induction dose at 30-40 minute intervals, as required. Analgesia was 
provided by pre-operative administration of carprofen (3 mg.kg-1 s.c.). Throughout 
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surgical procedures, the body temperature of each rat was maintained using a 
heating pad. 
C.2.3.2. Catheterization surgeries 
Two indwelling catheters were surgically implanted in each rat using standard 
surgical techniques: one in the carotid artery for collection of serial blood samples 
and one in the external right jugular vein to facilitate intravenous drug 
administration (Thrivikraman et al., 2002; Huang et al., 2006; Heiser, 2007). All 
catheters were pyrogen-free polyethylene tubing (Instech Laboratories, Plymouth 
Meeting, PA). The arterial and venous catheters consisted of BPE-T25 tubing 
(0.018"ID x 0.036"OD) and BPE-T50 tubing (0.023"ID x 0.038"OD), respectively. The 
catheters were subcutaneously tunnelled to the back of the neck of the rat, where 
they were exteriorized and connected to three-way Discofix® stopcocks (B. Braun). 
To prevent clotting the catheters were filled with a heparinised saline solution (20 
IU.ml-1).  
C.2.3.3. Blood sampling experiments 
After successful catheterization surgeries, rats were administered imipramine 
either intravenously or by oral administration. Initial experiments were carried out 
on anaesthetized animals, while later experiments were carried out on conscious 
freely moving animals. In one case where the intravenous line was not patent, 
imipramine was administered by i.p. injection rather than by i.v. injection. Following 
imipramine administration, blood samples were taken at regular intervals up to 300 
minutes post-imipramine administration. Blood samples (~ 250 µl) were 
immediately centrifuged at 5000 rpm for 5 minutes, plasma taken and stored at -
20oC or -80oC until extraction for analysis by HPLC with electrochemical detection. 
At the conclusion of the experiment, rats were euthanized by administration of 
intravenous sodium pentobarbitone (euthatal). 
C.2.3.4. Plasma extraction 
Imipramine and its active metabolite desipramine were extracted from plasma 
using a liquid-liquid extraction technique as described previously (Clarke et al., 
2009), with some modifications. Briefly, 98 µl of plasma was spiked with 2 µl of the 
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internal standard, trimipramine, to yield a final concentration of 20 ng.ml-1 
trimipramine. To this trimipramine-spiked plasma, 1 ml of sodium hydroxide (2 M) 
and 3 ml of water were added. Extraction was carried out in 7.5 ml of 1.5% isoamyl 
alcohol in n-heptane by vortexing for 30 seconds, followed by agitation on a 
mechanical shaker for 15 min and then centrifugation at 5000 RPM for 15 min at 
20°C. The upper solvent layer was transferred to a tube containing 200 µl of 25 mM 
OPA, vortexed for 30 seconds, then agitated on a mechanical shaker for 15 min 
followed by centrifugation at 5000 rpm for 15 min at room temperature.  Twenty 
microlitres of the lower aqueous phase was injected onto the HPLC system for 
analysis. This reliability and efficiency of this extraction technique was validated 
before use by extracting blank plasma samples spiked with known concentrations 
(100 ng.ml-1) of imipramine and desipramine. 
C.2.3.5. Determination of diurnal variations in plasma corticosterone 
concentrations 
Serial blood samples (~200 µl) were taken at two-hourly intervals from one drug-
naive rat on the day following successful catheterizations. Blood samples were 
immediately centrifuged at 5000 rpm for 5 minutes at 4°C, plasma taken and stored 
at -20oC until assayed. Plasma corticosterone concentrations were determined 
using a commercially available enzyme-linked immunosorbent assay (ELISA) kit 
(Enzo Life Sciences, USA) according to the manufacturer's instructions. 
C.2.3.6. Development and validation of microdialysis technique 
C.2.3.7. Dialysis probe construction and calibration 
Vertical concentric microdialysis probes were constructed as described elsewhere 
(Page and Lucki, 2002). Briefly, a piece of fused silica (ID 75 ± 3 µm, OD 150 ± 6 µm; 
CM Scientific Ltd, UK) was inserted through PE10 tubing (Instech Laboratories, 
Plymouth Meeting, PA). A Spectra/Por® Micro-dialysis Hollow Fiber regenerated 
cellulose semipermeable membrane with a 13 kD molecular weight cut-off 
(Spectrum Laboratories, Inc.) was placed over the fused silica and into the PE10 
tubing, and fixed in place using epoxy adhesive. The open end of the 
semipermeable membrane was sealed with a 0.5 mm epoxy plug, and the active 
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area of the fibre, where diffusion takes place across the membrane, was limited to 
3 mm in length by coating regions outside this range with epoxy adhesive. In vitro 
recovery experiments were carried out to demonstrate that imipramine and 
desipramine could be recovered using the microdialysis probes. These in vitro 
recovery experiments involved immersing each probe in a well of aCSF containing a 
known concentration (100 ng.ml-1) of imipramine and desipramine. The 
concentration of imipramine and desipramine present in the dialysis samples was 
expressed as a percentage of the known concentration in the well and this 
percentage is termed the recovery rate. 
C.2.3.8. Microdialysis surgery 
Rats were placed in a stereotaxic frame (Model 900 Small Animal Stereotaxic 
Instrument, David Kopf Instruments, Bilaney Consultants, St Julians, Sevenoaks, UK) 
with the skull flat. A small burr hole was made in the skull, centred 2.7 mm anterior 
and 0.7 mm lateral to bregma. The microdialysis probe was slowly lowered 5 mm 
from dura into the prefrontal cortex (PFC) (Paxinos and Watson, 1998) and secured 
with skull screws and dental acrylic. The inlet of the probe was connected to a fluid 
swivel (Instech Laboratories, Plymouth Meeting, PA) and the rats were single-
housed in cylindrical plexiglass containers (Instech Laboratories, Plymouth Meeting, 
PA) filled with bedding and food pellets. Artificial cerebrospinal fluid (aCSF: 147 mM 
NaCl, 1.7 mM CaCl2, 0.9 mM MgCl2, and 4mM KCl) was continuously perfused 
through each microdialysis probe at a rate of 1.5 μl.min-1 by a microlitre ‘Pico Plus’ 
syringe pump (Harvard Apparatus, Fircroft Way, Edenbridge, Kent UK). 
C.2.3.9. Microdialysis sampling experiments 
After successful microdialysis surgeries, rats were allowed to recover overnight 
prior to microdialysis sampling experiments on the following day during the optimal 
post-surgical period (de Lange et al., 2000). Microdialysis samples were taken 
before imipramine administration (blanks) and at 20 minute intervals following the 
administration of imipramine (30 mg.kg-1 i.p.) for 300 minutes. Imipramine and 
desipramine concentrations in the microdialysis samples were determined by HPLC 
analysis on the same day as they were collected without any extraction procedure.  
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C.3. Results 
C.3.1. Optimal potential for ECD detector 
The response (peak height) increased with increasing voltage applied across the 
electrode at all applied voltages tested for trimipramine and verapamil, while the 
response increased to a maximum at 700 mV for imipramine before decreasing at a 
higher voltage (Figure C.1). The response for desipramine reached a plateau at an 
applied voltage of 600 mV and declined at higher applied voltages. As the 
background noise increases with increasing applied voltage, it was decided that 600 
mV was the optimal voltage at which to analyse our samples. 
 
Figure C.1: Determination of optimal potential for ECD detection of analytes 
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C.3.2. Calibration curves of HPLC method 
There was a linear relationship between peak height and concentration for all three 
drugs tested as demonstrated by the r2 values listed below, all of which are greater 
than 0.99 (Figure C.2). This was the case across the entire concentration range (A), 
at low concentrations (as expected for microdialysis samples: B) and at higher 
concentrations (as expected in plasma samples: C). 
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Figure C.2: Calibration curves for imipramine, desipramine and trimipramine on 
HPLC-ECD 
A. Overall calibration curve for imipramine, desipramine and trimipramine over 
concentration range 1 ng.ml-1 to 5000 ng.ml-1 with r2 values listed on graph. B. 
Calibration curve for imipramine, desipramine and trimipramine at lower 
concentration range (1 ng.ml-1 to 62.5 ng.ml-1) with r2 values listed on graph. C. 
Calibration curve for imipramine, desipramine and trimipramine at higher 
concentration range (125 ng.ml-1 to 5000 ng.ml-1) with r2 values listed on graph. 
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C.3.3. Plasma extraction efficiency 
The extraction efficiency of our liquid-liquid extraction technique was determined 
by spiking blank plasma with a known concentration of imipramine, desipramine 
and trimipramine (100 ng.ml-1). The concentration of these drugs in our extracted 
samples was expressed as a percentage of the initial concentration and termed 
‘extraction efficiency’. As illustrated in Figure C.3, the extraction efficiency for all 
three compounds was > 80% and the extraction procedure was reliable and 
reproducible. 
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Figure C.3: Plasma extraction efficiency 
Percentage of the spiked concentration of desipramine, imipramine and the internal 
standard trimipramine obtained in extracted samples (n = 4 extractions) 
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C.3.4. Imipramine and desipramine plasma profiles in 
anaesthetized rats 
C.3.4.1. Following intravenous imipramine (15 mg.kg-1) administration 
Imipramine (15 mg.kg-1 i.v.) was administered to an anaesthetized rat immediately 
after successful completion of dual catheterization surgery. Anaesthesia was 
maintained for 90 minutes post-imipramine administration, and blood samples 
were taken at regular intervals. The concentration of imipramine and desipramine 
were determined at each time-point and are presented in the plasma profiles 
shown in Figure C.4. 
 
Figure C.4: Imipramine and desipramine plasma profiles in an anaesthetized 
animal after the intravenous administration of imipramine 15 mg.kg-1 (n = 1) 
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C.3.4.2. Following intraperitoneal imipramine (15 mg.kg-1) 
administration 
Following completion of the dual-catheterization surgery in one anaesthetized 
animal, the jugular vein catheter was not patent. Therefore, imipramine (15 mg.kg-
1) was administered i.p. rather than i.v., and plasma samples were taken at regular 
intervals up to 90 minutes. Anaesthesia was maintained throughout the sampling 
procedure. The resulting plasma imipramine and desipramine profiles are 
presented in Figure C.5. 
 
Figure C.5: Imipramine and desipramine plasma profiles in an anaesthetized 
animal after the intraperitoneal administration of imipramine 15 mg.kg-1 (n = 1) 
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C.3.5. Imipramine and desipramine plasma profiles in conscious 
freely moving rats  
C.3.5.1. Following intravenous imipramine (1 mg.kg-1) administration 
Following successful dual-catheterization surgery, one animal was allowed to 
recover overnight prior to imipramine (1 mg.kg-1 i.v.) administration while conscious 
and freely moving. This dose was tolerated without any adverse reaction, and 
plasma samples were taken at regular intervals up to 300 minutes post-imipramine 
administration. The resulting imipramine plasma profile is illustrated in Figure C.6. 
For technical reasons, desipramine concentrations could not be determined in 
these plasma samples. 
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Figure C.6: Imipramine plasma profile in a conscious freely moving animal 
following the intravenous administration of imipramine 1 mg.kg-1 (desipramine 
levels could not be determined for technical reasons) (n = 1) 
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C.3.5.2. Following intravenous imipramine (5 mg.kg-1) administration 
Following successful dual-catheterization surgery, imipramine (5 mg.kg-1 i.v.) was 
administered to six conscious freely moving animals. This dose was tolerated 
without any adverse reactions, and plasma samples were taken at regular intervals 
up to 300 minutes post-imipramine administration. The resulting mean imipramine 
and desipramine plasma profiles are illustrated in Figure C.7. 
 
Figure C.7: Imipramine and desipramine plasma profiles in conscious freely 
moving animals after the intravenous administration of imipramine 5 mg.kg-1 (n = 
6) 
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C.3.5.3. Following oral imipramine (30 mg.kg-1) administration 
Following successful dual-catheterization surgery, imipramine (30 mg.kg-1) was 
administered orally to three conscious freely moving animals. Plasma samples were 
taken at regular intervals up to 300 minutes post-imipramine administration. The 
resulting mean imipramine and desipramine plasma profiles are illustrated in Figure 
C.8. 
 
Figure C.8: Imipramine and desipramine plasma profiles in conscious freely 
moving animals after the oral administration of imipramine 30 mg.kg-1 (n = 6) 
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C.3.6. Diurnal variation in plasma corticosterone levels in a 
conscious freely moving rat one day after catheterization 
surgery 
Following overnight recovery after successful dual catheterization surgery, plasma 
samples were taken from one female rat every two hours between 8 am and 10 pm 
and plasma corticosterone levels were determined in each plasma sample. The 
resulting plot illustrating the diurnal variation in plasma corticosterone 
concentrations throughout the day is shown in Figure C.9. The overall mean plasma 
corticosterone concentration was 145.8 ng.ml-1. 
 
 
Figure C.9: Diurnal variation in plasma corticosterone levels as measured by serial 
blood sampling from an indwelling arterial catheter (n=1) 
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C.3.7. Microdialysis probe recovery – in vitro experiments 
The mean in vitro probe recovery by gain for desipramine (DMI), imipramine (IMI), 
verapamil (VERAP) and trimipramine (TRIM) are illustrated in Figure C.10 (n = 6 
probes). 
 
Figure C.10: In vitro probe recovery by gain from a 100 ng.ml-1 solution (n = 6 
probes) 
  
 
D
M
I
IM
I
V
ER
A
P
TR
IM
0
5
10
15
P
ro
b
e
 r
e
c
o
v
e
ry
 (
%
)
Appendix C: Establishment of techniques 
328 
C.3.8. Imipramine and desipramine dialysate profiles in 
conscious freely moving rats after intraperitoneal 
imipramine (30 mg.kg-1) administration 
Imipramine (30 mg.kg-1 i.p.) was administered to 3 rats on the day following 
successful microdialysis surgery and the resulting concentration of imipramine and 
desipramine in the microdialysis samples at different time intervals post-
imipramine administration was measured using HPLC-ECD. The imipramine and 
desipramine levels in all samples were quantifiable, and the resulting profiles are 
shown in Figure C.11. 
 
Figure C.11: Dialysate imipramine and desipramine concentration-time profiles 
following intraperitoneal imipramine administration (30 mg.kg-1) (n=3) 
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C.4. Discussion 
The present data demonstrate the success of our analytical and surgical techniques. 
We successfully developed a highly sensitive analytical technique which facilitated 
the determination of imipramine, desipramine and the internal standard 
trimipramine concentrations in the ng.ml-1 range. Furthermore, we successfully 
developed a surgical catheterization technique which facilitated the intravenous 
administration of imipramine via the jugular vein and serial blood sampling via the 
carotid artery. Using this catheterization technique, it was possible to repeatedly 
remove small volumes of blood (plasma) from a conscious freely moving animal 
after intravenous imipramine administration. We successfully developed a 
reproducible and efficient liquid-liquid extraction technique to extract imipramine 
and desipramine from plasma samples for HPLC analysis, with > 80 % extraction 
efficiency on average and very little variation between different extractions (Figure 
C.3). Therefore, using this optimised extraction procedure it was possible to 
determine plasma concentrations of imipramine and desipramine over time 
following intravenous imipramine administration, thereby generating 
pharmacokinetic profiles for imipramine and desipramine in both anaesthetized 
and conscious freely moving animals following imipramine delivery via various 
routes of administration. 
Initial experiments were carried out on a non-recovery basis. Therefore, a plasma 
pharmacokinetic profile for imipramine and desipramine was firstly determined in 
an anaesthetized animal for 90 minutes post-intravenous imipramine 
administration (Figure C.4). In a subsequent experiment the intravenous catheter 
was not patent, meaning it was not possible to administer imipramine 
intravenously, but it was possible to sample blood via the intra-arterial catheter. 
Therefore, imipramine was administered intraperitoneally to the anaesthetized rat 
and blood samples were taken for 90 minutes following imipramine administration 
(Figure C.5). Once an adequate level of surgical proficiency was attained, rats were 
allowed to recover overnight prior to drug administration and blood sampling. A 
pilot experiment to help determine an acceptable dose was carried out in one 
animal which received an i.v. dose of imipramine 1 mg.kg-1 (Figure C.6). This dose 
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was well-tolerated, and subsequent experiments used a higher imipramine dose of 
5 mg.kg-1 which was also well-tolerated. This 5 mg.kg-1 i.v. dose was repeated in 6 
animals, resulting in a typical intravenous drug concentration versus time plot for 
imipramine with low levels of variation at each time-point (Figure C.7). 
Furthermore, it was also possible to quantify desipramine levels in these plasma 
samples, thus yielding a plasma profile for desipramine in the conscious freely 
moving animal following imipramine administration. The concentration of 
desipramine in plasma gradually increased over time before declining, as was 
expected considering desipramine is a metabolite of imipramine.  
Further experiments were carried out in dual-catheterized animals which involved 
the oral administration of imipramine. The aim here was to demonstrate that the 
plasma profile of imipramine would be different following administration via the 
oral route compared to the intravenous route. This was the case as illustrated in 
Figure C.8. The high levels of variability observed at each time point reflect the 
variable nature of drug absorption from the gut (particularly in non-fasted animals, 
as was the case here), and supports our decision to administer imipramine 
intravenously, thereby reducing the variability in plasma levels. 
In addition to the determination of imipramine and desipramine plasma profiles 
after imipramine administration, we also determined plasma corticosterone levels 
in one dual-catheterized animal at various time-points on the day after 
catheterization surgery. The aim here was two-fold: firstly to demonstrate that we 
could detect the diurnal variation in plasma corticosterone levels using our 
catheterization technique and secondly to determine if the plasma corticosterone 
levels detected would be elevated relative to expected values. Corticosterone is the 
main stress hormone in rats, and circulating plasma corticosterone concentrations 
reflect the stress levels of the animal. As expected, we observed a diurnal variation 
in plasma corticosterone levels over the course of the day, with trough values 
observed in the morning shortly after turning the lights on and peak values in the 
evening shortly after turning the lights off (Figure C.9). This pattern is broadly in line 
with reports in the literature (Atkinson and Waddell, 1997). Furthermore, the mean 
plasma corticosterone concentration measured across the day (145.8 ng.ml-1) was 
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within the expected range for an unstressed female rat (Atkinson and Waddell, 
1997), thus indicating that the rat was not suffering from an increased level of 
stress on the day following catheterization surgery. 
The present study also aimed to establish the intracerebral microdialysis technique. 
To this end, in vitro experiments were firstly undertaken which demonstrated that 
imipramine, desipramine, verapamil and trimipramine could be reliably and 
reproducibly recovered in our ‘home-made’ probes from wells containing a 
standard 100 ng.ml-1 solution of these drugs (Figure C.10). The next step involved 
carrying out in vivo experiments to determine if imipramine and desipramine could 
be recovered from the brains of rats which had undergone microdialysis surgery. 
On the day after microdialysis surgery, imipramine (30 mg.kg-1 i.p.) was 
administered to these animals and microdialysis samples were collected over time. 
It was possible to detect both imipramine and desipramine in all of these samples, 
thus yielding an intracerebral concentration versus time profile for these drugs 
following i.p. administration (Figure C.11). This demonstrates the success of our 
intracerebral microdialysis technique. 
In conclusion, the present results demonstrate that it is possible to individually use 
our catheterization or microdialysis procedures, in combination with our HPLC-ECD 
analytical technique, to monitor fluctuations in imipramine and desipramine 
concentrations in plasma or the brain over time. The next step involves combining 
the two surgical procedures to monitor alterations in imipramine transport across 
the BBB in response to interventions such as P-gp inhibition. 
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Appendix D: Microdialysis probe construction 
 
D.1. Background information 
Microdialysis is a sampling technique used to collect small molecular weight 
substances from the extracellular fluid of the brain/spinal cord. Substances diffuse 
across a semi-permeable membrane down their concentration gradient. All 
microdialysis probes are composed of a length of tubular dialysis semipermeable 
membrane through which a solution, usually devoid of the analyte of interest 
(usually artificial cerebrospinal fluid), is constantly perfused. A variety of 
membranes are available which differ in pore size and the material used. Once the 
probe is inserted into the brain/spinal cord region of interest and perfusion begins, 
substances in the extracellular fluid diffuse through the membrane into the probe 
along their concentration gradient. The perfusate is infused slowly and continuously 
through the length of the dialysis probe into the outflow tubing where it can be 
collected for subsequent analyte quantification. 
D.2. Materials 
Polyethylene tubing (PE-10, PE-50) 
Fused silica 
Semipermeable membrane (choose specific molecular weight cutoff) 
Scissors 
Forceps 
Needles (orange) 
Epoxy adhesive glue-Epoxy Part A and Hardener Part B 
Ruler 
Microscope 
A4 sheet (for mixing glue) 
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D.3. Step-by-step guide 
D.3.1. Probe building 
1. Cut PE-10 (16 inches and 10 inches), PE-50 (2 inches) and Silica (19 inches) 
and hang on upturned sticky tape. If old probes available, can reuse PE-10 
for covering silica, and PE-50 if long enough. 
2. Put PE-50 over 16 inch PE-10 (may need to use blue 23G needle to loosen 
PE-50). Glue in place. 
3. Make hole in one side of PE-10 at the end which does not have PE-50 
attached (~4cm from top) using orange needle. Hold needle in right hand 
and have long side of PE-10 on right so that hole made forms lip which glue 
cannot get into.  
4. Know where the hole was made. Holding the PE-10 up with the hole facing 
up and slightly curved, feed silica in through short end of PE-10 and pull 
through hole. Leave a small bit of silica showing at the top of the PE-10. 
5. Cut membranes (about 12-15mm so that long enough to tuck in). Always 
hold membrane with forceps, never with fingers. To place membrane onto 
silica place membrane on microscope stage. Hold the membrane near top 
using forceps without applying pressure, and push silica into the membrane. 
Tuck a good amount of membrane under PE-10 so that glue won’t block it. 
Glue membrane in place. Measure membrane from end of glue spot to top 
of membrane under microscope. Want 6mm of membrane for prefrontal 
cortex, or 4.5mm for hippocampus, or otherwise as according to the 
literature, and chop off any excess using blade.  
6. Place wet glue in membrane tip and allow capillary action to work so that 
~0.75mm of the membrane is filled with glue on inside only. 
7. Need to block of some of the membrane from the connection with PE-10 so 
that only a certain amount will contribute to the ‘dialysing tip’. Active site 
for PFC=3mm, Hippocampus=2mm. Block off any remaining membrane 
using a very thin, smooth layer of glue. Mark the spot for blocking the 
membrane using fused silica. 
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8. Once top glue spot dry, push silica as close as possible to glue spot without 
touching (~0.2mm). Glue silica in place. Be very careful that the glue is not 
too runny at this stage as it may block the probe. 
9. Attach 10 inch PE-10 over silica and glue in place. 
D.3.2. Make aCSF (quantities for 500ml): 
NaCl   147mM  4.29534g 
KCl   4mM  0.1491g 
MgCl2.6H2O  0.9mM  0.091485g 
CaCl2   1.7mM  0.094335g 
Put 250ml HPLC grade water into 500ml glass bottle. Add salts. Make up to 500ml 
with HPLC grade water. Aliquot out by filtering using 0.2mcM filter attached to 
syringe. aCSF can be stored for a few weeks. 
D.3.3. Activate membrane of the probe 
Put ethanol in syringe (Terumo brand). Put blue needle into PE-50, attach syringe 
and push ethanol through finished probe to activate the membrane. Wait to see 
ethanol coming out the end of the silica-no blockages. Run aCSF through probe 
using a syringe and attach to pump running at 1.5µL/min with membrane immersed 
in medicine cup of aCSF (an activated membrane will shrink unless immersed in 
liquid). 
D.3.4. Setting up syringes in pump.  
Add filtered aCSF to 5ml syringe and mount on pump. End of barrel and end of 
insert should fit into gaps. Tighten side bars, then front, then back. Push out some 
aCSF and then click into place. Turn on, press run (1.5µL/min), make sure flow 
switch going the right way. Attach probes that are ready to it and immerse 
membrane in aCSF. Attach probe to orange frame and glue silica end below it.  
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Appendix E: Microdialysis surgery protocol 
E.1. Background information 
Microdialysis is a sensitive technique used to sample extracellular fluid for levels of 
drugs, drug metabolites, neurotransmitters, amino acids etc. It is renowned as a 
sensitive, versatile technique which has applications in elucidating 
neuropharmacology of drugs and diseases, as well as giving pharmacokinetic 
information on drug levels in the brain. While it was developed over 30 years ago in 
the 1970s and 1980s in Sweden, it has gained popularity as a useful and powerful 
sampling technique in recent times. This technique is known to hold many 
advantages over other available brain sampling techniques, including: 
 Continuous sample collection from live, awake, freely-moving animals pre- 
and post- drug administration/other manipulation 
 Measurement of free (unbound) drug concentrations = active form of drug 
 Measurement of drug/neurotransmitter levels in a specific area of the brain-
ability to measure levels in discrete regions 
 Collection of clean samples, that do not require extra purification prior to 
analysis 
 Potential application in wide range of species, from small rodents (mice, 
rats) to non-human primates 
E.2. Materials 
Stereotaxic frame 
Scalpel 
Clips 
Cotton buds 
Adrenaline 0.1% 
Blue needle 
Probe (calibrated) 
Screws 
Forceps 
Screwdriver 
Drill 
Marker 
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Dental cement (powder and solvent) 
Petri dish 
Spatula 
Spring 
Needle and thread 
Microdialysis cage 
Allen keys 
Bedding, Chow, Water bottle 
Tape 
E.3. Step-by-step guide 
1. Set up rat on stereotaxic frame. 
2. Make one incision from eyes to ears using scalpel.  
3. Use 4 clips to pull back skin from four corners. 
4. Use cotton buds to move away layer above skull. 
5. Dip cotton buds in adrenaline and dab over skull to constrict vessels and stop 
bleeding. 
6. This should allow time for bregma to appear. 
7. Mark bregma with marker.  
8. Take AP( anterior posterior) and ML (medial-lateral) co-ordinates. 
9. Calculate co-ordinates of where you want to go to-hippocampus, PFC etc. based 
on co-ordinates in literature/rat brain atlas. 
10. Move needle on stereotaxic frame to that point. 
11. Mark skull with needle. 
12. Use marker to mark spot also if required.  
13. Mark two other spots to the back of the area for screws which lend support 
(this makes a triangle type area). 
14. Drill all three holes (drill speed 4, only until drill pops back up). Make sure the 
microdialysis probe hole for entry is completely free of membrane by putting a 
needle in past skull to pop any remaining membrane. 
15. Place screws in back two holes, holding with forceps and screwing with 
screwdriver (may require downward pressure). 
16. Insert probe, making sure it enters center of the hole and is pointed straight 
downward. 
Appendix E: Microdialysis surgery protocol 
337 
17. As it is being lowered in, stop just when it is in past the level of the skull, and 
take DV (dorsal ventral) co-ordinates. Calculate how far into the brain the probe 
should be placed and lower it in. 
18. Mix some cement and solvent in a petri dish and start to cement the probe in 
place, using the screws for support. This will require many layers of glue. 
19. Place spring over probe and cement in place also. 
20. Start stitching up wound on nape of neck (from cannulations) while waiting for 
cement to dry. Once cement is dry, stitch up head. 
E.4. Post-surgery 
Place rat onto bedding in special cage. Attach spring using allen key to loosen 
holding arm. Make sure spring is loose enough that rat can move around. Using 
tape tie down silica. Attach PE-50 to syringe pump outlet. 
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Appendix F: Jugular Vein Catheterisation 
F.1. Methodological notes 
1. Making taps for JV and CA catheterisation. Clamp needle near base by 
holding with needle holder and cut using scalpel. 
 Blue needle for JV 
 Orange needle for CA 
2. Shave back of neck and top of chest (right hand side if rat lying with chest up 
and head towards you, legs away from you. Pull taught while shaving and 
shave with blade ‘scooping’. 
3. Give subcutaneous injection of Carprofen (100 µl Rimadyl in 5 ml saline). 
Pinch skin on back and inject ~0.8ml in bottom part of V. 
4. Swab shaved areas with alcohol to sterilize and wipe away excess hair. 
5. Make incision to right of centre along line of beating vein. Make incision 
using scissors. Holding skin with forceps (one arm inside and one out), pull 
subcutaneous tissue away from skin using another forceps. Make pouch 
below incision, pull away to right and small bit on left. 
6. Butterfly using needle holder, to separate subcutaneous tissue more.  
7. Make incision at back of neck using scissors. Pull subcutaneous tissue away 
from skin and tunnel to left using needle holder (pushing out against skin so 
as not to damage anything). 
8. Pull JV catheter through using needle-holder, blue marked end (2.5 cm from 
tip of catheter) pointed toward vein side. 
9. Insert catheter through 2 syringe barrels (to protect from chewing when rat 
regains consciousness). Attach 3-way tap with blue needle (with valve 
closed) to line and flush with 0.35ml-0.4ml saline.  
10. Pull apart subcutaneous tissue with small forceps and be careful once near 
vein. Isolate vein carefully from sides by pulling away fat/subcutaneous 
tissue. When isolated, put forceps with arms facing up under JV so that JV 
rests in dip of forceps. Thread double piece of thread through, and cut into 
two pieces.  
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11. Tie of top piece of string tightly to slow blood flow. Leave arms long and 
clamp out of the way using needle holder. 
12. Tie one very loose knot at the other end and attach clamp to it. 
13. Make nick in side of vein using spring scissors, use tweezers to open up nick 
just enough to put catheter in. Hold catheter using forceps just above blue 
mark. Push into vein as far as blue mark and quickly tie the knot at bottom 
very tightl. Cut excess suture string away from knot. 
14. Tie top piece of string around catheter and cut excess suture string away 
from knot. Check to see that line is patent by pushing in small bit of saline 
and drawing out and pushing back in small extra bit. 
15. Sew up SC tissue top (leave arms of knot long to loop around catheter) and 
bottom (don’t cut arms of knot). Make loop out of catheter and place into 
pouch. Loop bottom piece of string around catheter 3 or 4 times and tie 
knots them to secure in place. Check line is still patent and fill line with 
heparinised saline (0.4-0.45ml). Do the same on top. Sew up skin (mattress 
stitching works well). 
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Appendix G: Carotid Artery Catheterisation 
G.1. Methodological notes 
1. When catheterising both jugular vein and carotid artery, make incision at 
midline. Do jugular vein as per Appendix E. Try to ensure loop is pushed to 
the right so that carotid artery and jugular vein catheters are separated.  
2. Pull jugular vein, barrels and taps over to the left-hand side so that carotid 
artery line can be threaded through barrels. 
3. Start pulling apart subcutaneous tissue just to the left of midline. Do not go 
too near head. 
4. Work through subcutaneous tissue until muscles with upside down ‘V’ in 
middle is visible. Holding muscle on left with small forceps, tease apart from 
V using other small forceps. Reach carotid artery and vagus nerve 
(together). Tease apart tissue to isolate carotid artery and vagus. Scoop up 
using small forceps.  
5. Separate vagus from carotid. Using forceps make hole between carotid and 
vagus. Push against carotid rather than vagus. Insert small forceps into hole, 
and keeping pressure against carotid, separate carotid and vagus. Once 
carotid is free, clamp as close to the base as possible. Insert thread 
underneath and tie off at top. Throw loose knot in thread at bottom. Use 
needle holder on top thread to create tension on the vessel and drop over 
left hand side of head for correct angle. 
6. Using spring scissors, cut carotid top and side. Use straight forceps to open 
and insert CA tubing. Have catheter so that dip is angled into vein. Push in as 
far as clamp. Tighten thread over artery and catheter. Remove clamp and 
insert catheter to blue line. Tie thread. Stitch up subcutaneous, make loop 
etc as described in relation to jugular vein. 
7. Always check patency of catheters once in. Make sure to fill with saline 
before inserting into rat and heparinised saline after. 
 
